0000927653-23-000062.txt : 20230802 0000927653-23-000062.hdr.sgml : 20230802 20230802173023 ACCESSION NUMBER: 0000927653-23-000062 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230802 DATE AS OF CHANGE: 20230802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MCKESSON CORP CENTRAL INDEX KEY: 0000927653 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 943207296 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-13252 FILM NUMBER: 231137166 BUSINESS ADDRESS: STREET 1: 6555 STATE HIGHWAY 161 CITY: IRVING STATE: TX ZIP: 75039 BUSINESS PHONE: 972-446-4800 MAIL ADDRESS: STREET 1: 6555 STATE HIGHWAY 161 CITY: IRVING STATE: TX ZIP: 75039 FORMER COMPANY: FORMER CONFORMED NAME: MCKESSON HBOC INC DATE OF NAME CHANGE: 19990115 FORMER COMPANY: FORMER CONFORMED NAME: MCKESSON CORP DATE OF NAME CHANGE: 19950209 FORMER COMPANY: FORMER CONFORMED NAME: SP VENTURES INC DATE OF NAME CHANGE: 19940728 10-Q 1 mck-20230630.htm 10-Q mck-20230630
000092765303/312024Q1false00009276532023-04-012023-06-300000927653us-gaap:CommonStockMember2023-04-012023-06-300000927653mck:A1500NotesDue2025Member2023-04-012023-06-300000927653mck:A1625NotesDue2026Member2023-04-012023-06-300000927653mck:A3125NotesDue2029Member2023-04-012023-06-3000009276532023-06-30xbrli:sharesiso4217:USD00009276532022-04-012022-06-30iso4217:USDxbrli:shares00009276532023-03-310000927653us-gaap:CommonStockMember2023-03-310000927653us-gaap:AdditionalPaidInCapitalMember2023-03-310000927653us-gaap:RetainedEarningsMember2023-03-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000927653us-gaap:TreasuryStockCommonMember2023-03-310000927653us-gaap:NoncontrollingInterestMember2023-03-310000927653us-gaap:CommonStockMember2023-04-012023-06-300000927653us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000927653us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000927653us-gaap:RetainedEarningsMember2023-04-012023-06-300000927653us-gaap:NoncontrollingInterestMember2023-04-012023-06-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000927653us-gaap:CommonStockMember2023-06-300000927653us-gaap:AdditionalPaidInCapitalMember2023-06-300000927653us-gaap:RetainedEarningsMember2023-06-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000927653us-gaap:TreasuryStockCommonMember2023-06-300000927653us-gaap:NoncontrollingInterestMember2023-06-300000927653us-gaap:CommonStockMember2022-03-310000927653us-gaap:AdditionalPaidInCapitalMember2022-03-310000927653us-gaap:RetainedEarningsMember2022-03-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000927653us-gaap:TreasuryStockCommonMember2022-03-310000927653us-gaap:NoncontrollingInterestMember2022-03-3100009276532022-03-310000927653us-gaap:CommonStockMember2022-04-012022-06-300000927653us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300000927653us-gaap:TreasuryStockCommonMember2022-04-012022-06-300000927653us-gaap:RetainedEarningsMember2022-04-012022-06-300000927653us-gaap:NoncontrollingInterestMember2022-04-012022-06-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000927653us-gaap:CommonStockMember2022-06-300000927653us-gaap:AdditionalPaidInCapitalMember2022-06-300000927653us-gaap:RetainedEarningsMember2022-06-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000927653us-gaap:TreasuryStockCommonMember2022-06-300000927653us-gaap:NoncontrollingInterestMember2022-06-3000009276532022-06-30mck:segment0000927653mck:RxTsSegmentMembermck:RxSavingsSolutionsLLCMember2022-11-01xbrli:pure0000927653mck:RxTsSegmentMembermck:RxSavingsSolutionsLLCMember2022-11-012022-11-010000927653mck:RxTsSegmentMembersrt:MaximumMembermck:RxSavingsSolutionsLLCMember2022-11-010000927653mck:RxTsSegmentMembermck:RxSavingsSolutionsLLCMember2023-06-300000927653mck:RxTsSegmentMembermck:RxSavingsSolutionsLLCMember2023-03-310000927653mck:USPharmaceuticalSegmentMembermck:SCRIOncologyLLCMember2022-10-310000927653mck:USPharmaceuticalSegmentMembermck:SCRIOncologyLLCMember2022-10-312022-10-310000927653mck:SarahCannonResearchInstituteMembermck:USPharmaceuticalSegmentMembermck:SCRIOncologyLLCMember2022-10-310000927653mck:McKessonUSOncologyResearchMembermck:USPharmaceuticalSegmentMembermck:SCRIOncologyLLCMember2022-10-310000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:EUBusinessesDisposalGroupMember2023-04-012023-06-300000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:UKBusinessesDisposalGroupMember2022-04-06iso4217:GBP0000927653mck:AureliusElephantLimitedMembermck:InternationalSegmentMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-04-060000927653mck:AureliusElephantLimitedMembermck:InternationalSegmentMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-04-062022-04-060000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:UKBusinessesDisposalGroupMember2022-04-062022-04-060000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2023-03-310000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2023-01-012023-06-300000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2023-04-012023-06-300000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2023-04-012023-06-300000927653mck:PrescriptionTechnologySolutionsMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2023-04-012023-06-300000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2023-04-012023-06-300000927653us-gaap:CorporateNonSegmentMember2023-04-012023-06-300000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2022-04-012022-06-300000927653mck:PrescriptionTechnologySolutionsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2022-04-012022-06-300000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2022-04-012022-06-300000927653us-gaap:CorporateNonSegmentMember2022-04-012022-06-300000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2023-03-310000927653mck:PrescriptionTechnologySolutionsMemberus-gaap:OperatingSegmentsMember2023-03-310000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2023-03-310000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2023-03-310000927653us-gaap:CorporateNonSegmentMember2023-03-310000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2023-06-300000927653mck:PrescriptionTechnologySolutionsMemberus-gaap:OperatingSegmentsMember2023-06-300000927653us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2023-06-300000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2023-06-300000927653us-gaap:CorporateNonSegmentMember2023-06-300000927653us-gaap:AccruedLiabilitiesMember2023-03-310000927653us-gaap:OtherNoncurrentLiabilitiesMember2023-03-310000927653us-gaap:AccruedLiabilitiesMember2023-06-300000927653us-gaap:OtherNoncurrentLiabilitiesMember2023-06-300000927653srt:MinimumMember2023-06-300000927653srt:MaximumMember2023-06-300000927653us-gaap:EmployeeStockOptionMember2023-04-012023-06-300000927653us-gaap:EmployeeStockOptionMember2022-04-012022-06-300000927653us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300000927653us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300000927653mck:USPharmaceuticalSegmentMember2023-03-310000927653mck:PrescriptionTechnologySolutionsMember2023-03-310000927653mck:MedicalSurgicalSolutionsSegmentMember2023-03-310000927653mck:InternationalSegmentMember2023-03-310000927653mck:USPharmaceuticalSegmentMember2023-04-012023-06-300000927653mck:PrescriptionTechnologySolutionsMember2023-04-012023-06-300000927653mck:MedicalSurgicalSolutionsSegmentMember2023-04-012023-06-300000927653mck:InternationalSegmentMember2023-04-012023-06-300000927653mck:USPharmaceuticalSegmentMember2023-06-300000927653mck:PrescriptionTechnologySolutionsMember2023-06-300000927653mck:MedicalSurgicalSolutionsSegmentMember2023-06-300000927653mck:InternationalSegmentMember2023-06-300000927653us-gaap:CustomerRelationshipsMember2023-06-300000927653us-gaap:CustomerRelationshipsMember2023-03-310000927653us-gaap:ServiceAgreementsMember2023-06-300000927653us-gaap:ServiceAgreementsMember2023-03-310000927653us-gaap:TrademarksAndTradeNamesMember2023-06-300000927653us-gaap:TrademarksAndTradeNamesMember2023-03-310000927653us-gaap:TechnologyBasedIntangibleAssetsMember2023-06-300000927653us-gaap:TechnologyBasedIntangibleAssetsMember2023-03-310000927653us-gaap:OtherIntangibleAssetsMember2023-06-300000927653us-gaap:OtherIntangibleAssetsMember2023-03-310000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-06-300000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A090NotesDueDecember32025Memberus-gaap:LoansPayableMember2023-06-300000927653mck:A090NotesDueDecember32025Memberus-gaap:LoansPayableMember2023-03-310000927653us-gaap:LoansPayableMembermck:A525NotesDueFebruary152026Member2023-06-300000927653us-gaap:LoansPayableMembermck:A525NotesDueFebruary152026Member2023-03-310000927653us-gaap:LoansPayableMembermck:A130NotesDueAugust152026Member2023-06-300000927653us-gaap:LoansPayableMembermck:A130NotesDueAugust152026Member2023-03-310000927653us-gaap:LoansPayableMembermck:A765DebenturesDueMarch12027Member2023-06-300000927653us-gaap:LoansPayableMembermck:A765DebenturesDueMarch12027Member2023-03-310000927653us-gaap:LoansPayableMembermck:A395NotesDueFebruary162028Member2023-06-300000927653us-gaap:LoansPayableMembermck:A395NotesDueFebruary162028Member2023-03-310000927653mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember2023-06-300000927653mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember2023-03-310000927653us-gaap:LoansPayableMembermck:A475NotesDueMay302029Member2023-06-300000927653us-gaap:LoansPayableMembermck:A475NotesDueMay302029Member2023-03-310000927653us-gaap:LoansPayableMembermck:A510NotesDueJuly152033Member2023-06-300000927653us-gaap:LoansPayableMembermck:A510NotesDueJuly152033Member2023-03-310000927653mck:A600NotesDueMarch12041Memberus-gaap:LoansPayableMember2023-06-300000927653mck:A600NotesDueMarch12041Memberus-gaap:LoansPayableMember2023-03-310000927653mck:A488NotesDueMarch152044Memberus-gaap:LoansPayableMember2023-06-300000927653mck:A488NotesDueMarch152044Memberus-gaap:LoansPayableMember2023-03-310000927653us-gaap:LoansPayableMembermck:A150EuroNotesDueNovember172025Member2023-06-300000927653us-gaap:LoansPayableMembermck:A150EuroNotesDueNovember172025Member2023-03-310000927653us-gaap:LoansPayableMembermck:A163EuroNotesDueOctober302026Member2023-06-300000927653us-gaap:LoansPayableMembermck:A163EuroNotesDueOctober302026Member2023-03-310000927653mck:A313SterlingNotesDueFebruary172029Memberus-gaap:LoansPayableMember2023-06-300000927653mck:A313SterlingNotesDueFebruary172029Memberus-gaap:LoansPayableMember2023-03-310000927653mck:LeaseAndOtherObligationsMember2023-06-300000927653mck:LeaseAndOtherObligationsMember2023-03-310000927653mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember2023-06-150000927653us-gaap:LoansPayableMembermck:A510NotesDueJuly152033Member2023-06-150000927653mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember2023-06-152023-06-150000927653us-gaap:LoansPayableMembermck:A510NotesDueJuly152033Member2023-06-152023-06-150000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-06-150000927653srt:MinimumMemberus-gaap:LoansPayableMember2023-04-012023-06-300000927653us-gaap:LoansPayableMembersrt:MaximumMember2023-04-012023-06-300000927653us-gaap:LoansPayableMember2023-04-012023-06-300000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-06-162023-06-160000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-06-160000927653us-gaap:UnsecuredDebtMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-11-070000927653us-gaap:UnsecuredDebtMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2022-11-072022-11-070000927653mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2022-11-070000927653mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2019-09-250000927653mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2019-09-252019-09-250000927653us-gaap:UnsecuredDebtMembermck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMemberus-gaap:RevolvingCreditFacilityMember2022-04-012022-06-300000927653us-gaap:UnsecuredDebtMembermck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMemberus-gaap:RevolvingCreditFacilityMember2022-11-070000927653mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2023-04-012023-06-300000927653mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2023-06-300000927653us-gaap:CommercialPaperMember2023-06-300000927653us-gaap:CommercialPaperMember2023-04-012023-06-300000927653us-gaap:CommercialPaperMember2022-04-012022-06-300000927653us-gaap:CommercialPaperMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMembercurrency:EURus-gaap:FairValueHedgingMember2022-09-30iso4217:EUR0000927653us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermck:UKBusinessesDisposalGroupMember2022-04-012022-06-300000927653us-gaap:LoansPayableMembermck:BritishPoundSterlingDenominatedNotesMember2022-12-310000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:EuroDenominatedNotesMemberus-gaap:NetInvestmentHedgingMember2023-04-012023-06-300000927653us-gaap:DesignatedAsHedgingInstrumentMembermck:EuroDenominatedNotesMemberus-gaap:NetInvestmentHedgingMember2022-04-012022-06-300000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:NetInvestmentHedgingMember2023-06-30iso4217:CAD0000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:NetInvestmentHedgingMember2023-03-310000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:GBPus-gaap:FairValueHedgingMember2023-06-300000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:GBPus-gaap:FairValueHedgingMember2023-03-310000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EURus-gaap:FairValueHedgingMember2023-06-300000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EURus-gaap:FairValueHedgingMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMembercurrency:USD2023-06-300000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMembercurrency:USD2023-03-310000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMembercurrency:CAD2023-06-300000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMembercurrency:CAD2023-03-310000927653mck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMembercurrency:USD2023-06-300000927653mck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMembercurrency:USD2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-04-012023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-04-012023-06-300000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-06-150000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2023-04-012023-06-300000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-04-012022-06-300000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-04-012023-06-300000927653us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-04-012022-06-300000927653mck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-04-012023-06-300000927653mck:FixedInterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-04-012022-06-300000927653mck:CurrentAssetLiabilityMemberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000927653mck:CurrentAssetLiabilityMemberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000927653us-gaap:CurrencySwapMembermck:OtherNonCurrentAssetsAndLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000927653us-gaap:CurrencySwapMembermck:OtherNonCurrentAssetsAndLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000927653mck:OtherNonCurrentAssetsAndLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-06-300000927653mck:OtherNonCurrentAssetsAndLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2023-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMember2023-06-300000927653us-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000927653us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-06-300000927653us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-03-310000927653us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-06-300000927653us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-03-310000927653mck:NationalPrescriptionOpiateLitigationMember2023-06-30mck:distributormck:statemck:case0000927653mck:NationalPrescriptionOpiateLitigationMembermck:ThreeLargestUSPharmaceuticalDistributorsMember2023-04-012023-06-300000927653mck:NationalPrescriptionOpiateLitigationMembermck:StateOfAlabamaAndSubdivisionsMember2023-04-012023-06-300000927653mck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMembermck:StateOfWestVirginiaAndSubdivisionsMember2023-04-012023-06-30mck:jurisdiction0000927653mck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMembermck:CherokeeNationMember2023-04-012023-06-300000927653mck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMembermck:NativeAmericanTribesOtherThanCherokeeNationMember2023-04-012023-06-300000927653mck:NationalPrescriptionOpiateLitigationMembermck:NativeAmericanTribesOtherThanCherokeeNationMember2023-06-300000927653mck:NationalPrescriptionOpiateLitigationMember2023-06-300000927653mck:NationalPrescriptionOpiateLitigationMember2023-03-310000927653mck:NationalPrescriptionOpiateLitigationMemberus-gaap:SettledLitigationMember2023-04-012023-06-300000927653us-gaap:SubsequentEventMembermck:NationalPrescriptionOpiateLitigationMemberus-gaap:SettledLitigationMember2023-07-012023-07-310000927653country:USmck:NationalPrescriptionOpiateLitigationMember2023-06-300000927653mck:NationalPrescriptionOpiateLitigationMembercountry:CA2023-06-300000927653mck:IndividualClaimantMembermck:NationalPrescriptionOpiateLitigationMembercountry:CA2023-06-3000009276532018-12-12mck:officer0000927653mck:EvanstonPolicePensionFundVMcKessonCorporationMember2022-09-300000927653mck:EvanstonPolicePensionFundVMcKessonCorporationMember2023-03-310000927653mck:UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember2020-07-31mck:vote0000927653us-gaap:SubsequentEventMember2023-07-012023-07-310000927653mck:AcceleratedShareRepurchaseMember2022-05-012022-05-310000927653mck:AcceleratedShareRepurchaseMember2022-05-012022-08-310000927653mck:AcceleratedShareRepurchaseInitialShareSettlementMember2022-05-012022-05-310000927653mck:AcceleratedShareRepurchaseCompletionOfProgramMember2022-08-012022-08-310000927653mck:AcceleratedShareRepurchaseMember2022-02-012022-02-280000927653mck:AcceleratedShareRepurchaseMember2022-02-012022-05-310000927653mck:AcceleratedShareRepurchaseInitialShareSettlementMember2022-01-012022-03-310000927653mck:AcceleratedShareRepurchaseCompletionOfProgramMember2022-05-012022-05-310000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-04-012023-06-300000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-03-310000927653mck:OpenMarketShareRepurchaseTransactionsMember2022-04-012022-06-300000927653us-gaap:SubsequentEventMember2023-07-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-03-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-03-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-06-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-04-012023-06-300000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-04-012023-06-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-06-300000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-06-300000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-06-300000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-06-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2023-04-012023-06-300000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2022-03-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-03-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2022-04-012022-06-300000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-04-012022-06-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2022-06-300000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-06-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300000927653us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMember2022-04-012022-06-300000927653mck:USPharmaceuticalSegmentMember2022-04-012022-06-300000927653mck:PrescriptionTechnologySolutionsMember2022-04-012022-06-300000927653mck:MedicalSurgicalSolutionsSegmentMember2022-04-012022-06-300000927653mck:InternationalSegmentMember2022-04-012022-06-300000927653us-gaap:OperatingSegmentsMember2023-04-012023-06-300000927653us-gaap:OperatingSegmentsMember2022-04-012022-06-300000927653country:US2023-04-012023-06-300000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMembermck:EUBusinessesDisposalGroupMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2022-04-012022-06-300000927653us-gaap:CorporateNonSegmentMembermck:EUBusinessesDisposalGroupMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2022-04-012022-06-30
Table of Contents                                          
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to             
Commission File Number: 1-13252
mckessonlogoa01.jpg
McKESSON CORPORATION
(Exact name of registrant as specified in its charter)
Delaware94-3207296
(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer
Identification No.)
6555 State Hwy 161,
Irving, TX 75039
(Address of principal executive offices, including zip code)
(972) 446-4800
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
(Title of each class)(Trading Symbol)(Name of each exchange on which registered)
Common stock, $0.01 par valueMCKNew York Stock Exchange
1.500% Notes due 2025MCK25New York Stock Exchange
1.625% Notes due 2026MCK26New York Stock Exchange
3.125% Notes due 2029MCK29New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer 
Non-accelerated filer Smaller reporting company 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes      No  
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 134,902,380 shares of the issuer’s common stock were outstanding as of June 30, 2023.


McKESSON CORPORATION

TABLE OF CONTENTS
ItemPage
1
2
3
4
1
1A
2
3
4
5
6


2

McKESSON CORPORATION

PART I—FINANCIAL INFORMATION

Item 1.    Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
 
Three Months Ended June 30,
 20232022
Revenues$74,483 $67,154 
Cost of sales(71,461)(64,131)
Gross profit3,022 3,023 
Selling, distribution, general, and administrative expenses(1,870)(1,959)
Claims and litigation charges, net (5)
Restructuring, impairment, and related charges, net(52)(23)
Total operating expenses(1,922)(1,987)
Operating income1,100 1,036 
Other income, net38 15 
Interest expense(47)(45)
Income from continuing operations before income taxes1,091 1,006 
Income tax expense(94)(199)
Income from continuing operations997 807 
Income from discontinued operations, net of tax 2 
Net income997 809 
Net income attributable to noncontrolling interests(39)(41)
Net income attributable to McKesson Corporation$958 $768 
Earnings per common share attributable to McKesson Corporation
Diluted
Continuing operations
$7.02 $5.25 
Discontinued operations
 0.01 
Total
$7.02 $5.26 
Basic
Continuing operations
$7.07 $5.31 
Discontinued operations
 0.01 
Total
$7.07 $5.32 
Weighted-average common shares outstanding
Diluted136.6 145.9 
Basic135.5 144.2 

See Financial Notes
3

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)
 
 Three Months Ended June 30,
 20232022
Net income$997 $809 
Other comprehensive income, net of tax
Foreign currency translation adjustments
52 582 
Unrealized gains on cash flow and other hedges7 18 
Changes in retirement-related benefit plans
(2)36 
Other comprehensive income, net of tax57 636 
Comprehensive income1,054 1,445 
Comprehensive income attributable to noncontrolling interests(39)(91)
Comprehensive income attributable to McKesson Corporation$1,015 $1,354 

See Financial Notes
4

McKESSON CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per share amounts)
(Unaudited)
June 30, 2023March 31, 2023
ASSETS
Current assets
Cash and cash equivalents$2,636 $4,678 
Receivables, net21,860 19,410 
Inventories, net20,510 19,691 
Prepaid expenses and other533 513 
Total current assets45,539 44,292 
Property, plant, and equipment, net2,172 2,177 
Operating lease right-of-use assets1,693 1,635 
Goodwill9,971 9,947 
Intangible assets, net2,221 2,277 
Other non-current assets2,500 1,992 
Total assets$64,096 $62,320 
LIABILITIES AND DEFICIT
Current liabilities
Drafts and accounts payable$43,982 $42,490 
Current portion of long-term debt50 968 
Current portion of operating lease liabilities300 299 
Other accrued liabilities4,090 4,200 
Total current liabilities48,422 47,957 
Long-term debt5,611 4,626 
Long-term deferred tax liabilities1,139 1,387 
Long-term operating lease liabilities1,462 1,402 
Long-term litigation liabilities6,628 6,625 
Other non-current liabilities2,074 1,813 
McKesson Corporation stockholders’ deficit
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding
  
Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at June 30, 2023 and March 31, 2023, respectively
3 3 
Additional paid-in capital7,824 7,747 
Retained earnings13,182 12,295 
Accumulated other comprehensive loss(848)(905)
Treasury shares, at cost, 143 and 141 shares at June 30, 2023 and March 31, 2023, respectively
(21,763)(20,997)
Total McKesson Corporation stockholders’ deficit(1,602)(1,857)
Noncontrolling interests362 367 
Total deficit(1,240)(1,490)
Total liabilities and deficit$64,096 $62,320 
See Financial Notes
5

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(In millions, except per share amounts)
(Unaudited)

Three Months Ended June 30, 2023
Common StockAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive LossTreasuryNoncontrolling
Interests
Total
Deficit
SharesAmountCommon SharesAmount
Balance, March 31, 2023
277 $3 $7,747 $12,295 $(905)(141)$(20,997)$367 $(1,490)
Issuance of shares under employee plans, net of forfeitures1 — 27 — — — (93)— (66)
Share-based compensation— — 43 — — — — — 43 
Repurchase of common stock— — — — — (2)(673)— (673)
Net income— — — 958 — — — 39 997 
Other comprehensive income— — — — 57 — — — 57 
Cash dividends declared, $0.54 per common share
— — — (73)— — — — (73)
Payments to noncontrolling interests— — — — — — — (39)(39)
Other— — 7 2 — — — (5)4 
Balance, June 30, 2023
278 $3 $7,824 $13,182 $(848)(143)$(21,763)$362 $(1,240)


Three Months Ended June 30, 2022
Common StockAdditional Paid-in CapitalRetained EarningsAccumulated Other Comprehensive LossTreasuryNoncontrolling
Interests
Total
 Deficit
SharesAmountCommon SharesAmount
Balance, March 31, 2022
275 $2 $7,275 $9,030 $(1,534)(130)$(17,045)$480 $(1,792)
Issuance of shares under employee plans, net of forfeitures2 1 91 — — — (152)— (60)
Share-based compensation— — 40 — — — — — 40 
Repurchase of common stock— — (56)— — (3)(944)— (1,000)
Net income— — — 768 — — — 41 809 
Other comprehensive income— — — — 586 — — 50 636 
Cash dividends declared, $0.47 per common share
— — — (67)— — — — (67)
Payments to noncontrolling interests— — — — — — — (36)(36)
Reclassification of recurring compensation to other accrued liabilities— — — — — — — (2)(2)
Other— — — 1 — — — (1) 
Balance, June 30, 2022
277 $3 $7,350 $9,732 $(948)(133)$(18,141)$532 $(1,472)
See Financial Notes
6

McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)
 Three Months Ended June 30,
 20232022
OPERATING ACTIVITIES
Net income$997 $809 
Adjustments to reconcile to net cash used in operating activities:
Depreciation64 61 
Amortization95 87 
Long-lived asset impairment charges28  
Deferred taxes(235)109 
Credits associated with last-in, first-out inventory method32 (13)
Non-cash operating lease expense58 63 
Gain from sales of businesses and investments(19)(33)
European businesses held for sale 20 
Other non-cash items41 102 
Changes in assets and liabilities, net of acquisitions:
Receivables(2,380)(1,584)
Inventories(826)(955)
Drafts and accounts payable1,473 1,006 
Operating lease liabilities(80)(94)
Taxes236 37 
Litigation liabilities (370)
Other(536)(186)
Net cash used in operating activities(1,052)(941)
INVESTING ACTIVITIES
Payments for property, plant, and equipment(78)(71)
Capitalized software expenditures(46)(29)
Acquisitions, net of cash, cash equivalents, and restricted cash acquired (1)
Proceeds from sales of businesses and investments, net39 240 
Other(64)(100)
Net cash provided by (used in) investing activities(149)39 
FINANCING ACTIVITIES
Proceeds from short-term borrowings65  
Repayments of short-term borrowings(65) 
Proceeds from issuances of long-term debt991  
Repayments of long-term debt(268)(2)
Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt(647) 
Common stock transactions:
Issuances27 91 
Share repurchases(696)(1,000)
Dividends paid(74)(71)
Other(176)(199)
Net cash used in financing activities(843)(1,181)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash2 18 
Change in cash, cash equivalents, and restricted cash classified as Assets held for sale 470 
Net decrease in cash, cash equivalents, and restricted cash(2,042)(1,595)
Cash, cash equivalents, and restricted cash at beginning of period4,679 3,935 
Cash, cash equivalents, and restricted cash at end of period2,637 2,340 
Less: Restricted cash at end of period included in Prepaid expenses and other
(1)(107)
Cash and cash equivalents at end of period
$2,636 $2,233 
See Financial Notes
7

McKESSON CORPORATION
FINANCIAL NOTES
(UNAUDITED)

1.    Significant Accounting Policies
Nature of Operations: McKesson Corporation (“McKesson,” or the “Company,”) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (“RxTS”), Medical-Surgical Solutions, and International. Refer to Financial Note 12, “Segments of Business,” for additional information.
Basis of Presentation: The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.
The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net income attributable to noncontrolling interests” in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees.
Net income attributable to noncontrolling interests includes third-party equity interests in the Company’s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (“McKesson Europe”). The Company’s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company’s businesses in the European Union (“E.U.”) in October 2022, which is discussed further in Financial Note 2, “Business Acquisitions and Divestitures.”
The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (“VIE”). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method.
Fiscal Period: The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.
Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation.
Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.
The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May 9, 2023 (the “2023 Annual Report”).

8

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the “IRA”). Among other provisions, the IRA includes a 15% corporate minimum tax, a 1% excise tax on certain repurchases of an entity’s own common stock after December 31, 2022, and various drug pricing reforms. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures. The Company will continue to evaluate the full impact of these legislative changes as they are announced and implemented. Refer to Financial Note 11, “Stockholders' Deficit,” for further details regarding excise taxes incurred on the Company’s share repurchases during the three months ended June 30, 2023.
Recently Adopted Accounting Pronouncements
There were no accounting standards adopted by the Company during the three months ended June 30, 2023.
Recently Issued Accounting Pronouncements Not Yet Adopted
In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures.
2.    Business Acquisitions and Divestitures
Acquisitions
Rx Savings Solutions, LLC
On November 1, 2022, the Company completed its acquisition of 100% of the shares of Rx Savings Solutions, LLC (“RxSS”), a privately-owned company headquartered in Overland Park, Kansas, to further connect biopharma and payer services to patients. RxSS is a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. The purchase consideration included a payment of $600 million in cash made upon closing and a maximum of $275 million of contingent consideration based on RxSS’ operational and financial performance through calendar year 2025. The payment made upon closing was funded from cash on hand. The financial results of RxSS are included in the Company’s RxTS segment as of the acquisition date. The transaction was accounted for as a business combination.
The Company recorded a liability for the contingent consideration at its fair value of $92 million as of the acquisition date. The fair value of the contingent consideration liability was estimated using a Monte Carlo simulation model, utilizing internal cash flow projections which are Level 3 inputs under Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures. The contingent liability will be remeasured to fair value at each reporting date until the liability is settled with changes in fair value being recognized within “Selling, distribution, general, and administrative expenses” in the Company’s Condensed Consolidated Statements of Operations. During the three months ended June 30, 2023, the Company recognized a fair value adjustment gain of $28 million, which reduced its contingent consideration liability, based on the estimated amount and timing of projected operational and financial information and the probability of achievement of certain performance milestones. As of June 30, 2023 and March 31, 2023, the current portion of $45 million and $83 million, respectively, is included within “Other accrued liabilities” and the long-term portion of $19 million and $9 million, respectively, is included within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheets. Recognition of the initial fair value of this contingent consideration was a non-cash investing activity.
The purchase price allocation included acquired identifiable intangible assets of $229 million, primarily representing customer relationships and technology with a weighted average amortization period of 12 years, and goodwill of $463 million. Goodwill has been allocated to the Company’s RxTS segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition is deductible for tax purposes.

9

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
The following table summarizes the preliminary purchase price allocation for this acquisition:
(In millions)Amounts Recognized as of Acquisition Date (As Adjusted)
Purchase consideration:
Cash$600 
Contingent consideration92 
Total purchase consideration$692 
Identifiable assets acquired and liabilities assumed:
Current assets$5 
Intangible assets229 
Other non-current assets3 
Current liabilities(8)
Total identifiable net assets229 
Goodwill463 
Net assets acquired$692 
SCRI Oncology, LLC
On October 31, 2022, the Company completed a transaction with HCA Healthcare, Inc. (“HCA”) to form SCRI Oncology, LLC (“SCRI Oncology”), an oncology research business combining McKesson’s U.S. Oncology Research (“USOR”) and HCA’s Sarah Cannon Research Institute (“SCRI”) based in Nashville, Tennessee, to advance cancer care and increase access to oncology clinical research. Upon consummation of the transaction, McKesson owns a 51% controlling interest in the combined business, and the financial results are consolidated by the Company and reported within its U.S. Pharmaceutical segment as of the acquisition date. Transaction consideration included the transfer of full ownership interest in USOR to the combined business and $166 million of net cash paid to HCA, which was funded from cash on hand. The transaction was accounted for as a business combination.
The purchase price allocation included acquired identifiable intangible assets of $177 million, primarily representing customer relationships as well as trademarks and trade names with a weighted average amortization period of 17 years, and goodwill of $113 million. Goodwill has been allocated to the Company’s U.S. Pharmaceutical segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition of $46 million is deductible for tax purposes. The Company recorded noncontrolling interest of $222 million as a component of equity, which includes HCA’s proportionate interest in the identifiable net assets of SCRI at fair value of $202 million and its proportionate interest in the contributed net assets of USOR at carrying value of $20 million. The difference between the fair value of the Company’s acquired interest in SCRI net assets and the $166 million of net cash paid to HCA was recognized as additional paid in capital, as well as the Company’s reduction in ownership interest in USOR net assets.

10

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
The following table summarizes the preliminary purchase price allocation for this acquisition:
(In millions)Amounts Recognized as of Acquisition Date (As Adjusted)
Purchase consideration:
Cash$166 
Contribution of USOR40 
Total purchase consideration$206 
Identifiable assets acquired and liabilities assumed:
Receivables$224 
Property, plant, and equipment22 
Operating lease right-of-use assets31 
Intangible assets177 
Current liabilities(42)
Long-term operating lease liabilities(29)
Other non-current liabilities(43)
Total identifiable net assets340 
Noncontrolling interest(222)
Additional paid-in capital(25)
Goodwill113 
Net assets acquired$206 
The fair value of the acquired identifiable intangible assets from the acquisitions discussed above were determined by applying the income approach, using a discounted cash flow model in which cash flows anticipated over several periods are discounted to their present value using an appropriate rate that is commensurate with the risk inherent with the transaction. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The amounts presented above are subject to change as the Company’s fair value assessments are finalized. There have been no material changes to the purchase price allocation of these acquisitions since the acquisition date. Pro forma financial information has not been provided as these acquisitions did not have a material impact, individually, or in the aggregate, to the Company’s consolidated results of operations.
Divestitures
European Divestiture Activities
In July 2021, the Company announced its intention to exit its businesses in Europe. On October 31, 2022, the Company completed its previously announced transaction to sell certain of its businesses in the European Union (“E.U.”) located in France, Italy, Ireland, Portugal, Belgium, and Slovenia, along with its German headquarters and wound-care business, part of a shared services center in Lithuania, and its ownership stake in a joint venture in the Netherlands (“E.U. disposal group”) to the PHOENIX Group. During the three months ended June 30, 2022, the Company recorded a gain of $12 million to remeasure the E.U. disposal group to fair value less costs to sell which was recorded within “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statement of Operations. The Company’s measurement of the fair value of the E.U. disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreement. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.
On April 6, 2022, the Company completed the previously announced sale of its retail and distribution businesses in the United Kingdom (“U.K. disposal group”) to Aurelius Elephant Limited for a purchase price of £110 million (or, approximately $144 million), including certain adjustments. As part of the transaction, the Company divested net assets of $615 million and released $731 million of accumulated other comprehensive loss, within the International segment, and the buyer assumed and repaid a note payable to the Company of $118 million.

11

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
At June 30, 2023 and March 31, 2023, the Company had no assets or liabilities related to these European divestiture activities that met the criteria for classification as held for sale. Subsequent to the divestiture activities discussed above, the Company’s European operations primarily consist of its retail and distribution businesses in Norway.
Other
For the periods presented, the Company also completed de minimis acquisitions and divestitures within its operating segments. Financial results for the Company’s business acquisitions have been included in its consolidated financial statements as of their respective acquisition dates. Purchase prices for business acquisitions have been allocated based on estimated fair values at the respective acquisition dates.
3.    Restructuring, Impairment, and Related Charges, Net
The Company recorded restructuring, impairment, and related charges, net of $52 million and $23 million for the three months ended June 30, 2023 and 2022, respectively. These charges were included in “Restructuring, impairment, and related charges, net” in the Condensed Consolidated Statements of Operations.
Restructuring Initiatives
During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. The Company anticipates total charges of approximately $125 million across its RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $96 million of charges were recorded to date. For the three months ended June 30, 2023, the Company recorded charges of $36 million related to this program, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024.
Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following:
Three Months Ended June 30, 2023
(In millions)U.S. Pharmaceutical
Prescription Technology Solutions (1)
Medical-Surgical Solutions
International
Corporate (1)
Total
Severance and employee-related costs, net $1 $ $ $ $1 $2 
Exit and other-related costs (2)
1 2 2 5 12 22 
Asset impairments and accelerated depreciation   1 27 28 
Total$2 $2 $2 $6 $40 $52 
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.
(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

12

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Three Months Ended June 30, 2022
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternational
Corporate
Total
Severance and employee-related costs, net $3 $ $ $ $(1)$2 
Exit and other-related costs (1)
1 2 1 2 15 21 
Asset impairments and accelerated depreciation 5   (5) 
Total$4 $7 $1 $2 $9 $23 
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the three months ended June 30, 2023:
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotal
Balance, March 31, 2023 (1)
$15 $26 $3 $13 $35 $92 
Restructuring, impairment, and related charges, net2 2 2 6 40 52 
Non-cash charges   (1)(27)(28)
Cash payments(5)(13)(2)(2)(15)(37)
Other (2)
   (5) (5)
Balance, June 30, 2023 (3)
$12 $15 $3 $11 $33 $74 
(1)As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.
(2)Other primarily includes cumulative translation adjustments and transfers to certain other liabilities.
(3)As of June 30, 2023, the total reserve balance was $74 million, of which $44 million was recorded in “Other accrued liabilities” and $30 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.
4.    Income Taxes
Income tax expense related to continuing operations was as follows:
Three Months Ended June 30,
(Dollars in millions)20232022
Income tax expense$94 $199 
Reported income tax rate8.6 %19.8 %
Fluctuations in the Company’s reported income tax rates were primarily due to changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters.
During the three months ended June 30, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory, a net discrete tax benefit of $147 million was recognized in the first quarter of fiscal 2024.

13

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
During the three months ended June 30, 2022, the Company recognized a net discrete tax benefit of $45 million primarily related to the tax impact of share-based compensation.
As of June 30, 2023, the Company had $1.4 billion of unrecognized tax benefits, of which $1.3 billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year.     
The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year.
During the fourth quarter of fiscal 2023, the Internal Revenue Service (“IRS”) communicated proposed adjustments to taxable income reported in the Company’s fiscal 2018 and fiscal 2019 U.S. Federal Corporate Income Tax returns. The adjustments would increase the Company’s federal income tax liability in the range of $600 million to $700 million. The Company disagrees with the proposed adjustments and intends to pursue resolution through the administrative process with the IRS Independent Office of Appeals and, if necessary, through judicial remedies. During the first quarter of fiscal 2024, the Company filed a formal protest with the IRS. The Company does not anticipate a final resolution of these matters until fiscal 2026 or after. Although the final resolution of these matters is uncertain, the Company believes in the merits of its tax positions and believes that it has adequately reserved for any adjustments to the provision of income taxes that may ultimately result. However, if the IRS prevails in these matters, the assessed tax and interest could have a material adverse effect on the Company’s financial position, results of operations, and cash flows in future periods.
5.    Earnings Per Common Share
Basic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings per common share is similar to that of basic earnings per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than 1.0 million of potentially dilutive securities for the three months ended June 30, 2023 and 2022 were excluded from the computation of diluted earnings per common share as they were anti-dilutive.

14

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
The computations for basic and diluted earnings per common share were as follows:
Three Months Ended June 30,
(In millions, except per share amounts)20232022
Income from continuing operations$997 $807 
Net income attributable to noncontrolling interests(39)(41)
Income from continuing operations attributable to McKesson Corporation958 766 
Income from discontinued operations, net of tax 2 
Net income attributable to McKesson Corporation$958 $768 
Weighted-average common shares outstanding:
Basic135.5 144.2 
Effect of dilutive securities:
Stock options0.2 0.3 
Restricted stock units (1)
0.9 1.4 
Diluted136.6 145.9 
Earnings per common share attributable to McKesson Corporation: (2)
Diluted
Continuing operations$7.02 $5.25 
Discontinued operations 0.01 
Total$7.02 $5.26 
Basic
Continuing operations$7.07 $5.31 
Discontinued operations 0.01 
Total$7.07 $5.32 
(1)Includes dilutive effect from restricted stock units and performance-based stock units.
(2)Certain computations may reflect rounding adjustments.
6.    Goodwill and Intangible Assets, Net
Goodwill
The Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2024 and fiscal 2023 did not indicate any impairment of goodwill.

15

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Changes in the carrying amount of goodwill were as follows:
(In millions)
U.S. Pharmaceutical (1)
Prescription Technology SolutionsMedical-Surgical Solutions
International
Total
Balance, March 31, 2023$4,050 $2,005 $2,453 $1,439 $9,947 
Foreign currency translation adjustments, net   29 29 
Other adjustments (2)
(5)   (5)
Balance, June 30, 2023$4,045 $2,005 $2,453 $1,468 $9,971 
(1)The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe’s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.
(2)Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, “Business Acquisitions and Divestitures.”
Intangible Assets
Information regarding intangible assets was as follows:
 June 30, 2023March 31, 2023
(Dollars in millions)Weighted-
Average
Remaining
Amortization
Period
(Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Customer relationships12$2,984 $(1,801)$1,183 $2,971 $(1,765)$1,206 
Service agreements101,141 (641)500 1,137 (623)514 
Trademarks and trade names12843 (446)397 833 (430)403 
Technology11264 (133)131 264 (129)135 
Other6184 (174)10 193 (174)19 
Total $5,416 $(3,195)$2,221 $5,398 $(3,121)$2,277 
All intangible assets were subject to amortization as of June 30, 2023 and March 31, 2023. Amortization expense of intangible assets was $62 million and $56 million for the three months ended June 30, 2023 and 2022, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $185 million, $240 million, $208 million, $202 million, and $198 million for the remainder of fiscal 2024 and each of the succeeding years through fiscal 2028, respectively, and $1.2 billion thereafter.

16

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
7.    Debt and Financing Activities
Long-term debt consisted of the following:
(In millions)June 30, 2023March 31, 2023
U.S. Dollar notes (1) (2)
3.80% Notes due March 15, 2024
$ $918 
0.90% Notes due December 3, 2025
500 500 
5.25% Notes due February 15, 2026
499 499 
1.30% Notes due August 15, 2026
499 498 
7.65% Debentures due March 1, 2027
150 150 
3.95% Notes due February 16, 2028
343 343 
4.90% Notes due July 15, 2028
399  
4.75% Notes due May 30, 2029
196 196 
5.10% Notes due July 15, 2033
596  
6.00% Notes due March 1, 2041
218 218 
4.88% Notes due March 15, 2044
255 255 
Foreign currency notes (1) (3)
1.50% Euro Notes due November 17, 2025
653 649 
1.63% Euro Notes due October 30, 2026
545 542 
3.13% Sterling Notes due February 17, 2029
571 555 
Lease and other obligations237 271 
Total debt5,661 5,594 
Less: Current portion50 968 
Total long-term debt$5,611 $4,626 
(1)These notes are unsecured and unsubordinated obligations of the Company.
(2)Interest on these U.S. dollar notes is payable semi-annually.
(3)Interest on these foreign currency notes is payable annually.
Long-Term Debt
The Company’s long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At June 30, 2023 and March 31, 2023, $5.7 billion and $5.6 billion, respectively, of total debt was outstanding, of which $50 million and $968 million, respectively, was included under the caption “Current portion of long-term debt” in the Company’s Condensed Consolidated Balance Sheets.
Notes Offerings
On June 15, 2023, the Company completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million (the “2028 Notes”) and a public offering of 5.10% Notes due July 15, 2033 in a principal amount of $600 million (the “2033 Notes” and, together with the 2028 Notes, the “Notes”). Interest on the Notes is payable semi-annually on January 15th and July 15th of each year, commencing on January 15, 2024. Proceeds received from the issuance of the Notes, net of discounts and offering expenses, were $397 million for the 2028 Notes and $592 million for the 2033 Notes. The Company utilized a portion of the net proceeds from the offerings of the Notes to fund the purchase price payable with respect to the portion of the Company’s then outstanding 3.80% Notes due March 15, 2024 (the “2024 Notes”) that was validly tendered and accepted for purchase pursuant to the Concurrent Tender Offer (as defined below) and to effect the satisfaction and discharge of the remaining portion of the 2024 Notes, all of which is described further below. The remaining net proceeds from the offerings of the Notes is available for general corporate purposes.

17

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Each series of the Notes is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Company’s existing, and future unsecured and unsubordinated indebtedness that may be outstanding from time-to-time. The Notes are governed by an indenture and officers’ certificate that are materially similar to those of other series of notes issued by the Company. Upon at least 10 days’ and not more than 60 days’ notice to holders of the applicable series of the Notes, the Company may redeem either series of the Notes for cash in whole, at any time, or in part, from time to time, at redemption prices that include accrued and unpaid interest and a make-whole premium before a specified date, and at par plus accrued and unpaid interest thereafter until maturity, each as specified in the indenture and the officers’ certificate. If there were to occur both (1) a change of control of the Company and (2) a downgrade of the applicable series of the Notes below an investment grade rating by each of the Ratings Agencies (as defined in the officers’ certificate) within a specified period, then the Company would be required to make an offer to purchase those Notes at a price equal to 101% of the then outstanding principal amount of such Notes, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officers’ certificate for the Notes, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lenders’ consent. The indenture also contains customary events of default provisions.
Concurrent Tender Offer
On June 16, 2023, the Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the “Concurrent Tender Offer”). The Company paid an aggregate consideration of $268 million in the Concurrent Tender Offer to repurchase $271 million principal amount of the 2024 Notes at a repurchase price equal to 98.75% of the principal amount plus accrued and unpaid interest. The repurchase of the 2024 Notes accepted for purchase in the Concurrent Tender Offer was accounted for as a debt extinguishment.
Satisfaction and Discharge of the 2024 Notes
On June 16, 2023, after completing the Concurrent Tender Offer, the Company irrevocably deposited with the trustee under the indenture governing the 2024 Notes (the “2024 Notes Indenture”) U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest of the remaining $647 million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. The U.S. government obligations were purchased using a portion of the net proceeds from the offerings of the Notes. After the deposit of such funds with the trustee, the Company’s obligations under the 2024 Notes Indenture with respect to the 2024 Notes were satisfied and discharged and the transaction was accounted for as a debt extinguishment.
The total gain recognized on the debt extinguishments described above for the three months ended June 30, 2023 was $9 million and included within “Interest expense” in the Company’s Condensed Consolidated Statement of Operations.
Revolving Credit Facilities
On November 7, 2022, the Company entered into a Credit Agreement (the “2022 Credit Facility”), that provides a syndicated $4.0 billion five-year senior unsecured credit facility with a $3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. The 2022 Credit Facility is scheduled to mature in November 2027. The 2022 Credit Facility replaced the Company’s previous syndicated $4.0 billion five-year senior unsecured credit facility, dated as of September 25, 2019, as amended (the “2020 Credit Facility”), which was scheduled to mature in September 2024. The 2020 Credit Facility was terminated in connection with the execution of the 2022 Credit Facility. There were no borrowings under the 2020 Credit Facility during the three months ended June 30, 2022, and no amounts outstanding at the time of its termination. There were no borrowings under the 2022 Credit Facility during the three months ended June 30, 2023 and no amounts outstanding at June 30, 2023. At June 30, 2023, the Company was in compliance with all covenants under the 2022 Credit Facility.
Commercial Paper
The Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $4.0 billion in outstanding commercial paper notes. During the three months ended June 30, 2023, the Company borrowed and repaid $65 million under the program. During the three months ended June 30, 2022, there were no material borrowings under the program. At June 30, 2023 and March 31, 2023, there were no commercial paper notes outstanding.

18

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
8.    Hedging Activities
In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives as described below. In accordance with the Company’s policy, derivatives are only used for hedging purposes. It does not use derivatives for trading or speculative purposes. The Company uses different counterparties for its derivative contracts to minimize the exposure to credit risk but does not anticipate non-performance by these parties.
Foreign Currency Exchange Risk
The Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Canadian dollars, Euro, and British pounds sterling. Changes in foreign currency exchange rates could have a material adverse impact on the Company’s financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk.
Non-Derivative Instruments Designated as Hedges
Prior to the divestiture of the E.U. disposal group, the Company had €1.1 billion of Euro-denominated notes designated as non-derivative net investment hedges. These hedges were utilized to hedge portions of the Company’s net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. For all notes that were designated as net investment hedges and met effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates were recorded as foreign currency translation adjustments in “Accumulated other comprehensive loss” where they offset foreign currency translation gains and losses recorded on the Company’s net investments. To the extent foreign currency denominated notes designated as net investment hedges were ineffective, changes in carrying value attributable to the change in spot rates were recorded in earnings.
In connection with the divestiture of the E.U. disposal group in October 2022, the Euro-denominated notes described above were de-designated as net investment hedges.
In connection with the sale of the U.K. disposal group in April 2022, the Company reclassified $26 million of gains from accumulated other comprehensive loss to “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statement of Operations for the three months ended June 30, 2022. This amount related to the Company’s £450 million of British pound sterling-denominated notes, which were previously accounted for as net investment hedges until de-designated in fiscal 2020, and was included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities of the disposal group to fair value less costs to sell.
Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:
Three Months Ended June 30,
(In millions)20232022
Non-derivatives designated as net investment hedges: (1)
Euro-denominated notes $ $64 
(1)There was no ineffectiveness in these hedges for the three months ended June 30, 2022.

19

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Derivative Instruments
At June 30, 2023 and March 31, 2023, the notional amounts of the Company’s outstanding derivatives were as follows:
June 30, 2023March 31, 2023
(In millions)Currency
Maturity Date (1)
Notional
Derivatives designated as net investment hedges: (2)
Cross-currency swaps (3)
CADNov-24 to Mar-25C$1,500 C$1,500 
Derivatives designated as fair value hedges: (2)
Cross-currency swaps (4)
GBPNov-28£450 £450 
Cross-currency swaps (4)
EURAug-25 to Jul-261,100 1,100 
Floating interest rate swaps (5)
USDFeb-26 to Sep-29$1,250 $1,250 
Derivatives designated as cash flow hedges: (2)
Cross-currency swaps (3)
CADJan-24C$400 C$400 
Fixed interest rate swaps (6)
USDJun-23$ $450 
(1)The maturity date reflected is for outstanding derivatives as of June 30, 2023.
(2)There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.
(3)The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.
(4)Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes.
(5)Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates.
(6)The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.
Net Investment Hedges
The Company uses cross-currency swaps to hedge portions of the Company’s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Company’s net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Fair Value Hedges
The Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains from the changes in the Company’s fair value hedges recorded in earnings were largely offset by the losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive income (loss).

20

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Cash Flow Hedges
From time to time, the Company enters into cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency rates and also enters into forward contracts to hedge the variability of future benchmark interest rates on planned bond issuances. The effective portion of changes in the fair value of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses reclassified from accumulated other comprehensive loss and recorded in “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statements of Operations were not material for the three months ended June 30, 2023 and 2022.
The Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges in fiscal 2023 with a notional amount of $450 million, and in the first quarter of fiscal 2024 with a notional amount of $50 million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500 million cash flow hedges were terminated and the proceeds are amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, “Debt and Financing Activities,” for additional information on the public offering of the 2033 Notes.
Derivatives Not Designated as Hedges
Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statements of Operations. The Company did not have any outstanding derivative instruments not designated as hedges during the periods presented.
Other Information on Derivative Instruments
Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:
Three Months Ended June 30,
(In millions)20232022
Derivatives designated as net investment hedges:
Cross-currency swaps$(20)$12 
Derivatives designated as cash flow and other hedges:
Cross-currency swaps (1)
$(6)$(2)
Fixed interest rate swaps
16 27 
(1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.

21

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Information regarding the fair value of derivatives on a gross basis were as follows:
Balance Sheet
Caption
June 30, 2023March 31, 2023
Fair Value of
Derivative
U.S. Dollar NotionalFair Value of
Derivative
U.S. Dollar Notional
(In millions)AssetLiabilityAssetLiability
Derivatives designated for hedge accounting:
Cross-currency swaps (current)Prepaid expenses and other/Other accrued liabilities$ $2 $301 $5 $ $301 
Cross-currency swaps (non-current)Other non-current assets/liabilities84 12 2,760 74 2 2,760 
Interest rate swaps (non-current)Other non-current assets/liabilities 39 1,250 1 15 1,700 
Total$84 $53 $80 $17 
Refer to Financial Note 9, "Fair Value Measurements," for more information on these recurring fair value measurements.
9.     Fair Value Measurements
The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, Fair Value Measurements and Disclosures. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:
Level 1 - quoted prices in active markets for identical assets or liabilities.
Level 2 - significant other observable market-based inputs.
Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
Cash and cash equivalents at June 30, 2023 and March 31, 2023 included investments in money market funds of $806 million and $1.4 billion, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.
Fair values of the Company’s interest rate swaps and cross-currency swaps were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, “Hedging Activities,” for fair values and other information on the Company’s derivatives.
The Company holds investments in equity securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $237 million at June 30, 2023 and March 31, 2023. These investments primarily consist of equity securities without readily determinable fair values and are included in “Other non-current assets” in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains as well as impairment charges related to these investments are included within “Other income, net” in the Condensed Consolidated Statements of Operations and were not material for the three months ended June 30, 2023 and 2022.

22

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company’s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell.
At June 30, 2023 and March 31, 2023, the contingent consideration liability related to the Company’s acquisition of RxSS in November 2022 was measured at fair value on a nonrecurring basis. Refer to Financial Note 2, “Business Acquisitions and Divestitures," for more information on this transaction.
The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information.
There were no other material assets or liabilities measured at fair value on a nonrecurring basis at June 30, 2023 and March 31, 2023.
Other Fair Value Disclosures
At June 30, 2023 and March 31, 2023, the carrying amounts of cash, certain cash equivalents, restricted cash, receivables, drafts and accounts payable, short-term borrowings, and other current assets and liabilities approximated their estimated fair values because of the short-term maturity of these financial instruments.
The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance.
The Company’s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company’s long-term debt was as follows:
June 30, 2023March 31, 2023
(In millions)Carrying ValueFair ValueCarrying ValueFair Value
Long-term debt, including current maturities$5,661 $5,335 $5,594 $5,386 
The estimated fair value of the Company’s long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.
Goodwill
Fair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow (“DCF”) model to determine the fair value of each reporting unit.
Long-lived Assets
The Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement.

23

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value.
10.    Commitments and Contingent Liabilities
In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in Financial Note 17 to the Company’s 2023 Annual Report, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.
Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within “Claims and litigation charges, net” in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.
I. Litigation and Claims Involving Distribution of Controlled Substances
The Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacies. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. They have sought monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), state and federal controlled substances laws, and other statutes. Because of the many uncertainties associated with opioid-related litigation matters, the Company is not able to conclude that a liability is probable or provide a reasonable estimate for the range of ultimate possible loss for opioid-related litigation matters other than those for which an accrual is described below.

24

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
State and Local Government Claims
The Company and two other national pharmaceutical distributors (collectively “Distributors”) entered into a settlement agreement (the “Settlement”) and consent judgment with 48 states and their participating subdivisions, as well as the District of Columbia and all eligible territories (the “Settling Governmental Entities”). Approximately 2,300 cases have been dismissed. The Distributors did not admit liability or wrongdoing and do not waive any defenses pursuant to the Settlement. Under the Settlement, the Company has paid the Settling Governmental Entities approximately $1.0 billion as of June 30, 2023, and additionally will pay the Settling Governmental Entities up to approximately $6.8 billion through 2038. A minimum of 85% of the Settlement payments must be used by state and local governmental entities to remediate the opioid epidemic, while the remainder relates to plaintiffs’ attorneys’ fees and costs and will be paid out through 2030. Under the Settlement, the Distributors will establish a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. Alabama and West Virginia did not participate in the Settlement. Under a separate settlement agreement with Alabama and its subdivisions, the Company has paid approximately $42 million as of June 30, 2023, and additionally will pay approximately $132 million through 2031. The Company previously settled with the state of West Virginia in 2018, so West Virginia and its subdivisions were not eligible to participate in the Settlement. Under a separate settlement agreement, the Company has paid certain West Virginia subdivisions approximately $38 million as of June 30, 2023, and additionally will pay approximately $114 million through 2033. That agreement does not include school districts or the claims of Cabell County and the City of Huntington. After a trial, the claims of Cabell County and the City of Huntington, were decided in the Company’s favor on July 4, 2022. Those subdivisions appealed that decision.
Some other state and local governmental subdivisions did not participate in the Settlement, including certain municipal governments, government hospitals, school districts, and government-affiliated third-party payors. The Company contends that those subdivisions’ claims are foreclosed by the Settlement or other dispositive defenses, but the subdivisions contend that their claims are not foreclosed. The City of Baltimore, Maryland, is one such subdivision, and a trial of its claims is scheduled to begin September 26, 2024. An accrual for the remaining governmental subdivision claims is reflected in the total estimated liability for opioid-related claims in a manner consistent with how Settlement amounts were allocated to Settling Governmental Entities.
Native American Tribe Claims
The Company also entered into settlement agreements for opioid-related claims of federally recognized Native American tribes. Under those agreements, the Company has paid the settling Native American tribes approximately $56 million as of June 30, 2023, and additionally will pay approximately $140 million through 2027. A minimum of 85% of the total settlement payments must be used by the settling Native American tribes to remediate the opioid epidemic.
The Company’s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:
(In millions)June 30, 2023March 31, 2023
Current litigation liabilities (1)
$545 $548 
Long-term litigation liabilities6,628 6,625 
Total litigation liabilities$7,173 $7,173 
(1)These amounts, recorded in “Other accrued liabilities” in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.
During the three months ended June 30, 2023, the Company made no payments associated with the Settlement and the separate settlement agreements for opioid-related claims discussed above. In July 2023, the Company made payments totaling $529 million associated with the Settlement and separate settlement agreements.
Non-Governmental Plaintiff Claims
The Company is also a defendant in approximately 400 opioid-related cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement agreements described above or in the charges recorded by the Company.

25

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Canadian Plaintiff Claims
The Company and its Canadian affiliate are also defendants in four opioid-related cases pending in Canada. These cases involve the claims of the provincial governments, a group representing indigenous people, as well as one case brought by an individual.
Defense of Opioids Claims
The Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense in such matters. Other than the settlement agreements and the U.S. governmental subdivision claims described above, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company’s financial position, cash flows or liquidity, or results of operations.
II. Other Litigation and Claims
On December 12, 2018, the Company received a purported class action complaint in the United States District Court for the Northern District of California, alleging that McKesson and two of its former officers, CEO John Hammergren and CFO James Beer, violated the Securities Exchange Act of 1934 by reporting profits and revenues from 2013 until early 2017 that were false and misleading, due to an alleged undisclosed conspiracy to fix the prices of generic drugs. Evanston Police Pension Fund v. McKesson Corporation, No. 3:18-06525. In October 2022, the parties reached an agreement in principle to settle this class action lawsuit for an amount covered in full by the Company’s insurance policy. This settlement does not include any admission of liability, and defendants expressly deny wrongdoing. The Company’s estimated probable loss, entirely offset by probable loss recovery from the Company’s insurers, was $141 million, both of which were recognized in the Condensed Consolidated Balance Sheet as of September 30, 2022 within “Other accrued liabilities” and “Prepaid expenses and other.” In February 2023, the insurance carriers funded the settlement, and the probable loss and loss recovery of $141 million have been reversed in the Consolidated Balance Sheet as of March 31, 2023. On July 14, 2023, the court granted the motion for final approval of the settlement.
In July 2020, the Company was served with a first amended qui tam complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the U.S., 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA. The U.S. and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. On May 5, 2022, the district court granted the Company’s motion to dismiss the complaint, but granted the plaintiff leave to amend the complaint. The relator filed the second amended complaint on June 7, 2022, which was dismissed on March 28, 2023. On April 26, 2023, the relator filed a notice of appeal to the United States Court of Appeals for the Second Circuit.
III. Government Subpoenas and Investigations
From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business.
11.    Stockholders' Deficit
Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Company’s Board of Directors (the “Board”).
In July 2023, the quarterly dividend was raised from $0.54 to $0.62 per share of common stock for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors.

26

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Share Repurchase Plans
The Board has authorized the repurchase of McKesson’s common stock. The Company may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase (“ASR”) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company’s stock price, corporate and regulatory requirements, tax implications, restrictions under the Company’s debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions. The ASR programs discussed below were designed to comply with Rule 10b5-1(c).
Effective January 1, 2023, the Company’s repurchase of McKesson’s common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the IRA. Excise taxes incurred on share repurchases of an entity’s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholders’ equity within “Treasury shares” in the Company’s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholders’ Deficit. Excise taxes are not reflected in the Company’s remaining authorization for the repurchase of McKesson’s common stock.
In May 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.0 billion of the Company’s common stock. The total number of shares repurchased under this ASR program was 3.1 million shares at an average price per share of $321.05. The Company received 2.6 million shares as the initial share settlement, and in August 2022, the Company received an additional 0.5 million shares upon the completion of this ASR program.
In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company’s common stock. The total number of shares repurchased under this ASR program was 5.1 million shares at an average price per share of $295.16. The Company received 4.8 million shares as the initial share settlement in the fourth quarter of fiscal 2022, and in May 2022, the Company received an additional 0.3 million shares upon the completion of this ASR program.
During the three months ended June 30, 2023, the Company repurchased 1.8 million of the Company’s shares of common stock for $673 million through open market transactions at an average price per share of $379.14. Of the total dollar value, $4 million was accrued within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet for excise taxes incurred during the three months ended June 30, 2023. As of March 31, 2023, the Company had $27 million accrued within “Other accrued liabilities” for share repurchases that were executed in late March 2023, which settled in early April 2023. There were no open market share repurchases during the three months ended June 30, 2022.
The total remaining authorization outstanding for repurchases of the Company’s common stock at June 30, 2023 was $2.9 billion. In July 2023, the Board approved an increase of $6.0 billion in the authorization for repurchase of McKesson’s common stock.

27

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
Accumulated Other Comprehensive Loss
Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:
Foreign Currency Translation Adjustments
(In millions)
Foreign Currency Translation Adjustments, Net of Tax (1)
Unrealized Losses on Net Investment Hedges,
Net of Tax
Unrealized Gains (Losses) on Cash Flow and Other Hedges,
Net of Tax
Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive Loss
Balance, March 31, 2023$(847)$(14)$(36)$(8)$(905)
Other comprehensive income (loss) before reclassifications67 (15)⁽²⁾7 (2)57 
Amounts reclassified to earnings and other      
Other comprehensive income (loss)67 (15)7 (2)57 
Less: amounts attributable to noncontrolling interests     
Other comprehensive income (loss) attributable to McKesson67 (15)7 (2)57 
Balance, June 30, 2023$(780)$(29)$(29)$(10)$(848)
(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.
(2)Amounts recorded for the three months ended June 30, 2023 include losses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.
Foreign Currency Translation Adjustments
(In millions)
Foreign Currency Translation Adjustments, Net of Tax (1)
Unrealized Gains (Losses) on Net Investment Hedges,
Net of Tax
Unrealized Gains on Cash Flow and Other Hedges,
Net of Tax
Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive Loss
Balance, March 31, 2022$(1,504)$10 $27 $(67)$(1,534)
Other comprehensive income (loss) before reclassifications(176)45 ⁽²⁾18 12 (101)
Amounts reclassified to earnings and other (3)
730 (17) 24 737 
Other comprehensive income554 28 

18 36 636 
Less: amounts attributable to noncontrolling interests47   3 50 
Other comprehensive income attributable to McKesson507 28 18 33 586 
Balance, June 30, 2022$(997)$38 $45 $(34)$(948)
(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.
(2)Amounts recorded for the three months ended June 30, 2022 include gains of $64 million related to net investment hedges from Euro-denominated notes and gains of $12 million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $31 million.

28

McKESSON CORPORATION
FINANCIAL NOTES (CONTINUED)
(UNAUDITED)
(3)Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations.
12.    Segments of Business
The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources.
The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the U.S. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.
The RxTS segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS serves our biopharma and life sciences partners, delivering innovative solutions that help people get the medicine they need to live healthier lives. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.
The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKesson’s own line of high-quality products through a network of distribution centers in the U.S.
The International segment includes the Company’s operations in Canada and Europe, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Company’s Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and includes Rexall Health retail pharmacies. The Company completed the divestitures of the U.K. disposal group in April 2022 and the E.U. disposal group in October 2022, as discussed in Financial Note 2, “Business Acquisitions and Divestitures.” The Company’s remaining operations in Europe provide distribution and services to wholesale, institutional, and retail customers in Norway where it owns, partners, or franchises with retail pharmacies.

29

McKESSON CORPORATION
FINANCIAL NOTES (CONCLUDED)
(UNAUDITED)
Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals was as follows:
 Three Months Ended June 30,
(In millions)20232022
Segment revenues (1)
U.S. Pharmaceutical$67,160 $56,947 
Prescription Technology Solutions1,244 1,066 
Medical-Surgical Solutions2,611 2,592 
International3,468 6,549 
Total revenues$74,483 $67,154 
Segment operating profit (loss) (2)
U.S. Pharmaceutical (3)
$827 $696 
Prescription Technology Solutions (4)
231 144 
Medical-Surgical Solutions227 256 
International (5)
57 (6)
Subtotal1,342 1,090 
Corporate expenses, net (6)
(204)(39)
Interest expense(47)(45)
Income from continuing operations before income taxes$1,091 $1,006 
(1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment’s total revenues, less than 37% of the RxTS segment’s total revenues, less than 1% of the Medical-Surgical Solutions segment’s total revenues, and less than 1% of the International segment’s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.
(2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company’s reportable segments.
(3)The Company’s U.S. Pharmaceutical segment’s operating profit includes the following:
cash receipts for the Company’s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and
a charge of $32 million and a credit of $13 million related to the last-in, first-out (“LIFO”) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.
(4)The Company’s RxTS segment’s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28 million, which reduced the Company’s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”
(5)The Company’s International segment’s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”
(6)Corporate expenses, net includes the following:
restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” and
a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”

30

McKESSON CORPORATION
FINANCIAL REVIEW
(UNAUDITED)

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.
INDEX TO MANAGEMENT’S DISCUSSION AND ANALYSIS
GENERAL
Management’s discussion and analysis of financial condition and results of operations, referred to as the “Financial Review,” is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of McKesson Corporation together with its subsidiaries (collectively, the “Company,” “McKesson,” “we,” “our,” or “us,” and other similar pronouns). This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q (“Quarterly Report”) and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 previously filed with the Securities and Exchange Commission (the “SEC”) on May 9, 2023 (“2023 Annual Report”).
Our fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean our fiscal year.
Certain statements in this report constitute forward-looking statements. See “Cautionary Notice About Forward-Looking Statements” included in this Quarterly Report.
Overview of our Business:
We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.
We report our financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (“RxTS”), Medical-Surgical Solutions, and International. Our organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects as well as the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of individual business activities. We evaluate the performance of our operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes.

31

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
The following summarizes our four reportable segments. Refer to Financial Note 12, “Segments of Business,” to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information regarding our reportable segments.
U.S. Pharmaceutical is a reportable segment that distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (“U.S.”). This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.
Prescription Technology Solutions is a reportable segment that combines automation and our ability to navigate the healthcare ecosystems to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address patients’ medication access, affordability, and adherence challenges. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.
Medical-Surgical Solutions is a reportable segment that provides medical-surgical supply distribution, logistics, and other services to healthcare providers in the U.S., including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKesson’s own line of high-quality products through a network of distribution centers within the U.S.
International is a reportable segment that includes our operations in Canada and Europe, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. Our operations in Canada deliver medicines, supplies, and information technology solutions throughout Canada and includes Rexall Health pharmacies. During fiscal 2023, we completed transactions to sell certain of our businesses in the European Union (“E.U. disposal group”), and our retail and distribution businesses in the United Kingdom (“U.K. disposal group”). Our remaining operations in Europe provide distribution and services to wholesale, institutional, and retail customers in Norway where we own, partner, or franchise with retail pharmacies. Refer to Financial Note 2, “Business Acquisitions and Divestitures,” to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information regarding these divestiture transactions.
Executive Summary:
The following summary provides highlights and key factors that impacted our business, operating results, financial condition, and liquidity for the three months ended June 30, 2023:
For the three months ended June 30, 2023 compared to the prior year, revenues increased by 11%, gross profit was flat, total operating expenses decreased by 3%, and other income, net increased by $23 million. Refer to the “Overview of Consolidated Results” section below for an analysis of these changes;
Diluted earnings per common share from continuing operations attributable to McKesson Corporation increased to $7.02 from $5.25 in the three months ended June 30, 2023 compared to the prior year period;
For the three months ended June 30, 2023, we recognized a net discrete tax benefit of $147 million related to the repatriation of certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions;
For the three months ended June 30, 2023, we received $118 million related to our share of antitrust settlements. This amount was recorded as a gain within "Cost of sales" in the Condensed Consolidated Statement of Operations within our U.S. Pharmaceutical segment;
On June 15, 2023, we completed a public offering of 4.90% Notes due June 15, 2028 in a principal amount of $400 million and 5.10% Notes due July 15, 2033 in a principal amount of $600 million, for proceeds received, net of discounts and offering expenses, of $397 million and $592 million, respectively. A portion of the net proceeds from these offerings was utilized to fund the repurchase of our 3.80% Notes due March 15, 2024 (the “2024 Notes”) discussed below, while the remaining net proceeds is available for general corporate purposes;

32

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
On June 16, 2023, we completed a cash tender offer for any and all of our 2024 Notes with a principal amount of $918 million. Using a portion of the net proceeds from the June 15, 2023 notes offering described above, we paid an aggregate consideration of $268 million to repurchase $271 million of principal amount of the 2024 Notes plus any accrued and unpaid interest;
Following the consummation of the cash tender offer discussed above, on June 16, 2023, we irrevocably deposited U.S. government obligations with the trustee under the indenture governing the 2024 Notes sufficient to fund the payment of accrued and unpaid interest of the remaining $647 million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. Refer to Financial Note 7, “Debt and Financing Activities,” to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information;
We returned $770 million of cash to shareholders during the three months ended June 30, 2023 through $696 million of common stock repurchases through open market transactions and $74 million of dividend payments. The total remaining authorization outstanding for repurchases of the Company’s common stock at June 30, 2023 was $2.9 billion; and
In July 2023, our Board of Directors (the “Board”) approved an increase of $6.0 billion in the authorization for repurchase of the Company’s common stock and raised our quarterly dividend from $0.54 to $0.62 per share of common stock.
Trends and Uncertainties:
Legislative Developments
On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the “IRA”). Among other provisions, the IRA includes a 15% corporate minimum tax, a 1% excise tax on certain repurchases of an entity’s own common stock after December 31, 2022, and various drug pricing reforms. Based on our ongoing assessment, we do not anticipate that this guidance will have a material impact on our consolidated financial statements or related disclosures; however, we will continue to evaluate the full impact of these legislative changes as they are announced and implemented. Refer to Financial Note 11, “Stockholders' Deficit,” to the accompanying condensed consolidated financial statements included in this Quarterly Report for further details regarding excise taxes incurred on our share repurchases during the three months ended June 30, 2023.
COVID-19
The U.S. federal government and World Health Organization suspended their respective public health emergencies in regards to the SARS-CoV-2 coronavirus (“COVID-19”) in May 2023. We have experienced a decrease in revenues and operating profit within our U.S. Pharmaceutical segment from COVID-19 vaccine distribution, and within our Medical-Surgical Solutions segment from COVID-19 tests and the assembly and distribution of ancillary supply kits needed to administer COVID-19 vaccines. These decreases were driven by a decline in demand and we anticipate these decreases to persist throughout fiscal 2024. The impacts of these programs and COVID-19 tests were not material to revenues and operating profit for the three months ended June 30, 2023. For additional disclosure of trends and uncertainties due to COVID-19, refer to Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations in Part II of our 2023 Annual Report.

33

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Opioid-Related Litigation and Claims
As described in the discussion of opioid-related matters in Financial Note 10, “Commitments and Contingent Liabilities,” to the financial statements accompanying this Quarterly Report, we are a defendant in many legal proceedings asserting claims related to the distribution of controlled substances (opioids) in federal and state courts throughout the U.S., and in Puerto Rico and Canada. The plaintiffs in these actions have included state attorneys general, county and municipal governments, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. The Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense. Other than as to the settlement agreements and the U.S. governmental subdivision claims described in Financial Note 10, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company’s financial position, cash flows or liquidity, or results of operations. Our total estimated liability for opioid-related claims was $7.2 billion as of June 30, 2023, of which $545 million was included in “Other accrued liabilities” for the amount estimated to be paid within the next twelve months, and the remaining liability was included in “Long-term litigation liabilities” in our Condensed Consolidated Balance Sheet. In July 2023, the Company made payments totaling $529 million associated with various settlement agreements for opioid-related claims of states, subdivisions, and Native American tribes.
RESULTS OF OPERATIONS
Overview of Consolidated Results:
(Dollars in millions, except per share data)Three Months Ended June 30,  
20232022Change
Revenues$74,483 $67,154 11 %
Gross profit3,022 3,023 — 
Gross profit margin4.06 %4.50 %(44)bp
Total operating expenses$(1,922)$(1,987)(3)%
Total operating expenses as a percentage of revenues2.58 %2.96 %(38)bp
Other income, net$38 $15 153 %
Interest expense(47)(45)
Income from continuing operations before income taxes1,091 1,006 
Income tax expense(94)(199)(53)
Reported income tax rate8.6 %19.8 %(1,120)bp
Income from continuing operations$997 $807 24 %
Income from discontinued operations, net of tax— (100)
Net income997 809 23 
Net income attributable to noncontrolling interests(39)(41)(5)
Net income attributable to McKesson Corporation$958 $768 25 %
Diluted earnings per common share attributable to McKesson Corporation
Continuing operations$7.02 $5.25 34 %
Discontinued operations— 0.01 (100)
Total$7.02 $5.26 33 %
Weighted-average diluted common shares outstanding136.6 145.9 (6)%
bp - basis points

34

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Revenues
Revenues increased for the three months ended June 30, 2023 compared to the same prior year period largely due to market growth in our U.S. Pharmaceutical segment, including higher volumes from retail national account customers and growth in specialty pharmaceuticals. Market growth includes growing drug utilization, price increases, and newly launched products, partially offset by price deflation associated with branded to generic drug conversion. This revenue growth was partially offset by lower revenues in our International segment driven by the completed divestiture of our E.U. disposal group and unfavorable effects of foreign currency exchange fluctuations.
Gross Profit
Gross profit was flat for the three months ended June 30, 2023 compared to the same prior year period primarily driven by the completed divestiture of our E.U. disposal group and unfavorable effects of foreign currency exchange fluctuations in our International segment, partially offset by our share of antitrust settlements received in the first quarter of fiscal 2024, growth of specialty pharmaceuticals and increased contributions from our generics programs in our U.S. Pharmaceutical segment, and increased volumes with new and existing customers in our RxTS segment.
For the three months ended June 30, 2023, we recognized a gain of $118 million related to our share of antitrust settlements. We recognized this amount within "Cost of sales" in the Condensed Consolidated Statement of Operations within our U.S. Pharmaceutical segment.
A last-in, first-out (“LIFO”) inventory charge of $32 million and a credit of $13 million were recognized during the three months ended June 30, 2023 and 2022, respectively. A LIFO charge in the first quarter of fiscal 2024 compared a LIFO credit in the same prior year period was primarily due to higher estimated brand inflation and higher brand inventory levels as well as lower estimated generics deflation, partially offset by higher estimated off patent launch activity.
Our U.S. Pharmaceutical business uses the LIFO method of accounting for the majority of its inventories, which results in cost of sales that more closely reflects replacement cost than under other accounting methods. The business’ practice is to pass on to customers published price changes from suppliers. Manufacturers generally provide us with price protection, which limits price related inventory losses. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non-pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non-pharmaceutical products held in inventory. Our quarterly LIFO adjustment is based on our estimates of the annual LIFO credit which is impacted by expected changes in year-end inventory quantities, product mix, and manufacturer pricing practices, which may be influenced by market and other external factors. Changes to any of the above factors could have a material impact to our annual LIFO adjustment. The actual valuation of inventory under the LIFO method is calculated at the end of the fiscal year.
Total Operating Expenses
A summary of the components of our total operating expenses for the three months ended June 30, 2023 and 2022 is as follows:
Selling, distribution, general, and administrative expenses (“SDG&A”): SDG&A consists of personnel costs, transportation costs, depreciation and amortization, lease costs, professional fee expenses, administrative expenses, remeasurement charges to the lower of carrying value or fair value less costs to sell, and other general charges.
Claims and litigation charges, net: These charges include adjustments for estimated probable settlements related to our controlled substance monitoring and reporting, and opioid-related claims, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. Legal fees to defend claims, which are expensed as incurred, are included within SDG&A.
Restructuring, impairment, and related charges, net: Charges recorded under this component include those incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted, as well as long-lived asset impairments.

35

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Three Months Ended June 30,
(Dollars in millions)20232022Change
Selling, distribution, general, and administrative expenses$1,870 $1,959 (5)%
Claims and litigation charges, net— (100)
Restructuring, impairment, and related charges, net52 23 126 
Total operating expenses$1,922 $1,987 (3)%
Percent of revenues2.58 %2.96 %(38)bp
bp - basis points
For the three months ended June 30, 2023, total operating expenses and total operating expenses as a percentage of revenues decreased compared to the same prior year period. Total operating expenses were impacted by the following significant items:
SDG&A for the three months ended June 30, 2023 reflects lower operating expenses due to the completed divestiture of our E.U. disposal group in fiscal 2023;
Claims and litigation charges, net was not material. Refer to the Opioid-Related Litigation and Claims section of "Trends and Uncertainties" for further discussion;
Restructuring, impairment, and related charges, net for three months ended June 30, 2023 and 2022 were $52 million and $23 million, respectively, as discussed in more detail below under “Restructuring Initiatives;” and
Total operating expenses were favorably impacted by foreign currency exchange fluctuations for the three months ended June 30, 2023 and 2022.
Goodwill Impairment
We evaluate goodwill for impairment on an annual basis in the first fiscal quarter, and at an interim date if indicators of potential impairment exist. The annual impairment testing performed in fiscal 2024 and fiscal 2023 did not indicate any impairment of goodwill and no goodwill impairment charges were recorded during the three months ended June 30, 2023 and 2022. However, other risks, expenses, and future developments, such as additional government actions, increased regulatory uncertainty, and material changes in key market assumptions limit our ability to estimate projected cash flows, which could adversely affect the fair value of various reporting units in future periods, including our McKesson Canada reporting unit within our International segment, where the risk of a material goodwill impairment is higher than other reporting units.
Restructuring Initiatives
We recorded restructuring, impairment, and related charges of $52 million and $23 million for the three months ended June 30, 2023 and 2022, respectively. These charges were included in “Restructuring, impairment, and related charges, net” in the Condensed Consolidated Statements of Operations.
During the fourth quarter of fiscal 2023, we approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying our infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. We anticipate total charges of approximately $125 million across our RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $96 million of charges were recorded to date. For the three months ended June 30, 2023, we recorded charges of $36 million related to this program, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024.
Refer to Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information on our restructuring initiatives.

36

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Other Income, Net
Other income, net increased for the three months ended June 30, 2023 compared to the same prior year period primarily due to a favorable impact to interest income from higher interest rates on certain of our cash balances compared to the prior year period.
Interest Expense
Interest expense increased for the three months ended June 30, 2023 compared to the same prior year period primarily due to the impact of higher interest rates on our derivative portfolio, partially offset by a $9 million gain on debt extinguishment in the first quarter of fiscal 2024, as discussed in more detail in Financial Note 7, “Debt and Financing Activities,” to the accompanying condensed consolidated financial statements included in this Quarterly Report. Interest expense may fluctuate based on timing, amounts, and interest rates of term debt repaid and new term debt issued, as well as amounts incurred associated with financing fees.
Income Tax Expense
For the three months ended June 30, 2023 and 2022, we recorded income tax expense of $94 million and $199 million, respectively. Our reported income tax rates were 8.6% and 19.8% for the three months ended June 30, 2023 and 2022, respectively. Fluctuations in our reported income tax rates are primarily due to changes in our business mix of earnings between various taxing jurisdictions, and discrete tax benefits recognized in the quarters, including a net discrete tax benefit of $147 million recognized in the first quarter of fiscal 2024 related to the repatriation of certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. Refer to Financial Note 4, “Income Taxes,” to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information.
Income from Discontinued Operations, Net of Tax
Income from discontinued operations, net of tax, was $2 million for the three months ended June 30, 2022. Subsequent to our divestiture of the E.U. disposal group in October 2022, we no longer have discontinued operations.
Net Income Attributable to Noncontrolling Interests
Net income attributable to noncontrolling interests for the three months ended June 30, 2023 and 2022 primarily represents the proportionate results of third-party equity interests in the Company’s consolidated entities of ClarusONE Sourcing Services LLP and Vantage Oncology Holdings, LLC. For the three months ended June 30, 2023, net income attributable to noncontrolling interests also includes the proportionate results of third-party equity interest in SCRI Oncology, LLC.
Net Income Attributable to McKesson Corporation
Net income attributable to McKesson Corporation was $958 million and $768 million for the three months ended June 30, 2023 and 2022, respectively. Diluted earnings per common share attributable to McKesson Corporation was $7.02 and $5.26 for the three months ended June 30, 2023 and 2022, respectively. Our diluted earnings per share reflects the cumulative effects of share repurchases during each period.
Weighted-Average Diluted Common Shares Outstanding
Diluted earnings per common share was calculated based on a weighted-average number of shares outstanding of 136.6 million and 145.9 million for the three months ended June 30, 2023 and 2022, respectively. Weighted-average diluted shares outstanding for the three months ended June 30, 2023 decreased from the same prior year period primarily due to the cumulative effect of share repurchases.

37

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Overview of Segment Results:
Segment Revenues:
 Three Months Ended June 30,  
(Dollars in millions)20232022Change
Segment revenues
U.S. Pharmaceutical$67,160 $56,947 18 %
Prescription Technology Solutions1,244 1,066 17 
Medical-Surgical Solutions2,611 2,592 
International3,468 6,549 (47)
Total revenues$74,483 $67,154 11 %
U.S. Pharmaceutical
Three Months Ended June 30, 2023 vs. 2022
U.S. Pharmaceutical revenues for the three months ended June 30, 2023 increased $10.2 billion or 18% compared to the same prior year period. Within the segment, sales to pharmacies and institutional healthcare providers increased $9.6 billion and sales to specialty practices and other increased $613 million. Overall, these increases were primarily due to market growth, including higher volumes from retail national account customers, growth in specialty pharmaceuticals, and branded pharmaceutical price increases, partially offset by branded to generic drug conversions.
Prescription Technology Solutions
Three Months Ended June 30, 2023 vs. 2022
RxTS revenues for the three months ended June 30, 2023 increased $178 million or 17% compared to the same prior year period due to increased volume with new and existing customers primarily in our third-party logistics and wholesale distribution services, as well as higher technology service revenues.
Medical-Surgical Solutions
Three Months Ended June 30, 2023 vs. 2022
Medical-Surgical Solutions revenues for the three months ended June 30, 2023 increased $19 million or 1% compared to the same prior year period. Within the segment, sales to extended care customers increased $76 million, and sales to primary care customers decreased $4 million. The decrease in our primary care business was driven by lower sales of COVID-19 tests, largely offset by underlying core business growth. Other sales declined $53 million driven by lower contribution from the kitting and distribution of ancillary supplies used to administer COVID-19 vaccines.
International
Three Months Ended June 30, 2023 vs. 2022
International revenues for the three months ended June 30, 2023 decreased $3.1 billion or 47% compared to the same prior year period which included unfavorable effects of foreign currency exchange fluctuations of $199 million. Within the segment, sales in Europe declined by $3.1 billion largely due to the completed divestiture of our E.U. disposal group in the third quarter of fiscal 2023, partially offset by increased sales in Canada of $238 million primarily driven by higher pharmaceutical distribution volumes.

38

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Segment Operating Profit (Loss) and Corporate Expenses, Net:
 Three Months Ended June 30,   
(Dollars in millions)20232022Change
Segment operating profit (loss) (1)
U.S. Pharmaceutical (2)
$827 $696 19 %
Prescription Technology Solutions (3)
231 144 60 
Medical-Surgical Solutions227 256 (11)
International (4)
57 (6)— 
Subtotal1,342 1,090 23 
Corporate expenses, net (5)
(204)(39)423 
Interest expense(47)(45)
Income from continuing operations before income taxes$1,091 $1,006 %
Segment operating profit (loss) margin
U.S. Pharmaceutical 1.23 %1.22 %bp
Prescription Technology Solutions18.57 13.51 506 
Medical-Surgical Solutions8.69 9.88 (119)
International1.64 (0.09)173 
All percentage changes displayed above which are not meaningful are displayed as zero percent.
bp - basis points
(1)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for our reportable segments.
(2)Operating profit for our U.S. Pharmaceutical segment includes the following:
cash receipts for our share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and
a charge of $32 million and a credit of $13 million related to the LIFO method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.
(3)Operating profit for our RxTS segment for the three months ended June 30, 2023 includes a fair value adjustment gain of $28 million which reduced our contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures,” to the accompanying condensed consolidated financial statements included in this Quarterly Report.
(4)Operating loss for our International segment includes charges of $94 million for the three months ended June 30, 2022 to remeasure the assets and liabilities of our E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures,” to the accompanying condensed consolidated financial statements included in this Quarterly Report.
(5)Corporate expenses, net includes the following:
restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net,” to the accompanying condensed consolidated financial statements included in this Quarterly Report; and
a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from our E.U. disposal group.


39

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
U.S. Pharmaceutical
Three Months Ended June 30, 2023 vs. 2022
Operating profit for this segment increased for the three months ended June 30, 2023 compared to the same prior year period primarily due to an increase from net cash proceeds received of $118 million representing our share of antitrust legal settlements and growth in specialty pharmaceuticals, partially offset by a LIFO charge in the first quarter of fiscal 2024 compared to a credit in the same prior year period.
Prescription Technology Solutions
Three Months Ended June 30, 2023 vs. 2022
Operating profit for this segment increased for the three months ended June 30, 2023 compared to the same prior year period driven by increased volumes with new and existing customers due to growth in our access solutions, primarily related to electronic prior authorization services.
Medical-Surgical Solutions
Three Months Ended June 30, 2023 vs. 2022
Operating profit for this segment decreased for the three months ended June 30, 2023 compared to the same prior year period due to a lower contribution from kitting and distribution of ancillary supplies for COVID-19 vaccines and higher employee-related expenses to support core business growth, partially offset by growth in extended care and our core primary care businesses.
International
Three Months Ended June 30, 2023 vs. 2022
Operating profit for this segment for the three months ended June 30, 2023 compared to an operating loss in the same prior year period was primarily as a result of remeasurement charges recorded in the prior year related to the E.U. disposal group, partially offset by lower contributions from the European operations divested in fiscal 2023.
Corporate Expenses, Net
Three Months Ended June 30, 2023 vs. 2022
Corporate expenses, net increased for the three months ended June 30, 2023 compared to the same prior year period primarily as a result of remeasurement gains recorded in the prior year related to the E.U. disposal group, and higher restructuring charges recorded in fiscal 2024. This was partially offset by a favorable impact to interest income from higher interest rates on certain of our cash balances compared to the prior year period.
Business Combinations
Refer to Financial Note 2, “Business Acquisitions and Divestitures,” to the accompanying condensed consolidated financial statements included in this Quarterly Report for our disclosures on business combinations.
New Accounting Pronouncements
New accounting pronouncements that we have recently adopted as well as those that have been recently issued but not yet adopted by us are included in Financial Note 1, “Significant Accounting Policies,” to the accompanying condensed consolidated financial statements included in this Quarterly Report.

40

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES
We expect our available cash generated from operations and our short-term investment portfolio, together with our existing sources of liquidity from our credit facilities, commercial paper program, and other borrowings will be sufficient to fund our short-term and long-term capital expenditures, working capital, and other cash requirements. We remain adequately capitalized, including access to liquidity from our $4.0 billion revolving credit facility. At June 30, 2023, we were in compliance with all debt covenants, and believe we have the ability to continue to meet our debt covenants in the future.
The following table summarizes the net change in cash, cash equivalents, and restricted cash for the periods shown:
Three Months Ended June 30,
(Dollars in millions)20232022Change
Net cash provided by (used in):
Operating activities$(1,052)$(941)$(111)
Investing activities(149)39 (188)
Financing activities(843)(1,181)338 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash18 (16)
Change in cash, cash equivalents, and restricted cash classified as Assets held for sale (1)
— 470 (470)
Net change in cash, cash equivalents, and restricted cash$(2,042)$(1,595)$(447)
(1)The fiscal 2023 change reflects a reversal of cash, cash equivalents, and restricted cash previously classified as assets held for sale at March 31, 2022 as part of the U.K. disposal group and is offset by cash outflows primarily related to the settlement of liabilities which is reflected in operating activities.
Operating Activities
Operating activities used cash of $1.1 billion and $941 million during the three months ended June 30, 2023 and 2022, respectively. Cash flows from operations can be significantly impacted by factors such as the timing of receipts from customers, inventory receipts, and payments to vendors. Additionally, working capital is primarily a function of sales and purchase volumes, inventory requirements, and vendor payment terms.
Operating activities for the three months ended June 30, 2023 were affected by net income of $1.0 billion, adjusted for non-cash items, as well as increases in receivables of $2.4 billion, drafts and accounts payable of $1.5 billion, and inventories of $826 million, all primarily driven by higher revenues and timing.
Operating activities for the three months ended June 30, 2022 were affected by net income of $809 million, adjusted for non-cash items, as well as increases in receivables of $1.6 billion, drafts and accounts payable of $1.0 billion, and inventory of $955 million, all primarily driven by higher revenues and timing. Our litigation liabilities also decreased by $370 million primarily driven by payments made during the first quarter of fiscal 2023 associated with various settlement agreements for opioid-related claims of states, subdivisions, and Native American tribes, as discussed in more detail in Financial Note 10, “Commitments and Contingent Liabilities,” to the accompanying condensed consolidated financial statements included in this Quarterly Report .
Investing Activities
Investing activities used cash of $149 million and provided cash of $39 million during the three months ended June 30, 2023 and 2022, respectively. Investing activities for the three months ended June 30, 2023 and 2022 includes $124 million and $100 million, respectively, in capital expenditures for property, plant, and equipment and capitalized software. Investing activities for the three months ended June 30, 2022 also includes proceeds from sales of businesses and investments of $240 million, primarily due to the completed divestiture of our U.K. disposal group in April 2022.

41

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Financing Activities
Financing activities used cash of $843 million and $1.2 billion during the three months ended June 30, 2023 and 2022, respectively. On June 15, 2023, we completed a public offering of 4.90% Notes due June 15, 2028 in a principal amount of $400 million and 5.10% Notes due July 15, 2033 in a principal amount of $600 million, for proceeds received, net of discounts and offering expenses, of $397 million and $592 million, respectively. A portion of the net proceeds from these notes was utilized to fund the repurchase of our 2024 Notes discussed below, while the remaining net proceeds is available for general corporate purposes.
On June 16, 2023, we completed a cash tender offer for any and all of our 2024 Notes with a principal amount of $918 million. Using a portion of the proceeds from the June 15, 2023 notes offering described above, we paid an aggregate consideration of $268 million to repurchase $271 million principal amount of the 2024 Notes. Following the consummation of this tender offer, on June 16, 2023, we irrevocably deposited U.S. government obligations with the trustee under the indenture governing the 2024 Notes sufficient to fund the payment of accrued and unpaid interest of the remaining $647 million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date.
Financing activities for the three months ended June 30, 2023 and 2022 includes $696 million and $1.0 billion of cash paid for share repurchases, respectively, as well as $74 million and $71 million of cash paid for dividends, respectively.
Cash used for other financing activities generally includes the cash value of shares surrendered for tax withholding and payments to noncontrolling interests.
Share Repurchase Plans
The Board has authorized the repurchase of McKesson’s common stock. We may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase (“ASR”) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended (“Exchange Act”). The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions. The ASR programs discussed below were designed to comply with Rule 10b5-1(c).
Effective January 1, 2023, the Company’s repurchase of McKesson’s common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the IRA. Excise taxes incurred on share repurchases of an entity’s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholders’ equity within “Treasury shares” in the Company’s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholders’ Deficit. Excise taxes are not reflected in the Company’s remaining authorization for the repurchase of McKesson’s common stock.
In May 2022, we entered into an ASR program with a third-party financial institution to repurchase $1.0 billion of the Company’s common stock. The total number of shares repurchased under this ASR program was 3.1 million shares at an average price per share of $321.05. We received 2.6 million shares as the initial share settlement, and in August 2022, we received an additional 0.5 million shares upon the completion of this ASR program.
In February 2022, we entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company’s common stock. The total number of shares repurchased under this ASR program was 5.1 million shares at an average price per share of $295.16. We received 4.8 million shares as the initial share settlement in the fourth quarter of fiscal 2022, and in May 2022, we received an additional 0.3 million shares upon the completion of this ASR program.
During the three months ended June 30, 2023, we repurchased 1.8 million of the Company’s shares of common stock for $673 million through open market transactions at an average price per share of $379.14. Of the total dollar value, $4 million was accrued within “Other non-current liabilities” in our Condensed Consolidated Balance Sheet for excise taxes incurred during the three months ended June 30, 2023. As of March 31, 2023, we had $27 million accrued within “Other accrued liabilities” for share repurchases that were executed in late March 2023, which settled in early April 2023. There were no open market share repurchases during the three months ended June 30, 2022.

42

McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
The total remaining authorization outstanding for repurchases of the Company’s common stock at June 30, 2023 was $2.9 billion. In July 2023, the Board approved an increase of $6.0 billion in the authorization for repurchase of McKesson’s common stock.
Selected Measures of Liquidity and Capital Resources
(Dollars in millions)June 30, 2023March 31, 2023
Cash, cash equivalents, and restricted cash$2,637 $4,679 
Working capital(2,883)(3,665)
Debt to capital ratio (1)
115.4 %120.5 %
(1)This ratio describes the relationship and changes within our capital resources, and is computed as total debt divided by the sum of total debt and McKesson stockholders’ deficit, which excludes noncontrolling interests and accumulated other comprehensive loss.
Cash equivalents, which are readily convertible to known amounts of cash, are carried at fair value. Cash equivalents are primarily invested in AAA-rated U.S. government money market funds, short-term deposits with financial institutions, and short-term commercial papers issued by non-financial institutions. Deposits with financial institutions are primarily denominated in U.S. dollars and the functional currencies of our foreign subsidiaries, including Canadian dollars, Euro, and British pounds sterling. Deposits could exceed the amounts insured by the Federal Deposit Insurance Corporation in the U.S. and similar deposit insurance programs in other jurisdictions. We mitigate the risk of our short-term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles and investment strategies of money market funds.
Our cash and cash equivalents balance as of June 30, 2023 and March 31, 2023 included approximately $616 million and $1.3 billion of cash held by our subsidiaries outside of the U.S., respectively. Our primary intent is to utilize this cash for foreign operations for an indefinite period of time. Although the vast majority of cash held outside the U.S. is available for repatriation, doing so could subject us to foreign withholding taxes and state income taxes. We may remit foreign earnings to the U.S. to the extent it is tax efficient to do so. We do not anticipate the tax impact from remitting these earnings to be material. Following enactment of the 2017 Tax Cuts and Jobs Act, the repatriation of cash to the U.S. is generally no longer taxable for federal income tax purposes.
Working capital primarily includes cash and cash equivalents, receivables, inventories, and prepaid expenses, net of drafts and accounts payable, current portion of long-term debt, current portion of operating lease liabilities, and other accrued liabilities. Our businesses require substantial investments in working capital that are susceptible to large variations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity and other requirements.
Consolidated working capital increased at June 30, 2023 compared to March 31, 2023 primarily due to an increase in receivables, net and inventories, driven by higher revenues and timing, and a decrease in the current portion of long-term debt largely funded by an issuance of long-term debt in the first quarter of 2024. These were partially offset by a decrease in cash and cash equivalents and increase in drafts and accounts payable driven by the aforementioned increased revenues and timing.
Our debt to capital ratio decreased for the three months ended June 30, 2023 due to net income attributable to McKesson for the quarter and issuance of new long-term debt, partially offset by share repurchases and dividend payments as well as repayments of long-term debt.
In July 2023, we raised our quarterly dividend from $0.54 to $0.62 per share of common stock for dividends declared on or after such date by the Board. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon our future earnings, financial condition, capital requirements, legal requirements, and other factors.

43

McKESSON CORPORATION
FINANCIAL REVIEW (CONCLUDED)
(UNAUDITED)
Capital Resources
We fund our working capital requirements primarily with cash and cash equivalents, proceeds from short-term borrowings from our commercial paper issuances, and longer-term credit agreements and debt offerings. Funds necessary for future debt maturities and our other cash requirements, including any future payments that may be made related to our total estimated litigation liability of $7.2 billion as of June 30, 2023 payable under the terms of various settlement agreements for opioid-related claims, are expected to be met by existing cash balances, cash flow from operations, existing credit sources, and future borrowings. Long-term debt markets and commercial paper markets, our primary sources of capital after cash flow from operations, are open and accessible to us should we decide to access those markets. Detailed information regarding our debt and financing activities is included in Financial Note 7, “Debt and Financing Activities,” to the accompanying condensed consolidated financial statements included in this Quarterly Report.
We believe that our future operating cash flow, financial assets, and access to capital and credit markets, including our credit facilities, give us the ability to meet our financing needs for the foreseeable future. However, there can be no assurance that an increase in volatility or disruption in the global capital and credit markets will not impair our liquidity or increase our costs of borrowing.
CAUTIONARY NOTICE ABOUT FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans, assumptions, or intentions may also include forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, they include, but are not limited to, the factors discussed in the “Risk Factors” section in Item 1A of Part I of the 2023 Annual Report and in our publicly available SEC filings and press releases. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date such statements were first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to any forward-looking statements to reflect events or circumstances after the date the statements are made, or to reflect the occurrence of unanticipated events.
AVAILABLE INFORMATION
We routinely post on our company website, and via our social media channels, information that may be material to investors, including details and updates to information disclosed elsewhere, which may include business developments, earnings and financial performance, sustainability matters, and materials for presentations to investors and financial analysts. Investors are encouraged to monitor our website www.mckesson.com. Interested parties can sign up on our website, including our Investor Relations site, to receive automated e-mail alerts, such as via RSS newsfeed, when we post certain information. Interested parties can also follow our social media feed @McKesson on Twitter. The content on any website or social media channel is not incorporated by reference into this report, unless expressly noted otherwise.



44

McKESSON CORPORATION

Item 3.Quantitative and Qualitative Disclosures about Market Risk.
We believe there has been no material change in our exposure to risks associated with fluctuations in interest and foreign currency exchange rates as disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.
Item 4.Controls and Procedures.
Our Chief Executive Officer and our Chief Financial Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s “disclosure controls and procedures” (as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.
There were no changes in our “internal control over financial reporting” (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that occurred during the three months ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


45

McKESSON CORPORATION
PART II—OTHER INFORMATION

Item 1.Legal Proceedings.
The information set forth in Financial Note 10, “Commitments and Contingent Liabilities,” to the accompanying condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, and in Financial Note 17, “Commitments and Contingent Liabilities,” to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023, is incorporated herein by reference. Disclosure of an environmental proceeding with a governmental agency generally is included only if we expect monetary sanctions in the proceeding to exceed $1 million, unless otherwise material.

Item 1A.Risk Factors.
Other than factual updates discussed in this Quarterly Report on Form 10-Q, there have been no material changes for the period covered by this Quarterly Report on Form 10-Q to the risk factors disclosed in Part I of Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.
Our Board of Directors has authorized the repurchase of McKesson’s common stock. We may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions.
Refer to Financial Note 11, “Stockholders' Deficit,” to the accompanying condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for a full discussion of the Company’s share repurchases for the three months ended June 30, 2023 and 2022.
The following table provides information on the Company’s share repurchases during the three months ended June 30, 2023:
 
Share Repurchases (1)
(In millions, except price per share)Total Number
of Shares
Purchased
Average Price
Paid Per Share (2)
Total Number of
Shares Purchased
as Part of Publicly
Announced
Program (3)
Approximate
Dollar Value of
Shares that May
Yet Be Purchased Under the Programs (2)
April 1, 2023 – April 30, 20230.7 $363.11 0.7 $3,361 
May 1, 2023 – May 31, 20230.5 378.52 0.5 3,158 
June 1, 2023 – June 30, 20230.6 393.22 0.6 2,944 
Total1.8 1.8 
(1)This table does not include the value of equity awards surrendered to satisfy tax withholding obligations or forfeitures of equity awards.
(2)The average price paid per share and the remaining authorization outstanding for repurchases of the Company’s common stock excludes $4 million of excise taxes incurred on share repurchases for the three months ended June 30, 2023.
(3)In July 2022, the Board authorized the Company to repurchase up to an additional $4.0 billion of its shares of common stock. The authorization has no expiration date.
In July 2023, the Board approved an increase of $6.0 billion in the authorization for repurchase of McKesson’s common stock.


46

McKESSON CORPORATION

Item 3.Defaults Upon Senior Securities.
None.

Item 4.Mine Safety Disclosures.
Not applicable.

Item 5.Other Information.
None.


47

McKESSON CORPORATION

Item 6.Exhibits.
Exhibits identified in parentheses below are on file with the SEC and are incorporated by reference as exhibits hereto.
Exhibit
Number
Description
4.1
10.1†*
10.2†*
31.1†
31.2†
32††
101
The following materials from the McKesson Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Condensed Consolidated Statements of Operations, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Stockholders’ Equity (Deficit), (v) Condensed Consolidated Statements of Cash Flows, and (vi) related Financial Notes.
104Cover Page Interactive Data File (formatted as iXBRL and contained in Exhibit 101).

*    Management contract or compensation plan or arrangement in which directors and/or executive officers are eligible to participate.
†    Filed herewith.
††    Furnished herewith.

48

McKESSON CORPORATION

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
MCKESSON CORPORATION
Date:August 2, 2023 /s/ Britt J. Vitalone
 Britt J. Vitalone
 Executive Vice President and Chief Financial Officer
 
 
MCKESSON CORPORATION
Date:August 2, 2023 /s/ Napoleon B. Rutledge Jr.
 Napoleon B. Rutledge Jr.
 Senior Vice President and Controller


49
EX-10.1 2 mck_ex101x2022stockplanstcs.htm EX-10.1 Document
Exhibit 10.1
OUTSIDE DIRECTOR
Div Equiv Cash
McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
RESTRICTED STOCK UNITS GRANTED TO
OUTSIDE DIRECTORS PURSUANT TO THE 2022 STOCK PLAN

I.INTRODUCTION
The following terms and conditions shall apply to Restricted Stock Unit Awards granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any regulations and rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.RESTRICTED STOCK UNITS
1.Award Agreement. A Restricted Stock Unit Award granted to an Outside Director under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Outside Director and the Corporation setting forth the terms and conditions of the Restricted Stock Unit Award. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Outside Director’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.
2.Terms and Conditions. The Administrator administering the Plan has authority to determine the Outside Directors to whom, and the time or times at which, grants of Restricted Stock Units will be made, the number of Units to be awarded, and all other terms and conditions of such awards. With respect to annual Restricted Stock Unit Awards granted to Outside Directors under the Plan, such awards shall be subject to the following terms, conditions and restrictions.
(A)Grant Date. Each Outside Director may be granted a Restricted Stock Unit Award on the date of each annual meeting of stockholders. An Outside Director that is elected to the Board between annual meetings of stockholders may also be granted a Restricted Stock Unit Award on the date that the Board determines in its sole discretion.
(B)Number of Restricted Stock Units. Unless otherwise determined by the Board or the Governance Committee of the Board (the “Governance Committee”), the number of Restricted Stock Units (“Units”) granted for the annual meeting grant will be determined by dividing the Fair Market Value of a Share on the date of grant into $200,000 (with any fractional Unit rounded up to the nearest whole Unit). In addition to such grant, unless otherwise determined by the Board or the Governance Committee, the Independent Chair shall be granted an annual meeting grant determined by dividing the Fair Market Value of a Share on the date of grant into $120,000 (with any fractional Unit rounded up to the nearest whole Unit). Notwithstanding the foregoing, in no event shall the aggregate number of Units granted to any Outside Director pursuant to such annual meeting grant or grants exceed 5,000. A newly elected Outside Director may receive a prorated annual meeting grant effective upon the date of the Outside Director’s election to the Board.
(C)No Restrictions. Each Restricted Stock Unit Award granted to an Outside Director will be fully vested on the date of grant.
3.Dividend Equivalents. Dividend equivalents in respect of Restricted Stock Units, if granted in tandem with such Units, will be credited on behalf of an Outside Director to a deferred cash account until such time as the underlying Shares are issued.
4.Assignability. An Outside Director shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.
2022 Stock Plan STC (Outside Director)


5.No Stockholder Rights. Neither an Outside Director nor any person entitled to exercise an Outside Director’s rights in the event of the Outside Director’s death shall have any of the rights of a stockholder with respect to a Restricted Stock Unit Award except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the underlying Shares paid upon the settlement of any Restricted Stock Unit Award as described in Section II.6 below.
6.Time of Payment of Restricted Stock Units. Except as noted in Section II.7 below, Restricted Stock Units granted to Outside Directors shall not be paid until after the Outside Director’s separation of service with the Corporation (“Automatic Deferral Requirement”). “Separation from service” shall have the meaning provided under the McKesson Corporation Deferred Compensation Administration Plan III (“DCAP III”). Payment shall be made in Shares in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Outside Director’s unrestricted interest in the number of Shares subject to the Restricted Stock Unit Award.
7.Satisfaction of Director Stock Ownership Guidelines. For those Outside Directors who have met the Director Stock Ownership Guidelines in effect at the time, Restricted Stock Unit grants shall not be subject to the Automatic Deferral Requirement and such grants will be immediately converted into Shares and distributed to the Outside Director; provided, however, that the Outside Director may elect to defer receipt of the Shares underlying the Restricted Stock Units.
8.Deferrals of Restricted Stock Units. Deferrals of Restricted Stock Units, whether elective or pursuant to the Automatic Deferral Requirement, shall be subject to the terms and conditions of DCAP III.
III.MISCELLANEOUS
1.No Effect on Terms of Service with the Corporation. Nothing contained in this Statement of Terms and Conditions, the Plan or a Restricted Stock Unit Agreement shall affect the Corporation’s right to terminate the service of any Outside Director.
2.Grants to Outside Directors in Foreign Countries. If an Outside Director is not a United States citizen or resident, the Board has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust a Restricted Stock Unit Award to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Outside Director’s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Outside Director to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.Information Notification. Any information required to be given under the terms of a Restricted Stock Unit Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to an Outside Director shall be addressed to the Outside Director at the address indicated beneath the Outside Director’s name on the Restricted Stock Unit Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office. The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein. Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient. Emails to the Corporation shall be delivered to CorpSecretary@McKesson.com.
4.Electronic Delivery. The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.
5.Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan, under this Statement of Terms and Conditions, or under a Restricted Stock Unit Agreement, shall be conclusive and binding on all persons.
6.No Effect on Other Benefit Plans. Nothing herein contained shall affect an Outside Director’s right, if any, to participate in and receive benefits from and in accordance with the then current provisions of any benefit plan or program offered by the Corporation.
2



7.Withholding. Each Outside Director shall agree to make appropriate arrangements with the Corporation for satisfaction of any applicable federal, state or local income tax withholding requirements or payroll tax requirements, if any is required.
8.Data Privacy Information and Consent.
(A)Data Collection and Usage. The Corporation may collect, process and use certain personal information about the Outside Director, including, but not limited to, the Outside Director’s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares held in the Corporation, details of all Restricted Stock Units or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Outside Director’s favor (“Data”), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Outside Director’s consent.
(B)Stock Plan Administration Service Providers. The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Outside Director may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.
(C)International Data Transfers. The Corporation and its service providers are based in the United States. The Outside Director’s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation’s legal basis, where required, for the transfer of Data is the Outside Director’s consent.
(D)Data Retention. The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Outside Director’s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws. In the latter case, the Outside Director understands and acknowledges that the Corporation’s legal basis for the processing of the Outside Director’s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Outside Director’s interests, rights or freedoms. When the Corporation no longer needs the Outside Director’s Data for any of the above purposes, the Outside Director understands the Corporation will remove it from its systems.
(E)Voluntariness and Consequences of Consent Denial or Withdrawal. Participation in the Plan is voluntary and the Outside Director is providing the consents herein on a purely voluntary basis. If the Outside Director does not consent, or if the Outside Director later seeks to revoke the Outside Director’s consent, the Outside Director’s retainer and fees from or services with the Corporation will not be affected; the only consequence of refusing or withdrawing the Outside Director’s consent is that the Corporation would not be able to grant Awards to the Outside Director or administer or maintain such Awards.
(F)Data Subject Rights. The Outside Director may have a number of rights under data privacy laws in the Outside Director’s jurisdiction. Depending on where the Outside Director is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Outside Director and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or supplementation of Data about the Outside Director that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Outside Director’s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Outside Director feels its processing is inappropriate, (v) request portability of the Outside Director’s Data that the Outside Director has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Outside Director’s service on the Board and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Outside Director’s jurisdiction, and/or (viii) receive a list with the names and addresses of any potential recipients of Data. To receive clarification regarding these rights or to exercise these rights, the Outside Director can contact the Corporate Secretary.
By accepting the Award and indicating consent via the Corporation’s acceptance procedure, the Outside Director is declaring that he or she agrees with the data processing practices described herein and consents to the
3



collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.
9.Severability. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
10.Successors. This Statement of Terms and Conditions and the Restricted Stock Unit Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Outside Director” as used herein shall include the Outside Director’s Beneficiary.
11.Delaware Law. The interpretation, performance, and enforcement of this Statement of Terms and Conditions and all Restricted Stock Unit Agreements shall be governed by the laws of the State of Delaware.

4



OUTSIDE DIRECTOR
Div Equiv Units
McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
RESTRICTED STOCK UNITS GRANTED TO
OUTSIDE DIRECTORS PURSUANT TO THE 2022 STOCK PLAN

I.INTRODUCTION
The following terms and conditions shall apply to Restricted Stock Unit Awards granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any regulations and rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.RESTRICTED STOCK UNITS
1.Award Agreement. A Restricted Stock Unit Award granted to an Outside Director under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Outside Director and the Corporation setting forth the terms and conditions of the Restricted Stock Unit Award. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Outside Director’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.
2.Terms and Conditions. The Administrator administering the Plan has authority to determine the Outside Directors to whom, and the time or times at which, grants of Restricted Stock Units will be made, the number of Units to be awarded, and all other terms and conditions of such awards. With respect to annual Restricted Stock Unit Awards granted to Outside Directors under the Plan, such awards shall be subject to the following terms, conditions and restrictions.
(A)Grant Date. Each Outside Director may be granted a Restricted Stock Unit Award on the date of each annual meeting of stockholders. An Outside Director that is elected to the Board between annual meetings of stockholders may also be granted a Restricted Stock Unit Award on the date that the Board determines in its sole discretion.
(B)Number of Restricted Stock Units. Unless otherwise determined by the Board or the Governance Committee of the Board (the “Governance Committee”), the number of Restricted Stock Units (“Units”) granted for the annual meeting grant will be determined by dividing the Fair Market Value of a Share on the date of grant into $200,000 (with any fractional
Unit rounded up to the nearest whole Unit). In addition to such grant, unless otherwise determined by the Board or the Governance Committee, the Independent Chair shall be granted an annual meeting grant determined by dividing the Fair Market Value of a Share on the date of grant into $120,000 (with any fractional Unit rounded up to the nearest whole Unit). Notwithstanding the foregoing, in no event shall the aggregate number of Units granted to any Outside Director pursuant to such annual meeting grant or grants exceed 5,000. A newly elected Outside Director may receive a prorated annual meeting grant effective upon the date of the Outside Director’s election to the Board.
(C)No Restrictions. Each Restricted Stock Unit Award granted to an Outside Director will be fully vested on the date of grant.
3.Dividend Equivalents. Dividend equivalents in respect of Restricted Stock Units, if granted in tandem with such Units, will be converted into additional Restricted Stock Units, which will be subject to all of the terms and conditions of the underlying Restricted Stock Unit Award. The number of such additional Restricted Stock Units shall be calculated by dividing (a) the aggregate amount or value of the dividends paid with respect to that number of Shares equal to the number of Restricted Stock Units credited as of the record date for such dividend by (b) the Fair Market Value per Share on the payment date for such dividend.
2022 Stock Plan STC (Outside Director)


4.Assignability. An Outside Director shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.
5.No Stockholder Rights. Neither an Outside Director nor any person entitled to exercise an Outside Director’s rights in the event of the Outside Director’s death shall have any of the rights of a stockholder with respect to a Restricted Stock Unit Award except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the underlying Shares paid upon the settlement of any Restricted Stock Unit Award as described in Section II.6 below.
6.Time of Payment of Restricted Stock Units. Except as noted in Section II.7 below, Restricted Stock Units granted to Outside Directors shall not be paid until after the Outside Director’s separation of service with the Corporation (“Automatic Deferral Requirement”). “Separation from service” shall have the meaning provided under the McKesson Corporation Deferred Compensation Administration Plan III (“DCAP III”). Payment shall be made in Shares in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Outside Director’s unrestricted interest in the number of Shares subject to the Restricted Stock Unit Award. Any fractional Shares resulting from the accumulation of dividend equivalents shall be paid in cash.
7.Satisfaction of Director Stock Ownership Guidelines. For those Outside Directors who have met the Director Stock Ownership Guidelines in effect at the time, Restricted Stock Unit grants shall not be subject to the Automatic Deferral Requirement and such grants will be immediately converted into Shares and distributed to the Outside Director; provided, however, that the Outside Director may elect to defer receipt of the Shares underlying the Restricted Stock Units.
8.Deferrals of Restricted Stock Units. Deferrals of Restricted Stock Units, whether elective or pursuant to the Automatic Deferral Requirement, shall be subject to the terms and conditions of DCAP III.
III.MISCELLANEOUS
1.No Effect on Terms of Service with the Corporation. Nothing contained in this Statement of Terms and Conditions, the Plan or a Restricted Stock Unit Agreement shall affect the Corporation’s right to terminate the service of any Outside Director.
2.Grants to Outside Directors in Foreign Countries. If an Outside Director is not a United States citizen or resident, the Board has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust a Restricted Stock Unit Award to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Outside Director’s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Outside Director to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.Information Notification. Any information required to be given under the terms of a Restricted Stock Unit Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to an Outside Director shall be addressed to the Outside Director at the address indicated beneath the Outside Director’s name on the Restricted Stock Unit Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office. The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein. Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient. Emails to the Corporation shall be delivered to CorpSecretary@McKesson.com.
4.Electronic Delivery. The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.
5.Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan, under this Statement of Terms and Conditions, or under a Restricted Stock Unit Agreement, shall be conclusive and binding on all persons.
2



6.No Effect on Other Benefit Plans. Nothing herein contained shall affect an Outside Director’s right, if any, to participate in and receive benefits from and in accordance with the then current provisions of any benefit plan or program offered by the Corporation.
7.Withholding. Each Outside Director shall agree to make appropriate arrangements with the Corporation for satisfaction of any applicable federal, state or local income tax withholding requirements or payroll tax requirements, if any is required.
8.Data Privacy Information and Consent.
(A)Data Collection and Usage. The Corporation may collect, process and use certain personal information about the Outside Director, including, but not limited to, the Outside Director’s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares held in the Corporation, details of all Restricted Stock Units or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Outside Director’s favor (“Data”), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Outside Director’s consent.
(B)Stock Plan Administration Service Providers. The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Outside Director may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.
(C)International Data Transfers. The Corporation and its service providers are based in the United States. The Outside Director’s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation’s legal basis, where required, for the transfer of Data is the Outside Director’s consent.
(D)Data Retention. The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Outside Director’s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws. In the latter case, the Outside Director understands and acknowledges that the Corporation’s legal basis for the processing of the Outside Director’s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Outside Director’s interests, rights or freedoms. When the Corporation no longer needs the Outside Director’s Data for any of the above purposes, the Outside Director understands the Corporation will remove it from its systems.
(E)Voluntariness and Consequences of Consent Denial or Withdrawal. Participation in the Plan is voluntary and the Outside Director is providing the consents herein on a purely voluntary basis. If the Outside Director does not consent, or if the Outside Director later seeks to revoke the Outside Director’s consent, the Outside Director’s retainer and fees from or services with the Corporation will not be affected; the only consequence of refusing or withdrawing the Outside Director’s consent is that the Corporation would not be able to grant Awards to the Outside Director or administer or maintain such Awards.
(F)Data Subject Rights. The Outside Director may have a number of rights under data privacy laws in the Outside Director’s jurisdiction. Depending on where the Outside Director is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Outside Director and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or supplementation of Data about the Outside Director that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Outside Director’s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Outside Director feels its processing is inappropriate, (v) request portability of the Outside Director’s Data that the Outside Director has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Outside Director’s service on the Board and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Outside Director’s jurisdiction, and/or (viii) receive a list with the names and addresses of any potential
3



recipients of Data. To receive clarification regarding these rights or to exercise these rights, the Outside Director can contact the Corporate Secretary.
By accepting the Award and indicating consent via the Corporation’s acceptance procedure, the Outside Director is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.
9.Severability. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
10.Successors. This Statement of Terms and Conditions and the Restricted Stock Unit Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Outside Director” as used herein shall include the Outside Director’s Beneficiary.
11.Delaware Law. The interpretation, performance, and enforcement of this Statement of Terms and Conditions and all Restricted Stock Unit Agreements shall be governed by the laws of the State of Delaware
4



EXECUTIVE OFFICERS

McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS
AND PERFORMANCE STOCK UNITS GRANTED TO EXECUTIVE OFFICERS
PURSUANT TO THE 2022 STOCK PLAN
For Grants Beginning May 23, 2023
I.INTRODUCTION
The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.OPTIONS
1.Option Agreement. An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option. Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Option Agreement. The Option is also subject to the terms and conditions of the Plan.
2.Exercise Price. The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.
3.Option Period. An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section II.4 as modified by the rules set forth in Sections II.5 and VI. The Option Period shall be not more than seven years from the Grant Date.
4.Vesting of Right to Exercise Options.
(A)Subject to Sections II.5 and VI, an Option shall be exercisable during the Option Period in accordance with the vesting terms and conditions established on the Grant Date and specified in the Option Grant Notice.
(B)Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections II.5 and VI. No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option. In no event shall the Corporation be required to issue fractional Shares.
5.Limits on Option Period and Acceleration of Vesting. The Option Period may end before the Expiration Date, and in certain circumstances the vesting schedule of an Option may be accelerated (subject to the provisions of Section VI), as follows:
(A)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long-Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i) 90 days after the date of the Participant’s termination of employment and (ii) the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable at the time of such termination of employment. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
2022 Stock Plan STC (EO)



(B)Notwithstanding any other provision in this Section II.5, if a Participant’s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.
(C)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long-Term Disability, the vesting schedule of the Participant’s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant’s termination of employment and (ii) the Expiration Date.
(D)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i) the Option shall be exercisable only to the extent that it was exercisable at the time of such retirement and (ii) the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.
(E)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement:
(i)If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement; or
(ii)If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.
(F)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and
(i)The Participant has attained the requirements for Normal Retirement on or prior to the Participant’s termination date, then such Option shall be subject to the Normal Retirement provisions of Section II.5(E); or
(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and
(a)The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D); or
(b)The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date; or
(iii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant’s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the original vesting schedule as though the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply.
(G)If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant’s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and
2



(b) the Expiration Date, and the Participant’s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount) remaining on the date of death.
(H)If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date. Upon the Participant’s subsequent termination of employment, the post-termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant’s initial termination of employment and the Participant's re-hire date; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).
6.Method of Exercise. A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows:
(A)By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised. Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following:  cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States. Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise. The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant’s personal check. Payment may also be made by delivery (including by FAX transmission) to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VIII.6) and to transfer the proceeds of such sale to the Corporation.
(B)If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof; provided that such assurance shall be deemed inapplicable to (i) any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be) filed and become effective under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii) any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.
(C)As soon as practicable after receipt of the notice and the assurance described in Sections II.6(A) and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section VIII.6) and without other incidental expense to the Participant, credit the purchased Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the purchased Shares; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.
7.Limitations on Transfer. An Option shall, during a Participant’s lifetime, be exercisable only by the Participant. No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution. Notwithstanding the foregoing: (A) unless otherwise determined by the Administrator in its sole discretion, a Participant may designate a beneficiary to succeed, after the Participant’s death, to all of the Participant’s Options outstanding on the date of death; (B) a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act; and (C) any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the
3



Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity. In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.
8.No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to such Shares upon the exercise of an Option.
III.RESTRICTED STOCK
1.Restricted Stock Agreement. A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award. Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Agreement. The Restricted Stock Award is also subject to the terms and conditions of the Plan.
2.Rights with Respect to Shares of Restricted Stock. Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s interest in the Restricted Stock. From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.
3.Special Restrictions. Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.
(A)Restrictions. Until the restrictions imposed on any Restricted Stock grant shall lapse (the “Restriction Period”), Shares of Restricted Stock granted to a Participant (i) shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii) shall, if the Participant’s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section III.3(B) or Section III.3(C)) be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)Death or Long-Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination; or
(ii)Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions,
4



this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.
(C)Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

(i)The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant’s termination date or (b) would have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then any time-vesting Restricted Stock Award shall be subject to the Normal Retirement provisions of Section III.3(B)(ii); or

(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then the restrictions applicable to any time-vesting Restricted Stock Award shall lapse upon the Participant’s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant’s termination date.

Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.

(D)Restriction on Sale. The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the vesting and settlement of a Restricted Stock Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
4.Dividends. Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award. Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.
5.Election to Recognize Gross Income in the Year of Grant. If any Participant who is a U.S. taxpayer validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section VIII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.
6.Restrictive Legend. Each book entry in the records of the Corporation’s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and/or the Restricted Stock Agreement.
7.Expiration of Restriction Period. If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant’s interest in the unrestricted Shares shall be entered on the records of the Corporation’s transfer agent.
IV.RESTRICTED STOCK UNITS
1.Restricted Stock Unit Agreement. Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units. Each Restricted Stock Unit Grant Notice shall incorporate
5



by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.
2.Special Restrictions. Restricted Stock Units granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.
(A)Restrictions. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)Death or Long-Term Disability, then the restrictions imposed on any Award of Restricted Stock Units shall lapse on the date of such termination; or
(ii)Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period.

(C)Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

(i)The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant’s termination date or (b) would have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then any time-vesting Restricted Stock Unit Award shall be subject to the Normal Retirement provisions of Section IV.2(B)(ii); or

(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then the restrictions applicable to any time-vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date.

(D)Restriction on Sale. The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the settlement of Restricted Stock Units, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
3.Dividend Equivalents. Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units. Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units, and cash dividends shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit Award, and to which the cash dividends relate, are distributed. Stock dividends shall be converted into additional Restricted Stock Units, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units, including the same vesting restrictions as the underlying Award.
6



4.Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.
5.No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units.
6.Time of Payment of Restricted Stock Units. Upon the lapse of the restriction imposed on Restricted Stock Units, all Restricted Stock Units that were not forfeited pursuant to Section IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i), or Section VI shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse. Payment shall be made in Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares subject to the Restricted Stock Units.
Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant’s brokerage account of record as soon as reasonably practicable after the earlier of the Participant’s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VIII.14. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Unit Award due to a Participant’s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).
V.PERFORMANCE STOCK UNITS
1.Award Agreement. Performance Stock Unit Awards shall be evidenced by a Performance Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Stock Unit Award. Performance Stock Unit Awards are “Performance Awards” as provided under Section 10 of the Plan. Each Performance Stock Unit Agreement shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Performance Stock Unit Agreement. Performance Stock Unit Awards are also subject to the terms and conditions of the Plan.
2.Number of Shares Granted Based on Performance. The performance period of a Performance Stock Unit Award shall be greater than one year, and performance shall be based on such criteria as the Compensation Committee shall determine in its discretion at the beginning of the performance period. Following the end of the performance period, the Compensation Committee shall determine the extent to which the criteria have been achieved, and shall authorize the grant and issuance of Shares in respect of the Performance Stock Unit Award.
3.Special Conditions. Performance Stock Unit Awards shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Compensation Committee, consistent with the terms of the Plan.
(A)Forfeiture. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan or in Section V.3(B) or Section V.3(C)) prior to the end of the performance period, any then-outstanding Performance Stock Units shall be canceled, and all the rights of the Participant to such Award shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Compensation Committee may otherwise expressly determine.
(B)Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision contained herein or in the Plan or the Award Agreement to the contrary, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
7



(i)Death or Long-Term Disability, the Participant shall be eligible to receive, following completion of the applicable performance period, a prorated portion of each such Performance Stock Unit Award, equal to (1) the target number of Performance Stock Units subject to such Award, multiplied by (2) the performance criteria determined by the Compensation Committee to apply to such Award, multiplied by (3) a fraction, the numerator of which is the number of whole calendar months, rounded down to the nearest whole month, during which the Participant provided Service to the Corporation or an Affiliate during the performance period applicable to such Award, and the denominator of which is the number of calendar months in such performance period; provided, that for purposes of this clause (3), “whole calendar months” shall be calculated commencing on the applicable Grant Date; provided, however, that in no event shall such amount exceed any applicable cap or limitation set forth in the Performance Stock Unit Grant Notice; or
(ii)Normal Retirement on or after the first anniversary of the Grant Date, the Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through the date on which the Compensation Committee determines performance against the applicable performance goals.
Amounts, if any, to be paid under this Section V.3(B) shall be paid in accordance with Section V.7 and, if applicable, Section VIII.14.
(C)Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary, if the Participant has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date and ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:
(i)The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant’s termination date or (b) would have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then any Performance Stock Unit Award shall be subject to the Normal Retirement provisions of Section V.3(B)(ii); or
(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then if such Participant’s termination date is no greater than six months prior to the date on which the Compensation Committee determines performance against the applicable performance goals, such Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through such performance determination date.
Amounts, if any, to be paid under this Section V.3(C) shall be paid in accordance with Section V.7 and, if applicable, Section VIII.14.
(D)Restriction on Sale of Shares. The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives with respect to the settlement of a Performance Stock Unit Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
4.Dividend Equivalents. Unless otherwise determined by the Compensation Committee in its sole discretion, Dividend Equivalents shall not be accrued with respect to Performance Stock Unit Awards during the performance period.
5.Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber all or any portion of a Performance Stock Unit Award.
6.No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to a Performance Stock Unit Award, except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any Performance Stock Unit Award.
8



7.Time of Payment of Performance Stock Units. The Compensation Committee shall determine the extent to which Shares are payable pursuant to a Performance Stock Unit Award as soon as practicable following the end of the performance period, and such Shares shall be paid as soon as practicable thereafter and in any event no later than the end of the period under which payment would be deemed to be a “short-term deferral” as defined in the regulations under Code Section 409A. Payment shall be made in the form of Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares earned pursuant to the Performance Stock Unit Award.
VI.SPECIAL FORFEITURE AND REPAYMENT RULES
Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result:
1.Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation. In addition, any Award of Restricted Stock or Restricted Stock Units as to which the restrictions have not lapsed shall immediately and automatically be forfeited, Performance Stock Unit Awards shall immediately and automatically be forfeited and any such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.
2.If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise. In addition, if the restrictions imposed on any Award of Restricted Stock or Restricted Stock Units (including any unpaid dividends or Dividend Equivalents) lapsed, or any Performance Stock Unit Award was settled, within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested.
3.The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates:
(A)Discloses to others, or takes or uses for the Participant’s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know-how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment, whether or not they are the Participant’s work product. Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained;
(B)Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant’s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise;
(C)Fails to provide the Corporation with at least 30 days’ written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates. As used herein, “business in competition” means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant’s employment with the Corporation or its Affiliates;
(D)Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant’s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment with the Corporation or any of its Affiliates;
9



(E)Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party;
(F)Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates; or
(G)Fails to meet the Participant’s continuing obligations with respect to non-disclosure, non-competition and/or non-solicitation under the Participant’s agreement with the Corporation or any Affiliate.
The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.
Any provision of this Section VI which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section VI.
VII.CHANGE IN CONTROL
If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an “Exchange”), any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation’s assets either directly or through one or more subsidiaries) (the “Surviving Company”) which are traded on an Exchange (a “Replacement Award”), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option; (ii) in the case of a Performance Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Performance Stock Unit Award (determined using the Corporation’s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such Replacement Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation’s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award; provided, however, that in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Stock Unit Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.
If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Stock Unit Award shall be replaced with a Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Unit Award shall be equal to the number of Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award; provided however, that, in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant
10



for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14).
VIII.MISCELLANEOUS
1.No Effect on Terms of Employment. Participation in the Plan shall not create a right to further employment with the Participant’s employer (the “Employer”) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.
2.Grants to Participants in Foreign Countries. In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Participant’s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.Information Notification. Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office. The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein, and a delivery receipt and a read receipt are made part of the message.  Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient. Emails to the Corporation shall be delivered to CorpSecretary@McKesson.com.
4.Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.
5.No Effect on Other Benefit Plans. Nothing herein contained shall affect a Participant’s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.
6.Withholding. Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance contributions, payroll tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and legally applicable to the Participant (“Tax-Related Items”), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer. The Participant further acknowledges that the Corporation and/or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting, settlement or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and/or dividend equivalents; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (1) withholding from the Participant’s wages or other cash compensation paid to the Participant by the Corporation and/or the Employer; (2) withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant’s behalf pursuant to this authorization and any other authorization the Corporation and/or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares); (3) withholding Shares to be issued upon grant, vesting/settlement or exercise, as applicable; or (4) any other method of withholding determined by the Corporation and to the extent required by applicable law or the Plan, approved by the Compensation Committee. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New
11



York Stock Exchange on the date that the amount of tax to be withheld is determined. In no event, however, shall the Corporation be required to issue fractional Shares. With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and/or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.
The Corporation or the Employer may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in the Participant’s jurisdictions(s). If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant’s participation in the Plan. In the event any excess amounts are withheld to satisfy the obligation for Tax-Related Items, the Participant may be entitled to receive a refund of any over-withheld amount (with no entitlement to the Share equivalent), or if not refunded by the Corporation or the Employer, the Participant must seek a refund from the local tax authorities to the extent the Participant wishes to recover the over-withheld amount in the form of a refund. In the event of under-withholding, the Participant may be required to pay any additional Tax-Related Items directly to the applicable tax authority or to the Corporation and/or the Employer.
Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.
The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.
7.Successors. The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Participant” as used herein shall include the Participant’s Beneficiary.
8.Delaware Law. The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.
9.Nature of Grant. In accepting the grant, the Participant acknowledges that:
(A)the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time;
(B)the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past;
(C)all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation;
(D)the Participant is voluntarily participating in the Plan;
(E)the Award and the Shares subject to the Award, and the income from and value of same, are not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments;
(F)the Award will not be interpreted to form an employment contract or relationship with the Corporation; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation;
(G)the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(H)if the underlying Shares do not increase in value, the Options will have no value;
12



(I)in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant’s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever, and whether or not such forfeiture is later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise; provided that, notwithstanding the foregoing, in the event any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim;
(J)for purposes of an Award, the Participant’s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation’s other Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant’s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law (for example, the Participant’s period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any); similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation’s other Affiliates and will not be extended by any notice period mandated under local law; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee for purposes of an Award (including whether the Participant may still be considered to be providing services while on a leave of absence);
(K)the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant’s acquisition or sale of Shares; and
(L)the Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.
10.Data Privacy Information and Consent.
(A)Data Collection and Usage. The Corporation and the Employer may collect, process and use certain personal information about the Participant, including, but not limited to, the Participant’s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Stock Units, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Employee’s favor (“Data”), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Participant’s consent.
(B)Stock Plan Administration Service Providers. The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Participant may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.
(C)International Data Transfers. The Corporation and its service providers are based in the United States. The Participant’s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation’s legal basis, where required, for the transfer of Data is the Participant’s consent.
(D)Data Retention. The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws. In the latter case, the Participant understands and acknowledges that the Corporation’s legal basis for the processing of the Participant’s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Participant’s interests, rights or freedoms. When the
13



Corporation no longer needs the Participant’s Data for any of the above purposes, the Participant understands the Corporation will remove it from its systems.
(E)Voluntariness and Consequences of Consent Denial or Withdrawal. Participation in the Plan is voluntary and the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later seeks to revoke the Participant’s consent, the Participant’s salary from or employment with the Employer will not be affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Corporation would not be able to grant Awards to the Participant or administer or maintain such Awards.
(F)Data Subject Rights. The Participant may have a number of rights under data privacy laws in the Participant’s jurisdiction. Depending on where the Participant is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Participant and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or supplementation of Data about the Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Participant’s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Participant feels its processing is inappropriate, (v) request portability of the Participant’s Data that the Participant has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Participant’s employment and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Participant’s jurisdiction, and/or (viii) receive a list with the names and addresses of any potential recipients of Data. To receive clarification regarding these rights or to exercise these rights, the Participant can contact his or her local human resources representative.
By accepting the Award and indicating consent via the Corporation’s acceptance procedure, the Participant is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.
11.Severability. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
12.Language. The Participant acknowledges that the Participant is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in the English language, and, accordingly, understands the provisions of the Plan and this Statement of Terms and Conditions. If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control unless otherwise required by local law.
13.Electronic Delivery. The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.
14.Section 409A. If (A) the Participant is a Specified Employee at the time of the Participant’s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the “Deferred Compensation Benefits”) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.
14



IX.DEFINITIONS
When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below:
1.Award Agreement” means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Stock Unit Award or Other Share-Based Award, as applicable.
2.Cause” means termination of the Participant’s employment with the Corporation or an Affiliate upon the Participant’s negligent or willful engagement in misconduct which, in the sole determination of the Chief Executive Officer of the Corporation (or the Chief Executive Officer’s designee), is injurious to the Corporation, its employees, or its customers.
3.Early Retirement” means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant’s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term “service” shall include years and completed whole months of service.
4.Family Member” means any person identified as an “immediate family” member in Rule 16(a)-1(e) of the Exchange Act, as such Rule may be amended from time to time. Notwithstanding the foregoing, the Administrator may designate any other person(s) or entity(ies) as a “family member.”
5.    “Good Reason” means any of the following actions, if taken without the express written consent of the Participant:
(A)    Any material change by the Corporation in the Participant’s functions, duties, or responsibilities, which change would cause the Participant’s position with the Corporation to become of less dignity, responsibility, importance, or scope from the position and attributes that applied to the Participant immediately prior to the Change in Control;
(B)    Any significant reduction in the Participant’s aggregate base annual salary and target incentive opportunity, as in effect immediately prior to the Change in Control;
(C)    Any material failure by the Corporation to comply with any of the provisions of an Award subsequent to a Change in Control;
(D)    The Corporation’s requiring the Participant to be based at any location which would increase the Participant’s regular one-way commute by more than 25 miles from that in effect immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant’s responsibilities; or
(E)    Any change in the person to whom the Participant reports, as this relationship existed immediately prior to a Change in Control;
Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant’s notice to remedy the Good Reason condition; provided further that the Participant’s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason.
6.    “Expiration Date” means the date that an Option expires as set forth in the Option Grant Notice as the “Expiration Date.”
7.    “Grant Date” means the date the Administrator grants the Award.
8.    “Grant Notice” means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.
15



9.    “Long-Term Disability” means a physical or mental condition in respect of which the administrator of the Corporation’s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits; or, if the Participant is not then a participant in the Corporation’s long-term disability plan, a physical or mental condition that the administrator of the Corporation’s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.
10.    “Normal Retirement” means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, “service” shall mean completed whole years of service (12 consecutive months).
11.    “Option Period” means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section II.5, ending on the Expiration Date.
12.    “Separation from Service” means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant’s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).
13.    “Severance” means termination of employment with the Corporation or an Affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan or the McKesson Corporation Severance Policy for Executive Employees, as applicable, in accordance with the terms and conditions of such plans. A Participant outside the United States who is not qualified for participation in and entitlement to the benefits under such plans will nonetheless be treated for the limited purposes of his or her Awards, and subject to the provisions of Section VIII.9 of this Statement of Terms and Conditions, as terminated by reason of Severance to the extent his or her employment with the Corporation or an Affiliate is terminated and he or she would satisfy the conditions for termination for reason of Severance but for the fact that such plan is only applicable to employees of the Corporation or an Affiliate in the United States who qualify for participation in that plan.
14.     “Short-Term Disability” means short-term disability as defined in the Corporation’s short-term disability plan.
15.    “Specified Employee” means those employees identified by the Corporation as "Specified Employees" for purposes of Code Section 409A.
16.    “Stock Ownership Policy” means the Corporation’s Stock Ownership Policy, as amended from time to time, which can be found on McKNet. A Participant or a Participant’s beneficiary may also request a copy of the Stock Ownership Policy by writing to the Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039 or emailing CorpSecretary@McKesson.com.
16



EMPLOYEES SUBJECT TO STOCK OWNERSHIP POLICY

McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS
AND PERFORMANCE STOCK UNITS GRANTED TO EMPLOYEES SUBJECT TO STOCK OWNERSHIP POLICY PURSUANT TO THE 2022 STOCK PLAN
For Grants beginning May 23, 2023
I.INTRODUCTION
The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.OPTIONS
1.Option Agreement. An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option. Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Option Agreement. The Option is also subject to the terms and conditions of the Plan.
2.Exercise Price. The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.
3.Option Period. An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section II.4 as modified by the rules set forth in Sections II.5 and VI. The Option Period shall be not more than seven years from the Grant Date.
4.Vesting of Right to Exercise Options.
(A)Subject to Sections II.5 and VI, an Option shall be exercisable during the Option Period in accordance with the vesting terms and conditions established on the Grant Date and specified in the Option Grant Notice.
(B)Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections II.5 and VI. No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option. In no event shall the Corporation be required to issue fractional Shares.
5.Limits on Option Period and Acceleration of Vesting. The Option Period may end before the Expiration Date, and in certain circumstances the vesting schedule of an Option may be accelerated (subject to the provisions of Section VI), as follows:
(A)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long-Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i) 90 days after the date of the Participant’s termination of employment and (ii) the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable at the time of such termination of employment. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
2022 Stock Plan STC (Emp Subj to SOP)



(B)Notwithstanding any other provision in this Section II.5, if a Participant’s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.
(C)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long-Term Disability, the vesting schedule of the Participant’s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant’s termination of employment and (ii) the Expiration Date.
(D)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i) the Option shall be exercisable only to the extent that it was exercisable at the time of such retirement and (ii) the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.
(E)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement:
(i)If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement; or
(ii)If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.
(F)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and
(i)The Participant has attained the requirements for Normal Retirement on or prior to the Participant’s termination date, then such Option shall be subject to the Normal Retirement provisions of Section II.5(E); or
(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and
(a)The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D); or
(b)The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date; or
(iii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant’s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the original vesting schedule as though the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply.
(G)If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant’s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and
2



(b) the Expiration Date, and the Participant’s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount) remaining on the date of death.
(H)If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date. Upon the Participant’s subsequent termination of employment, the post-termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant’s initial termination of employment and the Participant's re-hire date; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).
6.Method of Exercise. A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows:
(A)By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised. Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following:  cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States. Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise. The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant’s personal check. Payment may also be made by delivery (including by FAX transmission) to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VIII.6) and to transfer the proceeds of such sale to the Corporation.
(B)If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof; provided that such assurance shall be deemed inapplicable to (i) any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be) filed and become effective under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii) any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.
(C)As soon as practicable after receipt of the notice and the assurance described in Sections II.6(A) and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section VIII.6) and without other incidental expense to the Participant, credit the purchased Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the purchased Shares; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.
7.Limitations on Transfer. An Option shall, during a Participant’s lifetime, be exercisable only by the Participant. No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution. Notwithstanding the foregoing: (A) unless otherwise determined by the Administrator in its sole discretion, a Participant may designate a beneficiary to succeed, after the Participant’s death, to all of the Participant’s Options outstanding on the date of death; (B) a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act; and (C) any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the
3



Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity. In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.
8.No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to such Shares upon the exercise of an Option.
III.RESTRICTED STOCK
1.Restricted Stock Agreement. A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award. Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Agreement. The Restricted Stock Award is also subject to the terms and conditions of the Plan.
2.Rights with Respect to Shares of Restricted Stock. Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s interest in the Restricted Stock. From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.
3.Special Restrictions. Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.
(A)Restrictions. Until the restrictions imposed on any Restricted Stock grant shall lapse (the “Restriction Period”), Shares of Restricted Stock granted to a Participant (i) shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii) shall, if the Participant’s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section III.3(B) or Section III.3(C)) be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)Death or Long-Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination; or
(ii)Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions,
4



this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.
(C)Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

(i)The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant’s termination date or (b) would have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then any time-vesting Restricted Stock Award shall be subject to the Normal Retirement provisions of Section III.3(B)(ii); or

(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then the restrictions applicable to any time-vesting Restricted Stock Award shall lapse upon the Participant’s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant’s termination date.

Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.

(D)Restriction on Sale. The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the vesting and settlement of a Restricted Stock Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
4.Dividends. Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award. Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.
5.Election to Recognize Gross Income in the Year of Grant. If any Participant who is a U.S. taxpayer validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section VIII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.
6.Restrictive Legend. Each book entry in the records of the Corporation’s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and/or the Restricted Stock Agreement.
7.Expiration of Restriction Period. If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant’s interest in the unrestricted Shares shall be entered on the records of the Corporation’s transfer agent.
IV.RESTRICTED STOCK UNITS
1.Restricted Stock Unit Agreement. Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units. Each Restricted Stock Unit Grant Notice shall incorporate by
5



reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.
2.Special Restrictions. Restricted Stock Units granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.
(A)Restrictions. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)Death or Long-Term Disability, then the restrictions imposed on any Award of Restricted Stock Units shall lapse on the date of such termination; or
(ii)Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period.

(C)Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

(i)The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant’s termination date or (b) would have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then any time-vesting Restricted Stock Unit Award shall be subject to the Normal Retirement provisions of Section IV.2(B)(ii); or

(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then the restrictions applicable to any time-vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date.

(D)Restriction on Sale. The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the settlement of Restricted Stock Units, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
3.Dividend Equivalents. Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units. Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units, and cash dividends shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit Award, and to which the cash dividends relate, are distributed. Stock dividends shall be converted into additional Restricted Stock Units, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units, including the same vesting restrictions as the underlying Award.
6



4.Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.
5.No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units.
6.Time of Payment of Restricted Stock Units. Upon the lapse of the restriction imposed on Restricted Stock Units, all Restricted Stock Units that were not forfeited pursuant to Section IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i), or Section VI shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse. Payment shall be made in Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares subject to the Restricted Stock Units.
Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant’s brokerage account of record as soon as reasonably practicable after the earlier of the Participant’s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VIII.14. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Unit Award due to a Participant’s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).
V.PERFORMANCE STOCK UNITS
1.Award Agreement. Performance Stock Unit Awards shall be evidenced by a Performance Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Stock Unit Award. Performance Stock Unit Awards are “Performance Awards” as provided under Section 10 of the Plan. Each Performance Stock Unit Agreement shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Performance Stock Unit Agreement. Performance Stock Unit Awards are also subject to the terms and conditions of the Plan.
2.Number of Shares Granted Based on Performance. The performance period of a Performance Stock Unit Award shall be greater than one year, and performance shall be based on such criteria as the Compensation Committee shall determine in its discretion at the beginning of the performance period. Following the end of the performance period, the Compensation Committee shall determine the extent to which the criteria have been achieved, and shall authorize the grant and issuance of Shares in respect of the Performance Stock Unit Award.
3.Special Conditions. Performance Stock Unit Awards shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Compensation Committee, consistent with the terms of the Plan.
(A)Forfeiture. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan or in Section V.3(B) or Section V.3(C)) prior to the end of the performance period, any then-outstanding Performance Stock Units shall be canceled, and all the rights of the Participant to such Award shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Compensation Committee may otherwise expressly determine.
(B)Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision contained herein or in the Plan or the Award Agreement to the contrary, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
7



(i)Death or Long-Term Disability, the Participant shall be eligible to receive, following completion of the applicable performance period, a prorated portion of each such Performance Stock Unit Award, equal to (1) the target number of Performance Stock Units subject to such Award, multiplied by (2) the performance criteria determined by the Compensation Committee to apply to such Award, multiplied by (3) a fraction, the numerator of which is the number of whole calendar months, rounded down to the nearest whole month, during which the Participant provided Service to the Corporation or an Affiliate during the performance period applicable to such Award, and the denominator of which is the number of calendar months in such performance period; provided, that for purposes of this clause (3), “whole calendar months” shall be calculated commencing on the applicable Grant Date; provided, however, that in no event shall such amount exceed any applicable cap or limitation set forth in the Performance Stock Unit Grant Notice; or
(ii)Normal Retirement on or after the first anniversary of the Grant Date, the Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through the date on which the Compensation Committee determines performance against the applicable performance goals.
Amounts, if any, to be paid under this Section V.3(B) shall be paid in accordance with Section V.7 and, if applicable, Section VIII.14.
(C)Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary, if the Participant has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date and ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:
(i)The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant’s termination date or (b) would have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then any Performance Stock Unit Award shall be subject to the Normal Retirement provisions of Section V.3(B)(ii); or
(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then if such Participant’s termination date is no greater than six months prior to the date on which the Compensation Committee determines performance against the applicable performance goals, such Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through such performance determination date.
Amounts, if any, to be paid under this Section V.3(C) shall be paid in accordance with Section V.7 and, if applicable, Section VIII.14.
(D)Restriction on Sale of Shares. The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives with respect to the settlement of a Performance Stock Unit Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.
4.Dividend Equivalents. Unless otherwise determined by the Compensation Committee in its sole discretion, Dividend Equivalents shall not be accrued with respect to Performance Stock Unit Awards during the performance period.
5.Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber all or any portion of a Performance Stock Unit Award.
6.No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to a Performance Stock Unit Award, except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any Performance Stock Unit Award.
8



7.Time of Payment of Performance Stock Units. The Compensation Committee shall determine the extent to which Shares are payable pursuant to a Performance Stock Unit Award as soon as practicable following the end of the performance period, and such Shares shall be paid as soon as practicable thereafter and in any event no later than the end of the period under which payment would be deemed to be a “short-term deferral” as defined in the regulations under Code Section 409A. Payment shall be made in the form of Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares earned pursuant to the Performance Stock Unit Award.
VI.SPECIAL FORFEITURE AND REPAYMENT RULES
Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result:
1.Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation. In addition, any Award of Restricted Stock or Restricted Stock Units as to which the restrictions have not lapsed shall immediately and automatically be forfeited, Performance Stock Unit Awards shall immediately and automatically be forfeited and any such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.
2.If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise. In addition, if the restrictions imposed on any Award of Restricted Stock or Restricted Stock Units (including any unpaid dividends or Dividend Equivalents) lapsed, or any Performance Stock Unit Award was settled, within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested.
3.The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates:
(A)Discloses to others, or takes or uses for the Participant’s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know-how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment, whether or not they are the Participant’s work product. Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained;
(B)Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant’s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise;
(C)Fails to provide the Corporation with at least 30 days’ written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates. As used herein, “business in competition” means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant’s employment with the Corporation or its Affiliates;
(D)Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant’s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment with the Corporation or any of its Affiliates;
9



(E)Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party;
(F)Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates; or
(G)Fails to meet the Participant’s continuing obligations with respect to non-disclosure, non-competition and/or non-solicitation under the Participant’s agreement with the Corporation or any Affiliate.
The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.
Any provision of this Section VI which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section VI.
VII.CHANGE IN CONTROL
If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an “Exchange”), any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation’s assets either directly or through one or more subsidiaries) (the “Surviving Company”) which are traded on an Exchange (a “Replacement Award”), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option; (ii) in the case of a Performance Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Performance Stock Unit Award (determined using the Corporation’s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such Replacement Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation’s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award; provided, however, that in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Stock Unit Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.
If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Stock Unit Award shall be replaced with a Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Unit Award shall be equal to the number of Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award; provided however, that, in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant
10



for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14).
VIII.MISCELLANEOUS
1.No Effect on Terms of Employment. Participation in the Plan shall not create a right to further employment with the Participant’s employer (the “Employer”) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.
2.Grants to Participants in Foreign Countries. In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Participant’s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.Information Notification. Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office. The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein, and a delivery receipt and a read receipt are made part of the message.  Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient. Emails to the Corporation shall be delivered to CorpSecretary@McKesson.com.
4.Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.
5.No Effect on Other Benefit Plans. Nothing herein contained shall affect a Participant’s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.
6.Withholding. Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance contributions, payroll tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and legally applicable to the Participant (“Tax-Related Items”), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer. The Participant further acknowledges that the Corporation and/or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting, settlement or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and/or dividend equivalents; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (1) withholding from the Participant’s wages or other cash compensation paid to the Participant by the Corporation and/or the Employer; (2) withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant’s behalf pursuant to this authorization and any other authorization the Corporation and/or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares); (3) withholding Shares to be issued upon grant, vesting/settlement or exercise, as applicable; or (4) any other method of withholding determined by the Corporation and to the extent required by applicable law or the Plan, approved by the Compensation Committee. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New
11



York Stock Exchange on the date that the amount of tax to be withheld is determined. In no event, however, shall the Corporation be required to issue fractional Shares. With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and/or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.
The Corporation or the Employer may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in the Participant’s jurisdiction(s). If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant’s participation in the Plan. In the event any excess amounts are withheld to satisfy the obligation for Tax-Related Items, the Participant may be entitled to receive a refund of any over-withheld amount (with no entitlement to the Share equivalent), or if not refunded by the Corporation or the Employer, the Participant must seek a refund from the local tax authorities to the extent the Participant wishes to recover the over-withheld amount in the form of a refund. In the event of under-withholding, the Participant may be required to pay any additional Tax-Related Items directly to the applicable tax authority or to the Corporation and/or the Employer.
Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.
The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.
7.Successors. The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Participant” as used herein shall include the Participant’s Beneficiary.
8.Delaware Law. The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.
9.Nature of Grant. In accepting the grant, the Participant acknowledges that:
(A)the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time;
(B)the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past;
(C)all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation;
(D)the Participant is voluntarily participating in the Plan;
(E)the Award and the Shares subject to the Award, and the income from and value of same, are not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments;
(F)the Award will not be interpreted to form an employment contract or relationship with the Corporation; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation;
(G)the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(H)if the underlying Shares do not increase in value, the Options will have no value;
12



(I)in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant’s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever, and whether or not such forfeiture is later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise; provided that, notwithstanding the foregoing, in the event any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim;
(J)for purposes of an Award, the Participant’s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation’s other Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant’s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law (for example, the Participant’s period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any); similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation’s other Affiliates and will not be extended by any notice period mandated under local law; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee for purposes of an Award (including whether the Participant may still be considered to be providing services while on a leave of absence);
(K)the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant’s acquisition or sale of Shares; and
(L)the Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.
10.Data Privacy Information and Consent.
(A)Data Collection and Usage. The Corporation and the Employer may collect, process and use certain personal information about the Participant, including, but not limited to, the Participant’s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Stock Units, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Employee’s favor (“Data”), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Participant’s consent.
(B)Stock Plan Administration Service Providers. The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Participant may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.
(C)International Data Transfers. The Corporation and its service providers are based in the United States. The Participant’s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation’s legal basis, where required, for the transfer of Data is the Participant’s consent.
(D)Data Retention. The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws. In the latter case, the Participant understands and acknowledges that the Corporation’s legal basis for the processing of the Participant’s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Participant’s interests, rights or freedoms. When the
13



Corporation no longer needs the Participant’s Data for any of the above purposes, the Participant understands the Corporation will remove it from its systems.
(E)Voluntariness and Consequences of Consent Denial or Withdrawal. Participation in the Plan is voluntary and the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later seeks to revoke the Participant’s consent, the Participant’s salary from or employment with the Employer will not be affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Corporation would not be able to grant Awards to the Participant or administer or maintain such Awards.
(F)Data Subject Rights. The Participant may have a number of rights under data privacy laws in the Participant’s jurisdiction. Depending on where the Participant is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Participant and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or supplementation of Data about the Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Participant’s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Participant feels its processing is inappropriate, (v) request portability of the Participant’s Data that the Participant has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Participant’s employment and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Participant’s jurisdiction, and/or (viii) receive a list with the names and addresses of any potential recipients of Data. To receive clarification regarding these rights or to exercise these rights, the Participant can contact his or her local human resources representative.
By accepting the Award and indicating consent via the Corporation’s acceptance procedure, the Participant is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.
11.Severability. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
12.Language. The Participant acknowledges that the Participant is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in the English language, and, accordingly, understands the provisions of the Plan and this Statement of Terms and Conditions. If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control unless otherwise required by local law.
13.Electronic Delivery. The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.
14.Section 409A. If (A) the Participant is a Specified Employee at the time of the Participant’s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the “Deferred Compensation Benefits”) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.
14



IX.DEFINITIONS
When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below:
1.Award Agreement” means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Stock Unit Award or Other Share-Based Award, as applicable.
2.Cause” means termination of the Participant’s employment with the Corporation or an Affiliate upon the Participant’s negligent or willful engagement in misconduct which, in the sole determination of the Chief Executive Officer of the Corporation (or the Chief Executive Officer’s designee), is injurious to the Corporation, its employees, or its customers.
3.Early Retirement” means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant’s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term “service” shall include years and completed whole months of service.
4.Family Member” means any person identified as an “immediate family” member in Rule 16(a)-1(e) of the Exchange Act, as such Rule may be amended from time to time. Notwithstanding the foregoing, the Administrator may designate any other person(s) or entity(ies) as a “family member.”
5.    “Good Reason” means any of the following actions, if taken without the express written consent of the Participant:
(A)    Any material change by the Corporation in the Participant’s functions, duties, or responsibilities, which change would cause the Participant’s position with the Corporation to become of less dignity, responsibility, importance, or scope from the position and attributes that applied to the Participant immediately prior to the Change in Control; provided, however, that, any such change attributable to the Corporation’s no longer being a company with publicly traded common stock shall not constitute Good Reason; and provided, further, that a reduction in the Participant’s functions, duties or responsibilities solely by virtue of the Corporation being acquired and made part of a larger entity (for example, if following a Change in Control the Participant retains the Participant’s position, or has a comparable position, with respect to a division or subsidiary of the acquirer that contains the Corporation’s business) shall not constitute Good Reason;
(B)    Any significant reduction in the Participant’s aggregate base annual salary and target incentive opportunity, as in effect immediately prior to the Change in Control;
(C)    Any material failure by the Corporation to comply with any of the provisions of an Award subsequent to a Change in Control; or
(D)    The Corporation’s requiring the Participant to be based at any location which would increase the Participant’s regular one-way commute by more than 25 miles from that in effect immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant’s responsibilities;
Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant’s notice to remedy the Good Reason condition; provided further that the Participant’s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason.
6.    “Expiration Date” means the date that an Option expires as set forth in the Option Grant Notice as the “Expiration Date.”
7.    “Grant Date” means the date the Administrator grants the Award.
8.    “Grant Notice” means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.
15



9.    “Long-Term Disability” means a physical or mental condition in respect of which the administrator of the Corporation’s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits; or, if the Participant is not then a participant in the Corporation’s long-term disability plan, a physical or mental condition that the administrator of the Corporation’s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.
10.    “Normal Retirement” means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, “service” shall mean completed whole years of service (12 consecutive months).
11.    “Option Period” means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section II.5, ending on the Expiration Date.
12.    “Separation from Service” means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant’s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).
13.    “Severance” means termination of employment with the Corporation or an Affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan or the McKesson Corporation Severance Policy for Executive Employees, as applicable, in accordance with the terms and conditions of such plans. A Participant outside the United States who is not qualified for participation in and entitlement to the benefits under such plans will nonetheless be treated for the limited purposes of his or her Awards, and subject to the provisions of Section VIII.9 of this Statement of Terms and Conditions, as terminated by reason of Severance to the extent his or her employment with the Corporation or an Affiliate is terminated and he or she would satisfy the conditions for termination for reason of Severance but for the fact that such plan is only applicable to employees of the Corporation or an Affiliate in the United States who qualify for participation in that plan.
14.     “Short-Term Disability” means short-term disability as defined in the Corporation’s short-term disability plan.
15.    “Specified Employee” means those employees identified by the Corporation as "Specified Employees" for purposes of Code Section 409A.
16.    “Stock Ownership Policy” means the Corporation’s Stock Ownership Policy, as amended from time to time, which can be found on McKNet. A Participant or a Participant’s beneficiary may also request a copy of the Stock Ownership Policy by writing to the Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039 or emailing CorpSecretary@McKesson.com.
16



EMPLOYEES

McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO
OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS
AND PERFORMANCE STOCK UNITS GRANTED TO EMPLOYEES
PURSUANT TO THE 2022 STOCK PLAN
For Grants Beginning May 23, 2023
I.INTRODUCTION
The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.
II.OPTIONS
1.Option Agreement. An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option. Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Option Agreement. The Option is also subject to the terms and conditions of the Plan.
2.Exercise Price. The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.
3.Option Period. An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section II.4 as modified by the rules set forth in Sections II.5 and VI. The Option Period shall be not more than seven years from the Grant Date.
4.Vesting of Right to Exercise Options.
(A)Subject to Sections II.5 and VI, an Option shall be exercisable during the Option Period in accordance with the vesting terms and conditions established on the Grant Date and specified in the Option Grant Notice.
(B)Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections II.5 and VI. No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option. In no event shall the Corporation be required to issue fractional Shares.
5.Limits on Option Period and Acceleration of Vesting. The Option Period may end before the Expiration Date, and in certain circumstances the vesting schedule of an Option may be accelerated (subject to the provisions of Section VI), as follows:
(A)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long-Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i) 90 days after the date of the Participant’s termination of employment and (ii) the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable at the time of such termination of employment. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.



(B)Notwithstanding any other provision in this Section II.5, if a Participant’s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.
(C)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long-Term Disability, the vesting schedule of the Participant’s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant’s termination of employment and (ii) the Expiration Date.
(D)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i) the Option shall be exercisable only to the extent that it was exercisable at the time of such retirement and (ii) the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.
(E)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement:
(i)If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement; or
(ii)If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.
(F)If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and
(i)The Participant has attained the requirements for Normal Retirement on or prior to the Participant’s termination date, then such Option shall be subject to the Normal Retirement provisions of Section II.5(E); or
(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and
(a)The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D); or
(b)The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date; or
(iii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant’s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the original vesting schedule as though the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply.
(G)If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant’s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and
2



(b) the Expiration Date, and the Participant’s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount) remaining on the date of death.
(H)If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date. Upon the Participant’s subsequent termination of employment, the post-termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant’s initial termination of employment and the Participant's re-hire date; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).
6.Method of Exercise. A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows:
(A)By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised. Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following:  cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States. Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise. The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant’s personal check. Payment may also be made by delivery (including by FAX transmission) to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VIII.6) and to transfer the proceeds of such sale to the Corporation.
(B)If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof; provided that such assurance shall be deemed inapplicable to (i) any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be) filed and become effective under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii) any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.
(C)As soon as practicable after receipt of the notice and the assurance described in Sections II.6(A) and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section VIII.6) and without other incidental expense to the Participant, credit the purchased Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the purchased Shares; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.
7.Limitations on Transfer. An Option shall, during a Participant’s lifetime, be exercisable only by the Participant. No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution. Notwithstanding the foregoing: (A) unless otherwise determined by the Administrator in its sole discretion, a Participant may designate a beneficiary to succeed, after the Participant’s death, to all of the Participant’s Options outstanding on the date of death; (B) a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act; and (C) any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the
3



Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity. In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.
8.No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to such Shares upon the exercise of an Option.
III.RESTRICTED STOCK
1.Restricted Stock Agreement. A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award. Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Agreement. The Restricted Stock Award is also subject to the terms and conditions of the Plan.
2.Rights with Respect to Shares of Restricted Stock. Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation’s transfer agent recording the Participant’s interest in the Restricted Stock. From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.
3.Special Restrictions. Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.
(A)Restrictions. Until the restrictions imposed on any Restricted Stock grant shall lapse (the “Restriction Period”), Shares of Restricted Stock granted to a Participant (i) shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii) shall, if the Participant’s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section III.3(B) or Section III.3(C)) be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)Death or Long-Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination; or
(ii)Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions,
4



this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.
(C)Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

(i)The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant’s termination date or (b) would have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then any time-vesting Restricted Stock Award shall be subject to the Normal Retirement provisions of Section III.3(B)(ii); or

(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then the restrictions applicable to any time-vesting Restricted Stock Award shall lapse upon the Participant’s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant’s termination date.

Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant’s Normal Retirement eligibility.

4.Dividends. Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award. Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.
5.Election to Recognize Gross Income in the Year of Grant. If any Participant who is a U.S. taxpayer validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section VIII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.
6.Restrictive Legend. Each book entry in the records of the Corporation’s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and/or the Restricted Stock Agreement.
7.Expiration of Restriction Period. If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant’s interest in the unrestricted Shares shall be entered on the records of the Corporation’s transfer agent.
IV.RESTRICTED STOCK UNITS
1.Restricted Stock Unit Agreement. Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan.
5



2.Special Restrictions. Restricted Stock Units granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.
(A)Restrictions. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.
(B)Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)Death or Long-Term Disability, then the restrictions imposed on any Award of Restricted Stock Units shall lapse on the date of such termination; or
(ii)Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period.

(C)Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:

(i)The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant’s termination date or (b) would have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then any time-vesting Restricted Stock Unit Award shall be subject to the Normal Retirement provisions of Section IV.2(B)(ii); or

(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then the restrictions applicable to any time-vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date.

3.Dividend Equivalents. Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units. Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units, and cash dividends shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit Award, and to which the cash dividends relate, are distributed. Stock dividends shall be converted into additional Restricted Stock Units, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units, including the same vesting restrictions as the underlying Award.
4.Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.
5.No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units.
6



6.Time of Payment of Restricted Stock Units. Upon the lapse of the restriction imposed on Restricted Stock Units, all Restricted Stock Units that were not forfeited pursuant to Section IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i), or Section VI shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse. Payment shall be made in Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares subject to the Restricted Stock Units.
Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant’s brokerage account of record as soon as reasonably practicable after the earlier of the Participant’s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VIII.14. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Unit Award due to a Participant’s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).
V.PERFORMANCE STOCK UNITS
1.Award Agreement. Performance Stock Unit Awards shall be evidenced by a Performance Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Stock Unit Award. Performance Stock Unit Awards are “Performance Awards” as provided under Section 10 of the Plan. Each Performance Stock Unit Agreement shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant’s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Performance Stock Unit Agreement. Performance Stock Unit Awards are also subject to the terms and conditions of the Plan.
2.Number of Shares Granted Based on Performance. The performance period of a Performance Stock Unit Award shall be greater than one year, and performance shall be based on such criteria as the Compensation Committee shall determine in its discretion at the beginning of the performance period. Following the end of the performance period, the Compensation Committee shall determine the extent to which the criteria have been achieved, and shall authorize the grant and issuance of Shares in respect of the Performance Stock Unit Award.
3.Special Conditions. Performance Stock Unit Awards shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Compensation Committee, consistent with the terms of the Plan.
(A)Forfeiture. If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan or in Section V.3(B) or Section V.3(C)) prior to the end of the performance period, any then-outstanding Performance Stock Units shall be canceled, and all the rights of the Participant to such Award shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Compensation Committee may otherwise expressly determine.
(B)Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement. Notwithstanding any provision contained herein or in the Plan or the Award Agreement to the contrary, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of:
(i)Death or Long-Term Disability, the Participant shall be eligible to receive, following completion of the applicable performance period, a prorated portion of each such Performance Stock Unit Award, equal to (1) the target number of Performance Stock Units subject to such Award, multiplied by (2) the performance criteria determined by the Compensation Committee to apply to such Award, multiplied by (3) a fraction, the numerator of which is the number of whole calendar months, rounded down to the nearest whole month, during which the Participant provided Service to the Corporation or an Affiliate during the performance period applicable to such Award, and the denominator of which is the number of calendar months in such performance period; provided, that for purposes of this clause (3), “whole calendar months” shall be calculated commencing on the applicable Grant Date;
7



provided, however, that in no event shall such amount exceed any applicable cap or limitation set forth in the Performance Stock Unit Grant Notice; or
(ii)Normal Retirement on or after the first anniversary of the Grant Date, the Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through the date on which the Compensation Committee determines performance against the applicable performance goals.
Amounts, if any, to be paid under this Section V.3(B) shall be paid in accordance with Section V.7 and, if applicable, Section VIII.14.
(C)Termination of Employment by Reason of Severance. Notwithstanding any provision to the contrary, if the Participant has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date and ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and:
(i)The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant’s termination date or (b) would have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then any Performance Stock Unit Award shall be subject to the Normal Retirement provisions of Section V.3(B)(ii); or
(ii)The Participant has not attained the requirements for Normal Retirement on or prior to the Participant’s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant’s termination date, then if such Participant’s termination date is no greater than six months prior to the date on which the Compensation Committee determines performance against the applicable performance goals, such Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through such performance determination date.
Amounts, if any, to be paid under this Section V.3(C) shall be paid in accordance with Section V.7 and, if applicable, Section VIII.14.
4.Dividend Equivalents. Unless otherwise determined by the Compensation Committee in its sole discretion, Dividend Equivalents shall not be accrued with respect to Performance Stock Unit Awards during the performance period.
5.Assignability. A Participant shall not be permitted to sell, transfer, pledge, assign or encumber all or any portion of a Performance Stock Unit Award.
6.No Stockholder Rights. Neither a Participant nor any person entitled to exercise a Participant’s rights in the event of the Participant’s death shall have any of the rights of a stockholder with respect to a Performance Stock Unit Award, except to the extent that a book entry has been entered in the records of the Corporation’s transfer agent with respect to the Shares paid upon the settlement of any Performance Stock Unit Award.
7.Time of Payment of Performance Stock Units. The Compensation Committee shall determine the extent to which Shares are payable pursuant to a Performance Stock Unit Award as soon as practicable following the end of the performance period, and such Shares shall be paid as soon as practicable thereafter and in any event no later than the end of the period under which payment would be deemed to be a “short-term deferral” as defined in the regulations under Code Section 409A. Payment shall be made in the form of Shares to the Participant’s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation’s transfer agent recording the Participant’s unrestricted interest in the number of Shares earned pursuant to the Performance Stock Unit Award.
VI.SPECIAL FORFEITURE AND REPAYMENT RULES
Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result:
8



1.Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation. In addition, any Award of Restricted Stock or Restricted Stock Units as to which the restrictions have not lapsed shall immediately and automatically be forfeited, Performance Stock Unit Awards shall immediately and automatically be forfeited and any such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.
2.If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise. In addition, if the restrictions imposed on any Award of Restricted Stock or Restricted Stock Units (including any unpaid dividends or Dividend Equivalents) lapsed, or any Performance Stock Unit Award was settled, within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested.
3.The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates:
(A)Discloses to others, or takes or uses for the Participant’s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know-how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment, whether or not they are the Participant’s work product. Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained;
(B)Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant’s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise;
(C)Fails to provide the Corporation with at least 30 days’ written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates. As used herein, “business in competition” means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant’s employment with the Corporation or its Affiliates;
(D)Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant’s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant’s employment with the Corporation or any of its Affiliates;
(E)Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party;
(F)Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates; or
(G)Fails to meet the Participant’s continuing obligations with respect to non-disclosure, non-competition and/or non-solicitation under the Participant’s agreement with the Corporation or any Affiliate.
The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.
9



Any provision of this Section VI which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section VI.
VII.CHANGE IN CONTROL
If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an “Exchange”), any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation’s assets either directly or through one or more subsidiaries) (the “Surviving Company”) which are traded on an Exchange (a “Replacement Award”), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option; (ii) in the case of a Performance Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Performance Stock Unit Award (determined using the Corporation’s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such Replacement Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company’s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation’s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award; provided, however, that in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Stock Unit Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.
If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Stock Unit Award shall be replaced with a Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Unit Award shall be equal to the number of Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award; provided however, that, in the event of the Participant’s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14).
VIII.MISCELLANEOUS
1.No Effect on Terms of Employment. Participation in the Plan shall not create a right to further employment with the Participant’s employer (the “Employer”) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.
2.Grants to Participants in Foreign Countries. In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Participant’s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or
10



advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.
3.Information Notification. Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office. The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein, and a delivery receipt and a read receipt are made part of the message.  Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient. Emails to the Corporation shall be delivered to CorpSecretary@McKesson.com.
4.Administrator Decisions Conclusive. All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.
5.No Effect on Other Benefit Plans. Nothing herein contained shall affect a Participant’s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.
6.Withholding. Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance contributions, payroll tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and legally applicable to the Participant (“Tax-Related Items”), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer. The Participant further acknowledges that the Corporation and/or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting, settlement or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and/or dividend equivalents; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (1) withholding from the Participant’s wages or other cash compensation paid to the Participant by the Corporation and/or the Employer; (2) withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant’s behalf pursuant to this authorization and any other authorization the Corporation and/or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares); (3) withholding Shares to be issued upon grant, vesting/settlement or exercise, as applicable; or (4) any other method of withholding determined by the Corporation and to the extent required by applicable law or the Plan, approved by the Compensation Committee. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New York Stock Exchange on the date that the amount of tax to be withheld is determined. In no event, however, shall the Corporation be required to issue fractional Shares. With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and/or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.
The Corporation or the Employer may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in the Participant’s jurisdiction(s). If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant’s participation in the Plan. In the event any excess amounts are withheld to satisfy the obligation for Tax-Related Items, the Participant may be entitled to receive a refund of any over-withheld amount (with no entitlement to the Share equivalent), or if not refunded by the Corporation or the
11



Employer, the Participant must seek a refund from the local tax authorities to the extent the Participant wishes to recover the over-withheld amount in the form of a refund. In the event of under-withholding, the Participant may be required to pay any additional Tax-Related Items directly to the applicable tax authority or to the Corporation and/or the Employer.
Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.
The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.
7.Successors. The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. “Participant” as used herein shall include the Participant’s Beneficiary.
8.Delaware Law. The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.
9.Nature of Grant. In accepting the grant, the Participant acknowledges that:
(A)the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time;
(B)the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past;
(C)all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation;
(D)the Participant is voluntarily participating in the Plan;
(E)the Award and the Shares subject to the Award, and the income from and value of same, are not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments;
(F)the Award will not be interpreted to form an employment contract or relationship with the Corporation; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation;
(G)the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty;
(H)if the underlying Shares do not increase in value, the Options will have no value;
(I)in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant’s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever, and whether or not such forfeiture is later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise; provided that, notwithstanding the foregoing, in the event any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim;
(J)for purposes of an Award, the Participant’s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation’s other Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of
12



the Participant’s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant’s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law (for example, the Participant’s period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any); similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation’s other Affiliates and will not be extended by any notice period mandated under local law; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee for purposes of an Award (including whether the Participant may still be considered to be providing services while on a leave of absence);
(K)the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant’s acquisition or sale of Shares; and
(L)the Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.
10.Data Privacy Information and Consent.
(A)Data Collection and Usage. The Corporation and the Employer may collect, process and use certain personal information about the Participant, including, but not limited to, the Participant’s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Stock Units, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Employee’s favor (“Data”), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Participant’s consent.
(B)Stock Plan Administration Service Providers. The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Participant may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.
(C)International Data Transfers. The Corporation and its service providers are based in the United States. The Participant’s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation’s legal basis, where required, for the transfer of Data is the Participant’s consent.
(D)Data Retention. The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws. In the latter case, the Participant understands and acknowledges that the Corporation’s legal basis for the processing of the Participant’s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Participant’s interests, rights or freedoms. When the Corporation no longer needs the Participant’s Data for any of the above purposes, the Participant understands the Corporation will remove it from its systems.
(E)Voluntariness and Consequences of Consent Denial or Withdrawal. Participation in the Plan is voluntary and the Participant is providing the consents herein on a purely voluntary basis. If the Participant does not consent, or if the Participant later seeks to revoke the Participant’s consent, the Participant’s salary from or employment with the Employer will not be affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Corporation would not be able to grant Awards to the Participant or administer or maintain such Awards.
(F)Data Subject Rights. The Participant may have a number of rights under data privacy laws in the Participant’s jurisdiction. Depending on where the Participant is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Participant and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or
13



supplementation of Data about the Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Participant’s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Participant feels its processing is inappropriate, (v) request portability of the Participant’s Data that the Participant has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Participant’s employment and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Participant’s jurisdiction, and/or (viii) receive a list with the names and addresses of any potential recipients of Data. To receive clarification regarding these rights or to exercise these rights, the Participant can contact his or her local human resources representative.
By accepting the Award and indicating consent via the Corporation’s acceptance procedure, the Participant is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.
11.Severability. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
12.Language. The Participant acknowledges that the Participant is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in the English language, and, accordingly, understands the provisions of the Plan and this Statement of Terms and Conditions. If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control unless otherwise required by local law.
13.Electronic Delivery. The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.
14.Section 409A. If (A) the Participant is a Specified Employee at the time of the Participant’s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the “Deferred Compensation Benefits”) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.
IX.DEFINITIONS
When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below:
1.Award Agreement” means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Award, Performance Stock Unit Award or Other Share-Based Award, as applicable.
2.Cause” means termination of the Participant’s employment with the Corporation or an Affiliate upon the Participant’s negligent or willful engagement in misconduct which, in the sole determination of the Chief Executive Officer of the Corporation (or the Chief Executive Officer’s designee), is injurious to the Corporation, its employees, or its customers.
14



3.Early Retirement” means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant’s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term “service” shall include years and completed whole months of service.
4.Family Member” means any person identified as an “immediate family” member in Rule 16(a)-1(e) of the Exchange Act, as such Rule may be amended from time to time. Notwithstanding the foregoing, the Administrator may designate any other person(s) or entity(ies) as a “family member.”
5.    “Good Reason” means any of the following actions, if taken without the express written consent of the Participant:
(A)    Any material change by the Corporation in the Participant’s functions, duties, or responsibilities, which change would cause the Participant’s position with the Corporation to become of less dignity, responsibility, importance, or scope from the position and attributes that applied to the Participant immediately prior to the Change in Control; provided, however, that, any such change attributable to the Corporation’s no longer being a company with publicly traded common stock shall not constitute Good Reason; and provided, further, that a reduction in the Participant’s functions, duties or responsibilities solely by virtue of the Corporation being acquired and made part of a larger entity (for example, if following a Change in Control the Participant retains the Participant’s position, or has a comparable position, with respect to a division or subsidiary of the acquirer that contains the Corporation’s business) shall not constitute Good Reason;
(B)    Any significant reduction in the Participant’s aggregate base annual salary and target incentive opportunity, as in effect immediately prior to the Change in Control;
(C)    Any material failure by the Corporation to comply with any of the provisions of an Award subsequent to a Change in Control; or
(D)    The Corporation’s requiring the Participant to be based at any location which would increase the Participant’s regular one-way commute by more than 25 miles from that in effect immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant’s responsibilities;
Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant’s notice to remedy the Good Reason condition; provided further that the Participant’s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason.
6.    “Expiration Date” means the date that an Option expires as set forth in the Option Grant Notice as the “Expiration Date.”
7.    “Grant Date” means the date the Administrator grants the Award.
8.    “Grant Notice” means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.
9.    “Long-Term Disability” means a physical or mental condition in respect of which the administrator of the Corporation’s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits; or, if the Participant is not then a participant in the Corporation’s long-term disability plan, a physical or mental condition that the administrator of the Corporation’s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.
10.    “Normal Retirement” means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, “service” shall mean completed whole years of service (12 consecutive months).
15



11.    “Option Period” means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section II.5, ending on the Expiration Date.
12.    “Separation from Service” means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant’s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).
13.    “Severance” means termination of employment with the Corporation or an Affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan or the McKesson Corporation Severance Policy for Executive Employees, as applicable, in accordance with the terms and conditions of such plans. A Participant outside the United States who is not qualified for participation in and entitlement to the benefits under such plans will nonetheless be treated for the limited purposes of his or her Awards, and subject to the provisions of Section VIII.9 of this Statement of Terms and Conditions, as terminated by reason of Severance to the extent his or her employment with the Corporation or an Affiliate is terminated and he or she would satisfy the conditions for termination for reason of Severance but for the fact that such plan is only applicable to employees of the Corporation or an Affiliate in the United States who qualify for participation in that plan.
14.     “Short-Term Disability” means short-term disability as defined in the Corporation’s short-term disability plan.
15.    “Specified Employee” means those employees identified by the Corporation as "Specified Employees" for purposes of Code Section 409A.
16




OUTSIDE DIRECTOR

FORM OF
MCKESSON CORPORATION 2022 STOCK PLAN
RESTRICTED STOCK UNIT GRANT NOTICE

    
Grantee Name:

Number of RSUs Granted:

Date of Grant:

Vesting Schedule: 100% vested on grant date.

McKesson Corporation (the “Company”) is pleased to grant you restricted stock units (“RSUs”) under the Company’s 2022 Stock Plan, as may be amended from time to time (the “Plan”) to receive shares of common stock of the Company (“Shares”). This Grant Notice (“Notice”), together with the Statement of Terms and Conditions, as provided as an attachment to this Notice (the “ST&Cs”), constitute your Restricted Stock Unit Agreement, which along with the Plan set forth the terms of your grant.

Below is a list of documents that are made available to you in connection with this Notice. PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF RSUs. This grant, along with any other outstanding awards under the Plan, can be viewed on the Fidelity web site at www.Netbenefits.com.

By signing below, I acknowledge that:
1.    I agree to receive copies of the stockholder information, including copies of any annual report, proxy and Form 10-K, from the Investors section of the McKesson website at www.mckesson.com; and
2.    I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-855-466-2547); and
3.    I have access to the Company’s web site; and
4.    I consent to receiving electronically a copy of the documents set forth above and attachments to this Notice; and
5.    The Plan and ST&Cs are incorporated by reference to this Notice; and
6.    The Company recommends that the Grantee consult with a tax advisor prior to accepting this grant of RSUs; and
7.    I accept ALL the terms and conditions as set forth in the Plan and the ST&Cs applicable to this grant of RSUs.

IN WITNESS WHEREOF, the Grantee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.

By:

Brian S. Tyler    Grantee Signature Date
Chief Executive Officer
McKesson Corporation

ATTACHMENTS:
* 2022 Stock Plan
* 2022 Stock Plan Prospectus for Non-Employee Directors
* ST&Cs
* Hedging and Pledging Policy
* Appendix (Outside U.S. - country specific)

August 2022

17




Employee
FORM OF
MCKESSON CORPORATION 2022 STOCK PLAN
RESTRICTED STOCK UNIT GRANT NOTICE

Grantee Name:
Number of RSUs Granted:
Date of Grant:
Vesting Schedule:Please see Appendix

McKesson Corporation (the “Company”) is pleased to grant you restricted stock units (“RSUs”) under the Company’s 2022 Stock Plan (the “Plan”) which represent the contingent right to receive shares of common stock of the Company (“Shares”). This Grant Notice (“Notice”), together with the Statement of Terms and Conditions, as provided as an attachment to this Notice (the “ST&Cs”), constitute your Restricted Stock Unit Agreement. Your Restricted Stock Unit Agreement and your RSUs are subject to the terms of the Plan, which incorporates by reference the Company’s Compensation Recoupment Policy (the “Recoupment Policy”) and the Company’s Stock Ownership Policy (the “Stock Ownership Policy”), as both are amended from time to time).

Below is a list of documents that are made available to you in connection with this Notice. PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF RSUs. This grant, along with any other outstanding awards under the Plan, can be viewed on the Fidelity web site at www.Netbenefits.com.

By signing below, I acknowledge that:
1.I agree to receive copies of the Plan, the Plan prospectus and other Plan information, including information prepared to comply with the laws outside the United States, from the Company’s website and stockholder information, including copies of any annual report, proxy and Form 10-K, from the Investors section of the McKesson website at www.mckesson.com; and
2.I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-855-466-2547); and
3.I have access to the Company’s web site; and
4.I consent to receiving electronically a copy of the documents set forth above and attachments to this Notice; and
5.The Plan (including the Recoupment Policy and Stock Ownership Policy) and ST&Cs are incorporated by reference to this Notice; and
6.The Company recommends that the Grantee consult with a tax advisor prior to accepting this grant of RSUs; and
7.I accept ALL the terms and conditions as set forth in the Plan and ST&Cs applicable to this grant of RSUs.

IN WITNESS WHEREOF, the Grantee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.
Brian S. Tyler                            Grantee Signature     Date
Chief Executive Officer            
McKesson Corporation

ATTACHMENTS:
* 2022 Stock Plan
* 2022 Stock Plan Prospectus
* ST&Cs Applicable to __________
* Compensation Recoupment Policy
* Hedging and Pledging Policy (Section 16 only)
* Stock Ownership Policy (EOT only)
* Appendix (Outside U.S. – country-specific)

August 2022

18



FORM OF
MCKESSON CORPORATION 2022 STOCK PLAN
PERFORMANCE STOCK UNIT GRANT NOTICE

Grantee Name:
Target PSUs Granted:
Date of Grant:
Performance Period:FY 20__ - FY 20__

McKesson Corporation (the “Company”) is pleased to grant you target performance stock units (“PSUs”) under the Company’s 2022 Stock Plan (the “Plan”). This Grant Notice (“Notice”), together with the Statement of Terms and Conditions, as provided with this Notice (the “ST&Cs”), constitute your Performance Stock Unit Agreement. Your Performance Stock Unit Agreement and your PSUs are subject to the terms of the Plan, which incorporates by reference the Company’s Compensation Recoupment Policy (the “Recoupment Policy”), and the Company’s Stock Ownership Policy (the “Stock Ownership Policy”), as both are amended from time to time.
Your PSUs will be earned subject to the Company’s attainment of performance goals that have been pre-established by the Compensation and Talent Committee (the “Committee”) of the Company’s Board of Directors. You may receive 0% - 200% of the target number of PSUs set forth above. PSUs, if earned, will be paid in the form of shares of the Company’s Common Stock (“Shares”) that are not subject to any further vesting restrictions. The Committee has the sole discretion to determine the Company’s performance against the pre-established goals after completion of the performance period, and to authorize the grant of Shares.
Below is a list of documents that are made available to you in connection with this Notice. PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF PSUs. This grant, along with any other outstanding awards under the Plan, can be viewed on the Fidelity web site at www.Netbenefits.com.

By signing below, I acknowledge that:
1.I agree to receive copies of the Plan, the Plan prospectus and other Plan information, including information prepared to comply with the laws outside the United States, from the Company’s website and stockholder information, including copies of any annual report, proxy and Form 10-K, from the Investors section of the McKesson website at www.mckesson.com; and
2.I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-855-466-2547); and
3.I have access to the Company’s web site; and
4.I consent to receiving electronically a copy of the documents set forth above and attachments to this Notice; and
5.The Plan (including the Recoupment Policy and Stock Ownership Policy) and ST&Cs are incorporated by reference to this Notice; and
6.I should consult with a tax advisor prior to accepting this grant of PSUs or taking any other action with respect to this grant of PSUs; and
7.I accept ALL the terms and conditions as set forth in the Plan and ST&Cs applicable to this grant of PSUs.

IN WITNESS WHEREOF, the Grantee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.
Brian S. Tyler                            Grantee Signature     Date
Chief Executive Officer            
McKesson Corporation

Plan Documents and Related Policies
* 2022 Stock Plan
* 2022 Stock Plan Prospectus
* ST&Cs Applicable to __________________
* Compensation Recoupment Policy
* Hedging and Pledging Policy (Section 16 only)
* Stock Ownership Policy (EOT only)
* Appendix (Outside U.S. - country specific)

August 2022
19

EX-10.2 3 mck_ex102xmipstcsmay2023.htm EX-10.2 Document
Exhibit 10.2
FORM OF
McKESSON CORPORATION
STATEMENT OF TERMS AND CONDITIONS
APPLICABLE TO AWARDS
PURSUANT TO THE MANAGEMENT INCENTIVE PLAN
Effective May 23, 2023
The following terms and conditions shall apply to awards made under the McKesson Corporation Management Incentive Plan (the “Plan”) to an executive, managerial or professional employee of the Company who is specifically designated as a participant in the Plan. Capitalized terms used herein are defined in the Plan or in Section 10. In the event these terms and conditions conflict with the terms of the Plan document, the Plan document shall control.
1.Participant.
Only an active employee of the Company who is employed in an executive, managerial or professional capacity may be designated as a Participant under the Plan; provided, however, that designation as a Participant is contingent upon the execution and delivery to the Company of an agreement, within a period following presentment and in a form that is satisfactory to the Company, regarding confidentiality, intellectual property and/or other restrictive covenants, as well as compliance with such agreement; and provided, further, that the Committee shall determine in its sole discretion whether the Participant has complied with the provisions of any such agreement, which determination shall be conclusive and binding on all interested persons.
The Committee shall review those employees who are eligible to participate in the Plan and recommended by management and determine which of those employees will become Plan Participants. The Committee may add to or delete individuals from the list of designated Participants at any time and from time to time, at its sole discretion. The Committee has delegated the authority to approve Plan Participants to the Chief Executive Officer of the Company.
Participation in the Plan during the Performance Period does not guarantee payment of an Actual Award under the Plan for the Performance Period. Participation in the Plan during one Performance Period does not guarantee participation during a subsequent Performance Period.
2.Individual Target Award.
The Individual Target Award is the percentage of base annual salary specified at the beginning of the Performance Period (or beginning of participation, if later) for a Participant.
A.Newly Eligible Employees.
A newly hired employee, or an employee who is promoted into or transferred from an ineligible position to an eligible position during a Performance Period, may be designated a Participant with an Individual Target Award for that Performance Period.
B.Transfers, Promotions and Demotions.
A Participant who moves during the Performance Period from one eligible position to a new eligible position with a higher Individual Target Award will, in general, have the determination of his or her Actual Award prorated between the two Individual Target Awards.
A Participant who during the Performance Period is demoted to or transferred to a new eligible position with a lower Individual Target Award will have the determination of his or her Actual Award prorated in management’s discretion.
A Participant who during the Performance Period is demoted from or transferred from an eligible position to an ineligible position will have the determination of his or her Actual Award prorated in management’s discretion.
Notwithstanding the foregoing, any proration must be based on the achievement of Performance Goals for the Performance Period.
1


3.Performance Measures and Goals.
Each Participant shall have one or more Individual Performance Measures. Individual Performance Measures may be quantitative, qualitative or both. The Performance Goals (defined in Article F of the Plan) established for each segment of the Company are referred to as the Business Scorecard. A Participant’s Individual Performance Measures and the Performance Goals, taken as a whole, will determine the amount of the Participant’s Actual Award.
A Participant who changes jobs and / or organizations during the Performance Period may have different Business Scorecards applicable to each job / organization. The Participant may, in management’s discretion, have the determination of his or her Actual Award prorated between the two Business Scorecards.
4.Individual Performance Modifier.
Actual Awards will be adjusted, in management’s discretion, to reflect the Participant’s individual contribution to Business Scorecard results and the Participant’s Individual Performance Measures.
5.Other Individual Requirements.
Notwithstanding any provision of the Plan to the contrary, no amount shall be payable with respect to the Performance Period unless the Committee certifies that it is satisfied that the requirements (performance or otherwise) associated with such payment have been fully met. Such requirements may include, but are not limited to:
Completion of the Company’s Legal and Regulatory Compliance and Ethics Training Program.
6.Award Determination.
Any payment to a Participant shall be based on Business Scorecard results during the Performance Period as modified by the Participant’s Individual Performance Modifier. The Actual Award is determined by:
Taking the Covered Compensation received during the Performance Period;
Multiplying by the Individual Target Award;
Multiplying that result by the Business Scorecard results (actual vs. target);
Adjusting the result determined above, up or down, by the Individual Performance Modifier.
Management and the Committee shall review and approve, modify or disapprove the Actual Award, if any, to be paid to a Participant for the Performance Period. Management and the Committee reserve the right to reduce or increase or eliminate the individual payments determined according to the above method. No Personal Modifier shall exceed 150%.
7.Effect of a Termination of Employment, Prior to the End of the Performance Period, on Awards.
A.Termination of Employment for Other Than Death, Retirement, Severance or Long-Term Disability.
If the Participant ceases to be a bona fide employee of the Company prior to the payment of the Actual Award, for any reason other than death, Retirement, Severance or Long-Term Disability, the Participant’s interest in the Awards shall be forfeited and no amount shall be payable to the Participant with respect to service during the Performance Period.
B.Termination of Employment by Reason of Death or Long-Term Disability.
If the Participant ceases to be a bona fide employee of the Company due to death or Long-Term Disability during the Performance Period, the Participant (or the Participant’s Beneficiary, if payment is made on account of the death of the Participant) shall be entitled to receive an Actual Award as calculated under Paragraph 6 above.
2


C.Termination of Employment by Reason of Retirement.
If the Participant ceases to be a bona fide employee of the Company due to Retirement prior to January 1 of the Performance Period, the Participant’s interest in the Awards shall be forfeited and no amount shall be payable to the Participant with respect to service during the Performance Period.
If the Participant ceases to be a bona fide employee of the Company due to Retirement on or after January 1 of the Performance Period, the Participant shall be entitled to receive an Actual Award as calculated under Paragraph 6 above.
D.Termination of Employment by Reason of Severance.
If the Participant ceases to be a bona fide employee of the Company due to Severance prior to January 1 of the Performance Period, the Participant’s interest in the Awards shall be forfeited and no amount shall be payable to the Participant with respect to service during the Performance Period.
If the Participant ceases to be a bona fide employee of the Company due to Severance on or after January 1 of the Performance Period, the Participant shall be entitled to receive an Actual Award as calculated under Paragraph 6 above.
8.Data Privacy.
By accepting the Award, the Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of his or her personal data as described in this document by and among, as applicable, the Participant’s employer (the “Employer”) and the Company for the exclusive purpose of implementing, administering and managing participation in the Plan.
The Participant understands that the Company and the Employer hold certain personal information about the Participant, including but not limited to his or her name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any shares of Company stock or directorships held in the Company, details of all compensation or any other entitlement to Company-sponsored benefits for the purpose of implementing, administering and managing the Plan (“Data”). The Participant understands that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the Participant’s country or elsewhere, such as in the United States of America, and that the recipient’s country may have different data privacy laws and protections than the Participant’s country. The Participant understands that he or she may request a list with the names and addresses of any potential recipients of the Data by contacting the local human resources representative. The Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing participation in the Plan. The Participant understands that Data will be held only as long as is necessary to implement, administer and manage his or her participation in the Plan. The Participant understands that he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, without cost, by contacting in writing the local human resources representative. The Participant understands, however, that refusing or withdrawing consent may affect his or her ability to participate in the Plan. For more information on the consequences of refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the local human resources representative.
9.GOVERNING LAW.
The law of the State of Delaware shall govern all question concerning the construction, validity and interpretation of the Plan and any Awards, without regard to the state’s conflict of laws rules.
10.Definitions.
Capitalized terms shall have the same meaning as provided in the Plan. Additional capitalized text that is not included in the Plan, but is used in this Statement of Terms and Conditions, shall have the meaning set forth below:
(a)    “Actual Award” means the finally determined amount payable under the Plan for a Performance Period.
(b)    “Awards” means, collectively, Individual Target Awards and Actual Awards.
3


(c)    “Covered Compensation” means regular wages earned by and paid to the Participant during the Performance Period, including any Paid Time Off (PTO) pay. Covered Compensation does not include any other compensation received during the Performance Period, including, but not limited to, earnings received during a paid leave, overtime or commission pay.
(d)    “Long-Term Disability” means a physical or mental condition in respect of which the administrator of the Company’s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits; or, if the Participant is not then a participant in the Company’s long-term disability plan, a physical or mental condition that the administrator of the Company’s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.
(e)    “Retirement” means termination from the Company with age plus years of service equal to at least 65.
(f)    “Severance” means termination of employment with the Company and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan or the Amended and Restated McKesson Corporation Severance Policy for Executive Employees, as applicable, in accordance with the terms and conditions of such plans. A Participant outside the United States who is not qualified for participation in and entitlement to the benefits under such plans will nonetheless be treated for the limited purposes of his or her Awards as terminated by reason of Severance to the extent his or her employment with the Company is terminated and he or she would satisfy the conditions for termination for reason of Severance but for the fact that such plan is only applicable to employees of the Company in the United States who qualify for participation in that plan.

4
EX-31.1 4 mck_exhibit311x630202310-q.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brian S. Tyler, certify that:
1.I have reviewed this quarterly report on Form 10-Q of McKesson Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:August 2, 2023 /s/  Brian S. Tyler
 Brian S. Tyler
 Chief Executive Officer


EX-31.2 5 mck_exhibit312x630202310-q.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Britt J. Vitalone, certify that:
1.I have reviewed this quarterly report on Form 10-Q of McKesson Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:August 2, 2023 /s/ Britt J. Vitalone
 Britt J. Vitalone
 Executive Vice President and Chief Financial Officer


EX-32.1 6 mck_exhibit32x630202310-q.htm EX-32.1 Document

Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the quarterly report of McKesson Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, each hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/  Brian S. Tyler 
Brian S. Tyler
Chief Executive Officer 
August 2, 2023 
 
/s/ Britt J. Vitalone 
Britt J. Vitalone
Executive Vice President and Chief Financial Officer 
August 2, 2023 
 

This certification accompanies the Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002, and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
A signed original of this written statement required by Section 906 has been provided to McKesson Corporation and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-101.SCH 7 mck-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Business Acquisitions and Divestitures link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Restructuring, Impairment, and Related Charges, Net link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Earnings Per Common Share link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Goodwill and Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Debt and Financing Activities link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Hedging Activities link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Commitments and Contingent Liabilities link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Segments of Business link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - Business Acquisitions and Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Restructuring, Impairment, and Related Charges, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Earnings Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - Goodwill and Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - Debt and Financing Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Commitments and Contingent Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Segments of Business (Tables) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Business Acquisitions and Divestitures - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Business Acquisitions and Divestitures - Divestitures and Other (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - Earnings Per Common Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954725 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954726 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954727 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954728 - Disclosure - Debt and Financing Activities - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954729 - Disclosure - Debt and Financing Activities - Long-Term Debt Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954730 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954731 - Disclosure - Debt and Financing Activities - Commercial Paper Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954732 - Disclosure - Hedging Activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954733 - Disclosure - Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954734 - Disclosure - Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details) link:presentationLink link:calculationLink link:definitionLink 9954735 - Disclosure - Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954736 - Disclosure - Hedging Activities - Schedule of Fair Value of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954737 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954738 - Disclosure - Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954739 - Disclosure - Commitments and Contingent Liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954740 - Disclosure - Commitments and Contingent Liabilities - Estimated Accrual Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9954741 - Disclosure - Stockholders' Deficit - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954742 - Disclosure - Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) link:presentationLink link:calculationLink link:definitionLink 9954743 - Disclosure - Segments of Business - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954744 - Disclosure - Segments of Business - Reportable operating segment (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mck-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 mck-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 mck-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Issuance of shares under employee plans, net of forfeitures (in shares) Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Other accrued liabilities Accrued Liabilities, Current Other Non-Current Liabilities Other Noncurrent Liabilities [Member] Discontinued operations (in usd per share) Discontinued operations (in usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Statistical Measurement [Domain] Statistical Measurement [Domain] U.S. Dollar, notional amount, liability Derivative Liability, Notional Amount Credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Underlying Security Market Price Change Underlying Security Market Price Change, Percent Derivatives designated as net investment hedges: Other comprehensive income (loss), net investment hedge, gain (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Repayments of short-term borrowings Repayments of Short-Term Debt Debt and Financing Activities Debt Disclosure [Text Block] Long-term litigation liabilities Estimated Litigation Liability, Noncurrent Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Cash payments to acquire business Cash Cash Payments to Acquire Businesses, Gross Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Long-term deferred tax liabilities Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Fixed interest rate swaps Fixed Interest Rate Swap [Member] Fixed Interest Rate Swap Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Segment Reporting [Abstract] Segment Reporting [Abstract] Drafts and accounts payable Accounts Payable, Current Taxes Increase (Decrease) in Accrued Taxes Payable European businesses held for sale European businesses, disposal group, losses (gains) Loss (gain) to remeasure disposal group to fair value Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Restatement Determination Date: Restatement Determination Date [Axis] Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Complaints filed against the entity Loss Contingency, Pending Claims, Number Insider Trading Policies and Procedures [Line Items] Long-lived asset impairment charges Other Asset Impairment Charges Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Deficit Equity [Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Income Taxes Income Tax Disclosure [Text Block] Ownership [Axis] Ownership [Axis] CAD Canada, Dollars Unrealized Losses on Net Investment Hedges, Net of Tax AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest [Member] AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest Property, plant, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Current liabilities Liabilities, Current [Abstract] 5.10% Notes due July 15, 2033 5.10% Notes Due July 15, 2033 [Member] 5.10% Notes Due July 15, 2033 Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Dividends paid Payments of Ordinary Dividends, Common Stock Total (in dollars per share) Earnings Per Share, Diluted Fair value of derivative, liability Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Common stock transactions: Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised [Abstract] United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA [Member] United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA Goodwill [Roll Forward] Goodwill [Roll Forward] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Treasury shares (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares 3.80% Notes due March 15, 2024 3.80% Notes Due March 15, 2024 [Member] 3.80% Notes Due March 15, 2024 Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net income attributable to McKesson Corporation Net Income (Loss) Attributable to Parent Net Income (Loss) Total current liabilities Liabilities, Current Derivative, Name [Domain] Derivative Contract [Domain] Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Number of votes per share of common stock permitted on proposals presented to stockholders (vote) Common Stock, Voting Rights, Number of Votes Per Common Share Common Stock, Voting Rights, Number of Votes Per Common Share All Currencies [Domain] All Currencies [Domain] Long-term debt Debt and Lease Obligation LIABILITIES AND DEFICIT Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Repurchase of common stock Shares repurchased Stock Repurchased During Period, Value McKesson Corporation stockholders’ deficit Equity, Attributable to Parent [Abstract] 4.75% Notes due May 30, 2029 4.75% Notes Due May 30, 2029 [Member] 4.75% Notes Due May 30, 2029 Receivables Increase (Decrease) in Receivables Other Other Intangible Assets [Member] Schedule of computations for basic and diluted earnings per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Goods and Services Sold Income Tax Contingency [Table] Income Tax Contingency [Table] Litigation Status [Domain] Litigation Status [Domain] Executive Category: Executive Category [Axis] Weighted average life of intangibles Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Senior Unsecured Credit Facility (the 2022 Credit Facility) Senior Unsecured Credit Facility (the 2022 Credit Facility) [Member] Senior Unsecured Credit Facility (the 2022 Credit Facility) Fair value, inputs, level 1 Fair Value, Inputs, Level 1 [Member] Other Restructuring Reserve, Translation and Other Adjustment Name Measure Name Name Forgone Recovery, Individual Name An individual Individual Claimant [Member] Individual Claimant GBP United Kingdom, Pounds Goodwill Beginning balance Ending balance Goodwill Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Portion of settlement award to be used by state and local government for remediation (percent) Litigation Settlement, Award Amount To Be Used by State and Local Government Litigation Settlement, Award Amount To Be Used by State and Local Government Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Lease and other obligations Lease and Other Obligations [Member] Lease and Other Obligations Estimated annual amortization expense, 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Restructuring and related cost, incurred cost to date Restructuring and Related Cost, Incurred Cost Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Derivative, notional amount Notional Derivative, Notional Amount Dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Repayments of commercial paper Repayments of Commercial Paper Measurement Frequency [Axis] Measurement Frequency [Axis] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Reclassification of gains from AOCI Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Restricted stock units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Credit facility term Debt Instrument, Term Accrued Liabilities Accrued Liabilities [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Proceeds from sales of businesses and investments, net Proceeds from Divestiture of Businesses and Interests in Affiliates Line of Credit Facility [Table] Line of Credit Facility [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Three Largest U.S. Pharmaceutical Distributors Three Largest U.S. Pharmaceutical Distributors [Member] Three Largest U.S. Pharmaceutical Distributors Changes in assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Assets [Abstract] Schedule of Fair Value of Derivatives Fair Value, by Balance Sheet Grouping [Table Text Block] Segment operating profit (loss) Operating Income (Loss) [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Proceeds from debt issuance Proceeds from Debt, Net of Issuance Costs Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Loss contingency, number of cases dismissed Loss Contingency, Number Of Cases Dismissed Loss Contingency, Number Of Cases Dismissed 1.30% Notes due August 15, 2026 1.30% Notes Due August 15, 2026 [Member] 1.30% Notes Due August 15, 2026 INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Litigation Status [Axis] Litigation Status [Axis] Beginning balance Ending balance Restructuring Reserve Senior Unsecured Credit Facility (the 2020 Credit Facility) Senior Unsecured Credit Facility (the 2020 Credit Facility) [Member] Senior Unsecured Credit Facility (the 2020 Credit Facility) [Member] Award Type [Axis] Award Type [Axis] Potentially dilutive securities excluded from diluted earnings per share (less than) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Gain on debt extinguishment Gain (Loss) on Extinguishment of Debt Hedging Designation [Axis] Hedging Designation [Axis] Goodwill [Line Items] Goodwill [Line Items] Estimated annual amortization expense, remainder of 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Trading Arrangement: Trading Arrangement [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Derivative termination proceeds, amortization period (in years) Derivative, Termination Proceeds, Amortization Period Derivative, Termination Proceeds, Amortization Period Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Non-cash charges Restructuring Reserve, Settled without Cash Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Prescription Technology Solutions Prescription Technology Solutions [Member] International Segment [Member] Current portion of operating lease liabilities Operating Lease, Liability, Current Accelerated Share Repurchase, Completion Of Program Accelerated Share Repurchase, Completion Of Program [Member] Accelerated Share Repurchase, Completion Of Program Results of Operations Comparability of Prior Year Financial Data, Policy [Policy Text Block] Amortization expense of intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Noncontrolling interest Noncontrolling interest Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Average price of shares repurchased (in usd per share) Shares Acquired, Average Cost Per Share Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] U.S. Dollar notional amount, asset Derivative Asset, Notional Amount Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Loss contingency, claims settled, number of jurisdictions not participating in settlement Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement Fair Value Debt Instrument, Fair Value Disclosure Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Loans payable Term Loan Loans Payable [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Total purchase consideration Total purchase consideration Business Combination, Consideration Transferred Gross profit Gross Profit British Pound Sterling Denominated Notes British Pound Sterling Denominated Notes [Member] British Pound Sterling Denominated Notes [Member] Severance and employee-related costs, net Severance Costs Current portion of long-term debt Less: Current portion Long-Term Debt and Lease Obligation, Current Treasury shares, at cost, 143 and 141 shares at June 30, 2023 and March 31, 2023, respectively Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Total debt Debt outstanding Carrying Value Long-Term Debt Selling, distribution, general, and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Stock options Employee Stock Option [Member] Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] 0.90% Notes due December 3, 2025 0.90% Notes Due December 3, 2025 [Member] 0.90% Notes Due December 3, 2025 Other Proceeds from (Payments for) Other Financing Activities Debt principal redeemed Debt Instrument, Repurchased Face Amount Maximum Maximum [Member] Comprehensive income attributable to McKesson Corporation Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Restructuring, Impairment, and Related Costs Restructuring and Related Costs [Table Text Block] Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Derivatives designated as net investment hedges Cross-currency swaps Net Investment Hedges Currency Swap [Member] Discontinued operations (in usd per share) Discontinued operations (in usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Entity Address, Address Line One Entity Address, Address Line One Other non-current assets/liabilities Other Non-Current Assets and Liabilities [Member] Other Non-Current Assets and Liabilities Other non-cash items Other Noncash Income (Expense) Evanston Police Pension Fund v. McKesson Corporation Evanston Police Pension Fund v. McKesson Corporation [Member] Evanston Police Pension Fund v. McKesson Corporation Business Acquisition [Axis] Business Acquisition [Axis] Long-term operating lease liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Term Operating Lease Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Term Operating Lease Liabilities Excise taxes Excise Tax Payable, Current Excise Tax Payable, Current Trademarks and trade names Trademarks and Trade Names [Member] Subsequent Event Subsequent Event [Member] Derivative [Table] Derivative [Table] State of West Virginia and Subdivisions State of West Virginia and Subdivisions [Member] State of West Virginia and Subdivisions Schedule of information regarding intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Other non-current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accelerated Share Repurchase Accelerated Share Repurchase [Member] Accelerated Share Repurchase [Member] Schedule of Restructuring and Asset Impairment Charges Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Other Comprehensive Income (Loss) before Reclassifications, Tax Other Comprehensive Income (Loss) before Reclassifications, Tax Less: amounts attributable to noncontrolling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Accelerated Share Repurchases [Table] Accelerated Share Repurchases [Table] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Operating Segments Operating Segments [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Tax expense (benefit), intra-entity transfers of assets other than inventory, amount Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Diluted Earnings Per Share, Diluted [Abstract] Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation adjustments, net Goodwill, Foreign Currency Translation Gain (Loss) Inventories, net Inventory, Net Earnings (loss) per common share attributable to McKesson: EPS, Basic and Diluted [Abstract] Earnings Per Share, Basic and Diluted Statistical Measurement [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest Other non-current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Share repurchases Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] SCRI Oncology, LLC SCRI Oncology, LLC [Member] SCRI Oncology, LLC Business Acquisitions and Divestitures Mergers, Acquisitions and Dispositions Disclosures [Text Block] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Claims and litigation charges, net Gain (Loss) Related to Litigation Settlement Name Outstanding Recovery, Individual Name Debt principal amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Divested net assets Disposal Group, Including Discontinued Operation, Assets Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Fair Value Measurements Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Continuing operations (in usd per share) Continuing operations (in usd per share) Income (Loss) from Continuing Operations, Per Basic Share Estimated annual amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Disposal Group Name [Domain] Disposal Group Name [Domain] Basic Earnings Per Share, Basic [Abstract] PEO PEO [Member] Loss contingency, estimate of possible loss Loss Contingency, Estimate of Possible Loss Other Stockholders' Equity, Other Proceeds from short-term borrowings Proceeds from Short-Term Debt Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Income from continuing operations Income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Shares repurchased Treasury Stock, Value, Acquired, Par Value Method Fair value of derivative, asset Derivative Asset, Subject to Master Netting Arrangement, before Offset Schedule of Estimated Accrual Liability Schedule of Loss Contingencies by Contingency [Table Text Block] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Investments in equity securities Equity Securities, FV-NI, Current Rx Savings Solutions, LLC Rx Savings Solutions, LLC [Member] Rx Savings Solutions, LLC Derivatives designated as cash flow and other hedges: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 6.00% Notes due March 1, 2041 6.00% Notes Due March 1, 2041 [Member] 6.00% Notes Due March 1, 2041 Floating interest rate swaps Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Income from continuing operations attributable to McKesson Corporation Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Reported income tax expense (benefit) rates (percent) Effective Income Tax Rate Reconciliation, Percent Current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member] Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit Credit Facility [Axis] Credit Facility [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Settled Litigation Settled Litigation [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Canada CANADA Disposed of by sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Number of reportable segments Number of Reportable Segments Earnings per common share attributable to McKesson Corporation Earnings Per Share [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at June 30, 2023 and March 31, 2023, respectively Common Stock, Value, Issued Redemption price percentage of principal (percent) Debt Instrument, Redemption Price, Percentage Current litigation liabilities Loss Contingency, Accrual, Current USD United States of America, Dollars Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] RxTs Segment RxTs Segment [Member] RxTs Segment 1.500% Notes Due 2025 1.500% Notes Due 2025 [Member] 1.500% Notes Due 2025 Total current assets Assets, Current SCRI Sarah Cannon Research Institute [Member] Sarah Cannon Research Institute Contingent consideration Contingent consideration Business Combination, Contingent Consideration, Liability All Individuals All Individuals [Member] Litigation Case [Domain] Litigation Case [Domain] Amortization Amortization Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Other non-current liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Held-for-sale Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Authorized repurchase amount (up to) Stock Repurchase Program, Authorized Amount Goodwill and Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] Repurchase of common stock (in shares) Share repurchases (in shares) Stock Repurchased During Period, Shares Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Unrecognized tax benefits Unrecognized Tax Benefits Tax expense (benefit), share-based payment arrangement Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount PEO Name PEO Name Schedule of information regarding changes in accumulated other comprehensive income (loss), net of tax, by component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Corporate income (expenses), net Corporate Operating Expense and Other Income, Net Corporate Operating Expense and Other Income, Net Less: Restricted cash at end of period included in Prepaid expenses and other Restricted Cash, Current Accelerated Share Repurchase, Initial Share Settlement Accelerated Share Repurchase, Initial Share Settlement [Member] Accelerated Share Repurchase, Initial Share Settlement Schedule of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Accelerated Share Repurchases [Line Items] Accelerated Share Repurchases [Line Items] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Medical-Surgical Solutions Medical-Surgical Solutions Segment [Member] Medical-Surgical Solutions Segment [Member] Other current liabilities Business Combination, Contingent Consideration, Liability, Current Class of Stock [Axis] Class of Stock [Axis] Entities [Table] Entities [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] State of Alabama and Subdivisions State of Alabama and Subdivisions [Member] State of Alabama and Subdivisions Corporate Corporate, Non-Segment [Member] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Award payable under proposed framework Litigation Settlement, Amount Awarded to Other Party Gain from sales of businesses and investments Gain (Loss) on Disposition of Other Assets 7.65% Debentures due March 1, 2027 7.65% Debentures Due March 1, 2027 [Member] 7.65% Debentures Due March 1, 2027 Number of states in which court cases are pending Loss Contingency, Number of States Loss Contingency, Number of States Cherokee Nation Cherokee Nation [Member] Cherokee Nation EUR Euro Member Countries, Euro Interest rate on debt instrument (percent) Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Number of states filed on behalf of Loss Contingency, Number of States Filed On Behalf Of Loss Contingency, Number of States Filed On Behalf Of Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Information [Line Items] Entity Information [Line Items] Business Combination and Asset Acquisition [Abstract] Total McKesson Corporation stockholders’ deficit Equity, Attributable to Parent Commercial Paper Commercial Paper [Member] Consolidation Items [Axis] Consolidation Items [Axis] Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Gross purchase price Disposal Group, Including Discontinued Operation, Consideration, Expected Disposal Group, Including Discontinued Operation, Consideration, Expected Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Long-term debt Total long-term debt Long-Term Debt and Lease Obligation Income from continuing operations before income taxes Income from continuing operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest National Prescription Opioid Litigation National Prescription Opiate Litigation [Member] In re: National Prescription Opiate Litigation [Member] Restructuring, Impairment, and Related Charges, Net Restructuring and Related Activities Disclosure [Text Block] Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member] Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Fair value, inputs, level 2 Fair Value, Inputs, Level 2 [Member] Net Investment Hedges Net Investment Hedging Net Investment Hedging [Member] Entity Emerging Growth Company Entity Emerging Growth Company Contribution of USOR Business Combination, Consideration Transferred, Ownership Interest Business Combination, Consideration Transferred, Ownership Interest Change in cash, cash equivalents, and restricted cash classified as Assets held for sale Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease) Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease) Disposal Group Classification [Domain] Disposal Group Classification [Domain] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] 3.125% Notes Due 2029 3.125% Notes Due 2029 [Member] 3.125% Notes Due 2029 Acquired identifiable intangible assets Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Unrealized Losses and Other Components of Benefit Plans, Net of Tax Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Title Trading Arrangement, Individual Title Non-cash operating lease expense Operating Lease, Expense E.U. Businesses (Disposal Group) E.U. Businesses (Disposal Group) [Member] E.U. Businesses (Disposal Group) Common Stock Common Stock [Member] Changes in retirement-related benefit plans Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Earnings Per Common Share Earnings Per Share [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] 1.63% Euro Notes due October 30, 2026 1.63% Euro Notes Due October 30, 2026 [Member] 1.63% Euro Notes Due October 30, 2026 Total deficit Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Payments to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Minimum Minimum [Member] Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt Proceeds from legal settlements Proceeds from Legal Settlements Property, plant, and equipment, net Property, Plant and Equipment, Net Weighted-average common shares outstanding Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Additional paid-in capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Additional-Paid-In Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Additional-Paid-In Capital Receivables, net Receivables, Net, Current Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Probable loss recovery Estimated Insurance Recoveries Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Foreign Currency Translation Adjustments, Net of Tax Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] 4.88% Notes due March 15, 2044 4.88% Notes Due March 15, 2044 [Member] 4.88% Notes Due March 15, 2044 Cash dividends declared Dividends, Common Stock, Cash ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Proceeds from issuances of long-term debt Proceeds from Issuance of Long-Term Debt Operating lease liabilities Increase (Decrease) in Operating Lease Liability 3.95% Notes due February 16, 2028 3.95% Notes Due February 16, 2028 [Member] 3.95% Notes Due February 16, 2028 Fiscal Period Fiscal Period, Policy [Policy Text Block] Net income Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income from discontinued operations, net of tax Income from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Identifiable assets acquired and liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingent Liabilities Commitments and Contingencies Disclosure [Text Block] Continuing operations (in usd per share) Continuing operations (in usd per share) Income (Loss) from Continuing Operations, Per Diluted Share Other Payments for (Proceeds from) Other Investing Activities Business acquisition, percentage of controlling interest in combined business Business Acquisition, Percentage of Voting Interests Acquired Retained Earnings Retained Earnings [Member] Goodwill, expected tax deductible amount Business Acquisition, Goodwill, Expected Tax Deductible Amount Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] 1.50% Euro Notes due November 17, 2025 1.50% Euro Notes Due November 17, 2025 [Member] 1.50% Euro Notes Due November 17, 2025 Total liabilities and deficit Liabilities and Equity Other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Weighted- Average Remaining Amortization Period (Years) Finite-Lived Intangible Assets, Remaining Amortization Period Exit and other-related costs Business Exit Costs Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Unrealized gains on cash flow and other hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Total (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Derivative, notional amount, entered into during period Derivative, Notional Amount, Entered Into During Period Derivative, Notional Amount, Entered Into During Period Accounting Policies [Abstract] Accounting Policies [Abstract] Service agreements Service Agreements [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Currency [Axis] Currency [Axis] Expected total pre-tax charges Restructuring and Related Cost, Expected Cost Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals Schedule of Segment Reporting Information, by Segment [Table Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Restructuring costs, anticipated total charges Total Restructuring, impairment, and related charges, net Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Other adjustments Goodwill, Purchase Accounting Adjustments Unsecured Debt Unsecured Debt [Member] Purchase consideration: Business Combinations [Abstract] Authorized amount available for future repurchases Stock Repurchase Program, Remaining Authorized Repurchase Amount Technology Technology-Based Intangible Assets [Member] Termination Date Trading Arrangement Termination Date U.K. Disposal Group (Disposal Group) U.K. Businesses (Disposal Group) [Member] U.K. Businesses (Disposal Group) Drafts and accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Proceeds from collection of notes receivable Proceeds from Collection of Notes Receivable Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest Operating lease right-of-use assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets Number of other national distributors named in suit Loss Contingency, Number of Other Defendants Loss Contingency, Number of Other Defendants Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Derivative, by Nature [Axis] Derivative Instrument [Axis] Adjustments to reconcile to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Tax liability increase due to proposed adjustment to taxable income Income Tax Examination, Estimate Of Possible Liability Adjustment Income Tax Examination, Estimate Of Possible Liability Adjustment All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Accumulated other comprehensive loss adjustment Reclassification from AOCI, Current Period, Tax Award Timing Disclosures [Line Items] Asset impairments and accelerated depreciation Asset Impairment Charges, Including Accelerated Depreciation Asset Impairment Charges, Including Accelerated Depreciation Compensation Amount Outstanding Recovery Compensation Amount Three National Pharmaceutical Distributors Three National Pharmaceutical Distributors [Member] Three National Pharmaceutical Distributors Prepaid expenses and other/Other accrued liabilities Current Asset / Liability [Member] Current Asset / Liability [Member] Comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Long-term litigation liabilities Loss Contingency, Accrual, Noncurrent Revenue derived from services, percentage (approximately or less than) Revenue Derived From Services, Percentage Revenue Derived From Services, Percentage Additional paid-in capital Additional Paid in Capital Debt instrument, redemption period (in days) Debt Instrument, Redemption Period Debt Instrument, Redemption Period Subsequent Event Type [Axis] Subsequent Event Type [Axis] Restructuring Plan [Axis] Restructuring Plan [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Credits associated with last-in, first-out inventory method Pre-tax credits related to LIFO accounting Inventory, LIFO Reserve, Period Charge Prepaid expenses and other Prepaid Expense and Other Assets, Current Estimated annual amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Insider Trading Arrangements [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] 1.625% Notes Due 2026 1.625% Notes Due 2026 [Member] 1.625% Notes Due 2026 Issuance of shares under employee plans, net of forfeitures Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Reclassification of recurring compensation to other accrued liabilities Noncontrolling Interest, Decrease from Reclassification to Liability Noncontrolling Interest, Decrease from Reclassification to Liability Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Open Market Share Repurchase Transactions Open Market Share Repurchase Transactions [Member] Open Market Share Repurchase Transactions [Member] Estimated annual amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Capitalized software expenditures Payments to Acquire Software Fair value adjustment gain Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Noncontrolling interests Equity, Attributable to Noncontrolling Interest Cash payments Payments for Restructuring Document Period End Date Document Period End Date Borrowings under facility Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Native American Tribes Other Than Cherokee Nation Native American Tribes Other Than Cherokee Nation [Member] Native American Tribes Other Than Cherokee Nation Repayments of long-term debt Repayments of long-term debt Repayments of Long-Term Debt Treasury Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total litigation liabilities Loss Contingency Accrual Litigation settlement, amount awarded to other party, percentage of total settlement to be used to remediate damages Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Estimated annual amortization expense, thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Income tax expense Income tax expense (benefit) related to continuing operations Income Tax Expense (Benefit) Derivatives designated for hedge accounting Designated as Hedging Instrument [Member] 4.90% Notes due July 15, 2028 4.90% Notes Due July 15, 2028 [Member] 4.90% Notes Due July 15, 2028 Receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Fair Value Measurements Fair Value Disclosures [Text Block] Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Aurelius Elephant Limited Aurelius Elephant Limited [Member] Aurelius Elephant Limited Name Trading Arrangement, Individual Name Amounts reclassified to earnings and other Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other comprehensive income (loss) Other comprehensive income (loss) attributable to McKesson Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Settlement payment Payments for Legal Settlements Equity [Abstract] Equity [Abstract] Revenues Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] 5.25% Notes due February 15, 2026 5.25% Notes Due February 15, 2026 [Member] 5.25% Notes Due February 15, 2026 Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Fair Value Hedges Fair Value Hedging [Member] Deferred taxes Increase (Decrease) in Deferred Income Taxes Cash and cash equivalents Cash and cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value Acquisitions, net of cash, cash equivalents, and restricted cash acquired Payments to Acquire Businesses, Net of Cash Acquired Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Credit Facility [Domain] Credit Facility [Domain] International Segment International International Segment [Member] International Segment Common stock repurchased (in shares) Treasury Stock, Shares, Acquired Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Commercial paper Long-Term Commercial Paper, Current Diluted (in usd per share) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted U.S. Pharmaceutical U.S. Pharmaceutical Segment [Member] U.S. Pharmaceutical Segment [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] 3.13% Sterling Notes due February 17, 2029 3.13% Sterling Notes Due February 17, 2029 [Member] 3.13% Sterling Notes Due February 17, 2029 Money market funds at carrying value Money Market Funds, at Carrying Value Payments for property, plant, and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Proceeds from issuance of commercial paper Proceeds from Issuance of Commercial Paper Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition United States UNITED STATES Fair Value, Recurring Fair Value, Recurring [Member] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Other non-current liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Cash Flow Hedges Cash Flow Hedging [Member] Total operating expenses Operating Expenses Segments of Business Segment Reporting Disclosure [Text Block] Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating income Total operating profit (loss) Operating Income (Loss) Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Total Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] Segment revenues Revenues [Abstract] Litigation liabilities Increase (Decrease) in Litigation Reserve Increase (Decrease) in Litigation Reserve Restructuring, impairment, and related charges, net Restructuring, impairment, and related charges, net Restructuring, Impairment and Other Related Charges Restructuring, Impairment and Other Related Charges Other comprehensive income, net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Issuances Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Business Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] USOR McKesson U.S. Oncology Research [Member] McKesson U.S. Oncology Research Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Segment Reporting Information, Profit (Loss) [Abstract] Segment Reporting Information, Profit (Loss) [Abstract] Schedule of Long-Term Debt Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Amounts outstanding under facility Long-Term Line of Credit Customer relationships Customer Relationships [Member] Euro Denominated Notes Euro Denominated Notes [Member] Euro Denominated Notes [Member] Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization [Member] Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization Number of former officers Loss Contingency, Number of Former Officers Loss Contingency, Number of Former Officers Noncontrolling Interests Noncontrolling Interest [Member] EX-101.PRE 11 mck-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 mck-20230630_g1.jpg begin 644 mck-20230630_g1.jpg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htm IDEA: XBRL DOCUMENT v3.23.2
Cover
3 Months Ended
Jun. 30, 2023
shares
Entity Information [Line Items]  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Jun. 30, 2023
Document Transition Report false
Entity File Number 1-13252
Entity Registrant Name McKESSON CORPORATION
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 94-3207296
Entity Address, Address Line One 6555 State Hwy 161
Entity Address, City or Town Irving
Entity Address, State or Province TX
Entity Address, Postal Zip Code 75039
City Area Code 972
Local Phone Number 446-4800
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 134,902,380
Entity Central Index Key 0000927653
Document Fiscal Year Focus 2024
Document Fiscal Period Focus Q1
Amendment Flag false
Current Fiscal Year End Date --03-31
Common Stock  
Entity Information [Line Items]  
Title of 12(b) Security Common stock, $0.01 par value
Trading Symbol MCK
Security Exchange Name NYSE
1.500% Notes Due 2025  
Entity Information [Line Items]  
Title of 12(b) Security 1.500% Notes due 2025
Trading Symbol MCK25
Security Exchange Name NYSE
1.625% Notes Due 2026  
Entity Information [Line Items]  
Title of 12(b) Security 1.625% Notes due 2026
Trading Symbol MCK26
Security Exchange Name NYSE
3.125% Notes Due 2029  
Entity Information [Line Items]  
Title of 12(b) Security 3.125% Notes due 2029
Trading Symbol MCK29
Security Exchange Name NYSE
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenues $ 74,483 $ 67,154
Cost of sales (71,461) (64,131)
Gross profit 3,022 3,023
Selling, distribution, general, and administrative expenses (1,870) (1,959)
Claims and litigation charges, net 0 (5)
Restructuring, impairment, and related charges, net (52) (23)
Total operating expenses (1,922) (1,987)
Operating income 1,100 1,036
Other income, net 38 15
Interest expense (47) (45)
Income from continuing operations before income taxes 1,091 1,006
Income tax expense (94) (199)
Income from continuing operations 997 807
Income from discontinued operations, net of tax 0 2
Net income 997 809
Net income attributable to noncontrolling interests (39) (41)
Net income attributable to McKesson Corporation $ 958 $ 768
Diluted    
Continuing operations (in usd per share) $ 7.02 $ 5.25
Discontinued operations (in usd per share) 0 0.01
Total (in dollars per share) 7.02 5.26
Basic    
Continuing operations (in usd per share) 7.07 5.31
Discontinued operations (in usd per share) 0 0.01
Total (in dollars per share) $ 7.07 $ 5.32
Weighted-average common shares outstanding    
Diluted (in usd per share) 136.6 145.9
Basic (in shares) 135.5 144.2
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]    
Net income $ 997 $ 809
Other comprehensive income, net of tax    
Foreign currency translation adjustments 52 582
Unrealized gains on cash flow and other hedges 7 18
Changes in retirement-related benefit plans (2) 36
Other comprehensive income, net of tax 57 636
Comprehensive income 1,054 1,445
Comprehensive income attributable to noncontrolling interests (39) (91)
Comprehensive income attributable to McKesson Corporation $ 1,015 $ 1,354
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 30, 2023
Mar. 31, 2023
Current assets    
Cash and cash equivalents $ 2,636 $ 4,678
Receivables, net 21,860 19,410
Inventories, net 20,510 19,691
Prepaid expenses and other 533 513
Total current assets 45,539 44,292
Property, plant, and equipment, net 2,172 2,177
Operating lease right-of-use assets 1,693 1,635
Goodwill 9,971 9,947
Intangible assets, net 2,221 2,277
Other non-current assets 2,500 1,992
Total assets 64,096 62,320
Current liabilities    
Drafts and accounts payable 43,982 42,490
Current portion of long-term debt 50 968
Current portion of operating lease liabilities 300 299
Other accrued liabilities 4,090 4,200
Total current liabilities 48,422 47,957
Long-term debt 5,611 4,626
Long-term deferred tax liabilities 1,139 1,387
Long-term operating lease liabilities 1,462 1,402
Long-term litigation liabilities 6,628 6,625
Other non-current liabilities 2,074 1,813
McKesson Corporation stockholders’ deficit    
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding 0 0
Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at June 30, 2023 and March 31, 2023, respectively 3 3
Additional paid-in capital 7,824 7,747
Retained earnings 13,182 12,295
Accumulated other comprehensive loss (848) (905)
Treasury shares, at cost, 143 and 141 shares at June 30, 2023 and March 31, 2023, respectively (21,763) (20,997)
Total McKesson Corporation stockholders’ deficit (1,602) (1,857)
Noncontrolling interests 362 367
Total deficit (1,240) (1,490)
Total liabilities and deficit $ 64,096 $ 62,320
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2023
Mar. 31, 2023
McKesson Corporation stockholders’ deficit    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 100,000,000 100,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 800,000,000 800,000,000
Common stock, shares issued (in shares) 278,000,000 277,000,000
Treasury shares (in shares) 143,000,000 141,000,000
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury
Noncontrolling Interests
Beginning balance (in shares) at Mar. 31, 2022   275          
Beginning balance (in shares) at Mar. 31, 2022           (130)  
Beginning balance at Mar. 31, 2022 $ (1,792) $ 2 $ 7,275 $ 9,030 $ (1,534) $ (17,045) $ 480
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of shares under employee plans, net of forfeitures (in shares)   2          
Issuance of shares under employee plans, net of forfeitures (60) $ 1 91     (152)  
Share-based compensation 40   $ 40        
Repurchase of common stock (1,000)         $ (944)  
Repurchase of common stock (in shares)     (56)     (3)  
Net income (loss) 809     768     41
Other comprehensive income (loss) 636       586   50
Cash dividends declared (67)     (67)      
Payments to noncontrolling interests (36)           (36)
Reclassification of recurring compensation to other accrued liabilities (2)           (2)
Other 0     1     (1)
Ending balance (in shares) at Jun. 30, 2022   277          
Ending balance (in shares) at Jun. 30, 2022           (133)  
Ending balance at Jun. 30, 2022 $ (1,472) $ 3 $ 7,350 9,732 (948) $ (18,141) 532
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Dividends declared per common share (in dollars per share) $ 0.47            
Beginning balance (in shares) at Mar. 31, 2023   277          
Beginning balance (in shares) at Mar. 31, 2023 (141)         (141)  
Beginning balance at Mar. 31, 2023 $ (1,490) $ 3 7,747 12,295 (905) $ (20,997) 367
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of shares under employee plans, net of forfeitures (in shares)   1          
Issuance of shares under employee plans, net of forfeitures (66)   27     (93)  
Share-based compensation 43   43        
Repurchase of common stock (673)         $ (673)  
Repurchase of common stock (in shares)           (2)  
Net income (loss) 997     958     39
Other comprehensive income (loss) 57       57    
Cash dividends declared (73)     (73)      
Payments to noncontrolling interests (39)           (39)
Other $ 4   7 2     (5)
Ending balance (in shares) at Jun. 30, 2023   278          
Ending balance (in shares) at Jun. 30, 2023 (143)         (143)  
Ending balance at Jun. 30, 2023 $ (1,240) $ 3 $ 7,824 $ 13,182 $ (848) $ (21,763) $ 362
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Dividends declared per common share (in dollars per share) $ 0.54            
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) - $ / shares
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Statement of Stockholders' Equity [Abstract]    
Dividends declared per common share (in dollars per share) $ 0.54 $ 0.47
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
OPERATING ACTIVITIES    
Net income $ 997 $ 809
Adjustments to reconcile to net cash used in operating activities:    
Depreciation 64 61
Amortization 95 87
Long-lived asset impairment charges 28 0
Deferred taxes (235) 109
Credits associated with last-in, first-out inventory method 32 (13)
Non-cash operating lease expense 58 63
Gain from sales of businesses and investments (19) (33)
European businesses held for sale 0 20
Other non-cash items 41 102
Changes in assets and liabilities, net of acquisitions:    
Receivables (2,380) (1,584)
Inventories (826) (955)
Drafts and accounts payable 1,473 1,006
Operating lease liabilities (80) (94)
Taxes 236 37
Litigation liabilities 0 (370)
Other (536) (186)
Net cash used in operating activities (1,052) (941)
INVESTING ACTIVITIES    
Payments for property, plant, and equipment (78) (71)
Capitalized software expenditures (46) (29)
Acquisitions, net of cash, cash equivalents, and restricted cash acquired 0 (1)
Proceeds from sales of businesses and investments, net 39 240
Other (64) (100)
Net cash provided by (used in) investing activities (149) 39
FINANCING ACTIVITIES    
Proceeds from short-term borrowings 65 0
Repayments of short-term borrowings (65) 0
Proceeds from issuances of long-term debt 991 0
Repayments of long-term debt (268) (2)
Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt (647) 0
Common stock transactions:    
Issuances 27 91
Share repurchases (696) (1,000)
Dividends paid (74) (71)
Other (176) (199)
Net cash used in financing activities (843) (1,181)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 2 18
Change in cash, cash equivalents, and restricted cash classified as Assets held for sale 0 470
Net decrease in cash, cash equivalents, and restricted cash (2,042) (1,595)
Cash, cash equivalents, and restricted cash at beginning of period 4,679 3,935
Cash, cash equivalents, and restricted cash at end of period 2,637 2,340
Less: Restricted cash at end of period included in Prepaid expenses and other (1) (107)
Cash and cash equivalents at end of period $ 2,636 $ 2,233
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Significant Accounting Policies
3 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Significant Accounting Policies Significant Accounting Policies
Nature of Operations: McKesson Corporation (“McKesson,” or the “Company,”) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (“RxTS”), Medical-Surgical Solutions, and International. Refer to Financial Note 12, “Segments of Business,” for additional information.
Basis of Presentation: The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.
The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net income attributable to noncontrolling interests” in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees.
Net income attributable to noncontrolling interests includes third-party equity interests in the Company’s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (“McKesson Europe”). The Company’s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company’s businesses in the European Union (“E.U.”) in October 2022, which is discussed further in Financial Note 2, “Business Acquisitions and Divestitures.”
The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (“VIE”). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method.
Fiscal Period: The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.
Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation.
Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.
The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May 9, 2023 (the “2023 Annual Report”).
On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the “IRA”). Among other provisions, the IRA includes a 15% corporate minimum tax, a 1% excise tax on certain repurchases of an entity’s own common stock after December 31, 2022, and various drug pricing reforms. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures. The Company will continue to evaluate the full impact of these legislative changes as they are announced and implemented. Refer to Financial Note 11, “Stockholders' Deficit,” for further details regarding excise taxes incurred on the Company’s share repurchases during the three months ended June 30, 2023.
Recently Adopted Accounting Pronouncements
There were no accounting standards adopted by the Company during the three months ended June 30, 2023.
Recently Issued Accounting Pronouncements Not Yet Adopted
In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisitions and Divestitures
3 Months Ended
Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Acquisitions and Divestitures Business Acquisitions and Divestitures
Acquisitions
Rx Savings Solutions, LLC
On November 1, 2022, the Company completed its acquisition of 100% of the shares of Rx Savings Solutions, LLC (“RxSS”), a privately-owned company headquartered in Overland Park, Kansas, to further connect biopharma and payer services to patients. RxSS is a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. The purchase consideration included a payment of $600 million in cash made upon closing and a maximum of $275 million of contingent consideration based on RxSS’ operational and financial performance through calendar year 2025. The payment made upon closing was funded from cash on hand. The financial results of RxSS are included in the Company’s RxTS segment as of the acquisition date. The transaction was accounted for as a business combination.
The Company recorded a liability for the contingent consideration at its fair value of $92 million as of the acquisition date. The fair value of the contingent consideration liability was estimated using a Monte Carlo simulation model, utilizing internal cash flow projections which are Level 3 inputs under Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures. The contingent liability will be remeasured to fair value at each reporting date until the liability is settled with changes in fair value being recognized within “Selling, distribution, general, and administrative expenses” in the Company’s Condensed Consolidated Statements of Operations. During the three months ended June 30, 2023, the Company recognized a fair value adjustment gain of $28 million, which reduced its contingent consideration liability, based on the estimated amount and timing of projected operational and financial information and the probability of achievement of certain performance milestones. As of June 30, 2023 and March 31, 2023, the current portion of $45 million and $83 million, respectively, is included within “Other accrued liabilities” and the long-term portion of $19 million and $9 million, respectively, is included within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheets. Recognition of the initial fair value of this contingent consideration was a non-cash investing activity.
The purchase price allocation included acquired identifiable intangible assets of $229 million, primarily representing customer relationships and technology with a weighted average amortization period of 12 years, and goodwill of $463 million. Goodwill has been allocated to the Company’s RxTS segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition is deductible for tax purposes.
The following table summarizes the preliminary purchase price allocation for this acquisition:
(In millions)Amounts Recognized as of Acquisition Date (As Adjusted)
Purchase consideration:
Cash$600 
Contingent consideration92 
Total purchase consideration$692 
Identifiable assets acquired and liabilities assumed:
Current assets$
Intangible assets229 
Other non-current assets
Current liabilities(8)
Total identifiable net assets229 
Goodwill463 
Net assets acquired$692 
SCRI Oncology, LLC
On October 31, 2022, the Company completed a transaction with HCA Healthcare, Inc. (“HCA”) to form SCRI Oncology, LLC (“SCRI Oncology”), an oncology research business combining McKesson’s U.S. Oncology Research (“USOR”) and HCA’s Sarah Cannon Research Institute (“SCRI”) based in Nashville, Tennessee, to advance cancer care and increase access to oncology clinical research. Upon consummation of the transaction, McKesson owns a 51% controlling interest in the combined business, and the financial results are consolidated by the Company and reported within its U.S. Pharmaceutical segment as of the acquisition date. Transaction consideration included the transfer of full ownership interest in USOR to the combined business and $166 million of net cash paid to HCA, which was funded from cash on hand. The transaction was accounted for as a business combination.
The purchase price allocation included acquired identifiable intangible assets of $177 million, primarily representing customer relationships as well as trademarks and trade names with a weighted average amortization period of 17 years, and goodwill of $113 million. Goodwill has been allocated to the Company’s U.S. Pharmaceutical segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition of $46 million is deductible for tax purposes. The Company recorded noncontrolling interest of $222 million as a component of equity, which includes HCA’s proportionate interest in the identifiable net assets of SCRI at fair value of $202 million and its proportionate interest in the contributed net assets of USOR at carrying value of $20 million. The difference between the fair value of the Company’s acquired interest in SCRI net assets and the $166 million of net cash paid to HCA was recognized as additional paid in capital, as well as the Company’s reduction in ownership interest in USOR net assets.
The following table summarizes the preliminary purchase price allocation for this acquisition:
(In millions)Amounts Recognized as of Acquisition Date (As Adjusted)
Purchase consideration:
Cash$166 
Contribution of USOR40 
Total purchase consideration$206 
Identifiable assets acquired and liabilities assumed:
Receivables$224 
Property, plant, and equipment22 
Operating lease right-of-use assets31 
Intangible assets177 
Current liabilities(42)
Long-term operating lease liabilities(29)
Other non-current liabilities(43)
Total identifiable net assets340 
Noncontrolling interest(222)
Additional paid-in capital(25)
Goodwill113 
Net assets acquired$206 
The fair value of the acquired identifiable intangible assets from the acquisitions discussed above were determined by applying the income approach, using a discounted cash flow model in which cash flows anticipated over several periods are discounted to their present value using an appropriate rate that is commensurate with the risk inherent with the transaction. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The amounts presented above are subject to change as the Company’s fair value assessments are finalized. There have been no material changes to the purchase price allocation of these acquisitions since the acquisition date. Pro forma financial information has not been provided as these acquisitions did not have a material impact, individually, or in the aggregate, to the Company’s consolidated results of operations.
Divestitures
European Divestiture Activities
In July 2021, the Company announced its intention to exit its businesses in Europe. On October 31, 2022, the Company completed its previously announced transaction to sell certain of its businesses in the European Union (“E.U.”) located in France, Italy, Ireland, Portugal, Belgium, and Slovenia, along with its German headquarters and wound-care business, part of a shared services center in Lithuania, and its ownership stake in a joint venture in the Netherlands (“E.U. disposal group”) to the PHOENIX Group. During the three months ended June 30, 2022, the Company recorded a gain of $12 million to remeasure the E.U. disposal group to fair value less costs to sell which was recorded within “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statement of Operations. The Company’s measurement of the fair value of the E.U. disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreement. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.
On April 6, 2022, the Company completed the previously announced sale of its retail and distribution businesses in the United Kingdom (“U.K. disposal group”) to Aurelius Elephant Limited for a purchase price of £110 million (or, approximately $144 million), including certain adjustments. As part of the transaction, the Company divested net assets of $615 million and released $731 million of accumulated other comprehensive loss, within the International segment, and the buyer assumed and repaid a note payable to the Company of $118 million.
At June 30, 2023 and March 31, 2023, the Company had no assets or liabilities related to these European divestiture activities that met the criteria for classification as held for sale. Subsequent to the divestiture activities discussed above, the Company’s European operations primarily consist of its retail and distribution businesses in Norway.
Other
For the periods presented, the Company also completed de minimis acquisitions and divestitures within its operating segments. Financial results for the Company’s business acquisitions have been included in its consolidated financial statements as of their respective acquisition dates. Purchase prices for business acquisitions have been allocated based on estimated fair values at the respective acquisition dates.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring, Impairment, and Related Charges, Net
3 Months Ended
Jun. 30, 2023
Restructuring and Related Activities [Abstract]  
Restructuring, Impairment, and Related Charges, Net Restructuring, Impairment, and Related Charges, Net
The Company recorded restructuring, impairment, and related charges, net of $52 million and $23 million for the three months ended June 30, 2023 and 2022, respectively. These charges were included in “Restructuring, impairment, and related charges, net” in the Condensed Consolidated Statements of Operations.
Restructuring Initiatives
During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. The Company anticipates total charges of approximately $125 million across its RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $96 million of charges were recorded to date. For the three months ended June 30, 2023, the Company recorded charges of $36 million related to this program, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024.
Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following:
Three Months Ended June 30, 2023
(In millions)U.S. Pharmaceutical
Prescription Technology Solutions (1)
Medical-Surgical Solutions
International
Corporate (1)
Total
Severance and employee-related costs, net $$— $— $— $$
Exit and other-related costs (2)
12 22 
Asset impairments and accelerated depreciation— — — 27 28 
Total$$$$$40 $52 
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.
(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Three Months Ended June 30, 2022
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternational
Corporate
Total
Severance and employee-related costs, net $$— $— $— $(1)$
Exit and other-related costs (1)
15 21 
Asset impairments and accelerated depreciation— — — (5)— 
Total$$$$$$23 
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the three months ended June 30, 2023:
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotal
Balance, March 31, 2023 (1)
$15 $26 $$13 $35 $92 
Restructuring, impairment, and related charges, net40 52 
Non-cash charges— — — (1)(27)(28)
Cash payments(5)(13)(2)(2)(15)(37)
Other (2)
— — — (5)— (5)
Balance, June 30, 2023 (3)
$12 $15 $$11 $33 $74 
(1)As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.
(2)Other primarily includes cumulative translation adjustments and transfers to certain other liabilities.
(3)As of June 30, 2023, the total reserve balance was $74 million, of which $44 million was recorded in “Other accrued liabilities” and $30 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes
3 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Income tax expense related to continuing operations was as follows:
Three Months Ended June 30,
(Dollars in millions)20232022
Income tax expense$94 $199 
Reported income tax rate8.6 %19.8 %
Fluctuations in the Company’s reported income tax rates were primarily due to changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters.
During the three months ended June 30, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory, a net discrete tax benefit of $147 million was recognized in the first quarter of fiscal 2024.
During the three months ended June 30, 2022, the Company recognized a net discrete tax benefit of $45 million primarily related to the tax impact of share-based compensation.
As of June 30, 2023, the Company had $1.4 billion of unrecognized tax benefits, of which $1.3 billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year.     
The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year.
During the fourth quarter of fiscal 2023, the Internal Revenue Service (“IRS”) communicated proposed adjustments to taxable income reported in the Company’s fiscal 2018 and fiscal 2019 U.S. Federal Corporate Income Tax returns. The adjustments would increase the Company’s federal income tax liability in the range of $600 million to $700 million. The Company disagrees with the proposed adjustments and intends to pursue resolution through the administrative process with the IRS Independent Office of Appeals and, if necessary, through judicial remedies. During the first quarter of fiscal 2024, the Company filed a formal protest with the IRS. The Company does not anticipate a final resolution of these matters until fiscal 2026 or after. Although the final resolution of these matters is uncertain, the Company believes in the merits of its tax positions and believes that it has adequately reserved for any adjustments to the provision of income taxes that may ultimately result. However, if the IRS prevails in these matters, the assessed tax and interest could have a material adverse effect on the Company’s financial position, results of operations, and cash flows in future periods.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Common Share
3 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Earnings Per Common Share Earnings Per Common ShareBasic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings per common share is similar to that of basic earnings per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than 1.0 million of potentially dilutive securities for the three months ended June 30, 2023 and 2022 were excluded from the computation of diluted earnings per common share as they were anti-dilutive.
The computations for basic and diluted earnings per common share were as follows:
Three Months Ended June 30,
(In millions, except per share amounts)20232022
Income from continuing operations$997 $807 
Net income attributable to noncontrolling interests(39)(41)
Income from continuing operations attributable to McKesson Corporation958 766 
Income from discontinued operations, net of tax— 
Net income attributable to McKesson Corporation$958 $768 
Weighted-average common shares outstanding:
Basic135.5 144.2 
Effect of dilutive securities:
Stock options0.2 0.3 
Restricted stock units (1)
0.9 1.4 
Diluted136.6 145.9 
Earnings per common share attributable to McKesson Corporation: (2)
Diluted
Continuing operations$7.02 $5.25 
Discontinued operations— 0.01 
Total$7.02 $5.26 
Basic
Continuing operations$7.07 $5.31 
Discontinued operations— 0.01 
Total$7.07 $5.32 
(1)Includes dilutive effect from restricted stock units and performance-based stock units.
(2)Certain computations may reflect rounding adjustments.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Goodwill and Intangible Assets, Net
3 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
Goodwill
The Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2024 and fiscal 2023 did not indicate any impairment of goodwill.
Changes in the carrying amount of goodwill were as follows:
(In millions)
U.S. Pharmaceutical (1)
Prescription Technology SolutionsMedical-Surgical Solutions
International
Total
Balance, March 31, 2023$4,050 $2,005 $2,453 $1,439 $9,947 
Foreign currency translation adjustments, net— — — 29 29 
Other adjustments (2)
(5)— — — (5)
Balance, June 30, 2023$4,045 $2,005 $2,453 $1,468 $9,971 
(1)The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe’s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.
(2)Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, “Business Acquisitions and Divestitures.”
Intangible Assets
Information regarding intangible assets was as follows:
 June 30, 2023March 31, 2023
(Dollars in millions)Weighted-
Average
Remaining
Amortization
Period
(Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Customer relationships12$2,984 $(1,801)$1,183 $2,971 $(1,765)$1,206 
Service agreements101,141 (641)500 1,137 (623)514 
Trademarks and trade names12843 (446)397 833 (430)403 
Technology11264 (133)131 264 (129)135 
Other6184 (174)10 193 (174)19 
Total $5,416 $(3,195)$2,221 $5,398 $(3,121)$2,277 
All intangible assets were subject to amortization as of June 30, 2023 and March 31, 2023. Amortization expense of intangible assets was $62 million and $56 million for the three months ended June 30, 2023 and 2022, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $185 million, $240 million, $208 million, $202 million, and $198 million for the remainder of fiscal 2024 and each of the succeeding years through fiscal 2028, respectively, and $1.2 billion thereafter.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Debt and Financing Activities
3 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Debt and Financing Activities Debt and Financing Activities
Long-term debt consisted of the following:
(In millions)June 30, 2023March 31, 2023
U.S. Dollar notes (1) (2)
3.80% Notes due March 15, 2024
$— $918 
0.90% Notes due December 3, 2025
500 500 
5.25% Notes due February 15, 2026
499 499 
1.30% Notes due August 15, 2026
499 498 
7.65% Debentures due March 1, 2027
150 150 
3.95% Notes due February 16, 2028
343 343 
4.90% Notes due July 15, 2028
399 — 
4.75% Notes due May 30, 2029
196 196 
5.10% Notes due July 15, 2033
596 — 
6.00% Notes due March 1, 2041
218 218 
4.88% Notes due March 15, 2044
255 255 
Foreign currency notes (1) (3)
1.50% Euro Notes due November 17, 2025
653 649 
1.63% Euro Notes due October 30, 2026
545 542 
3.13% Sterling Notes due February 17, 2029
571 555 
Lease and other obligations237 271 
Total debt5,661 5,594 
Less: Current portion50 968 
Total long-term debt$5,611 $4,626 
(1)These notes are unsecured and unsubordinated obligations of the Company.
(2)Interest on these U.S. dollar notes is payable semi-annually.
(3)Interest on these foreign currency notes is payable annually.
Long-Term Debt
The Company’s long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At June 30, 2023 and March 31, 2023, $5.7 billion and $5.6 billion, respectively, of total debt was outstanding, of which $50 million and $968 million, respectively, was included under the caption “Current portion of long-term debt” in the Company’s Condensed Consolidated Balance Sheets.
Notes Offerings
On June 15, 2023, the Company completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million (the “2028 Notes”) and a public offering of 5.10% Notes due July 15, 2033 in a principal amount of $600 million (the “2033 Notes” and, together with the 2028 Notes, the “Notes”). Interest on the Notes is payable semi-annually on January 15th and July 15th of each year, commencing on January 15, 2024. Proceeds received from the issuance of the Notes, net of discounts and offering expenses, were $397 million for the 2028 Notes and $592 million for the 2033 Notes. The Company utilized a portion of the net proceeds from the offerings of the Notes to fund the purchase price payable with respect to the portion of the Company’s then outstanding 3.80% Notes due March 15, 2024 (the “2024 Notes”) that was validly tendered and accepted for purchase pursuant to the Concurrent Tender Offer (as defined below) and to effect the satisfaction and discharge of the remaining portion of the 2024 Notes, all of which is described further below. The remaining net proceeds from the offerings of the Notes is available for general corporate purposes.
Each series of the Notes is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Company’s existing, and future unsecured and unsubordinated indebtedness that may be outstanding from time-to-time. The Notes are governed by an indenture and officers’ certificate that are materially similar to those of other series of notes issued by the Company. Upon at least 10 days’ and not more than 60 days’ notice to holders of the applicable series of the Notes, the Company may redeem either series of the Notes for cash in whole, at any time, or in part, from time to time, at redemption prices that include accrued and unpaid interest and a make-whole premium before a specified date, and at par plus accrued and unpaid interest thereafter until maturity, each as specified in the indenture and the officers’ certificate. If there were to occur both (1) a change of control of the Company and (2) a downgrade of the applicable series of the Notes below an investment grade rating by each of the Ratings Agencies (as defined in the officers’ certificate) within a specified period, then the Company would be required to make an offer to purchase those Notes at a price equal to 101% of the then outstanding principal amount of such Notes, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officers’ certificate for the Notes, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lenders’ consent. The indenture also contains customary events of default provisions.
Concurrent Tender Offer
On June 16, 2023, the Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the “Concurrent Tender Offer”). The Company paid an aggregate consideration of $268 million in the Concurrent Tender Offer to repurchase $271 million principal amount of the 2024 Notes at a repurchase price equal to 98.75% of the principal amount plus accrued and unpaid interest. The repurchase of the 2024 Notes accepted for purchase in the Concurrent Tender Offer was accounted for as a debt extinguishment.
Satisfaction and Discharge of the 2024 Notes
On June 16, 2023, after completing the Concurrent Tender Offer, the Company irrevocably deposited with the trustee under the indenture governing the 2024 Notes (the “2024 Notes Indenture”) U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest of the remaining $647 million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. The U.S. government obligations were purchased using a portion of the net proceeds from the offerings of the Notes. After the deposit of such funds with the trustee, the Company’s obligations under the 2024 Notes Indenture with respect to the 2024 Notes were satisfied and discharged and the transaction was accounted for as a debt extinguishment.
The total gain recognized on the debt extinguishments described above for the three months ended June 30, 2023 was $9 million and included within “Interest expense” in the Company’s Condensed Consolidated Statement of Operations.
Revolving Credit Facilities
On November 7, 2022, the Company entered into a Credit Agreement (the “2022 Credit Facility”), that provides a syndicated $4.0 billion five-year senior unsecured credit facility with a $3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. The 2022 Credit Facility is scheduled to mature in November 2027. The 2022 Credit Facility replaced the Company’s previous syndicated $4.0 billion five-year senior unsecured credit facility, dated as of September 25, 2019, as amended (the “2020 Credit Facility”), which was scheduled to mature in September 2024. The 2020 Credit Facility was terminated in connection with the execution of the 2022 Credit Facility. There were no borrowings under the 2020 Credit Facility during the three months ended June 30, 2022, and no amounts outstanding at the time of its termination. There were no borrowings under the 2022 Credit Facility during the three months ended June 30, 2023 and no amounts outstanding at June 30, 2023. At June 30, 2023, the Company was in compliance with all covenants under the 2022 Credit Facility.
Commercial Paper
The Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $4.0 billion in outstanding commercial paper notes. During the three months ended June 30, 2023, the Company borrowed and repaid $65 million under the program. During the three months ended June 30, 2022, there were no material borrowings under the program. At June 30, 2023 and March 31, 2023, there were no commercial paper notes outstanding.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Hedging Activities
3 Months Ended
Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging Activities Hedging Activities
In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives as described below. In accordance with the Company’s policy, derivatives are only used for hedging purposes. It does not use derivatives for trading or speculative purposes. The Company uses different counterparties for its derivative contracts to minimize the exposure to credit risk but does not anticipate non-performance by these parties.
Foreign Currency Exchange Risk
The Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Canadian dollars, Euro, and British pounds sterling. Changes in foreign currency exchange rates could have a material adverse impact on the Company’s financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk.
Non-Derivative Instruments Designated as Hedges
Prior to the divestiture of the E.U. disposal group, the Company had €1.1 billion of Euro-denominated notes designated as non-derivative net investment hedges. These hedges were utilized to hedge portions of the Company’s net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. For all notes that were designated as net investment hedges and met effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates were recorded as foreign currency translation adjustments in “Accumulated other comprehensive loss” where they offset foreign currency translation gains and losses recorded on the Company’s net investments. To the extent foreign currency denominated notes designated as net investment hedges were ineffective, changes in carrying value attributable to the change in spot rates were recorded in earnings.
In connection with the divestiture of the E.U. disposal group in October 2022, the Euro-denominated notes described above were de-designated as net investment hedges.
In connection with the sale of the U.K. disposal group in April 2022, the Company reclassified $26 million of gains from accumulated other comprehensive loss to “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statement of Operations for the three months ended June 30, 2022. This amount related to the Company’s £450 million of British pound sterling-denominated notes, which were previously accounted for as net investment hedges until de-designated in fiscal 2020, and was included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities of the disposal group to fair value less costs to sell.
Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:
Three Months Ended June 30,
(In millions)20232022
Non-derivatives designated as net investment hedges: (1)
Euro-denominated notes $— $64 
(1)There was no ineffectiveness in these hedges for the three months ended June 30, 2022.
Derivative Instruments
At June 30, 2023 and March 31, 2023, the notional amounts of the Company’s outstanding derivatives were as follows:
June 30, 2023March 31, 2023
(In millions)Currency
Maturity Date (1)
Notional
Derivatives designated as net investment hedges: (2)
Cross-currency swaps (3)
CADNov-24 to Mar-25C$1,500 C$1,500 
Derivatives designated as fair value hedges: (2)
Cross-currency swaps (4)
GBPNov-28£450 £450 
Cross-currency swaps (4)
EURAug-25 to Jul-261,100 1,100 
Floating interest rate swaps (5)
USDFeb-26 to Sep-29$1,250 $1,250 
Derivatives designated as cash flow hedges: (2)
Cross-currency swaps (3)
CADJan-24C$400 C$400 
Fixed interest rate swaps (6)
USDJun-23$— $450 
(1)The maturity date reflected is for outstanding derivatives as of June 30, 2023.
(2)There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.
(3)The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.
(4)Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes.
(5)Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates.
(6)The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.
Net Investment Hedges
The Company uses cross-currency swaps to hedge portions of the Company’s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Company’s net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.
Fair Value Hedges
The Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains from the changes in the Company’s fair value hedges recorded in earnings were largely offset by the losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive income (loss).
Cash Flow Hedges
From time to time, the Company enters into cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency rates and also enters into forward contracts to hedge the variability of future benchmark interest rates on planned bond issuances. The effective portion of changes in the fair value of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses reclassified from accumulated other comprehensive loss and recorded in “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statements of Operations were not material for the three months ended June 30, 2023 and 2022.
The Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges in fiscal 2023 with a notional amount of $450 million, and in the first quarter of fiscal 2024 with a notional amount of $50 million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500 million cash flow hedges were terminated and the proceeds are amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, “Debt and Financing Activities,” for additional information on the public offering of the 2033 Notes.
Derivatives Not Designated as Hedges
Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statements of Operations. The Company did not have any outstanding derivative instruments not designated as hedges during the periods presented.
Other Information on Derivative Instruments
Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:
Three Months Ended June 30,
(In millions)20232022
Derivatives designated as net investment hedges:
Cross-currency swaps$(20)$12 
Derivatives designated as cash flow and other hedges:
Cross-currency swaps (1)
$(6)$(2)
Fixed interest rate swaps
16 27 
(1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.
Information regarding the fair value of derivatives on a gross basis were as follows:
Balance Sheet
Caption
June 30, 2023March 31, 2023
Fair Value of
Derivative
U.S. Dollar NotionalFair Value of
Derivative
U.S. Dollar Notional
(In millions)AssetLiabilityAssetLiability
Derivatives designated for hedge accounting:
Cross-currency swaps (current)Prepaid expenses and other/Other accrued liabilities$— $$301 $$— $301 
Cross-currency swaps (non-current)Other non-current assets/liabilities84 12 2,760 74 2,760 
Interest rate swaps (non-current)Other non-current assets/liabilities— 39 1,250 15 1,700 
Total$84 $53 $80 $17 
Refer to Financial Note 9, "Fair Value Measurements," for more information on these recurring fair value measurements.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements
3 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, Fair Value Measurements and Disclosures. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:
Level 1 - quoted prices in active markets for identical assets or liabilities.
Level 2 - significant other observable market-based inputs.
Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
Cash and cash equivalents at June 30, 2023 and March 31, 2023 included investments in money market funds of $806 million and $1.4 billion, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.
Fair values of the Company’s interest rate swaps and cross-currency swaps were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, “Hedging Activities,” for fair values and other information on the Company’s derivatives.
The Company holds investments in equity securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $237 million at June 30, 2023 and March 31, 2023. These investments primarily consist of equity securities without readily determinable fair values and are included in “Other non-current assets” in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains as well as impairment charges related to these investments are included within “Other income, net” in the Condensed Consolidated Statements of Operations and were not material for the three months ended June 30, 2023 and 2022.
Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company’s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell.
At June 30, 2023 and March 31, 2023, the contingent consideration liability related to the Company’s acquisition of RxSS in November 2022 was measured at fair value on a nonrecurring basis. Refer to Financial Note 2, “Business Acquisitions and Divestitures," for more information on this transaction.
The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information.
There were no other material assets or liabilities measured at fair value on a nonrecurring basis at June 30, 2023 and March 31, 2023.
Other Fair Value Disclosures
At June 30, 2023 and March 31, 2023, the carrying amounts of cash, certain cash equivalents, restricted cash, receivables, drafts and accounts payable, short-term borrowings, and other current assets and liabilities approximated their estimated fair values because of the short-term maturity of these financial instruments.
The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance.
The Company’s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company’s long-term debt was as follows:
June 30, 2023March 31, 2023
(In millions)Carrying ValueFair ValueCarrying ValueFair Value
Long-term debt, including current maturities$5,661 $5,335 $5,594 $5,386 
The estimated fair value of the Company’s long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.
Goodwill
Fair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow (“DCF”) model to determine the fair value of each reporting unit.
Long-lived Assets
The Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement.
The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingent Liabilities
3 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingent Liabilities Commitments and Contingent Liabilities
In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in Financial Note 17 to the Company’s 2023 Annual Report, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.
Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within “Claims and litigation charges, net” in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.
I. Litigation and Claims Involving Distribution of Controlled Substances
The Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacies. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. They have sought monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), state and federal controlled substances laws, and other statutes. Because of the many uncertainties associated with opioid-related litigation matters, the Company is not able to conclude that a liability is probable or provide a reasonable estimate for the range of ultimate possible loss for opioid-related litigation matters other than those for which an accrual is described below.
State and Local Government Claims
The Company and two other national pharmaceutical distributors (collectively “Distributors”) entered into a settlement agreement (the “Settlement”) and consent judgment with 48 states and their participating subdivisions, as well as the District of Columbia and all eligible territories (the “Settling Governmental Entities”). Approximately 2,300 cases have been dismissed. The Distributors did not admit liability or wrongdoing and do not waive any defenses pursuant to the Settlement. Under the Settlement, the Company has paid the Settling Governmental Entities approximately $1.0 billion as of June 30, 2023, and additionally will pay the Settling Governmental Entities up to approximately $6.8 billion through 2038. A minimum of 85% of the Settlement payments must be used by state and local governmental entities to remediate the opioid epidemic, while the remainder relates to plaintiffs’ attorneys’ fees and costs and will be paid out through 2030. Under the Settlement, the Distributors will establish a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. Alabama and West Virginia did not participate in the Settlement. Under a separate settlement agreement with Alabama and its subdivisions, the Company has paid approximately $42 million as of June 30, 2023, and additionally will pay approximately $132 million through 2031. The Company previously settled with the state of West Virginia in 2018, so West Virginia and its subdivisions were not eligible to participate in the Settlement. Under a separate settlement agreement, the Company has paid certain West Virginia subdivisions approximately $38 million as of June 30, 2023, and additionally will pay approximately $114 million through 2033. That agreement does not include school districts or the claims of Cabell County and the City of Huntington. After a trial, the claims of Cabell County and the City of Huntington, were decided in the Company’s favor on July 4, 2022. Those subdivisions appealed that decision.
Some other state and local governmental subdivisions did not participate in the Settlement, including certain municipal governments, government hospitals, school districts, and government-affiliated third-party payors. The Company contends that those subdivisions’ claims are foreclosed by the Settlement or other dispositive defenses, but the subdivisions contend that their claims are not foreclosed. The City of Baltimore, Maryland, is one such subdivision, and a trial of its claims is scheduled to begin September 26, 2024. An accrual for the remaining governmental subdivision claims is reflected in the total estimated liability for opioid-related claims in a manner consistent with how Settlement amounts were allocated to Settling Governmental Entities.
Native American Tribe Claims
The Company also entered into settlement agreements for opioid-related claims of federally recognized Native American tribes. Under those agreements, the Company has paid the settling Native American tribes approximately $56 million as of June 30, 2023, and additionally will pay approximately $140 million through 2027. A minimum of 85% of the total settlement payments must be used by the settling Native American tribes to remediate the opioid epidemic.
The Company’s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:
(In millions)June 30, 2023March 31, 2023
Current litigation liabilities (1)
$545 $548 
Long-term litigation liabilities6,628 6,625 
Total litigation liabilities$7,173 $7,173 
(1)These amounts, recorded in “Other accrued liabilities” in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.
During the three months ended June 30, 2023, the Company made no payments associated with the Settlement and the separate settlement agreements for opioid-related claims discussed above. In July 2023, the Company made payments totaling $529 million associated with the Settlement and separate settlement agreements.
Non-Governmental Plaintiff Claims
The Company is also a defendant in approximately 400 opioid-related cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement agreements described above or in the charges recorded by the Company.
Canadian Plaintiff Claims
The Company and its Canadian affiliate are also defendants in four opioid-related cases pending in Canada. These cases involve the claims of the provincial governments, a group representing indigenous people, as well as one case brought by an individual.
Defense of Opioids Claims
The Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense in such matters. Other than the settlement agreements and the U.S. governmental subdivision claims described above, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company’s financial position, cash flows or liquidity, or results of operations.
II. Other Litigation and Claims
On December 12, 2018, the Company received a purported class action complaint in the United States District Court for the Northern District of California, alleging that McKesson and two of its former officers, CEO John Hammergren and CFO James Beer, violated the Securities Exchange Act of 1934 by reporting profits and revenues from 2013 until early 2017 that were false and misleading, due to an alleged undisclosed conspiracy to fix the prices of generic drugs. Evanston Police Pension Fund v. McKesson Corporation, No. 3:18-06525. In October 2022, the parties reached an agreement in principle to settle this class action lawsuit for an amount covered in full by the Company’s insurance policy. This settlement does not include any admission of liability, and defendants expressly deny wrongdoing. The Company’s estimated probable loss, entirely offset by probable loss recovery from the Company’s insurers, was $141 million, both of which were recognized in the Condensed Consolidated Balance Sheet as of September 30, 2022 within “Other accrued liabilities” and “Prepaid expenses and other.” In February 2023, the insurance carriers funded the settlement, and the probable loss and loss recovery of $141 million have been reversed in the Consolidated Balance Sheet as of March 31, 2023. On July 14, 2023, the court granted the motion for final approval of the settlement.
In July 2020, the Company was served with a first amended qui tam complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the U.S., 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA. The U.S. and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. On May 5, 2022, the district court granted the Company’s motion to dismiss the complaint, but granted the plaintiff leave to amend the complaint. The relator filed the second amended complaint on June 7, 2022, which was dismissed on March 28, 2023. On April 26, 2023, the relator filed a notice of appeal to the United States Court of Appeals for the Second Circuit.
III. Government Subpoenas and Investigations
From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Deficit
3 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders' Deficit Stockholders' Deficit
Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Company’s Board of Directors (the “Board”).
In July 2023, the quarterly dividend was raised from $0.54 to $0.62 per share of common stock for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors.
Share Repurchase Plans
The Board has authorized the repurchase of McKesson’s common stock. The Company may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase (“ASR”) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company’s stock price, corporate and regulatory requirements, tax implications, restrictions under the Company’s debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions. The ASR programs discussed below were designed to comply with Rule 10b5-1(c).
Effective January 1, 2023, the Company’s repurchase of McKesson’s common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the IRA. Excise taxes incurred on share repurchases of an entity’s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholders’ equity within “Treasury shares” in the Company’s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholders’ Deficit. Excise taxes are not reflected in the Company’s remaining authorization for the repurchase of McKesson’s common stock.
In May 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.0 billion of the Company’s common stock. The total number of shares repurchased under this ASR program was 3.1 million shares at an average price per share of $321.05. The Company received 2.6 million shares as the initial share settlement, and in August 2022, the Company received an additional 0.5 million shares upon the completion of this ASR program.
In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company’s common stock. The total number of shares repurchased under this ASR program was 5.1 million shares at an average price per share of $295.16. The Company received 4.8 million shares as the initial share settlement in the fourth quarter of fiscal 2022, and in May 2022, the Company received an additional 0.3 million shares upon the completion of this ASR program.
During the three months ended June 30, 2023, the Company repurchased 1.8 million of the Company’s shares of common stock for $673 million through open market transactions at an average price per share of $379.14. Of the total dollar value, $4 million was accrued within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet for excise taxes incurred during the three months ended June 30, 2023. As of March 31, 2023, the Company had $27 million accrued within “Other accrued liabilities” for share repurchases that were executed in late March 2023, which settled in early April 2023. There were no open market share repurchases during the three months ended June 30, 2022.
The total remaining authorization outstanding for repurchases of the Company’s common stock at June 30, 2023 was $2.9 billion. In July 2023, the Board approved an increase of $6.0 billion in the authorization for repurchase of McKesson’s common stock.
Accumulated Other Comprehensive Loss
Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:
Foreign Currency Translation Adjustments
(In millions)
Foreign Currency Translation Adjustments, Net of Tax (1)
Unrealized Losses on Net Investment Hedges,
Net of Tax
Unrealized Gains (Losses) on Cash Flow and Other Hedges,
Net of Tax
Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive Loss
Balance, March 31, 2023$(847)$(14)$(36)$(8)$(905)
Other comprehensive income (loss) before reclassifications67 (15)⁽²⁾(2)57 
Amounts reclassified to earnings and other — — — — — 
Other comprehensive income (loss)67 (15)(2)57 
Less: amounts attributable to noncontrolling interests— — — — — 
Other comprehensive income (loss) attributable to McKesson67 (15)(2)57 
Balance, June 30, 2023$(780)$(29)$(29)$(10)$(848)
(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.
(2)Amounts recorded for the three months ended June 30, 2023 include losses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.
Foreign Currency Translation Adjustments
(In millions)
Foreign Currency Translation Adjustments, Net of Tax (1)
Unrealized Gains (Losses) on Net Investment Hedges,
Net of Tax
Unrealized Gains on Cash Flow and Other Hedges,
Net of Tax
Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive Loss
Balance, March 31, 2022$(1,504)$10 $27 $(67)$(1,534)
Other comprehensive income (loss) before reclassifications(176)45 ⁽²⁾18 12 (101)
Amounts reclassified to earnings and other (3)
730 (17)— 24 737 
Other comprehensive income554 28 

18 36 636 
Less: amounts attributable to noncontrolling interests47 — — 50 
Other comprehensive income attributable to McKesson507 28 18 33 586 
Balance, June 30, 2022$(997)$38 $45 $(34)$(948)
(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.
(2)Amounts recorded for the three months ended June 30, 2022 include gains of $64 million related to net investment hedges from Euro-denominated notes and gains of $12 million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $31 million.
(3)Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Segments of Business
3 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Segments of Business Segments of Business
The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources.
The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the U.S. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.
The RxTS segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS serves our biopharma and life sciences partners, delivering innovative solutions that help people get the medicine they need to live healthier lives. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.
The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKesson’s own line of high-quality products through a network of distribution centers in the U.S.
The International segment includes the Company’s operations in Canada and Europe, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Company’s Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and includes Rexall Health retail pharmacies. The Company completed the divestitures of the U.K. disposal group in April 2022 and the E.U. disposal group in October 2022, as discussed in Financial Note 2, “Business Acquisitions and Divestitures.” The Company’s remaining operations in Europe provide distribution and services to wholesale, institutional, and retail customers in Norway where it owns, partners, or franchises with retail pharmacies.
Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals was as follows:
 Three Months Ended June 30,
(In millions)20232022
Segment revenues (1)
U.S. Pharmaceutical$67,160 $56,947 
Prescription Technology Solutions1,244 1,066 
Medical-Surgical Solutions2,611 2,592 
International3,468 6,549 
Total revenues$74,483 $67,154 
Segment operating profit (loss) (2)
U.S. Pharmaceutical (3)
$827 $696 
Prescription Technology Solutions (4)
231 144 
Medical-Surgical Solutions227 256 
International (5)
57 (6)
Subtotal1,342 1,090 
Corporate expenses, net (6)
(204)(39)
Interest expense(47)(45)
Income from continuing operations before income taxes$1,091 $1,006 
(1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment’s total revenues, less than 37% of the RxTS segment’s total revenues, less than 1% of the Medical-Surgical Solutions segment’s total revenues, and less than 1% of the International segment’s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.
(2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company’s reportable segments.
(3)The Company’s U.S. Pharmaceutical segment’s operating profit includes the following:
cash receipts for the Company’s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and
a charge of $32 million and a credit of $13 million related to the last-in, first-out (“LIFO”) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.
(4)The Company’s RxTS segment’s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28 million, which reduced the Company’s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”
(5)The Company’s International segment’s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”
(6)Corporate expenses, net includes the following:
restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” and
a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Pay vs Performance Disclosure - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Pay vs Performance Disclosure    
Net Income (Loss) Attributable to Parent $ 958 $ 768
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Significant Accounting Policies (Policies)
3 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation: The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.
The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net income attributable to noncontrolling interests” in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees.
Net income attributable to noncontrolling interests includes third-party equity interests in the Company’s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (“McKesson Europe”). The Company’s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company’s businesses in the European Union (“E.U.”) in October 2022, which is discussed further in Financial Note 2, “Business Acquisitions and Divestitures.”
The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (“VIE”). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method.
Fiscal Period Fiscal Period: The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.
Reclassification Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation.
Use of Estimates Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.
Results of Operations The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May 9, 2023 (the “2023 Annual Report”).
Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements
There were no accounting standards adopted by the Company during the three months ended June 30, 2023.
Recently Issued Accounting Pronouncements Not Yet Adopted
In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures
Commitments and Contingencies
In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in Financial Note 17 to the Company’s 2023 Annual Report, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.
Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within “Claims and litigation charges, net” in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisitions and Divestitures (Tables)
3 Months Ended
Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Identified Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary purchase price allocation for this acquisition:
(In millions)Amounts Recognized as of Acquisition Date (As Adjusted)
Purchase consideration:
Cash$600 
Contingent consideration92 
Total purchase consideration$692 
Identifiable assets acquired and liabilities assumed:
Current assets$
Intangible assets229 
Other non-current assets
Current liabilities(8)
Total identifiable net assets229 
Goodwill463 
Net assets acquired$692 
The following table summarizes the preliminary purchase price allocation for this acquisition:
(In millions)Amounts Recognized as of Acquisition Date (As Adjusted)
Purchase consideration:
Cash$166 
Contribution of USOR40 
Total purchase consideration$206 
Identifiable assets acquired and liabilities assumed:
Receivables$224 
Property, plant, and equipment22 
Operating lease right-of-use assets31 
Intangible assets177 
Current liabilities(42)
Long-term operating lease liabilities(29)
Other non-current liabilities(43)
Total identifiable net assets340 
Noncontrolling interest(222)
Additional paid-in capital(25)
Goodwill113 
Net assets acquired$206 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring, Impairment, and Related Charges, Net (Tables)
3 Months Ended
Jun. 30, 2023
Restructuring and Related Activities [Abstract]  
Restructuring, Impairment, and Related Costs
Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following:
Three Months Ended June 30, 2023
(In millions)U.S. Pharmaceutical
Prescription Technology Solutions (1)
Medical-Surgical Solutions
International
Corporate (1)
Total
Severance and employee-related costs, net $$— $— $— $$
Exit and other-related costs (2)
12 22 
Asset impairments and accelerated depreciation— — — 27 28 
Total$$$$$40 $52 
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.
(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Three Months Ended June 30, 2022
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternational
Corporate
Total
Severance and employee-related costs, net $$— $— $— $(1)$
Exit and other-related costs (1)
15 21 
Asset impairments and accelerated depreciation— — — (5)— 
Total$$$$$$23 
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Schedule of Restructuring and Asset Impairment Charges
The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the three months ended June 30, 2023:
(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotal
Balance, March 31, 2023 (1)
$15 $26 $$13 $35 $92 
Restructuring, impairment, and related charges, net40 52 
Non-cash charges— — — (1)(27)(28)
Cash payments(5)(13)(2)(2)(15)(37)
Other (2)
— — — (5)— (5)
Balance, June 30, 2023 (3)
$12 $15 $$11 $33 $74 
(1)As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.
(2)Other primarily includes cumulative translation adjustments and transfers to certain other liabilities.
(3)As of June 30, 2023, the total reserve balance was $74 million, of which $44 million was recorded in “Other accrued liabilities” and $30 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes (Tables)
3 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Expense (Benefit)
Income tax expense related to continuing operations was as follows:
Three Months Ended June 30,
(Dollars in millions)20232022
Income tax expense$94 $199 
Reported income tax rate8.6 %19.8 %
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Common Share (Tables)
3 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Schedule of computations for basic and diluted earnings per common share
The computations for basic and diluted earnings per common share were as follows:
Three Months Ended June 30,
(In millions, except per share amounts)20232022
Income from continuing operations$997 $807 
Net income attributable to noncontrolling interests(39)(41)
Income from continuing operations attributable to McKesson Corporation958 766 
Income from discontinued operations, net of tax— 
Net income attributable to McKesson Corporation$958 $768 
Weighted-average common shares outstanding:
Basic135.5 144.2 
Effect of dilutive securities:
Stock options0.2 0.3 
Restricted stock units (1)
0.9 1.4 
Diluted136.6 145.9 
Earnings per common share attributable to McKesson Corporation: (2)
Diluted
Continuing operations$7.02 $5.25 
Discontinued operations— 0.01 
Total$7.02 $5.26 
Basic
Continuing operations$7.07 $5.31 
Discontinued operations— 0.01 
Total$7.07 $5.32 
(1)Includes dilutive effect from restricted stock units and performance-based stock units.
(2)Certain computations may reflect rounding adjustments.
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Goodwill and Intangible Assets, Net (Tables)
3 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of goodwill were as follows:
(In millions)
U.S. Pharmaceutical (1)
Prescription Technology SolutionsMedical-Surgical Solutions
International
Total
Balance, March 31, 2023$4,050 $2,005 $2,453 $1,439 $9,947 
Foreign currency translation adjustments, net— — — 29 29 
Other adjustments (2)
(5)— — — (5)
Balance, June 30, 2023$4,045 $2,005 $2,453 $1,468 $9,971 
(1)The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe’s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.
(2)Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, “Business Acquisitions and Divestitures.”
Schedule of information regarding intangible assets
Information regarding intangible assets was as follows:
 June 30, 2023March 31, 2023
(Dollars in millions)Weighted-
Average
Remaining
Amortization
Period
(Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Customer relationships12$2,984 $(1,801)$1,183 $2,971 $(1,765)$1,206 
Service agreements101,141 (641)500 1,137 (623)514 
Trademarks and trade names12843 (446)397 833 (430)403 
Technology11264 (133)131 264 (129)135 
Other6184 (174)10 193 (174)19 
Total $5,416 $(3,195)$2,221 $5,398 $(3,121)$2,277 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Debt and Financing Activities (Tables)
3 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
Long-term debt consisted of the following:
(In millions)June 30, 2023March 31, 2023
U.S. Dollar notes (1) (2)
3.80% Notes due March 15, 2024
$— $918 
0.90% Notes due December 3, 2025
500 500 
5.25% Notes due February 15, 2026
499 499 
1.30% Notes due August 15, 2026
499 498 
7.65% Debentures due March 1, 2027
150 150 
3.95% Notes due February 16, 2028
343 343 
4.90% Notes due July 15, 2028
399 — 
4.75% Notes due May 30, 2029
196 196 
5.10% Notes due July 15, 2033
596 — 
6.00% Notes due March 1, 2041
218 218 
4.88% Notes due March 15, 2044
255 255 
Foreign currency notes (1) (3)
1.50% Euro Notes due November 17, 2025
653 649 
1.63% Euro Notes due October 30, 2026
545 542 
3.13% Sterling Notes due February 17, 2029
571 555 
Lease and other obligations237 271 
Total debt5,661 5,594 
Less: Current portion50 968 
Total long-term debt$5,611 $4,626 
(1)These notes are unsecured and unsubordinated obligations of the Company.
(2)Interest on these U.S. dollar notes is payable semi-annually.
(3)Interest on these foreign currency notes is payable annually.
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Hedging Activities (Tables)
3 Months Ended
Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments
Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:
Three Months Ended June 30,
(In millions)20232022
Non-derivatives designated as net investment hedges: (1)
Euro-denominated notes $— $64 
(1)There was no ineffectiveness in these hedges for the three months ended June 30, 2022.
Schedule of Notional Amounts of Outstanding Derivative Positions
At June 30, 2023 and March 31, 2023, the notional amounts of the Company’s outstanding derivatives were as follows:
June 30, 2023March 31, 2023
(In millions)Currency
Maturity Date (1)
Notional
Derivatives designated as net investment hedges: (2)
Cross-currency swaps (3)
CADNov-24 to Mar-25C$1,500 C$1,500 
Derivatives designated as fair value hedges: (2)
Cross-currency swaps (4)
GBPNov-28£450 £450 
Cross-currency swaps (4)
EURAug-25 to Jul-261,100 1,100 
Floating interest rate swaps (5)
USDFeb-26 to Sep-29$1,250 $1,250 
Derivatives designated as cash flow hedges: (2)
Cross-currency swaps (3)
CADJan-24C$400 C$400 
Fixed interest rate swaps (6)
USDJun-23$— $450 
(1)The maturity date reflected is for outstanding derivatives as of June 30, 2023.
(2)There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.
(3)The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.
(4)Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes.
(5)Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates.
(6)The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)
Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:
Three Months Ended June 30,
(In millions)20232022
Derivatives designated as net investment hedges:
Cross-currency swaps$(20)$12 
Derivatives designated as cash flow and other hedges:
Cross-currency swaps (1)
$(6)$(2)
Fixed interest rate swaps
16 27 
(1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)
Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:
Three Months Ended June 30,
(In millions)20232022
Derivatives designated as net investment hedges:
Cross-currency swaps$(20)$12 
Derivatives designated as cash flow and other hedges:
Cross-currency swaps (1)
$(6)$(2)
Fixed interest rate swaps
16 27 
(1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.
Schedule of Fair Value of Derivatives
Information regarding the fair value of derivatives on a gross basis were as follows:
Balance Sheet
Caption
June 30, 2023March 31, 2023
Fair Value of
Derivative
U.S. Dollar NotionalFair Value of
Derivative
U.S. Dollar Notional
(In millions)AssetLiabilityAssetLiability
Derivatives designated for hedge accounting:
Cross-currency swaps (current)Prepaid expenses and other/Other accrued liabilities$— $$301 $$— $301 
Cross-currency swaps (non-current)Other non-current assets/liabilities84 12 2,760 74 2,760 
Interest rate swaps (non-current)Other non-current assets/liabilities— 39 1,250 15 1,700 
Total$84 $53 $80 $17 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Tables)
3 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements
The Company’s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company’s long-term debt was as follows:
June 30, 2023March 31, 2023
(In millions)Carrying ValueFair ValueCarrying ValueFair Value
Long-term debt, including current maturities$5,661 $5,335 $5,594 $5,386 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingent Liabilities (Tables)
3 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Estimated Accrual Liability
The Company’s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:
(In millions)June 30, 2023March 31, 2023
Current litigation liabilities (1)
$545 $548 
Long-term litigation liabilities6,628 6,625 
Total litigation liabilities$7,173 $7,173 
(1)These amounts, recorded in “Other accrued liabilities” in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Deficit (Tables)
3 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Schedule of information regarding changes in accumulated other comprehensive income (loss), net of tax, by component
Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:
Foreign Currency Translation Adjustments
(In millions)
Foreign Currency Translation Adjustments, Net of Tax (1)
Unrealized Losses on Net Investment Hedges,
Net of Tax
Unrealized Gains (Losses) on Cash Flow and Other Hedges,
Net of Tax
Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive Loss
Balance, March 31, 2023$(847)$(14)$(36)$(8)$(905)
Other comprehensive income (loss) before reclassifications67 (15)⁽²⁾(2)57 
Amounts reclassified to earnings and other — — — — — 
Other comprehensive income (loss)67 (15)(2)57 
Less: amounts attributable to noncontrolling interests— — — — — 
Other comprehensive income (loss) attributable to McKesson67 (15)(2)57 
Balance, June 30, 2023$(780)$(29)$(29)$(10)$(848)
(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.
(2)Amounts recorded for the three months ended June 30, 2023 include losses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.
Foreign Currency Translation Adjustments
(In millions)
Foreign Currency Translation Adjustments, Net of Tax (1)
Unrealized Gains (Losses) on Net Investment Hedges,
Net of Tax
Unrealized Gains on Cash Flow and Other Hedges,
Net of Tax
Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive Loss
Balance, March 31, 2022$(1,504)$10 $27 $(67)$(1,534)
Other comprehensive income (loss) before reclassifications(176)45 ⁽²⁾18 12 (101)
Amounts reclassified to earnings and other (3)
730 (17)— 24 737 
Other comprehensive income554 28 

18 36 636 
Less: amounts attributable to noncontrolling interests47 — — 50 
Other comprehensive income attributable to McKesson507 28 18 33 586 
Balance, June 30, 2022$(997)$38 $45 $(34)$(948)
(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.
(2)Amounts recorded for the three months ended June 30, 2022 include gains of $64 million related to net investment hedges from Euro-denominated notes and gains of $12 million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $31 million.
(3)Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations.
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Segments of Business (Tables)
3 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals
Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals was as follows:
 Three Months Ended June 30,
(In millions)20232022
Segment revenues (1)
U.S. Pharmaceutical$67,160 $56,947 
Prescription Technology Solutions1,244 1,066 
Medical-Surgical Solutions2,611 2,592 
International3,468 6,549 
Total revenues$74,483 $67,154 
Segment operating profit (loss) (2)
U.S. Pharmaceutical (3)
$827 $696 
Prescription Technology Solutions (4)
231 144 
Medical-Surgical Solutions227 256 
International (5)
57 (6)
Subtotal1,342 1,090 
Corporate expenses, net (6)
(204)(39)
Interest expense(47)(45)
Income from continuing operations before income taxes$1,091 $1,006 
(1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment’s total revenues, less than 37% of the RxTS segment’s total revenues, less than 1% of the Medical-Surgical Solutions segment’s total revenues, and less than 1% of the International segment’s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.
(2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company’s reportable segments.
(3)The Company’s U.S. Pharmaceutical segment’s operating profit includes the following:
cash receipts for the Company’s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and
a charge of $32 million and a credit of $13 million related to the last-in, first-out (“LIFO”) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.
(4)The Company’s RxTS segment’s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28 million, which reduced the Company’s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”
(5)The Company’s International segment’s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”
(6)Corporate expenses, net includes the following:
restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” and
a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Significant Accounting Policies - Narrative (Details)
3 Months Ended
Jun. 30, 2023
segment
Accounting Policies [Abstract]  
Number of reportable segments 4
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisitions and Divestitures - Acquisitions (Details) - USD ($)
$ in Millions
3 Months Ended
Nov. 01, 2022
Oct. 31, 2022
Jun. 30, 2023
Mar. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Fair value adjustment gain     $ 28  
Goodwill     9,971 $ 9,947
U.S. Pharmaceutical        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Goodwill     4,045 4,050
Rx Savings Solutions, LLC | RxTs Segment        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Business acquisition, percentage of controlling interest in combined business 100.00%      
Cash payments to acquire business $ 600      
Contingent consideration 92      
Other current liabilities     45 83
Other non-current liabilities     $ 19 $ 9
Acquired identifiable intangible assets $ 229      
Weighted average life of intangibles 12 years      
Goodwill $ 463      
Rx Savings Solutions, LLC | RxTs Segment | Maximum        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Contingent consideration $ 275      
SCRI Oncology, LLC | U.S. Pharmaceutical        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Business acquisition, percentage of controlling interest in combined business   51.00%    
Cash payments to acquire business   $ 166    
Acquired identifiable intangible assets   $ 177    
Weighted average life of intangibles   17 years    
Goodwill   $ 113    
Goodwill, expected tax deductible amount   46    
Noncontrolling interest   222    
SCRI Oncology, LLC | U.S. Pharmaceutical | SCRI        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Noncontrolling interest   202    
SCRI Oncology, LLC | U.S. Pharmaceutical | USOR        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Noncontrolling interest   $ 20    
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details) - USD ($)
$ in Millions
Nov. 01, 2022
Jun. 30, 2023
Mar. 31, 2023
Identifiable assets acquired and liabilities assumed:      
Goodwill   $ 9,971 $ 9,947
Rx Savings Solutions, LLC | RxTs Segment      
Purchase consideration:      
Cash $ 600    
Contingent consideration 92    
Total purchase consideration 692    
Identifiable assets acquired and liabilities assumed:      
Current assets 5    
Intangible assets 229    
Other non-current assets 3    
Current liabilities (8)    
Total identifiable net assets 229    
Goodwill 463    
Net assets acquired $ 692    
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details) - USD ($)
$ in Millions
Oct. 31, 2022
Jun. 30, 2023
Mar. 31, 2023
Business Acquisition, Contingent Consideration [Line Items]      
Goodwill   $ 9,971 $ 9,947
U.S. Pharmaceutical      
Business Acquisition, Contingent Consideration [Line Items]      
Goodwill   $ 4,045 $ 4,050
SCRI Oncology, LLC | U.S. Pharmaceutical      
Business Acquisition, Contingent Consideration [Line Items]      
Cash $ 166    
Contribution of USOR 40    
Total purchase consideration 206    
Receivables 224    
Property, plant, and equipment 22    
Operating lease right-of-use assets 31    
Intangible assets 177    
Current liabilities (42)    
Long-term operating lease liabilities (29)    
Other non-current liabilities (43)    
Total identifiable net assets 340    
Noncontrolling interest (222)    
Additional paid-in capital (25)    
Goodwill 113    
Net assets acquired $ 206    
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Business Acquisitions and Divestitures - Divestitures and Other (Details)
£ in Millions, $ in Millions
3 Months Ended
Apr. 06, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Apr. 06, 2022
GBP (£)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
European businesses, disposal group, losses (gains)   $ 0 $ 20  
E.U. Businesses (Disposal Group) | Disposed of by sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
European businesses, disposal group, losses (gains)   $ (12)    
U.K. Disposal Group (Disposal Group) | Disposed of by sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Gross purchase price $ 144     £ 110
Proceeds from collection of notes receivable 118      
International Segment | Disposed of by sale | Aurelius Elephant Limited        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Divested net assets 615      
Accumulated other comprehensive loss adjustment $ 731      
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring, Impairment, and Related Charges, Net - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Mar. 31, 2023
Restructuring Cost and Reserve [Line Items]        
Restructuring, impairment, and related charges, net $ 52 $ 23    
Restructuring costs, anticipated total charges 52 $ 23    
Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization        
Restructuring Cost and Reserve [Line Items]        
Expected total pre-tax charges       $ 125
Restructuring and related cost, incurred cost to date     $ 96  
Restructuring costs, anticipated total charges $ 36      
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Restructuring Cost and Reserve [Line Items]    
Severance and employee-related costs, net $ 2 $ 2
Exit and other-related costs 22 21
Asset impairments and accelerated depreciation 28 0
Total 52 23
Operating Segments | U.S. Pharmaceutical    
Restructuring Cost and Reserve [Line Items]    
Severance and employee-related costs, net 1 3
Exit and other-related costs 1 1
Asset impairments and accelerated depreciation 0 0
Total 2 4
Operating Segments | Prescription Technology Solutions    
Restructuring Cost and Reserve [Line Items]    
Severance and employee-related costs, net 0 0
Exit and other-related costs 2 2
Asset impairments and accelerated depreciation 0 5
Total 2 7
Operating Segments | Medical-Surgical Solutions    
Restructuring Cost and Reserve [Line Items]    
Severance and employee-related costs, net 0 0
Exit and other-related costs 2 1
Asset impairments and accelerated depreciation 0 0
Total 2 1
Operating Segments | International    
Restructuring Cost and Reserve [Line Items]    
Severance and employee-related costs, net 0 0
Exit and other-related costs 5 2
Asset impairments and accelerated depreciation 1 0
Total 6 2
Corporate    
Restructuring Cost and Reserve [Line Items]    
Severance and employee-related costs, net 1 (1)
Exit and other-related costs 12 15
Asset impairments and accelerated depreciation 27 (5)
Total $ 40 $ 9
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Restructuring Reserve [Roll Forward]    
Beginning balance $ 92  
Restructuring, impairment, and related charges, net 52 $ 23
Non-cash charges (28)  
Cash payments (37)  
Other (5)  
Ending balance 74  
Operating Segments | U.S. Pharmaceutical    
Restructuring Reserve [Roll Forward]    
Beginning balance 15  
Restructuring, impairment, and related charges, net 2 4
Non-cash charges 0  
Cash payments (5)  
Other 0  
Ending balance 12  
Operating Segments | Prescription Technology Solutions    
Restructuring Reserve [Roll Forward]    
Beginning balance 26  
Restructuring, impairment, and related charges, net 2 7
Non-cash charges 0  
Cash payments (13)  
Other 0  
Ending balance 15  
Operating Segments | Medical-Surgical Solutions    
Restructuring Reserve [Roll Forward]    
Beginning balance 3  
Restructuring, impairment, and related charges, net 2 1
Non-cash charges 0  
Cash payments (2)  
Other 0  
Ending balance 3  
Operating Segments | International    
Restructuring Reserve [Roll Forward]    
Beginning balance 13  
Restructuring, impairment, and related charges, net 6 2
Non-cash charges (1)  
Cash payments (2)  
Other (5)  
Ending balance 11  
Corporate    
Restructuring Reserve [Roll Forward]    
Beginning balance 35  
Restructuring, impairment, and related charges, net 40 $ 9
Non-cash charges (27)  
Cash payments (15)  
Other 0  
Ending balance 33  
Accrued Liabilities    
Restructuring Reserve [Roll Forward]    
Beginning balance 66  
Ending balance 44  
Other Non-Current Liabilities    
Restructuring Reserve [Roll Forward]    
Beginning balance 26  
Ending balance $ 30  
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes - Schedule of Components of Income Tax Expense (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Tax Disclosure [Abstract]    
Income tax expense (benefit) related to continuing operations $ 94 $ 199
Reported income tax expense (benefit) rates (percent) 8.60% 19.80%
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Tax Contingency [Line Items]    
Tax expense (benefit), intra-entity transfers of assets other than inventory, amount $ (147)  
Tax expense (benefit), share-based payment arrangement   $ (45)
Unrecognized tax benefits 1,400  
Unrecognized tax benefits that would impact effective tax rate 1,300  
Minimum    
Income Tax Contingency [Line Items]    
Tax liability increase due to proposed adjustment to taxable income 600  
Maximum    
Income Tax Contingency [Line Items]    
Tax liability increase due to proposed adjustment to taxable income $ 700  
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Common Share - Narrative (Details) - shares
shares in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Earnings Per Share [Abstract]    
Potentially dilutive securities excluded from diluted earnings per share (less than) 1,000 1,000
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]    
Income from continuing operations $ 997 $ 807
Net income attributable to noncontrolling interests (39) (41)
Income from continuing operations attributable to McKesson Corporation 958 766
Income from discontinued operations, net of tax 0 2
Net income attributable to McKesson Corporation $ 958 $ 768
Weighted-average common shares outstanding:    
Basic (in shares) 135.5 144.2
Diluted (in shares) 136.6 145.9
Diluted    
Continuing operations (in usd per share) $ 7.02 $ 5.25
Discontinued operations (in usd per share) 0 0.01
Total (in dollars per share) 7.02 5.26
Basic    
Continuing operations (in usd per share) 7.07 5.31
Discontinued operations (in usd per share) 0 0.01
Total (in dollars per share) $ 7.07 $ 5.32
Stock options    
Weighted-average common shares outstanding:    
Effect of dilutive securities (in shares) 0.2 0.3
Restricted stock units    
Weighted-average common shares outstanding:    
Effect of dilutive securities (in shares) 0.9 1.4
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)
$ in Millions
3 Months Ended
Jun. 30, 2023
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 9,947
Foreign currency translation adjustments, net 29
Other adjustments (5)
Ending balance 9,971
U.S. Pharmaceutical  
Goodwill [Roll Forward]  
Beginning balance 4,050
Foreign currency translation adjustments, net 0
Other adjustments (5)
Ending balance 4,045
Prescription Technology Solutions  
Goodwill [Roll Forward]  
Beginning balance 2,005
Foreign currency translation adjustments, net 0
Other adjustments 0
Ending balance 2,005
Medical-Surgical Solutions  
Goodwill [Roll Forward]  
Beginning balance 2,453
Foreign currency translation adjustments, net 0
Other adjustments 0
Ending balance 2,453
International  
Goodwill [Roll Forward]  
Beginning balance 1,439
Foreign currency translation adjustments, net 29
Other adjustments 0
Ending balance $ 1,468
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Mar. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 5,416 $ 5,398
Accumulated Amortization (3,195) (3,121)
Net Carrying Amount $ 2,221 2,277
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Amortization Period (Years) 12 years  
Gross Carrying Amount $ 2,984 2,971
Accumulated Amortization (1,801) (1,765)
Net Carrying Amount $ 1,183 1,206
Service agreements    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Amortization Period (Years) 10 years  
Gross Carrying Amount $ 1,141 1,137
Accumulated Amortization (641) (623)
Net Carrying Amount $ 500 514
Trademarks and trade names    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Amortization Period (Years) 12 years  
Gross Carrying Amount $ 843 833
Accumulated Amortization (446) (430)
Net Carrying Amount $ 397 403
Technology    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Amortization Period (Years) 11 years  
Gross Carrying Amount $ 264 264
Accumulated Amortization (133) (129)
Net Carrying Amount $ 131 135
Other    
Finite-Lived Intangible Assets [Line Items]    
Weighted- Average Remaining Amortization Period (Years) 6 years  
Gross Carrying Amount $ 184 193
Accumulated Amortization (174) (174)
Net Carrying Amount $ 10 $ 19
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Goodwill and Intangible Assets, Net - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization expense of intangible assets $ 62 $ 56
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]    
Estimated annual amortization expense, remainder of 2024 185  
Estimated annual amortization expense, 2025 240  
Estimated annual amortization expense, 2026 208  
Estimated annual amortization expense, 2027 202  
Estimated annual amortization expense, 2028 198  
Estimated annual amortization expense, thereafter $ 1,200  
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Debt and Financing Activities - Schedule of Long-Term Debt (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Jun. 15, 2023
Mar. 31, 2023
Debt Instrument [Line Items]      
Total debt $ 5,661   $ 5,594
Less: Current portion 50   968
Total long-term debt $ 5,611   4,626
Loans payable | 3.80% Notes due March 15, 2024      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 3.80% 3.80%  
Total debt $ 0   918
Loans payable | 0.90% Notes due December 3, 2025      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 0.90%    
Total debt $ 500   500
Loans payable | 5.25% Notes due February 15, 2026      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 5.25%    
Total debt $ 499   499
Loans payable | 1.30% Notes due August 15, 2026      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 1.30%    
Total debt $ 499   498
Loans payable | 7.65% Debentures due March 1, 2027      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 7.65%    
Total debt $ 150   150
Loans payable | 3.95% Notes due February 16, 2028      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 3.95%    
Total debt $ 343   343
Loans payable | 4.90% Notes due July 15, 2028      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 4.90% 4.90%  
Total debt $ 399   0
Loans payable | 4.75% Notes due May 30, 2029      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 4.75%    
Total debt $ 196   196
Loans payable | 5.10% Notes due July 15, 2033      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 5.10% 5.10%  
Total debt $ 596   0
Loans payable | 6.00% Notes due March 1, 2041      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 6.00%    
Total debt $ 218   218
Loans payable | 4.88% Notes due March 15, 2044      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 4.88%    
Total debt $ 255   255
Loans payable | 1.50% Euro Notes due November 17, 2025      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 1.50%    
Total debt $ 653   649
Loans payable | 1.63% Euro Notes due October 30, 2026      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 1.63%    
Total debt $ 545   542
Loans payable | 3.13% Sterling Notes due February 17, 2029      
Debt Instrument [Line Items]      
Interest rate on debt instrument (percent) 3.13%    
Total debt $ 571   555
Lease and other obligations      
Debt Instrument [Line Items]      
Total debt $ 237   $ 271
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Debt and Financing Activities - Long-Term Debt Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 16, 2023
Jun. 15, 2023
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2023
Debt Instrument [Line Items]          
Long-term debt     $ 5,700   $ 5,600
Current portion of long-term debt     50   968
Repayments of long-term debt     268 $ 2  
Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt     647 $ 0  
Debt outstanding     5,661   5,594
Gain on debt extinguishment     $ 9    
Term Loan          
Debt Instrument [Line Items]          
Redemption price percentage of principal (percent)     101.00%    
Term Loan | Minimum          
Debt Instrument [Line Items]          
Debt instrument, redemption period (in days)     10 days    
Term Loan | Maximum          
Debt Instrument [Line Items]          
Debt instrument, redemption period (in days)     60 days    
4.90% Notes due July 15, 2028 | Term Loan          
Debt Instrument [Line Items]          
Interest rate on debt instrument (percent)   4.90% 4.90%    
Debt principal amount   $ 400      
Proceeds from debt issuance   $ 397      
Debt outstanding     $ 399   0
5.10% Notes due July 15, 2033 | Term Loan          
Debt Instrument [Line Items]          
Interest rate on debt instrument (percent)   5.10% 5.10%    
Debt principal amount   $ 600      
Proceeds from debt issuance   $ 592      
Debt outstanding     $ 596   0
3.80% Notes due March 15, 2024 | Term Loan          
Debt Instrument [Line Items]          
Interest rate on debt instrument (percent)   3.80% 3.80%    
Redemption price percentage of principal (percent) 98.75%        
Repayments of long-term debt $ 268        
Debt principal redeemed 271        
Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt $ 647        
Debt outstanding     $ 0   $ 918
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.23.2
Debt and Financing Activities - Revolving Credit Facilities Narrative (Details) - Unsecured Debt - Revolving Credit Facility - USD ($)
3 Months Ended
Nov. 07, 2022
Sep. 25, 2019
Jun. 30, 2023
Jun. 30, 2022
Senior Unsecured Credit Facility (the 2022 Credit Facility)        
Line of Credit Facility [Line Items]        
Credit facility, maximum borrowing capacity $ 4,000,000,000      
Credit facility term 5 years      
Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit        
Line of Credit Facility [Line Items]        
Credit facility, maximum borrowing capacity $ 3,600,000,000      
Borrowings under facility     $ 0  
Amounts outstanding under facility     $ 0  
Senior Unsecured Credit Facility (the 2020 Credit Facility)        
Line of Credit Facility [Line Items]        
Credit facility, maximum borrowing capacity   $ 4,000,000,000    
Credit facility term   5 years    
Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit        
Line of Credit Facility [Line Items]        
Borrowings under facility       $ 0
Amounts outstanding under facility $ 0      
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.23.2
Debt and Financing Activities - Commercial Paper Narrative (Details) - Commercial Paper - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2023
Line of Credit Facility [Line Items]      
Credit facility, maximum borrowing capacity $ 4,000    
Proceeds from issuance of commercial paper 65 $ 0  
Repayments of commercial paper 65    
Commercial paper $ 0   $ 0
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.23.2
Hedging Activities - Narrative (Details)
£ in Millions, $ in Millions, € in Billions
3 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2023
USD ($)
Jun. 15, 2023
USD ($)
Dec. 31, 2022
GBP (£)
Sep. 30, 2022
EUR (€)
Derivative [Line Items]            
Debt outstanding $ 5,661   $ 5,594      
Disposed of by sale | U.K. Disposal Group (Disposal Group)            
Derivative [Line Items]            
Reclassification of gains from AOCI   $ 26        
Fair Value Hedges | USD | Floating interest rate swaps | Derivatives designated for hedge accounting            
Derivative [Line Items]            
Derivative, notional amount 1,250   1,250      
Cash Flow Hedges | Floating interest rate swaps | Derivatives designated for hedge accounting            
Derivative [Line Items]            
Derivative, notional amount, entered into during period $ 50   450      
Derivative, notional amount       $ 500    
Derivative termination proceeds, amortization period (in years) 10 years          
Cash Flow Hedges | USD | Fixed interest rate swaps | Derivatives designated for hedge accounting            
Derivative [Line Items]            
Derivative, notional amount $ 0   $ 450      
Derivatives designated as net investment hedges | Fair Value Hedges | EUR | Derivatives designated for hedge accounting            
Derivative [Line Items]            
Derivative, notional amount | €           € 1.1
British Pound Sterling Denominated Notes | Term Loan            
Derivative [Line Items]            
Debt outstanding | £         £ 450  
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.23.2
Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Derivatives designated for hedge accounting | Net Investment Hedges | Euro Denominated Notes    
Derivatives, Fair Value [Line Items]    
Derivatives designated as net investment hedges: $ 0 $ 64
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.23.2
Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details) - Derivatives designated for hedge accounting
€ in Millions, £ in Millions, $ in Millions, $ in Millions
Jun. 30, 2023
EUR (€)
Jun. 30, 2023
CAD ($)
Jun. 30, 2023
GBP (£)
Jun. 30, 2023
USD ($)
Jun. 15, 2023
USD ($)
Mar. 31, 2023
EUR (€)
Mar. 31, 2023
CAD ($)
Mar. 31, 2023
GBP (£)
Mar. 31, 2023
USD ($)
Cross-currency swaps | Net Investment Hedges | CAD                  
Derivatives, Fair Value [Line Items]                  
Notional   $ 1,500         $ 1,500    
Cross-currency swaps | Fair Value Hedges | GBP                  
Derivatives, Fair Value [Line Items]                  
Notional | £     £ 450         £ 450  
Cross-currency swaps | Fair Value Hedges | EUR                  
Derivatives, Fair Value [Line Items]                  
Notional | € € 1,100         € 1,100      
Cross-currency swaps | Cash Flow Hedges | CAD                  
Derivatives, Fair Value [Line Items]                  
Notional   $ 400         $ 400    
Floating interest rate swaps | Fair Value Hedges | USD                  
Derivatives, Fair Value [Line Items]                  
Notional       $ 1,250         $ 1,250
Floating interest rate swaps | Cash Flow Hedges                  
Derivatives, Fair Value [Line Items]                  
Notional         $ 500        
Fixed interest rate swaps | Cash Flow Hedges | USD                  
Derivatives, Fair Value [Line Items]                  
Notional       $ 0         $ 450
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.23.2
Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details) - Derivatives designated for hedge accounting - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cross-currency swaps | Net Investment Hedging    
Derivatives, Fair Value [Line Items]    
Derivatives designated as cash flow and other hedges: $ (20) $ 12
Cross-currency swaps | Cash Flow Hedges    
Derivatives, Fair Value [Line Items]    
Derivatives designated as cash flow and other hedges: (6) (2)
Fixed interest rate swaps | Cash Flow Hedges    
Derivatives, Fair Value [Line Items]    
Derivatives designated as cash flow and other hedges: $ 16 $ 27
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.23.2
Hedging Activities - Schedule of Fair Value of Derivatives (Details) - Derivatives designated for hedge accounting - USD ($)
$ in Millions
Jun. 30, 2023
Mar. 31, 2023
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 84 $ 80
Fair value of derivative, liability 53 17
Net Investment Hedges | Prepaid expenses and other/Other accrued liabilities    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 0 5
Fair value of derivative, liability 2 0
U.S. Dollar notional amount, asset 301 301
Net Investment Hedges | Other non-current assets/liabilities    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 84 74
Fair value of derivative, liability 12 2
U.S. Dollar notional amount, asset 2,760 2,760
Floating interest rate swaps | Other non-current assets/liabilities    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 0 1
Fair value of derivative, liability 39 15
U.S. Dollar, notional amount, liability $ 1,250 $ 1,700
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Mar. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investments in equity securities $ 237 $ 237
Fair value, inputs, level 1 | Fair Value, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market funds at carrying value $ 806 $ 1,400
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Mar. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying Value $ 5,661 $ 5,594
Fair Value, Recurring | Fair value, inputs, level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Carrying Value 5,661 5,594
Fair Value $ 5,335 $ 5,386
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingent Liabilities - Narrative (Details)
$ in Millions
1 Months Ended 3 Months Ended
Jul. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
distributor
case
state
jurisdiction
Mar. 31, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jul. 31, 2020
state
Dec. 12, 2018
officer
Loss Contingencies [Line Items]            
Number of former officers | officer           2
National Prescription Opioid Litigation | United States            
Loss Contingencies [Line Items]            
Complaints filed against the entity | case   400        
National Prescription Opioid Litigation | Canada            
Loss Contingencies [Line Items]            
Complaints filed against the entity | case   4        
National Prescription Opioid Litigation | An individual | Canada            
Loss Contingencies [Line Items]            
Complaints filed against the entity | case   1        
Settled Litigation | National Prescription Opioid Litigation            
Loss Contingencies [Line Items]            
Settlement payment   $ 0        
Settled Litigation | National Prescription Opioid Litigation | Subsequent Event            
Loss Contingencies [Line Items]            
Settlement payment $ 529          
National Prescription Opioid Litigation            
Loss Contingencies [Line Items]            
Number of other national distributors named in suit | distributor   2        
Number of states in which court cases are pending | state   48        
Loss contingency, number of cases dismissed | case   2,300        
Portion of settlement award to be used by state and local government for remediation (percent)   85.00%        
Loss contingency, claims settled, number of jurisdictions not participating in settlement | jurisdiction   1        
National Prescription Opioid Litigation | State of Alabama and Subdivisions            
Loss Contingencies [Line Items]            
Settlement payment   $ 42        
Award payable under proposed framework   $ 132        
National Prescription Opioid Litigation | Native American Tribes Other Than Cherokee Nation            
Loss Contingencies [Line Items]            
Litigation settlement, amount awarded to other party, percentage of total settlement to be used to remediate damages   0.85        
National Prescription Opioid Litigation | Three Largest U.S. Pharmaceutical Distributors            
Loss Contingencies [Line Items]            
Settlement payment   $ 1,000        
Award payable under proposed framework   6,800        
National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | State of West Virginia and Subdivisions            
Loss Contingencies [Line Items]            
Settlement payment   38        
Award payable under proposed framework   114        
National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | Cherokee Nation            
Loss Contingencies [Line Items]            
Settlement payment   56        
National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | Native American Tribes Other Than Cherokee Nation            
Loss Contingencies [Line Items]            
Award payable under proposed framework   $ 140        
Evanston Police Pension Fund v. McKesson Corporation            
Loss Contingencies [Line Items]            
Loss contingency, estimate of possible loss     $ 141 $ 141    
Probable loss recovery     $ 141 $ 141    
United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA            
Loss Contingencies [Line Items]            
Number of states filed on behalf of | state         27  
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingent Liabilities - Estimated Accrual Liability (Details) - National Prescription Opioid Litigation - USD ($)
$ in Millions
Jun. 30, 2023
Mar. 31, 2023
Loss Contingencies [Line Items]    
Current litigation liabilities $ 545 $ 548
Long-term litigation liabilities 6,628 6,625
Total litigation liabilities $ 7,173 $ 7,173
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Deficit - Narrative (Details)
$ / shares in Units, shares in Millions, $ in Millions
1 Months Ended 3 Months Ended 4 Months Ended
Jul. 31, 2023
USD ($)
$ / shares
Aug. 31, 2022
shares
May 31, 2022
USD ($)
shares
Feb. 28, 2022
USD ($)
Jun. 30, 2023
USD ($)
vote
$ / shares
shares
Jun. 30, 2022
USD ($)
$ / shares
shares
Mar. 31, 2022
shares
Aug. 31, 2022
$ / shares
shares
May 31, 2022
$ / shares
shares
Mar. 31, 2023
USD ($)
Accelerated Share Repurchases [Line Items]                    
Number of votes per share of common stock permitted on proposals presented to stockholders (vote) | vote         1          
Dividends declared per common share (in dollars per share) | $ / shares         $ 0.54 $ 0.47        
Shares repurchased         $ 673 $ 1,000        
Excise taxes         4          
Other accrued liabilities         4,090         $ 4,200
Authorized amount available for future repurchases         $ 2,900          
Subsequent Event                    
Accelerated Share Repurchases [Line Items]                    
Dividends declared per common share (in dollars per share) | $ / shares $ 0.62                  
Authorized repurchase amount (up to) $ 6,000                  
Accelerated Share Repurchase                    
Accelerated Share Repurchases [Line Items]                    
Shares repurchased     $ 1,000 $ 1,500            
Share repurchases (in shares) | shares               3.1 5.1  
Average price of shares repurchased (in usd per share) | $ / shares               $ 321.05 $ 295.16  
Accelerated Share Repurchase, Initial Share Settlement                    
Accelerated Share Repurchases [Line Items]                    
Common stock repurchased (in shares) | shares     2.6       4.8      
Accelerated Share Repurchase, Completion Of Program                    
Accelerated Share Repurchases [Line Items]                    
Common stock repurchased (in shares) | shares   0.5 0.3              
Open Market Share Repurchase Transactions                    
Accelerated Share Repurchases [Line Items]                    
Average price of shares repurchased (in usd per share) | $ / shares         $ 379.14          
Common stock repurchased (in shares) | shares         1.8 0.0        
Shares repurchased         $ 673          
Other accrued liabilities                   $ 27
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) - USD ($)
$ in Millions
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ (1,490) $ (1,792)
Other comprehensive income, net of tax 57 636
Other comprehensive income (loss) attributable to McKesson 57 636
Ending balance (1,240) (1,472)
Derivatives designated for hedge accounting | Net Investment Hedging | Euro Denominated Notes    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Other comprehensive income (loss), net investment hedge, gain (loss) 0 64
Derivatives designated for hedge accounting | Cross-currency swaps    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Other comprehensive income (loss), net investment hedge, gain (loss) (20)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax   12
Total Accumulated Other Comprehensive Loss    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (905) (1,534)
Other comprehensive income (loss) before reclassifications 57 (101)
Amounts reclassified to earnings and other 0 737
Other comprehensive income, net of tax 57 636
Less: amounts attributable to noncontrolling interests 0 50
Other comprehensive income (loss) attributable to McKesson 57 586
Ending balance (848) (948)
Foreign Currency Translation Adjustments, Net of Tax    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (847) (1,504)
Other comprehensive income (loss) before reclassifications 67 (176)
Amounts reclassified to earnings and other 0 730
Other comprehensive income, net of tax 67 554
Less: amounts attributable to noncontrolling interests 0 47
Other comprehensive income (loss) attributable to McKesson 67 507
Ending balance (780) (997)
Unrealized Losses on Net Investment Hedges, Net of Tax    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (14) 10
Other comprehensive income (loss) before reclassifications (15) 45
Amounts reclassified to earnings and other 0 (17)
Other comprehensive income, net of tax (15) 28
Less: amounts attributable to noncontrolling interests 0 0
Other comprehensive income (loss) attributable to McKesson (15) 28
Ending balance (29) 38
Other Comprehensive Income (Loss) before Reclassifications, Tax 5 (31)
Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (36) 27
Other comprehensive income (loss) before reclassifications 7 18
Amounts reclassified to earnings and other 0 0
Other comprehensive income, net of tax 7 18
Less: amounts attributable to noncontrolling interests 0 0
Other comprehensive income (loss) attributable to McKesson 7 18
Ending balance (29) 45
Unrealized Losses and Other Components of Benefit Plans, Net of Tax    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (8) (67)
Other comprehensive income (loss) before reclassifications (2) 12
Amounts reclassified to earnings and other 0 24
Other comprehensive income, net of tax (2) 36
Less: amounts attributable to noncontrolling interests 0 3
Other comprehensive income (loss) attributable to McKesson (2) 33
Ending balance $ (10) $ (34)
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.23.2
Segments of Business - Narrative (Details)
3 Months Ended
Jun. 30, 2023
segment
Segment Reporting [Abstract]  
Number of reportable segments 4
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.23.2
Segments of Business - Reportable operating segment (Details)
$ in Millions
3 Months Ended
Jun. 30, 2023
USD ($)
segment
Jun. 30, 2022
USD ($)
Segment revenues    
Total revenues $ 74,483 $ 67,154
Segment operating profit (loss)    
Total operating profit (loss) 1,100 1,036
Corporate income (expenses), net (204) (39)
Interest expense (47) (45)
Income from continuing operations before income taxes $ 1,091 1,006
Number of reportable segments | segment 4  
Proceeds from legal settlements $ 118  
Pre-tax credits related to LIFO accounting (32) 13
Fair value adjustment gain 28  
Loss (gain) to remeasure disposal group to fair value 0 20
Restructuring costs, anticipated total charges $ 52 23
United States    
Segment operating profit (loss)    
Number of reportable segments | segment 3  
Operating Segments    
Segment operating profit (loss)    
Total operating profit (loss) $ 1,342 1,090
Corporate    
Segment operating profit (loss)    
Restructuring costs, anticipated total charges 40 9
Corporate | Held-for-sale | E.U. Businesses (Disposal Group)    
Segment operating profit (loss)    
Loss (gain) to remeasure disposal group to fair value   (106)
U.S. Pharmaceutical    
Segment revenues    
Total revenues 67,160 56,947
U.S. Pharmaceutical | Operating Segments    
Segment operating profit (loss)    
Total operating profit (loss) $ 827 696
Revenue derived from services, percentage (approximately or less than) 1.00%  
Pre-tax credits related to LIFO accounting $ (32) 13
Restructuring costs, anticipated total charges 2 4
Prescription Technology Solutions    
Segment revenues    
Total revenues 1,244 1,066
Prescription Technology Solutions | Operating Segments    
Segment operating profit (loss)    
Total operating profit (loss) $ 231 144
Revenue derived from services, percentage (approximately or less than) 37.00%  
Restructuring costs, anticipated total charges $ 2 7
Medical-Surgical Solutions    
Segment revenues    
Total revenues 2,611 2,592
Medical-Surgical Solutions | Operating Segments    
Segment operating profit (loss)    
Total operating profit (loss) $ 227 256
Revenue derived from services, percentage (approximately or less than) 1.00%  
Restructuring costs, anticipated total charges $ 2 1
International    
Segment revenues    
Total revenues 3,468 6,549
International | Operating Segments    
Segment operating profit (loss)    
Total operating profit (loss) $ 57 (6)
Revenue derived from services, percentage (approximately or less than) 1.00%  
Restructuring costs, anticipated total charges $ 6 2
International | Operating Segments | Held-for-sale | E.U. Businesses (Disposal Group)    
Segment operating profit (loss)    
Loss (gain) to remeasure disposal group to fair value   $ 94
XML 79 mck-20230630_htm.xml IDEA: XBRL DOCUMENT 0000927653 2023-04-01 2023-06-30 0000927653 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000927653 mck:A1500NotesDue2025Member 2023-04-01 2023-06-30 0000927653 mck:A1625NotesDue2026Member 2023-04-01 2023-06-30 0000927653 mck:A3125NotesDue2029Member 2023-04-01 2023-06-30 0000927653 2023-06-30 0000927653 2022-04-01 2022-06-30 0000927653 2023-03-31 0000927653 us-gaap:CommonStockMember 2023-03-31 0000927653 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000927653 us-gaap:RetainedEarningsMember 2023-03-31 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000927653 us-gaap:TreasuryStockCommonMember 2023-03-31 0000927653 us-gaap:NoncontrollingInterestMember 2023-03-31 0000927653 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000927653 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000927653 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000927653 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000927653 us-gaap:CommonStockMember 2023-06-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000927653 us-gaap:RetainedEarningsMember 2023-06-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000927653 us-gaap:TreasuryStockCommonMember 2023-06-30 0000927653 us-gaap:NoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:CommonStockMember 2022-03-31 0000927653 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000927653 us-gaap:RetainedEarningsMember 2022-03-31 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000927653 us-gaap:TreasuryStockCommonMember 2022-03-31 0000927653 us-gaap:NoncontrollingInterestMember 2022-03-31 0000927653 2022-03-31 0000927653 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000927653 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000927653 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000927653 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000927653 us-gaap:CommonStockMember 2022-06-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000927653 us-gaap:RetainedEarningsMember 2022-06-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000927653 us-gaap:TreasuryStockCommonMember 2022-06-30 0000927653 us-gaap:NoncontrollingInterestMember 2022-06-30 0000927653 2022-06-30 0000927653 mck:RxSavingsSolutionsLLCMember mck:RxTsSegmentMember 2022-11-01 0000927653 mck:RxSavingsSolutionsLLCMember mck:RxTsSegmentMember 2022-11-01 2022-11-01 0000927653 srt:MaximumMember mck:RxSavingsSolutionsLLCMember mck:RxTsSegmentMember 2022-11-01 0000927653 mck:RxSavingsSolutionsLLCMember mck:RxTsSegmentMember 2023-06-30 0000927653 mck:RxSavingsSolutionsLLCMember mck:RxTsSegmentMember 2023-03-31 0000927653 mck:SCRIOncologyLLCMember mck:USPharmaceuticalSegmentMember 2022-10-31 0000927653 mck:SCRIOncologyLLCMember mck:USPharmaceuticalSegmentMember 2022-10-31 2022-10-31 0000927653 mck:SarahCannonResearchInstituteMember mck:SCRIOncologyLLCMember mck:USPharmaceuticalSegmentMember 2022-10-31 0000927653 mck:McKessonUSOncologyResearchMember mck:SCRIOncologyLLCMember mck:USPharmaceuticalSegmentMember 2022-10-31 0000927653 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember mck:EUBusinessesDisposalGroupMember 2023-04-01 2023-06-30 0000927653 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember mck:UKBusinessesDisposalGroupMember 2022-04-06 0000927653 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember mck:InternationalSegmentMember mck:AureliusElephantLimitedMember 2022-04-06 0000927653 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember mck:InternationalSegmentMember mck:AureliusElephantLimitedMember 2022-04-06 2022-04-06 0000927653 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember mck:UKBusinessesDisposalGroupMember 2022-04-06 2022-04-06 0000927653 mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember 2023-03-31 0000927653 mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember 2023-01-01 2023-06-30 0000927653 mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember 2023-04-01 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:USPharmaceuticalSegmentMember 2023-04-01 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:PrescriptionTechnologySolutionsMember 2023-04-01 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:MedicalSurgicalSolutionsSegmentMember 2023-04-01 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:InternationalSegmentMember 2023-04-01 2023-06-30 0000927653 us-gaap:CorporateNonSegmentMember 2023-04-01 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:USPharmaceuticalSegmentMember 2022-04-01 2022-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:PrescriptionTechnologySolutionsMember 2022-04-01 2022-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:MedicalSurgicalSolutionsSegmentMember 2022-04-01 2022-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:InternationalSegmentMember 2022-04-01 2022-06-30 0000927653 us-gaap:CorporateNonSegmentMember 2022-04-01 2022-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:USPharmaceuticalSegmentMember 2023-03-31 0000927653 us-gaap:OperatingSegmentsMember mck:PrescriptionTechnologySolutionsMember 2023-03-31 0000927653 us-gaap:OperatingSegmentsMember mck:MedicalSurgicalSolutionsSegmentMember 2023-03-31 0000927653 us-gaap:OperatingSegmentsMember mck:InternationalSegmentMember 2023-03-31 0000927653 us-gaap:CorporateNonSegmentMember 2023-03-31 0000927653 us-gaap:OperatingSegmentsMember mck:USPharmaceuticalSegmentMember 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:PrescriptionTechnologySolutionsMember 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:MedicalSurgicalSolutionsSegmentMember 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember mck:InternationalSegmentMember 2023-06-30 0000927653 us-gaap:CorporateNonSegmentMember 2023-06-30 0000927653 us-gaap:AccruedLiabilitiesMember 2023-03-31 0000927653 us-gaap:OtherNoncurrentLiabilitiesMember 2023-03-31 0000927653 us-gaap:AccruedLiabilitiesMember 2023-06-30 0000927653 us-gaap:OtherNoncurrentLiabilitiesMember 2023-06-30 0000927653 srt:MinimumMember 2023-06-30 0000927653 srt:MaximumMember 2023-06-30 0000927653 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0000927653 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0000927653 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0000927653 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0000927653 mck:USPharmaceuticalSegmentMember 2023-03-31 0000927653 mck:PrescriptionTechnologySolutionsMember 2023-03-31 0000927653 mck:MedicalSurgicalSolutionsSegmentMember 2023-03-31 0000927653 mck:InternationalSegmentMember 2023-03-31 0000927653 mck:USPharmaceuticalSegmentMember 2023-04-01 2023-06-30 0000927653 mck:PrescriptionTechnologySolutionsMember 2023-04-01 2023-06-30 0000927653 mck:MedicalSurgicalSolutionsSegmentMember 2023-04-01 2023-06-30 0000927653 mck:InternationalSegmentMember 2023-04-01 2023-06-30 0000927653 mck:USPharmaceuticalSegmentMember 2023-06-30 0000927653 mck:PrescriptionTechnologySolutionsMember 2023-06-30 0000927653 mck:MedicalSurgicalSolutionsSegmentMember 2023-06-30 0000927653 mck:InternationalSegmentMember 2023-06-30 0000927653 us-gaap:CustomerRelationshipsMember 2023-06-30 0000927653 us-gaap:CustomerRelationshipsMember 2023-03-31 0000927653 us-gaap:ServiceAgreementsMember 2023-06-30 0000927653 us-gaap:ServiceAgreementsMember 2023-03-31 0000927653 us-gaap:TrademarksAndTradeNamesMember 2023-06-30 0000927653 us-gaap:TrademarksAndTradeNamesMember 2023-03-31 0000927653 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-06-30 0000927653 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-03-31 0000927653 us-gaap:OtherIntangibleAssetsMember 2023-06-30 0000927653 us-gaap:OtherIntangibleAssetsMember 2023-03-31 0000927653 mck:A380NotesDueMarch152024Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A380NotesDueMarch152024Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A090NotesDueDecember32025Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A090NotesDueDecember32025Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A525NotesDueFebruary152026Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A525NotesDueFebruary152026Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A130NotesDueAugust152026Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A130NotesDueAugust152026Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A765DebenturesDueMarch12027Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A765DebenturesDueMarch12027Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A395NotesDueFebruary162028Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A395NotesDueFebruary162028Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A490NotesDueJuly152028Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A490NotesDueJuly152028Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A475NotesDueMay302029Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A475NotesDueMay302029Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A510NotesDueJuly152033Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A510NotesDueJuly152033Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A600NotesDueMarch12041Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A600NotesDueMarch12041Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A488NotesDueMarch152044Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A488NotesDueMarch152044Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A150EuroNotesDueNovember172025Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A150EuroNotesDueNovember172025Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A163EuroNotesDueOctober302026Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A163EuroNotesDueOctober302026Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:A313SterlingNotesDueFebruary172029Member us-gaap:LoansPayableMember 2023-06-30 0000927653 mck:A313SterlingNotesDueFebruary172029Member us-gaap:LoansPayableMember 2023-03-31 0000927653 mck:LeaseAndOtherObligationsMember 2023-06-30 0000927653 mck:LeaseAndOtherObligationsMember 2023-03-31 0000927653 mck:A490NotesDueJuly152028Member us-gaap:LoansPayableMember 2023-06-15 0000927653 mck:A510NotesDueJuly152033Member us-gaap:LoansPayableMember 2023-06-15 0000927653 mck:A490NotesDueJuly152028Member us-gaap:LoansPayableMember 2023-06-15 2023-06-15 0000927653 mck:A510NotesDueJuly152033Member us-gaap:LoansPayableMember 2023-06-15 2023-06-15 0000927653 mck:A380NotesDueMarch152024Member us-gaap:LoansPayableMember 2023-06-15 0000927653 srt:MinimumMember us-gaap:LoansPayableMember 2023-04-01 2023-06-30 0000927653 srt:MaximumMember us-gaap:LoansPayableMember 2023-04-01 2023-06-30 0000927653 us-gaap:LoansPayableMember 2023-04-01 2023-06-30 0000927653 mck:A380NotesDueMarch152024Member us-gaap:LoansPayableMember 2023-06-16 2023-06-16 0000927653 mck:A380NotesDueMarch152024Member us-gaap:LoansPayableMember 2023-06-16 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember us-gaap:UnsecuredDebtMember 2022-11-07 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember us-gaap:UnsecuredDebtMember 2022-11-07 2022-11-07 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember us-gaap:UnsecuredDebtMember 2022-11-07 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember us-gaap:UnsecuredDebtMember 2019-09-25 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember us-gaap:UnsecuredDebtMember 2019-09-25 2019-09-25 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember us-gaap:UnsecuredDebtMember 2022-04-01 2022-06-30 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember us-gaap:UnsecuredDebtMember 2022-11-07 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember us-gaap:UnsecuredDebtMember 2023-04-01 2023-06-30 0000927653 us-gaap:RevolvingCreditFacilityMember mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember us-gaap:UnsecuredDebtMember 2023-06-30 0000927653 us-gaap:CommercialPaperMember 2023-06-30 0000927653 us-gaap:CommercialPaperMember 2023-04-01 2023-06-30 0000927653 us-gaap:CommercialPaperMember 2022-04-01 2022-06-30 0000927653 us-gaap:CommercialPaperMember 2023-03-31 0000927653 currency:EUR us-gaap:CurrencySwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000927653 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember mck:UKBusinessesDisposalGroupMember 2022-04-01 2022-06-30 0000927653 mck:BritishPoundSterlingDenominatedNotesMember us-gaap:LoansPayableMember 2022-12-31 0000927653 mck:EuroDenominatedNotesMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-04-01 2023-06-30 0000927653 mck:EuroDenominatedNotesMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-04-01 2022-06-30 0000927653 currency:CAD us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 currency:CAD us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 currency:GBP us-gaap:CurrencySwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 currency:GBP us-gaap:CurrencySwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 currency:EUR us-gaap:CurrencySwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 currency:EUR us-gaap:CurrencySwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 currency:USD us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 currency:USD us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 currency:CAD us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 currency:CAD us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 currency:USD mck:FixedInterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 currency:USD mck:FixedInterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-04-01 2023-03-31 0000927653 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-04-01 2023-06-30 0000927653 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-15 0000927653 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-04-01 2023-06-30 0000927653 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-04-01 2022-06-30 0000927653 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-04-01 2023-06-30 0000927653 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-04-01 2022-06-30 0000927653 mck:FixedInterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-04-01 2023-06-30 0000927653 mck:FixedInterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-04-01 2022-06-30 0000927653 mck:CurrentAssetLiabilityMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 mck:CurrentAssetLiabilityMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 mck:OtherNonCurrentAssetsAndLiabilitiesMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 mck:OtherNonCurrentAssetsAndLiabilitiesMember us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 mck:OtherNonCurrentAssetsAndLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 mck:OtherNonCurrentAssetsAndLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 us-gaap:DesignatedAsHedgingInstrumentMember 2023-06-30 0000927653 us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000927653 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000927653 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000927653 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000927653 mck:NationalPrescriptionOpiateLitigationMember 2023-06-30 0000927653 mck:NationalPrescriptionOpiateLitigationMember mck:ThreeLargestUSPharmaceuticalDistributorsMember 2023-04-01 2023-06-30 0000927653 mck:StateOfAlabamaAndSubdivisionsMember mck:NationalPrescriptionOpiateLitigationMember 2023-04-01 2023-06-30 0000927653 mck:StateOfWestVirginiaAndSubdivisionsMember mck:NationalPrescriptionOpiateLitigationMember mck:ThreeNationalPharmaceuticalDistributorsMember 2023-04-01 2023-06-30 0000927653 mck:CherokeeNationMember mck:NationalPrescriptionOpiateLitigationMember mck:ThreeNationalPharmaceuticalDistributorsMember 2023-04-01 2023-06-30 0000927653 mck:NativeAmericanTribesOtherThanCherokeeNationMember mck:NationalPrescriptionOpiateLitigationMember mck:ThreeNationalPharmaceuticalDistributorsMember 2023-04-01 2023-06-30 0000927653 mck:NativeAmericanTribesOtherThanCherokeeNationMember mck:NationalPrescriptionOpiateLitigationMember 2023-06-30 0000927653 mck:NationalPrescriptionOpiateLitigationMember 2023-06-30 0000927653 mck:NationalPrescriptionOpiateLitigationMember 2023-03-31 0000927653 us-gaap:SettledLitigationMember mck:NationalPrescriptionOpiateLitigationMember 2023-04-01 2023-06-30 0000927653 us-gaap:SettledLitigationMember mck:NationalPrescriptionOpiateLitigationMember us-gaap:SubsequentEventMember 2023-07-01 2023-07-31 0000927653 country:US mck:NationalPrescriptionOpiateLitigationMember 2023-06-30 0000927653 country:CA mck:NationalPrescriptionOpiateLitigationMember 2023-06-30 0000927653 mck:IndividualClaimantMember country:CA mck:NationalPrescriptionOpiateLitigationMember 2023-06-30 0000927653 2018-12-12 0000927653 mck:EvanstonPolicePensionFundVMcKessonCorporationMember 2022-09-30 0000927653 mck:EvanstonPolicePensionFundVMcKessonCorporationMember 2023-03-31 0000927653 mck:UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember 2020-07-31 0000927653 us-gaap:SubsequentEventMember 2023-07-01 2023-07-31 0000927653 mck:AcceleratedShareRepurchaseMember 2022-05-01 2022-05-31 0000927653 mck:AcceleratedShareRepurchaseMember 2022-05-01 2022-08-31 0000927653 mck:AcceleratedShareRepurchaseInitialShareSettlementMember 2022-05-01 2022-05-31 0000927653 mck:AcceleratedShareRepurchaseCompletionOfProgramMember 2022-08-01 2022-08-31 0000927653 mck:AcceleratedShareRepurchaseMember 2022-02-01 2022-02-28 0000927653 mck:AcceleratedShareRepurchaseMember 2022-02-01 2022-05-31 0000927653 mck:AcceleratedShareRepurchaseInitialShareSettlementMember 2022-01-01 2022-03-31 0000927653 mck:AcceleratedShareRepurchaseCompletionOfProgramMember 2022-05-01 2022-05-31 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2023-04-01 2023-06-30 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2023-03-31 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2022-04-01 2022-06-30 0000927653 us-gaap:SubsequentEventMember 2023-07-31 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2023-03-31 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-03-31 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 2023-06-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2023-04-01 2023-06-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-04-01 2023-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 2023-06-30 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-01 2023-06-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-04-01 2023-06-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2022-03-31 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-03-31 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-03-31 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-04-01 2022-06-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2022-04-01 2022-06-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-04-01 2022-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-04-01 2022-06-30 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-04-01 2022-06-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2022-06-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-06-30 0000927653 us-gaap:CurrencySwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-04-01 2022-06-30 0000927653 mck:USPharmaceuticalSegmentMember 2022-04-01 2022-06-30 0000927653 mck:PrescriptionTechnologySolutionsMember 2022-04-01 2022-06-30 0000927653 mck:MedicalSurgicalSolutionsSegmentMember 2022-04-01 2022-06-30 0000927653 mck:InternationalSegmentMember 2022-04-01 2022-06-30 0000927653 us-gaap:OperatingSegmentsMember 2023-04-01 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember 2022-04-01 2022-06-30 0000927653 country:US 2023-04-01 2023-06-30 0000927653 us-gaap:OperatingSegmentsMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember mck:EUBusinessesDisposalGroupMember mck:InternationalSegmentMember 2022-04-01 2022-06-30 0000927653 us-gaap:CorporateNonSegmentMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember mck:EUBusinessesDisposalGroupMember 2022-04-01 2022-06-30 shares iso4217:USD iso4217:USD shares mck:segment pure iso4217:GBP iso4217:EUR iso4217:CAD mck:distributor mck:state mck:case mck:jurisdiction mck:officer mck:vote 0000927653 --03-31 2024 Q1 false 10-Q true 2023-06-30 false 1-13252 McKESSON CORPORATION DE 94-3207296 6555 State Hwy 161 Irving TX 75039 972 446-4800 Common stock, $0.01 par value MCK NYSE 1.500% Notes due 2025 MCK25 NYSE 1.625% Notes due 2026 MCK26 NYSE 3.125% Notes due 2029 MCK29 NYSE Yes Yes Large Accelerated Filer false false false 134902380 74483000000 67154000000 71461000000 64131000000 3022000000 3023000000 1870000000 1959000000 0 -5000000 52000000 23000000 1922000000 1987000000 1100000000 1036000000 38000000 15000000 47000000 45000000 1091000000 1006000000 94000000 199000000 997000000 807000000 0 2000000 997000000 809000000 39000000 41000000 958000000 768000000 7.02 5.25 0 0.01 7.02 5.26 7.07 5.31 0 0.01 7.07 5.32 136600000 145900000 135500000 144200000 997000000 809000000 52000000 582000000 7000000 18000000 2000000 -36000000 57000000 636000000 1054000000 1445000000 39000000 91000000 1015000000 1354000000 2636000000 4678000000 21860000000 19410000000 20510000000 19691000000 533000000 513000000 45539000000 44292000000 2172000000 2177000000 1693000000 1635000000 9971000000 9947000000 2221000000 2277000000 2500000000 1992000000 64096000000 62320000000 43982000000 42490000000 50000000 968000000 300000000 299000000 4090000000 4200000000 48422000000 47957000000 5611000000 4626000000 1139000000 1387000000 1462000000 1402000000 6628000000 6625000000 2074000000 1813000000 0.01 0.01 100000000 100000000 0 0 0 0 0 0 0.01 0.01 800000000 800000000 278000000 277000000 3000000 3000000 7824000000 7747000000 13182000000 12295000000 -848000000 -905000000 143000000 141000000 21763000000 20997000000 -1602000000 -1857000000 362000000 367000000 -1240000000 -1490000000 64096000000 62320000000 277000000 3000000 7747000000 12295000000 -905000000 141000000 -20997000000 367000000 -1490000000 1000000 27000000 -93000000 -66000000 43000000 43000000 2000000 673000000 673000000 958000000 39000000 997000000 57000000 57000000 0.54 73000000 73000000 39000000 39000000 -7000000 -2000000 5000000 -4000000 278000000 3000000 7824000000 13182000000 -848000000 143000000 -21763000000 362000000 -1240000000 275000000 2000000 7275000000 9030000000 -1534000000 130000000 -17045000000 480000000 -1792000000 2000000 1000000 91000000 -152000000 -60000000 40000000 40000000 56000000 3000000 944000000 1000000000 768000000 41000000 809000000 586000000 50000000 636000000 0.47 67000000 67000000 36000000 36000000 2000000 2000000 -1000000 1000000 0 277000000 3000000 7350000000 9732000000 -948000000 133000000 -18141000000 532000000 -1472000000 997000000 809000000 64000000 61000000 95000000 87000000 28000000 0 235000000 -109000000 32000000 -13000000 58000000 63000000 19000000 33000000 0 20000000 -41000000 -102000000 2380000000 1584000000 826000000 955000000 1473000000 1006000000 -80000000 -94000000 236000000 37000000 0 -370000000 536000000 186000000 -1052000000 -941000000 78000000 71000000 46000000 29000000 0 1000000 39000000 240000000 64000000 100000000 -149000000 39000000 65000000 0 65000000 0 991000000 0 268000000 2000000 647000000 0 27000000 91000000 696000000 1000000000 74000000 71000000 -176000000 -199000000 -843000000 -1181000000 2000000 18000000 0 470000000 -2042000000 -1595000000 4679000000 3935000000 2637000000 2340000000 1000000 107000000 2636000000 2233000000 Significant Accounting Policies<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: McKesson Corporation (“McKesson,” or the “Company,”) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (“RxTS”), Medical-Surgical Solutions, and International. Refer to Financial Note 12, “Segments of Business,” for additional information.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net income attributable to noncontrolling interests” in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests includes third-party equity interests in the Company’s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (“McKesson Europe”). The Company’s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company’s businesses in the European Union (“E.U.”) in October 2022, which is discussed further in Financial Note 2, “Business Acquisitions and Divestitures.” </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (“VIE”). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal Period:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior period amounts have been reclassified to conform to the current year presentation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May 9, 2023 (the “2023 Annual Report”).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the “IRA”). Among other provisions, the IRA includes a 15% corporate minimum tax, a 1% excise tax on certain repurchases of an entity’s own common stock after December 31, 2022, and various drug pricing reforms. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures. The Company will continue to evaluate the full impact of these legislative changes as they are announced and implemented. Refer to Financial Note 11, “Stockholders' Deficit,” for further details regarding excise taxes incurred on the Company’s share repurchases during the three months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no accounting standards adopted by the Company during the three months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures.</span></div> 4 <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company’s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as “Net income attributable to noncontrolling interests” in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests includes third-party equity interests in the Company’s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (“McKesson Europe”). The Company’s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company’s businesses in the European Union (“E.U.”) in October 2022, which is discussed further in Financial Note 2, “Business Acquisitions and Divestitures.” </span></div>The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (“VIE”). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal Period:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior period amounts have been reclassified to conform to the current year presentation.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.</span> The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May 9, 2023 (the “2023 Annual Report”). <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no accounting standards adopted by the Company during the three months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span>, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures Business Acquisitions and Divestitures<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rx Savings Solutions, LLC</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, the Company completed its acquisition of 100% of the shares of Rx Savings Solutions, LLC (“RxSS”), a privately-owned company headquartered in Overland Park, Kansas, to further connect biopharma and payer services to patients. RxSS is a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. The purchase consideration included a payment of $600 million in cash made upon closing and a maximum of $275 million of contingent consideration based on RxSS’ operational and financial performance through calendar year 2025. The payment made upon closing was funded from cash on hand. The financial results of RxSS are included in the Company’s RxTS segment as of the acquisition date. The transaction was accounted for as a business combination.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a liability for the contingent consideration at its fair value of $92 million as of the acquisition date. The fair value of the contingent consideration liability was estimated using a Monte Carlo simulation model, utilizing internal cash flow projections which are Level 3 inputs under Accounting Standards Codification (“ASC”) Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The contingent liability will be remeasured to fair value at each reporting date until the liability is settled with changes in fair value being recognized within “Selling, distribution, general, and administrative expenses” in the Company’s Condensed Consolidated Statements of Operations. During the three months ended June 30, 2023, the Company recognized a fair value adjustment gain of $28 million, which reduced its contingent consideration liability, based on the estimated amount and timing of projected operational and financial information and the probability of achievement of certain performance milestones. As of June 30, 2023 and March 31, 2023, the current portion of $45 million and $83 million, respectively, is included within “Other accrued liabilities” and the long-term portion of $19 million and $9 million, respectively, is included within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheets. Recognition of the initial fair value of this contingent consideration was a non-cash investing activity. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation included acquired identifiable intangible assets of $229 million, primarily representing customer relationships and technology with a weighted average amortization period of 12 years, and goodwill of $463 million. Goodwill has been allocated to the Company’s RxTS segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition is deductible for tax purposes.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SCRI Oncology, LLC</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022, the Company completed a transaction with HCA Healthcare, Inc. (“HCA”) to form SCRI Oncology, LLC (“SCRI Oncology”), an oncology research business combining McKesson’s U.S. Oncology Research (“USOR”) and HCA’s Sarah Cannon Research Institute (“SCRI”) based in Nashville, Tennessee, to advance cancer care and increase access to oncology clinical research. Upon consummation of the transaction, McKesson owns a 51% controlling interest in the combined business, and the financial results are consolidated by the Company and reported within its U.S. Pharmaceutical segment as of the acquisition date. Transaction consideration included the transfer of full ownership interest in USOR to the combined business and $166 million of net cash paid to HCA, which was funded from cash on hand. The transaction was accounted for as a business combination.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation included acquired identifiable intangible assets of $177 million, primarily representing customer relationships as well as trademarks and trade names with a weighted average amortization period of 17 years, and goodwill of $113 million. Goodwill has been allocated to the Company’s U.S. Pharmaceutical segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition of $46 million is deductible for tax purposes. The Company recorded noncontrolling interest of $222 million as a component of equity, which includes HCA’s proportionate interest in the identifiable net assets of SCRI at fair value of $202 million and its proportionate interest in the contributed net assets of USOR at carrying value of $20 million. The difference between the fair value of the Company’s acquired interest in SCRI net assets and the $166 million of net cash paid to HCA was recognized as additional paid in capital, as well as the Company’s reduction in ownership interest in USOR net assets. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution of USOR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired identifiable intangible assets from the acquisitions discussed above were determined by applying the income approach, using a discounted cash flow model in which cash flows anticipated over several periods are discounted to their present value using an appropriate rate that is commensurate with the risk inherent with the transaction. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The amounts presented above are subject to change as the Company’s fair value assessments are finalized. There have been no material changes to the purchase price allocation of these acquisitions since the acquisition date. Pro forma financial information has not been provided as these acquisitions did not have a material impact, individually, or in the aggregate, to the Company’s consolidated results of operations.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Divestiture Activities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company announced its intention to exit its businesses in Europe. On October 31, 2022, the Company completed its previously announced transaction to sell certain of its businesses in the European Union (“E.U.”) located in France, Italy, Ireland, Portugal, Belgium, and Slovenia, along with its German headquarters and wound-care business, part of a shared services center in Lithuania, and its ownership stake in a joint venture in the Netherlands (“E.U. disposal group”) to the PHOENIX Group. During the three months ended June 30, 2022, the Company recorded a gain of $12 million to remeasure the E.U. disposal group to fair value less costs to sell which was recorded within “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statement of Operations. The Company’s measurement of the fair value of the E.U. disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreement. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company completed the previously announced sale of its retail and distribution businesses in the United Kingdom (“U.K. disposal group”) to Aurelius Elephant Limited for a purchase price of £110 million (or, approximately $144 million), including certain adjustments. As part of the transaction, the Company divested net assets of $615 million and released $731 million of accumulated other comprehensive loss, within the International segment, and the buyer assumed and repaid a note payable to the Company of $118 million.</span></div>At June 30, 2023 and March 31, 2023, the Company had no assets or liabilities related to these European divestiture activities that met the criteria for classification as held for sale. Subsequent to the divestiture activities discussed above, the Company’s European operations primarily consist of its retail and distribution businesses in Norway.<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, the Company also completed de minimis acquisitions and divestitures within its operating segments. Financial results for the Company’s business acquisitions have been included in its consolidated financial statements as of their respective acquisition dates. Purchase prices for business acquisitions have been allocated based on estimated fair values at the respective acquisition dates.</span></div> 1 600000000 275000000 92000000 -28000000 45000000 83000000 19000000 9000000 229000000 P12Y 463000000 <div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution of USOR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 600000000 92000000 692000000 5000000 229000000 3000000 8000000 229000000 463000000 692000000 0.51 166000000 177000000 P17Y 113000000 46000000 222000000 202000000 20000000 166000000 166000000 40000000 206000000 224000000 22000000 31000000 177000000 42000000 29000000 43000000 340000000 222000000 25000000 113000000 206000000 -12000000 110000000 144000000 615000000 731000000 118000000 Restructuring, Impairment, and Related Charges, Net<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded restructuring, impairment, and related charges, net of $52 million and $23 million for the three months ended June 30, 2023 and 2022, respectively. These charges were included in “Restructuring, impairment, and related charges, net” in the Condensed Consolidated Statements of Operations. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Initiatives</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. The Company anticipates total charges of approximately $125 million across its RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $96 million of charges were recorded to date. For the three months ended June 30, 2023, the Company recorded charges of $36 million related to this program, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the three months ended June 30, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment, and related charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of June 30, 2023, the total reserve balance was $74 million, of which $44 million was recorded in “Other accrued liabilities” and $30 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.</span></div> 52000000 23000000 125000000 96000000 36000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.</span></div> 1000000 0 0 0 1000000 2000000 1000000 2000000 2000000 5000000 12000000 22000000 0 0 0 1000000 27000000 28000000 2000000 2000000 2000000 6000000 40000000 52000000 3000000 0 0 0 -1000000 2000000 1000000 2000000 1000000 2000000 15000000 21000000 0 5000000 0 0 -5000000 0 4000000 7000000 1000000 2000000 9000000 23000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the three months ended June 30, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment, and related charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of June 30, 2023, the total reserve balance was $74 million, of which $44 million was recorded in “Other accrued liabilities” and $30 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.</span></div> 15000000 26000000 3000000 13000000 35000000 92000000 2000000 2000000 2000000 6000000 40000000 52000000 0 0 0 1000000 27000000 28000000 5000000 13000000 2000000 2000000 15000000 37000000 0 0 0 -5000000 0 -5000000 12000000 15000000 3000000 11000000 33000000 74000000 92000000 66000000 26000000 74000000 44000000 30000000 Income Taxes <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense related to continuing operations was as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in the Company’s reported income tax rates were primarily due to changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intra-Entity Transfers of Assets Other Than Inventory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a net discrete tax benefit of $147 million was recognized in the first quarter of fiscal 2024. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, the Company recognized a net discrete tax benefit of $45 million primarily related to the tax impact of share-based compensation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company had $1.4 billion of unrecognized tax benefits, of which $1.3 billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year.     </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year. </span></div>During the fourth quarter of fiscal 2023, the Internal Revenue Service (“IRS”) communicated proposed adjustments to taxable income reported in the Company’s fiscal 2018 and fiscal 2019 U.S. Federal Corporate Income Tax returns. The adjustments would increase the Company’s federal income tax liability in the range of $600 million to $700 million. The Company disagrees with the proposed adjustments and intends to pursue resolution through the administrative process with the IRS Independent Office of Appeals and, if necessary, through judicial remedies. During the first quarter of fiscal 2024, the Company filed a formal protest with the IRS. The Company does not anticipate a final resolution of these matters until fiscal 2026 or after. Although the final resolution of these matters is uncertain, the Company believes in the merits of its tax positions and believes that it has adequately reserved for any adjustments to the provision of income taxes that may ultimately result. However, if the IRS prevails in these matters, the assessed tax and interest could have a material adverse effect on the Company’s financial position, results of operations, and cash flows in future periods. <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense related to continuing operations was as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 94000000 199000000 0.086 0.198 -147000000 -45000000 1400000000 1300000000 600000000 700000000 Earnings Per Common ShareBasic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings per common share is similar to that of basic earnings per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than 1.0 million of potentially dilutive securities for the three months ended June 30, 2023 and 2022 were excluded from the computation of diluted earnings per common share as they were anti-dilutive.<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted earnings per common share were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to McKesson Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to McKesson Corporation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes dilutive effect from restricted stock units and performance-based stock units.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Certain computations may reflect rounding adjustments.</span></div> 1000000 1000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted earnings per common share were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to McKesson Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to McKesson Corporation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes dilutive effect from restricted stock units and performance-based stock units.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Certain computations may reflect rounding adjustments.</span></div> 997000000 807000000 39000000 41000000 958000000 766000000 0 2000000 958000000 768000000 135500000 144200000 200000 300000 900000 1400000 136600000 145900000 7.02 5.25 0 0.01 7.02 5.26 7.07 5.31 0 0.01 7.07 5.32 Goodwill and Intangible Assets, Net <div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2024 and fiscal 2023 did not indicate any impairment of goodwill. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,453 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,453 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,971 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe’s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, “Business Acquisitions and Divestitures.”</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding intangible assets was as follows: </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Amortization<br/>Period<br/>(Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,801)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,765)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and trade names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,416 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,195)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,121)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>All intangible assets were subject to amortization as of June 30, 2023 and March 31, 2023. Amortization expense of intangible assets was $62 million and $56 million for the three months ended June 30, 2023 and 2022, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $185 million, $240 million, $208 million, $202 million, and $198 million for the remainder of fiscal 2024 and each of the succeeding years through fiscal 2028, respectively, and $1.2 billion thereafter. <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,453 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,453 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,971 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe’s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, “Business Acquisitions and Divestitures.”</span></div> 4050000000 2005000000 2453000000 1439000000 9947000000 0 0 0 29000000 29000000 -5000000 0 0 0 -5000000 4045000000 2005000000 2453000000 1468000000 9971000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding intangible assets was as follows: </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Amortization<br/>Period<br/>(Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,801)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,765)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and trade names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,416 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,195)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,121)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P12Y 2984000000 1801000000 1183000000 2971000000 1765000000 1206000000 P10Y 1141000000 641000000 500000000 1137000000 623000000 514000000 P12Y 843000000 446000000 397000000 833000000 430000000 403000000 P11Y 264000000 133000000 131000000 264000000 129000000 135000000 P6Y 184000000 174000000 10000000 193000000 174000000 19000000 5416000000 3195000000 2221000000 5398000000 3121000000 2277000000 62000000 56000000 185000000 240000000 208000000 202000000 198000000 1200000000 Debt and Financing Activities<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">U.S. Dollar notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80% Notes due March 15, 2024</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90% Notes due December 3, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Notes due February 15, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due August 15, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65% Debentures due March 1, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95% Notes due February 16, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90% Notes due July 15, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Notes due May 30, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10% Notes due July 15, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00% Notes due March 1, 2041</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88% Notes due March 15, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Foreign currency notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50% Euro Notes due November 17, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63% Euro Notes due October 30, 2026 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13% Sterling Notes due February 17, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and other obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These notes are unsecured and unsubordinated obligations of the Company.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these U.S. dollar notes is payable semi-annually.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;padding-right:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these foreign currency notes is payable annually.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At June 30, 2023 and March 31, 2023, $5.7 billion and $5.6 billion, respectively, of total debt was outstanding, of which $50 million and $968 million, respectively, was included under the caption “Current portion of long-term debt” in the Company’s Condensed Consolidated Balance Sheets. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes Offerings</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2023, the Company completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million (the “2028 Notes”) and a public offering of 5.10% Notes due July 15, 2033 in a principal amount of $600 million (the “2033 Notes” and, together with the 2028 Notes, the “Notes”). Interest on the Notes is payable semi-annually on January 15th and July 15th of each year, commencing on January 15, 2024. Proceeds received from the issuance of the Notes, net of discounts and offering expenses, were $397 million for the 2028 Notes and $592 million for the 2033 Notes. The Company utilized a portion of the net proceeds from the offerings of the Notes to fund the purchase price payable with respect to the portion of the Company’s then outstanding 3.80% Notes due March 15, 2024 (the “2024 Notes”) that was validly tendered and accepted for purchase pursuant to the Concurrent Tender Offer (as defined below) and to effect the satisfaction and discharge of the remaining portion of the 2024 Notes, all of which is described further below. The remaining net proceeds from the offerings of the Notes is available for general corporate purposes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of the Notes is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Company’s existing, and future unsecured and unsubordinated indebtedness that may be outstanding from time-to-time. The Notes are governed by an indenture and officers’ certificate that are materially similar to those of other series of notes issued by the Company. Upon at least 10 days’ and not more than 60 days’ notice to holders of the applicable series of the Notes, the Company may redeem either series of the Notes for cash in whole, at any time, or in part, from time to time, at redemption prices that include accrued and unpaid interest and a make-whole premium before a specified date, and at par plus accrued and unpaid interest thereafter until maturity, each as specified in the indenture and the officers’ certificate. If there were to occur both (1) a change of control of the Company and (2) a downgrade of the applicable series of the Notes below an investment grade rating by each of the Ratings Agencies (as defined in the officers’ certificate) within a specified period, then the Company would be required to make an offer to purchase those Notes at a price equal to 101% of the then outstanding principal amount of such Notes, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officers’ certificate for the Notes, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lenders’ consent. The indenture also contains customary events of default provisions.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concurrent Tender Offer </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2023, the Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the “Concurrent Tender Offer”). The Company paid an aggregate consideration of $268 million in the Concurrent Tender Offer to repurchase $271 million principal amount of the 2024 Notes at a repurchase price equal to 98.75% of the principal amount plus accrued and unpaid interest. The repurchase of the 2024 Notes accepted for purchase in the Concurrent Tender Offer was accounted for as a debt extinguishment. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satisfaction and Discharge of the 2024 Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2023, after completing the Concurrent Tender Offer, the Company irrevocably deposited with the trustee under the indenture governing the 2024 Notes (the “2024 Notes Indenture”) U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest of the remaining $647 million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. The U.S. government obligations were purchased using a portion of the net proceeds from the offerings of the Notes. After the deposit of such funds with the trustee, the Company’s obligations under the 2024 Notes Indenture with respect to the 2024 Notes were satisfied and discharged and the transaction was accounted for as a debt extinguishment. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gain recognized on the debt extinguishments described above for the three months ended June 30, 2023 was $9 million and included within “Interest expense” in the Company’s Condensed Consolidated Statement of Operations. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2022, the Company entered into a Credit Agreement (the “2022 Credit Facility”), that provides a syndicated $4.0 billion five-year senior unsecured credit facility with a $3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. The 2022 Credit Facility is scheduled to mature in November 2027. The 2022 Credit Facility replaced the Company’s previous syndicated $4.0 billion five-year senior unsecured credit facility, dated as of September 25, 2019, as amended (the “2020 Credit Facility”), which was scheduled to mature in September 2024. The 2020 Credit Facility was terminated in connection with the execution of the 2022 Credit Facility. There were no borrowings under the 2020 Credit Facility during the three months ended June 30, 2022, and no amounts outstanding at the time of its termination. There were no borrowings under the 2022 Credit Facility during the three months ended June 30, 2023 and no amounts outstanding at June 30, 2023. At June 30, 2023, the Company was in compliance with all covenants under the 2022 Credit Facility. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $4.0 billion in outstanding commercial paper notes. During the three months ended June 30, 2023, the Company borrowed and repaid $65 million under the program. During the three months ended June 30, 2022, there were no material borrowings under the program. At June 30, 2023 and March 31, 2023, there were no commercial paper notes outstanding.</span></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">U.S. Dollar notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80% Notes due March 15, 2024</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90% Notes due December 3, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Notes due February 15, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due August 15, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65% Debentures due March 1, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95% Notes due February 16, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90% Notes due July 15, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Notes due May 30, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10% Notes due July 15, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00% Notes due March 1, 2041</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88% Notes due March 15, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Foreign currency notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50% Euro Notes due November 17, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63% Euro Notes due October 30, 2026 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13% Sterling Notes due February 17, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and other obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These notes are unsecured and unsubordinated obligations of the Company.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these U.S. dollar notes is payable semi-annually.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;padding-right:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these foreign currency notes is payable annually.</span></div> 0.0380 0 918000000 0.0090 500000000 500000000 0.0525 499000000 499000000 0.0130 499000000 498000000 0.0765 150000000 150000000 0.0395 343000000 343000000 0.0490 399000000 0 0.0475 196000000 196000000 0.0510 596000000 0 0.0600 218000000 218000000 0.0488 255000000 255000000 0.0150 653000000 649000000 0.0163 545000000 542000000 0.0313 571000000 555000000 237000000 271000000 5661000000 5594000000 50000000 968000000 5611000000 4626000000 5700000000 5600000000 50000000 968000000 0.0490 400000000 0.0510 600000000 397000000 592000000 0.0380 P10D P60D 1.01 268000000 271000000 0.9875 647000000 9000000 4000000000 P5Y 3600000000 4000000000 P5Y 0 0 0 0 4000000000 65000000 65000000 0 0 0 Hedging Activities <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives as described below. In accordance with the Company’s policy, derivatives are only used for hedging purposes. It does not use derivatives for trading or speculative purposes. The Company uses different counterparties for its derivative contracts to minimize the exposure to credit risk but does not anticipate non-performance by these parties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Canadian dollars, Euro, and British pounds sterling. Changes in foreign currency exchange rates could have a material adverse impact on the Company’s financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Derivative Instruments Designated as Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the divestiture of the E.U. disposal group, the Company had €1.1 billion of Euro-denominated notes designated as non-derivative net investment hedges. These hedges were utilized to hedge portions of the Company’s net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. For all notes that were designated as net investment hedges and met effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates were recorded as foreign currency translation adjustments in “Accumulated other comprehensive loss” where they offset foreign currency translation gains and losses recorded on the Company’s net investments. To the extent foreign currency denominated notes designated as net investment hedges were ineffective, changes in carrying value attributable to the change in spot rates were recorded in earnings. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the divestiture of the E.U. disposal group in October 2022, the Euro-denominated notes described above were de-designated as net investment hedges.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of the U.K. disposal group in April 2022, the Company reclassified $26 million of gains from accumulated other comprehensive loss to “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statement of Operations for the three months ended June 30, 2022. This amount related to the Company’s £450 million of British pound sterling-denominated notes, which were previously accounted for as net investment hedges until de-designated in fiscal 2020, and was included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities of the disposal group to fair value less costs to sell.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro-denominated notes </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and March 31, 2023, the notional amounts of the Company’s outstanding derivatives were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:42.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-24 to Mar-25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as fair value hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">£</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">£</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aug-25 to Jul-26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Feb-26 to Sep-29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jan-24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-23</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The maturity date reflected is for outstanding derivatives as of June 30, 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses cross-currency swaps to hedge portions of the Company’s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Company’s net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains from the changes in the Company’s fair value hedges recorded in earnings were largely offset by the losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive income (loss).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency rates and also enters into forward contracts to hedge the variability of future benchmark interest rates on planned bond issuances. The effective portion of changes in the fair value of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses reclassified from accumulated other comprehensive loss and recorded in “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statements of Operations were not material for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges in fiscal 2023 with a notional amount of $450 million, and in the first quarter of fiscal 2024 with a notional amount of $50 million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500 million cash flow hedges were terminated and the proceeds are amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, “Debt and Financing Activities,” for additional information on the public offering of the 2033 Notes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives Not Designated as Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statements of Operations. The Company did not have any outstanding derivative instruments not designated as hedges during the periods presented. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Information on Derivative Instruments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow and other hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the fair value of derivatives on a gross basis were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet <br/>Caption</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated for hedge accounting:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other/Other accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (non-current)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps (non-current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Financial Note 9, "Fair Value Measurements," for more information on these recurring fair value measurements.</span></div> 1100000000 26000000 450000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro-denominated notes </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2022.</span></div> 0 64000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and March 31, 2023, the notional amounts of the Company’s outstanding derivatives were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:42.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-24 to Mar-25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as fair value hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">£</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">£</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aug-25 to Jul-26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">€</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Feb-26 to Sep-29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jan-24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-23</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The maturity date reflected is for outstanding derivatives as of June 30, 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.</span></div> 1500000000 1500000000 450000000 450000000 1100000000 1100000000 1250000000 1250000000 400000000 400000000 0 450000000 450000000 50000000 500000000 P10Y <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow and other hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.</span></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow and other hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.</span></div> -20000000 12000000 -6000000 -2000000 16000000 27000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the fair value of derivatives on a gross basis were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet <br/>Caption</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated for hedge accounting:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other/Other accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (non-current)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps (non-current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 2000000 301000000 5000000 0 301000000 84000000 12000000 2760000000 74000000 2000000 2760000000 0 39000000 1250000000 1000000 15000000 1700000000 84000000 53000000 80000000 17000000 Fair Value Measurements <div style="margin-bottom:12pt;text-align:justify;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - significant other observable market-based inputs.</span></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents at June 30, 2023 and March 31, 2023 included investments in money market funds of $806 million and $1.4 billion, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values of the Company’s interest rate swaps and cross-currency swaps were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, “Hedging Activities,” for fair values and other information on the Company’s derivatives.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in equity securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $237 million at June 30, 2023 and March 31, 2023. These investments primarily consist of equity securities without readily determinable fair values and are included in “Other non-current assets” in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains as well as impairment charges related to these investments are included within “Other income, net” in the Condensed Consolidated Statements of Operations and were not material for the three months ended June 30, 2023 and 2022. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company’s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and March 31, 2023, the contingent consideration liability related to the Company’s acquisition of RxSS in November 2022 was measured at fair value on a nonrecurring basis. Refer to Financial Note 2, “Business Acquisitions and Divestitures," for more information on this transaction. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value on a nonrecurring basis at June 30, 2023 and March 31, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Disclosures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and March 31, 2023, the carrying amounts of cash, certain cash equivalents, restricted cash, receivables, drafts and accounts payable, short-term borrowings, and other current assets and liabilities approximated their estimated fair values because of the short-term maturity of these financial instruments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company’s long-term debt was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current maturities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,386 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company’s long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow (“DCF”) model to determine the fair value of each reporting unit.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement.</span></div>The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. 806000000 1400000000 237000000 237000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company’s long-term debt was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current maturities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,386 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 5661000000 5335000000 5594000000 5386000000 Commitments and Contingent Liabilities<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Note 1</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> to the Company’s 202</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Annual Report</a></span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within “Claims and litigation charges, net” in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I. Litigation and Claims Involving Distribution of Controlled Substances</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacies. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. They have sought monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), state and federal controlled substances laws, and other statutes. Because of the many uncertainties associated with opioid-related litigation matters, the Company is not able to conclude that a liability is probable or provide a reasonable estimate for the range of ultimate possible loss for opioid-related litigation matters other than those for which an accrual is described below. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State and Local Government Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and two other national pharmaceutical distributors (collectively “Distributors”) entered into a settlement agreement (the “Settlement”) and consent judgment with 48 states and their participating subdivisions, as well as the District of Columbia and all eligible territories (the “Settling Governmental Entities”). Approximately 2,300 cases have been dismissed. The Distributors did not admit liability or wrongdoing and do not waive any defenses pursuant to the Settlement. Under the Settlement, the Company has paid the Settling Governmental Entities approximately $1.0 billion as of June 30, 2023, and additionally will pay the Settling Governmental Entities up to approximately $6.8 billion through 2038. A minimum of 85% of the Settlement payments must be used by state and local governmental entities to remediate the opioid epidemic, while the remainder relates to plaintiffs’ attorneys’ fees and costs and will be paid out through 2030. Under the Settlement, the Distributors will establish a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. Alabama and West Virginia did not participate in the Settlement. Under a separate settlement agreement with Alabama and its subdivisions, the Company has paid approximately $42 million as of June 30, 2023, and additionally will pay approximately $132 million through 2031. The Company previously settled with the state of West Virginia in 2018, so West Virginia and its subdivisions were not eligible to participate in the Settlement. Under a separate settlement agreement, the Company has paid certain West Virginia subdivisions approximately $38 million as of June 30, 2023, and additionally will pay approximately $114 million through 2033. That agreement does not include school districts or the claims of Cabell County and the City of Huntington. After a trial, the claims of Cabell County and the City of Huntington, were decided in the Company’s favor on July 4, 2022. Those subdivisions appealed that decision. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some other state and local governmental subdivisions did not participate in the Settlement, including certain municipal governments, government hospitals, school districts, and government-affiliated third-party payors. The Company contends that those subdivisions’ claims are foreclosed by the Settlement or other dispositive defenses, but the subdivisions contend that their claims are not foreclosed. The City of Baltimore, Maryland, is one such subdivision, and a trial of its claims is scheduled to begin September 26, 2024. An accrual for the remaining governmental subdivision claims is reflected in the total estimated liability for opioid-related claims in a manner consistent with how Settlement amounts were allocated to Settling Governmental Entities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Native American Tribe Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also entered into settlement agreements for opioid-related claims of federally recognized Native American tribes. Under those agreements, the Company has paid the settling Native American tribes approximately $56 million as of June 30, 2023, and additionally will pay approximately $140 million through 2027. A minimum of 85% of the total settlement payments must be used by the settling Native American tribes to remediate the opioid epidemic.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current litigation liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term litigation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total litigation liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,173 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,173 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These amounts, recorded in “Other accrued liabilities” in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company made no payments associated with the Settlement and the separate settlement agreements for opioid-related claims discussed above. In July 2023, the Company made payments totaling $529 million associated with the Settlement and separate settlement agreements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Governmental Plaintiff Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a defendant in approximately 400 opioid-related cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement agreements described above or in the charges recorded by the Company. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Plaintiff Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its Canadian affiliate are also defendants in four opioid-related cases pending in Canada. These cases involve the claims of the provincial governments, a group representing indigenous people, as well as one case brought by an individual.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defense of Opioids Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense in such matters. Other than the settlement agreements and the U.S. governmental subdivision claims described above, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company’s financial position, cash flows or liquidity, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">II. Other Litigation and Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2018, the Company received a purported class action complaint in the United States District Court for the Northern District of California, alleging that McKesson and two of its former officers, CEO John Hammergren and CFO James Beer, violated the Securities Exchange Act of 1934 by reporting profits and revenues from 2013 until early 2017 that were false and misleading, due to an alleged undisclosed conspiracy to fix the prices of generic drugs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evanston Police Pension Fund v. McKesson Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:18-06525. In October 2022, the parties reached an agreement in principle to settle this class action lawsuit for an amount covered in full by the Company’s insurance policy. This settlement does not include any admission of liability, and defendants expressly deny wrongdoing. The Company’s estimated probable loss, entirely offset by probable loss recovery from the Company’s insurers, was $141 million, both of which were recognized in the Condensed Consolidated Balance Sheet as of September 30, 2022 within “Other accrued liabilities” and “Prepaid expenses and other.” In February 2023, the insurance carriers funded the settlement, and the probable loss and loss recovery of $141 million have been reversed in the Consolidated Balance Sheet as of March 31, 2023. On July 14, 2023, the court granted the motion for final approval of the settlement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company was served with a first amended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the U.S., 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States ex rel. Hart v. McKesson Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 15-cv-00903-RA. The U.S. and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. On May 5, 2022, the district court granted the Company’s motion to dismiss the complaint, but granted the plaintiff leave to amend the complaint. The relator filed the second amended complaint on June 7, 2022, which was dismissed on March 28, 2023. On April 26, 2023, the relator filed a notice of appeal to the United States Court of Appeals for the Second Circuit. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">III. Government Subpoenas and Investigations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business.</span></div> <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Note 1</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> to the Company’s 202</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Annual Report</a></span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within “Claims and litigation charges, net” in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.</span></div> 2 48 2300 1000000000 6800000000 0.85 42000000 132000000 38000000 114000000 1 56000000 140000000 0.85 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current litigation liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term litigation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total litigation liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,173 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,173 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These amounts, recorded in “Other accrued liabilities” in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.</span></div> 545000000 548000000 6628000000 6625000000 7173000000 7173000000 0 529000000 400 4 1 2 141000000 141000000 141000000 141000000 27 Stockholders' Deficit <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Company’s Board of Directors (the “Board”). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the quarterly dividend was raised from $0.54 to $0.62 per share of common stock for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Plans </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has authorized the repurchase of McKesson’s common stock. The Company may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase (“ASR”) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company’s stock price, corporate and regulatory requirements, tax implications, restrictions under the Company’s debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions. The ASR programs discussed below were designed to comply with Rule 10b5-1(c).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, the Company’s repurchase of McKesson’s common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the IRA. Excise taxes incurred on share repurchases of an entity’s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholders’ equity within “Treasury shares” in the Company’s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholders’ Deficit. Excise taxes are not reflected in the Company’s remaining authorization for the repurchase of McKesson’s common stock. </span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.0 billion of the Company’s common stock. The total number of shares repurchased under this ASR program was 3.1 million shares at an average price per share of $321.05. The Company received 2.6 million shares as the initial share settlement, and in August 2022, the Company received an additional 0.5 million shares upon the completion of this ASR program.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company’s common stock. The total number of shares repurchased under this ASR program was 5.1 million shares at an average price per share of $295.16. The Company received 4.8 million shares as the initial share settlement in the fourth quarter of fiscal 2022, and in May 2022, the Company received an additional 0.3 million shares upon the completion of this ASR program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company repurchased 1.8 million of the Company’s shares of common stock for $673 million through open market transactions at an average price per share of $379.14. Of the total dollar value, $4 million was accrued within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet for excise taxes incurred during the three months ended June 30, 2023. As of March 31, 2023, the Company had $27 million accrued within “Other accrued liabilities” for share repurchases that were executed in late March 2023, which settled in early April 2023. There were no open market share repurchases during the three months ended June 30, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total remaining authorization outstanding for repurchases of the Company’s common stock at June 30, 2023 was $2.9 billion. In July 2023, the Board approved an increase of $6.0 billion in the authorization for repurchase of McKesson’s common stock. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow and Other Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">⁽²⁾</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2023 includ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e l</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">osses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains on Cash Flow and Other Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">⁽²⁾</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2022 include gains of $64 million related to net investment hedges from Euro-denominated notes and gains of $12 million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $31 million.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations.</span> 1 0.54 0.62 1000000000 3100000 321.05 2600000 500000 1500000000 5100000 295.16 4800000 300000 1800000 673000000 379.14 4000000 27000000 0 2900000000 6000000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow and Other Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">⁽²⁾</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2023 includ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e l</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">osses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains on Cash Flow and Other Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">⁽²⁾</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company’s operations in Canada and Europe into the Company’s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2022 include gains of $64 million related to net investment hedges from Euro-denominated notes and gains of $12 million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $31 million.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within “Selling, distribution, general, and administrative expenses” in the Consolidated Statements of Operations.</span> -847000000 -14000000 -36000000 -8000000 -905000000 67000000 -15000000 7000000 -2000000 57000000 0 0 0 0 0 67000000 -15000000 7000000 -2000000 57000000 0 0 0 0 0 67000000 -15000000 7000000 -2000000 57000000 -780000000 -29000000 -29000000 -10000000 -848000000 -20000000 -5000000 -1504000000 10000000 27000000 -67000000 -1534000000 -176000000 45000000 18000000 12000000 -101000000 -730000000 17000000 0 -24000000 -737000000 554000000 28000000 18000000 36000000 636000000 47000000 0 0 3000000 50000000 507000000 28000000 18000000 33000000 586000000 -997000000 38000000 45000000 -34000000 -948000000 64000000 12000000 31000000 Segments of Business<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the U.S. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RxTS segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS serves our biopharma and life sciences partners, delivering innovative solutions that help people get the medicine they need to live healthier lives. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKesson’s own line of high-quality products through a network of distribution centers in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment includes the Company’s operations in Canada and Europe, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Company’s Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and includes Rexall Health retail pharmacies. The Company completed the divestitures of the U.K. disposal group in April 2022 and the E.U. disposal group in October 2022, as discussed in Financial Note 2, “Business Acquisitions and Divestitures.” The Company’s remaining operations in Europe provide distribution and services to wholesale, institutional, and retail customers in Norway where it owns, partners, or franchises with retail pharmacies. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,483 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,154 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating profit (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment’s total revenues, less than 37% of the RxTS segment’s total revenues, less than 1% of the Medical-Surgical Solutions segment’s total revenues, and less than 1% of the International segment’s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company’s reportable segments.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company’s U.S. Pharmaceutical segment’s operating profit includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">cash receipts for the Company’s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a charge of $32 million and a credit of $13 million related to the last-in, first-out (“LIFO”) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company’s RxTS segment’s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28 million, which reduced the Company’s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company’s International segment’s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Corporate expenses, net includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”</span></div> 4 <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,483 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,154 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating profit (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment’s total revenues, less than 37% of the RxTS segment’s total revenues, less than 1% of the Medical-Surgical Solutions segment’s total revenues, and less than 1% of the International segment’s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company’s reportable segments.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company’s U.S. Pharmaceutical segment’s operating profit includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">cash receipts for the Company’s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a charge of $32 million and a credit of $13 million related to the last-in, first-out (“LIFO”) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company’s RxTS segment’s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28 million, which reduced the Company’s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company’s International segment’s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Corporate expenses, net includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.”</span></div> 67160000000 56947000000 1244000000 1066000000 2611000000 2592000000 3468000000 6549000000 74483000000 67154000000 827000000 696000000 231000000 144000000 227000000 256000000 57000000 -6000000 1342000000 1090000000 204000000 39000000 47000000 45000000 1091000000 1006000000 0.01 0.37 0.01 0.01 3 118000000 32000000 -13000000 -28000000 94000000 40000000 -106000000 false false false false EXCEL 80 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

$+J&S=1I88>JV_7=$DS4EXW= M$6L]]PT4@6LP%XE?LU8%<9\57"]%,X&TW**!IRH0O.+:^1L(:#CGJYT>M2/> MU,83FH!ZRF/:!V\%_V>^!D"3=P)?9*96.2LX)LR%H-*,*_E?Z&-LG+!"<$5I M:0"0#MK5T=\?Q8+T->RUU%!#0OY[&)>=CQDY?'KT\A>1+\GH5Q0(@5_&8>3X M90B<10\PG7U[=B/:V04CV GPI;.YR2#]%4;E;C,,">P>H"+VBB0'@_P^N9VP M)5(YYQ".UAUYP4O 7]2M?F6!&]; M@'(\:GOR;4Z3FS + -[T2SQ&R]:-=W\-[M)&'[3F"3FE<;%LG =<:TJ4^.6, M F8I J^Y"M7&+=6\;A]O5?52*AD^)I0GW1&"60+@P,8HJ/)J< M3!)B0>3C;\SHK7$>H?-X."U\%TJTLM;MXQ*EFJ.Z9H6^AOY*8%%:VI?090E: M@7SC#G[+[0,7D7,WW81!4X(IH,73_',+\DBT S_\"F/R6&P$'!,U[S1ZK.S* MV$,(ZB%VP!@_IE]5@;PWL-FP"'FC*51EH N89D^]VU9(94]ZOP @Z9WH.8D> M[^2>?04U9'/E#-KB^9^H1$@7W==V#Z=/V,]"P[:*ZI9&=BA= ;E"5 M($/Z.S2QH9[>A@_\LS&I&8&FI$PLLY,*F<(/5)*D@ .=(5.0AQUJ!IK?TT@% M!C14K&( ?;J"9Q_GKFA37$;/-F8=KT!^VUW9. V%]V/,WV\O[TE M8+\W=Z*< _<$M1#V#SE^VZ#[L]NTS6[7#?]?=3HT'1%%IJ0TZ<:C8+G2A C= M2&WP'(A-.YZU90+C5(N0Z_!FNSK^XF266"&:>XM?^]*?FA-:XMU9G_$^O!$2 M&-:Q#&G8L@]M DZ$4 ?9,:M4'0 +N359=,UB,18LT*N_ F7'\HLD6BC=,V=; MA3I>AA;+2217;AOCK0?C$OV4L!N56@]\#VGPK0NZOZ:>>[-UYLXG;A,L=.1E MPUS;AY_M/?*@H9 :N0FO(6+0)\>6@L7^&I'2[VO[C>^<.C8-P)=-=5:[8)^( M__4!=86T<*L:A_24Q%+9V6:RG3<#7T@?3ZO>8F;>HB9O MW-X!;;9\H5WV0"ZY.4Z%_D(&VV,TMWS15#=9%H56?$VCXW[C-S<6G(.M!_W1 ML!C<3I1=NYDG%!!7QN=^Y3D7&4_>#$':[5L2.KKXQ9Q%R]&HH[RM4VKMMP8M M4;G-B(QP054?!%0UGMZ_6_;Y6^F0F7T,AHH%W/TGV[ M$"' M]2'LB7-WUMNTV] NNS+NQC:46_L7[]SO[!G<)'82U9^QT?'9V'/[.9J?A[^G?3^+S^5FPP2[P?<'1]W43Z1*@ M!YV8Y@8(^O]N%9YPH31-POZB&X*?CGQDHZ,5VL9C;+] M^F\N=%"15?I'1[B2242L4)?-EKT2V,/'9(*AG7B;JOH%2Y>>>DDG"Q;:=9.; MDPA3M=Y_-.^T?#30I($#<2.GI=^M&FT*+F('8.;$X6R "V0^I.OWI MYG5J]'Y$\9GCH#A6B]8='"A(]-#FDQAN"A#)FW:M?X;:2_([LB-:"EFI3D=* M(UUHTF;0)^D1H3@X<+J":X*Q63-44 *M>BG3Y7=[:1#!UEG Q4\'"8JH#M0Z M9.1^/1&N_S#2LQL4^5.DNC&$GO0IX&VX!ZP43]5]4U$_J2A!,Q2^K.!(U.%M MG*H+!CJ@ZHR=DJ=TNQ&[YU)_U]>JP]Y'1;JY"I].22R $[\OMF_;K[-7\:-D M-SU^V@69+^F>0HD%EAY-GI^.F(V?2^.#-U7X1#DWWILR_"S03 A+$TZI$0(W MI@?:H/UF??D_4$L#!!0 ( ,J+ E=$?FYQ7A, !8W 9 >&PO=V]R M:W-H965TOWCFFKJPE7GO56C*4OO=2U.XN^='IT?IP0>[6M?TX.3% MLXU>F5M3_[YY[_'MI%TEMZ6I@G65\F;Y_.CJ],G+=1N21/[G]/J;YAW\++0P5R[ MX@^;U^OG1Y='*C=+W13U!W?WDXG\7-!ZF2L"_U5W,O9B?J2R)M2NC)-!06DK M^:\_1SGT)ES.[IDPCQ/F3+=LQ%2^TK5^\ M;RWFU2^N75G:&E*N@])5KJY=5=MJA>_J%ZL7MK"U->'928V]:,9)%M=]*>O. M[UGW3+W%2NN@7E>YR8?S3T!C2^@\$?IR_N""/S?55)W-)FH^FY\]L-Y9R_@9 MKW?VGS*>@5_URH:L<*'Q1OWOU2+4'M;S?X>D()N<']Z$/.I)V.C,/#^"RP3C MM^;HQ=_^&]R?%#UVBCGV4#0@7BS_APK2% M5EOMK:EW-"$KM"UEJ\*L=*$VWF7&8.$5%L&.14.?T[BE=V5T*.-EVM94N?,8 MC C'0^GAQM5@P6(]655GP@+BG\IUB4"%"2NW-;XB7C'"5EL3ZL3K1)@'$QY^ M6M?8;*I^Z[%$KRW):+F$)'4-26J8V49[EBK8) '(YCT>>]PAZH3,VP7DN:"H M*DM6Z@UD"O/%O%_!A#I5C]-J<>^__>5R?OKX:2 ?4F?JJJH:#/Y@-L[7:J+N MUC9;J[PS?8!(:CQGQI+]HXY&SR"#8=:BUDA_6$L!O4,VU9_-E5,4U5^@MWQ'A:7 MR1+96L/]U!JJQAY(R)[-AJRH]'EF"QMA_V!I&K\C5Z.!29U[JGRWA(\^L'.K- S1 M-3;B93$$]K2@0:S@!TC4I6M@9:#L +'T:,)$:C%:D)7I1L(8,V@1"-E=!#2Q M6K?:%DP?&3B-Z@*-62YA!RSQ95.3X\&Z4QC-368#1R!Q-I^G4#&!!4'C.G 4 MC<.]636%KCFL,?-WMB@& C$*ZA56H6I7-*)X(9WYF:JWG8$?T *Y%U9&1B-. M.8[#&#@P>DVF42$\%C39>0II)+.8-W8L^6#,1U + 27"B)I.Z#'.PF=KTAI" M#91+^06$DMQCJ& %$O#$6V9E"^(H,H-FT+\S>AQ[O=D2K!.M9H.,#X8*6$.M M/C40K_$PB8$EW:T-QW11\$>POG8N;TUD36I@-\U9#VDX_!4!"P1])(=L[/F]);LL6?IT2A&9LXN -*\073/ RV2%"2& M7;7TY5$OHR16!$=[;"W,HI\R[HA>RVKK[=KZ=Y_D&"M;;(!]OV;VT#_C6FSE MYC,E"PYMPAB^M'Q-U15/"A$:X-V=A3]5BK+B?/;TNH> M/DT@!K H1W5B&"#!^FS.XKJEN"B)"?2]:T,HV5NP@:GNA'O $N%6_ KFYS;6 MV?PX/>G1U4*+FRE 6?N8X9HP4A8%^0D-&$6*ZU#$#L\MEJ(\P*P#IUCWLU>,H']&2=;2$EA:VM5UORTJ7 M>WOJPF$'TF%$6QNHJ@36QMH9HNK=VB%C:9A-NZ> O>$PT-TLD11AO#Z"-V]J M!.LTT$9ZU ;,0$_+940<\4] M.3 AOC;YM1!E'QE^D> H%%"4ZH(EIQ:"QYKZ0)FGLL<> ):WK0)^<10<_MZZ M9HJJXRA9W[FXGSBH+L8!IA]]U/<9*9,[44ALT0A>]48D8X!Q@A=V0RY\I?)@ M2O3*&_GT/>78FLAH5'K!5521.+(#6NC M2!%B2=OY 6WY*D8G229%4RZLYI4T96'XG61KX[VM!0+N44I[_+U?1;^&>9*! M)NJ1KST2#>YA.B^)/$N%UO- <=[EDG&X)$[ MR MK?2 V^].IS,%>@M.ZAQI?FZ 0E,#3+P_M5\@]IU ("HVOV*S9L/ME.&6CZ:7 M[98QP&.OLTMH@CJ/MFQ*HN/RXJ\IO'1\T\:">4J*K(!U#47LQ:X7TPIVJ4'K MQ"2"!,JCTD\5F'BY,AL$C=)F7-X6\DHP/\E>8@#/[I)S;')TZ3<]6)IH[YD+ ML5IBF2V,*$FR60$$* VG,P6C%D:>_%R',89PY MZ#PC,SV?PQK_*\<8N]A9MU)/[Z?#2F=#-:,TL(2KF#=9^G4LX(92@X3FL]-+ MY',W>G.(:T16;UC*7>1TWT3B]\@SHH$1:0.21I(ZN_Q6(C\]/R3R,Q*Y[MM* M[HP C8BI]W"QBH@A5AB4B/2"4M1U![&9>RM8\:>&2ZS:5;#W9-[7&C=:FW!%DJ2 S\G[/ YL0MP9*QR('FJ4@B2:2N#R")*TT/ MYMT;2@>+?97?#IKDT2;NJ4JZ+_WR8[]6(=JZL<=M^9@?*$B&;D;Q$)5=2#7^ M6#XIB*Y#QQW9VN1- M(=7R@DH.L+6I3;D ,_-';$'GL.$.R+;@F?,B:?,^P^AMX\V2<&AGN;7CA-PU M)@8-H1'H3NM4W&2N4-VF[D8;Z*E9W=.'CLT7=AK$"!AP[ @\#%6FZE?-NKLJ MC:?>O_J-$/M!.$X]J0%L/A04#Q81G?O'PJO8<0MIA:H-K\#>(!6WP[+4@ MR=3WC+);Z( B&1 =!)O]N'>87L1VJOC)5&"I=^&)^OZF2@(,/PS50!X/#S\[ MC5^OJ9M9U?W"M.B=FGY_^H/Z3EV<7_#?2Q2:U>J86KKW37@T>32_Y+\7ZC?6 MRCT#OU./)Z>/S]K_M%-L\8CS3;JV:-?V?,=1V6IVEC!V1&+RNXOYC[UP\$5R'R85<=55QX.0^SZ54(>" MJPT27W77@N7P/X@SYZC0Q^QSP;[PTO*+2F??7!"VMEMN\K3%6W>F]:W;G**' M2=2DDQY9(J"M0V.GMMA-VIS?=G4C\8_%F!DE.Y4& MJ47P>5 !J71H1[?@2L[C2#G#COS2-?O6R.I(]QTPJ->=)2'Q:\LG!V8$C/G, MDKIXP[DD9W=2NKWVD"C@;CI9=GMN\Z[?I+S/JE+8V4]F!U#=R 3W M88@PE M0?2 AMZ=CJ^]V'"P"MN[Z# AVUNK)65WHJ6PGQJ;I_/I>ZY W-PDM1T^<7M7 MP60S0>JG\TEL O2U@!A@[):%OVGH6DW,$!"='&'0+2J)AFVLK&Q[JABZSNLU M'<2T*.A7K 2ZJF%G%HZ 2CN)]WI!=KQP1/;"]I6WO+FQ-U9AXF WIG2DJMX'?HXWFF@(F*)D"?5 M<&E#8;1O MM[H*J/75>^ =@)SW\3+JFX9NCTT[.5['.U+T<@)M3-79D]/+X]FCB_D%I_IW M6>VX@$/Y+R:1[GMY CE\7M1K?T#W( HFNY%ND$0'N6LU,!W_8N=LAME38# MF<^4"^3B%V9U+?#$"GYW8C;W,LH&3;@> MU=!I E(3M7!T"+9,C5:RK%[E]Q^ WUBB=<5Z1)[ST3V#+P)NDF,<^QZ.0H 9 MLI0\UI[Y3=-H&-<;L_ -':1V6+)3;::]MQ1 "3*9?)1L)FV*&C9N *&%,DNW1L\V3K%-$+09]; MZ:(,^1K@Z]DP"),-\%7(?R4"B:=$]O44(A_P$F M#RZ#_/++M5C @8'7!"L'HP=+#S-*S^\'N>"*CAS^8;./"YU]9)DU-9!).MY^ MPS$\ID_D""&&CO@).TF_4^)\Q#CII#M& 2#%?O))KI-O DY%2S6?2SA19#RJ])\XC,,%D,&BB3B^.L^WQ;/;C[.SX MPY6$-T9L27-R?26JDQTG-QG=NL[E\F=-UEBU+5J"Q;)*9X)T92ZDZQ =7&UO M)-?>D/.VW^4N Z(&=2;I03H.XV.P2>\<#-9$*80UJO@N'=7;=FG;JU^!7?2M MWJF+22^#I;[O 4\=!^#HN7+_A[)']/#(G?1C^PNT%2%=RMM*2B]-%&<[3X24 M'$F\5.( $GW>.G0G16[$0]"/$Q\QZNO0G233((E0\\M>A+I"0BY2 S:&J.'. MFC(EV15=2.%N?CJE&UJ71 H,NN)!W7W76R'[VOH,"B&\"<#9NX)PVRPV#AJ5 MD' SN':NWG#RLZ4<#>+_0>3)1T]Q$0:ZGX"W8N.B?UV54VGRPU[W7\=+:L/F M?5LU<[/&Q5HH-;Y[-+?[<>MA7.:*:>:8M^ZBE">]N,&-84=\A,Q_861.C5>0!P7YK7!JWPT/_QQ/XVXPNSG3[KJ(1.A=R O?^G'--#OW$YZ?U6B4H* M_D56D)MQ\K.E]FG[HZ\K^:U3-UQ^,08O108*$-\24V?3QQ='RLNOL.1+[3;\ MRR=@/ 1Z_@A9P09H -[3[QC2%]J@_2G&PO=V]R:W-H965T'^WBV)56R907Y=GQH-<[._V]^L)[O5AZNG!\_KR4"W6M_,?RG<6GXT9*JG-5.&T*8=7\Q=Y% M_]GEB)[G!_ZIU9 M>\V6M+#]OI;^FFV'+3/IU)7)_J53OWRQ-]T3J9K+*O/OS>H'%>T9D[S$9([_ MBU5X=C#8$TGEO,GC8FB0ZR*\RMOHA]:":>^!!8.X8,!ZAXU8RY?2R_/GUJR$ MI:YJK//GU]XDGY8F2Y5U?Q@UJO2X'CPK\L2JZ8MCKB$%O,'Q$ MWK"Q<\CRA@_(>_6YTOY._/MBYKP%%/ZSR\8@8K1;!*7',U?*1+W8 _Z=LC=J M[_S[[_HGO;-'%!PU"HX>D_[T0'R#&/%*)DOAEM(J8>;"+Y6X,GDIB[OOOYL. M^I,S)Y"OSLLBU<5")";/D3".1 GM1*ELKKU7J3"%$C?&0THA2FM*XV2&^^2- M@NY[$U9%!00$D@#VFD3D<)XD5X@;"N=9=@,=XI*!>?=M71/I%NVMH872?:\ M\I557?:D;98/!6 @F]1P0F9L*;V%'>+0EPBKB<>SKEU%:JEUB%1-H1$[P M/0EB]5)5DONJTA3M4/W=U=*5M 50Y3IBK@M9)%JR3:DFH1T846J/2Q9@0#!) M2SR:J<6]:[2EP196S"7'O"NN.2+O55G99 EN%N\R63CV:U 3%X6L_-)8_5_" M'V[8]=.PZ&WRDW+.% VTVK'=C% .YZOY''B+D5]+<@$S'N7JR)LC>L5>UE2+ MI:#ZB;7V$RHLJ*=PDNL1#"JMOD&\$E&$C,ZI=PB>78>+Q+ZO,B7ZO=GXJ'^0'-;XN59) M91%\..W5+0S!-N(B83SV3XE$O#-BO&&T( M;DR<#HF'_D[$!+R16<70#LE,Q@1WA R*2*2W"FEH&^W1 M5[L*7JI-)+I. #7")'Q,P@)&55KSO3>U+&I/M:O-V=0B85"F$:QS:HKI4_!" M6B4UP[?+=S2*RC3U3K$J1-+YT*C*X(H$5"NU'=@K( R=/+;$.VD1MTEVK8NK" 6<5JX2E+6WV^]V> MF('=6C5ZV[C[12V@YE'&K+D)D-I0$Z 9=OL81L*6<245!M J.@[,$ FHXW:RKR0H$=4C'HGMR3Z-@6!,63!X(@ISPZ20)")^:3N*@6X($=SFZ$ MDV)I8#@(0F.WO573O3"7M=J=3=LYL*_5S#*3_5G1'?_9T1U_2W0'IUAV\D!T M1]WI5T:WZ69-9>&XV/1RL48]PH+@_0B!W _DXID8>Q ME]L53!F8C^JA=5N7M>O[+6\\$-*HUZY98_]DLM;_2TWF4])RHF.V!\U&Q(^4)%LQ2U5NR#\RNU)88HC+IH(8:8ED,NMWA]0'MAX MM;,\IT^/2E=BPK#:'W1/:ZK;-;3'P;-$,L:DYF8J5N3]DU89C#"[ M7\F_JHI?)$F54UN/W4*TR2BKEG0FB9;V9^,<] PGH^&0$W3 M"!D78K-C8=QD_9=$[/ZS%2G$P@%R( MW2&@^_UW_"(N^*C'M=:'D:T^DVF=J7 .#,Z^^/IEG6O5 M&BU^1I(]B\=.5)$P_LXJS\,:='D([W^@1MM;UGE_7]4FFILIA(!-ICT.W."T M_=(/%Z]H-N8=':> MU99T(L0PT)0+A4PE1_)597$OM)\/C-?&>N:GF+I(E[42F/[)#2W08/",\_63 MF":0F "GB9C>U!CVFD)J54@FBKJB%J_)^B4G;W!68K'XJ-90N)4L75T0>9P+ M>1I#3,/\+"8R;=?T]MV_DM[N4]93:>[I[+:UQU_ <@-.@VSK!PELW)O4.D'&]&0W@7&<3D\Y M*,,I_L&A5)!"73K]/WF1B^*YFEB$-*2./QPOC8?ZRE M K&_GP^Y24<3VX!O)R^JVY*FJC#F]=?$2 FP#G9SH"A;E,AGJHTO&S7)DTYF MS=>('[L_=>F$F+\)% L,HR4?X*\/C1'DW/")L9>:3CK$ZP8MO]!7B1C:ZZ_M M*J<+X!J4]+G23L<)%MY[JWVV>CK;,"@3=)%5FSR-90AXAD 4QL/E;-I8X#LLA(Z>8TUZDL6^-OE/S;@YGQWN3\=JEDJBP]@/MS PC$#[1!\V.4\_\!4$L#!!0 ( ,J+ M E>E?551V H *0= 9 >&PO=V]R:W-H965TVVXP"+>4C<$LEB74Z=*E*O;HS]T^5*>7%;%I5[/'KHT5Z5T M!Z96%4;6QI;2X]%N#EUMEI-[>G%X_JJ6&W6I_-?ZB\738922Z5)53IM*6+5^ M/7HS??EV0?-YPC^UNG&#WX(L61GS)SU\S%Z/)J20*E3J28+$GVOU3A4%"8(: MWUJ9H[@E+1S^[J1_8-MARTHZ]63!K%\Q8[[ 1:_F+]/+\ ME34WPM)L2*,?;"JOAG*ZHJ!<>HM1C77^_%)MX&+OA%F+MXW#J'.O#CTDT_AA MVDIY&Z3,'I$R%Y],Y7,GWE>9RK;7'T*CJ-:L4^OM[$F!?V^J S&?)&(VF/9LY9WOQI,\6%JHWUNMJ(?[]9.6\!BO_L,C=(6^R61HGRTM4R5:]'R 2G M[+4:G?_\TW0Y.7M"UT74=?&4]&>'Y,>EB*MFK&5UAXPB5SBA\6^M*UFE M6A9XZX!GO*W$VC2VG257A1*NE?A2?#VX/!!? =U"\)R6""=,[#)JPPYY7,A M,^2/IJ 3$8AU4S$Q.%Y56_,'B*+5TD.MSA.0GBJX ![1U;5RGIT05%\#/\;" M?\:""F 9[0!PA?4//-<9P^.EK"IER='!'#R#!1FEZEH6#11W/+%6ELFW2A4I MXPJ:E3PP/D-[+:!7F#1(AT)(A+1SUP[L1P4R0I=>->3$E97$A8G8*(19IXEPM:(4 M\W>)6&GC=*D+:8-;KI7=AVK[J6G(!:+>EI_99M,BTV":%;F"G#R%P?M6%0QQ M.#1#WG#F^D[/JUR[J!UF M0K2;:TZD:."<17J5Y90JS@7HIR"08UM0$XK!U M1)#K4EIX0Q LFTK[NWTJCE 0X2(I VVCX7%G^/(CH)-EFN0DK'"G)BIV,6"D MI LTD4-0I%=OJ$CK,^!:C*U"OF)V;ERM/:\K N]@'XWP['5)'SQ"5()D1[BQ M7>,YX/P0O1(X;F 32%]'4!#W10-R5=3L))!,R738]A^83E%< VB97.E"$Q1( MI,P@4A'TTAS(4]5&!4ZIL903#4BF[H;P*%.+G!E ($0!9)+ZN" 9N"/I[+3] MZSND7*4H P,&:"A(%'4A.[(&3,-\BC)(@CFCM14U#_F/"M%/HB6%7L/%V!;6 M &G2^HJ%9ZH Z5HR0%>5N0XD&CE*!]2RB% MB7J85@+X8Z@)IMIF^V34G2!,.&"Y==5-;@KE)!2/)$![=C+:H%U+JTW##&ME MS>DM ^U,5:W%.E5R7@G%H>JA 38.X@$]X1DG,^M:38Y\!IH+1 1R"]2PL5 MH/EX07Y(#&4[UW5S2?WB;LNDY+[EV_E R@Z@.4!>7Q+J_,XAIK*B, 7/TH[* MHJ IXC^\J!K+0HV M/%0@E:?DI:E;X&B-OWZ;&^YJR;AS[ M7N66'&*N,R" /":O=@,^@M$>?:':HH^8"P/CH\LNU"UX5?P:,!)4'S#D=B-$ M7%U55\/?CM@IC#(>+'!UC6Y_0T8IJ 3RRPVD>\/ONZ: M^3O:1NJ9:&Y"^,(4)#;% :,?8C?^V:!@809Y;S8YBWW\F_1;HYWNV]=?!EH> M\.SIV4[W6T4G=0+"-F0"3KI\W08";3#,[\AUE-2\Z[ ZM][M>0K2/QM[(U'" MJ,RAEZ3LH5H4JP-*W1K)F");L04WLSN"U/MEB =N@ *R=Z;&H _?T<$&C5$^ M4]1C&9L)$H27&76A&;<'IM 9-UK>@(>@I&2"6!MTBC[NUL,%^(Y7&"XR5^'"V3T\6Q^#*L;%=] M2O3L/DUFBP7^GRR73Q6!6;*<3O'_T>GL'O',D\7R1"R3H\6IN#*!?%L]7XCC M1;(XF;>*'2VB*8]U^./9;LO&\ST(.9D=DZC3Y3/L&B_@POE43&'=4W9!Y.QH M><^F\=&>.#H6X^6>N&Q6'$JX:+Z8D:-.)_TA,QXC$Z)O7C">3;#U>'ZZ%X0. M#RKCQ3&&%D5M34EX0:N:.YE6SSL].<:&$_[3\/?R9*!<-%YFV7%!.0S M%_)3;C96;1B28'#-0*?+"#H(U7#^K4:"*%3OZ=]ZWGKT[!+3Q6]%&M6>^ ;= M627FQU'0L-]]QLI>@^]W(X^*X^YRA\B=U?(1*4_55W06=%7(C;?2FVJPJ(]$ M>X3L6=1SVN\ZZU,I1.<#8LZV*CQEPO>R)1:N#;>-83 @D:QFF_JU/50''4MH MRP+(>&42M7^"(3OM#S@Q=Q60YV#H@5E;O4N@3(R^#'5M>8:^P1'CIPJ)[Q[5 MT^4R7&U(I)6W*# Q(;W][Y0\;KKQ71ZTO%M%!8"509^5MO\3(Q\Q@#K%))T M$D-+RN+FLRB-3VLBM8"Q#UO-XUAW$F_+1R&=W]?HE]?:XA>U)N.VCO_CXX?? MVR*]AZ;'YR9CLU(^_Y/?2&NZ;:I\.!D\UPI6,'05X():\9UW<7? K+DKG#LS M^4'\GKU]#+04:ZFMH#LE]./9'TVX-Q,;ND7IIWFJ=SDQ MP',=/NL='O :\'^ZB*"$-T!6X5Z.) M%0-T6?/7>19%^+$"_3V&H6H=[I7)QT-G+28_S!4\<5LBJH'7?*GA?M =\^B. MBZ'$1'P$?K0-MW/DDXL6X.^"\HGXK/Q9YYMM\HI9-D4O\8/6S>BBI)0XRCS( M*84#=.I;JFK*)@R&2D.G)JMRNCNY5@'$],I4S,K3@^&@D;/@F&!Z\ MJ?D[W,IXG(SX9ZXDF(PF8'QM8%W[0!O$#[/G_P-02P,$% @ RHL"5S1R M%K-4 @ LP4 !D !X;"]W;W)K&ULK51A3]LP M$/TKIPQ-(&TD)*4PED:B9=.8QE11L7UVDVMCX=B9?6GAW\]VTE!8J:9I7QK? M^=Z[>U??I6NE[TV)2/!0"6E&04E47X2AR4NLF#E6-4I[LU"Z8F1-O0Q-K9$5 M'E2),(ZB85@Q+H,L];ZISE+5D. 2IQI,4U5,/XY1J/4H. DVCEN^+,DYPBRM MV1)G2'?U5%LK[%D*7J$T7$G0N!@%ER<7DX&+]P$_.*[-UAF M865@BMJ_")DC7'&3"V4:C? >[F97<'AP! ? )=QP(6SO31J23>T(PKQ+,V[3 MQ*^D2>!&22H-?)(%%L_QH2VYKSO>U#V.]Q)^;>0Q)-$[B*,XV5'/Y._A\9YR MDKZ-B>=+_J6-N]K5T@UVT[G1O3 URW$4V-DTJ%<89&_?G RCC[NT_B>R9\H' MO?+!/O;LN]TTUS)7%<+A-V7,$5P2:3YOB,T% BF8,HV2=C6A91YZ9K=N5MF' MT_,T7&UK^S/F;/@4TY8<;KW_"O72KP4#N6HDM4^J]_:;Y](/W O_V&ZD=H$\ MT;3K[(;I)9<&!"XL971\9N=9MRNB-4C5?LKFBNS,^F-IMRIJ%V#O%TK1QG ) M^CV=_0902P,$% @ RHL"5UB-)I5$ @ B@8 !D !X;"]W;W)K&ULG95=;YLP%$#_BL6D/;6!0#ZV#)"2;M-2J5.4=MNS M@R]@U=C,-DG[[V<;PK(IH5)>P#;W'I]KQ"4^"/FL2@"-7BK&5>*56M<+WU=9 M"156(U$#-T]R(2NLS506OJHE8.*2*N:'03#S*TRYE\9N;2/36#2:40X;B513 M55B^KH")0^*-O>/"EA:EM@M^&M>X@$?0/^J--#._IQ!: 5=4<"0A3[SE>+&: MVW@7\)/"09V,D:UD)\2SG:Q)X@56"!ADVA*PN>WA#ABS(*/QNV-Z_98V\71\ MI']UM9M:=EC!G6"_*-%EXGWP$($<-TQOQ>$;=/5,+2\33+DK.K2QT47O'+]TYG"08SOF$L$L(G7>[D;/\C#5.8RD.2-IH0[,#5ZK+-G*4 MVY?RJ*5Y2DV>3M?F> E(]"0QH;Q 2RDQ+\ -WR$HN &A4$8#?"BOMS(\:(+O'-EWJ#= M*UIS0O>4-)B=J[J%3LY#[7>S4#7.(/',AZ% [L%+W[\;SX)/ \J37GDR1$^W M#0,T#G;3V_&I-EH24>O_#[G5'0;FF"D8$)OV8M-!SG?!;Z^0&X:^)3?KY697 MG=H32/,5X0MNP\RWW.:]V_SJ@QOV&^9>]/-/^D,%LG!=4*%,-%RWK:)?[1OM MLNTO?\/;+OV 94&Y0@QRDQJ,YN9URK;SM1,M:M=M=D*;WN6&I?E9@+0!YGDN MA#Y.[ ;][R?] U!+ P04 " #*BP)7/->]99(+ !&( &0 'AL+W=O M7YVKK/ M?J%4$%_KRO@7@T4(R[.C(U\L5"W]R"Z5P9N9=;4,^.KF1W[IE"QY4UT=G8S' MCXYJJJLNL7@^-!?O!>SQ>!'AR=/U_* MN9JH<+N\7=4$X;BLHD.+S5V!?. M)WIN]$P7T@1Q412V,4&;N;BQE2ZT\N)>_O3+\Z. \VC749%D7T;9)W?(/A5O MK D++ZY-J7)0X#\;,Q*GXZ$X&9^<'I!WVAI_RO).[Y"W MS^!_7TQ]< #+?_89'.4]V"^/,NC,+V6A7@R0(EZYE1J<__S3\:/QLP/:/FBU M?7!(^OFE]-H+.Q,W)-L$2;#>I^1!,?N5W"O[3'Q8*%%81,]X5=(G#S>5,N#+ M3!MI"BTKX;%:(5&#%]*4R+/"UDMI-N168P-\*IT2.&N)OZ70AI>X$ML5T!X6 MXM9H$CDA08#RBMW0:NBRK MWN[?+BYNVMVH7C@W**?KGN+0R#K>3WH'V.H:$D'?G)HW%7N!W4(O21\Q447C M=-!IV?778B'-7(DK6]?:JR21AR/Q_\8\@:..(Q*,36* MPV!K11K!X9Y,L86<5CC QC769%4)*XPCY6$WCH@0(C!ZD<+^MA,I0W!ZVH0L M[2Y)"28YK%=MH*[Z+IAL>?S=$OG ^!R)"WC?]PHY"TY9B)Y54:;%**"R&2^+ MB.N%7"DQ5Y[LR^9LUI]:1!O42N$D^2N M8*JB$/\-#V404CRU*^^CE$!T.J&_:B\JMI $!W+^]@V[JJ1K_+NWUV)B&U?0 MHPD*HR:WO7Y],Q0?X5:0%/$.ZE5VOA&_VXIV0LKKUU=#]NWDZOVK=@$__WNF MRLK;+M4=%1Q'*\CI@$6L$8!UZ-LJUD"@G59ZSD9"_E)N[D"P7Z 0(UE+I,I6 MIE\W#G1/7/S6UK"=5[F>Q8*RZ^8[+**H[!Y!VNY6LU(30G1 S2.M"N4"6&7. MU-W#IHU'8_->M5&/HI'M:">],GP]NNW:"):^*X*=*D<EFM:^;,O=6S0R@?5)Z&4Z'9P)&/0ZPIY0\&MGA<_GB@/=_V';_1\> M[/XOH1_TN$$/L^6^KO\#V\_VAF\6EVR4!-%50J92F8Y4CT@4<3,X!9GCN*)W50P>J>5G)50^+%)*CZ%Q&7., M"Y^MSS,@C>QU%EI\P8<:%1B%1/09S)LM2S*3>!F/V M'1YAXF57VI:##'NG+VVLA[$K%M(OQ S#_W:KF3'-4RTKCQ[T^415'L+^DQ;[ M3[Z3L:VJ'5W:EP"'Q7RXR^K6BK!P2HDZ3KN*IEV!656ULRI/0$3YLYADCG(XC"@.!7!HI&7WGQ[T@\ L&XI1.D)GB?6I, MO!CAO.R-$QEF^T0-MZ:N-#/'0'?+X]"WV]YWZ_M%/.T])Q%U%;IE 5.__T=K M9[\C1:_FSA/=.B2XK+1M/-PYTS1)M,9@^HJM:A,'\*KB_&!+CY;@ M'$#?TQ9]3[_7+^ R:'916AY8^]<-SAI\+J)7]T'R_R6;\ &LK!4CL!\^1-64 MTB'I9!(RW6P5XUZI^Q[ 1Z+5Z!6*]4&%0*7$O\"+L^HH?2PK$C(ZK:-=/2F3 M5MU+BS_@;+OG="MNEUSA,P6\F-RV#)!.N3\&=%Y2@?LHJT:)-TK2I$WJB7L? M4(,+\>1D_,O976NH&\;1HW<=,&FFG[@I61K;^ J)<#61H/LH1"#_Q9[ZLX6L MXW%W:S<^&'^^;@A=IZ(3X0*P+;V_Q7]''F(@RU+'T8((RK;X-%APS4->$U]I M\]HZ#$+4-Q '%ZE"YN;#+3B!9/O.1U*L:)B'#XGK5U+7J6&K.?409PNETH35 MS6EI';?2>#E*(PQM6P&4UF$QVG29KW26*$3P"^1%J7D\I?I2RAKM%1OF=J6< M(5MEE:;4;&LL;$QN48X#*JS?FGPB22 ?S5!]M&SONHCI1MI+#HB']VSL62

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end XML 81 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 278 309 1 false 106 0 false 14 false false R1.htm 0000001 - Document - Cover Sheet http://mckesson123.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Sheet http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) Sheet http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Disclosure - Significant Accounting Policies Sheet http://mckesson123.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Business Acquisitions and Divestitures Sheet http://mckesson123.com/role/BusinessAcquisitionsandDivestitures Business Acquisitions and Divestitures Notes 10 false false R11.htm 0000011 - Disclosure - Restructuring, Impairment, and Related Charges, Net Sheet http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet Restructuring, Impairment, and Related Charges, Net Notes 11 false false R12.htm 0000012 - Disclosure - Income Taxes Sheet http://mckesson123.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 0000013 - Disclosure - Earnings Per Common Share Sheet http://mckesson123.com/role/EarningsPerCommonShare Earnings Per Common Share Notes 13 false false R14.htm 0000014 - Disclosure - Goodwill and Intangible Assets, Net Sheet http://mckesson123.com/role/GoodwillandIntangibleAssetsNet Goodwill and Intangible Assets, Net Notes 14 false false R15.htm 0000015 - Disclosure - Debt and Financing Activities Sheet http://mckesson123.com/role/DebtandFinancingActivities Debt and Financing Activities Notes 15 false false R16.htm 0000016 - Disclosure - Hedging Activities Sheet http://mckesson123.com/role/HedgingActivities Hedging Activities Notes 16 false false R17.htm 0000017 - Disclosure - Fair Value Measurements Sheet http://mckesson123.com/role/FairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 0000018 - Disclosure - Commitments and Contingent Liabilities Sheet http://mckesson123.com/role/CommitmentsandContingentLiabilities Commitments and Contingent Liabilities Notes 18 false false R19.htm 0000019 - Disclosure - Stockholders' Deficit Sheet http://mckesson123.com/role/StockholdersDeficit Stockholders' Deficit Notes 19 false false R20.htm 0000020 - Disclosure - Segments of Business Sheet http://mckesson123.com/role/SegmentsofBusiness Segments of Business Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954701 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mckesson123.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://mckesson123.com/role/SignificantAccountingPolicies 23 false false R24.htm 9954702 - Disclosure - Business Acquisitions and Divestitures (Tables) Sheet http://mckesson123.com/role/BusinessAcquisitionsandDivestituresTables Business Acquisitions and Divestitures (Tables) Tables http://mckesson123.com/role/BusinessAcquisitionsandDivestitures 24 false false R25.htm 9954703 - Disclosure - Restructuring, Impairment, and Related Charges, Net (Tables) Sheet http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables Restructuring, Impairment, and Related Charges, Net (Tables) Tables http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet 25 false false R26.htm 9954704 - Disclosure - Income Taxes (Tables) Sheet http://mckesson123.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://mckesson123.com/role/IncomeTaxes 26 false false R27.htm 9954705 - Disclosure - Earnings Per Common Share (Tables) Sheet http://mckesson123.com/role/EarningsPerCommonShareTables Earnings Per Common Share (Tables) Tables http://mckesson123.com/role/EarningsPerCommonShare 27 false false R28.htm 9954706 - Disclosure - Goodwill and Intangible Assets, Net (Tables) Sheet http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables Goodwill and Intangible Assets, Net (Tables) Tables http://mckesson123.com/role/GoodwillandIntangibleAssetsNet 28 false false R29.htm 9954707 - Disclosure - Debt and Financing Activities (Tables) Sheet http://mckesson123.com/role/DebtandFinancingActivitiesTables Debt and Financing Activities (Tables) Tables http://mckesson123.com/role/DebtandFinancingActivities 29 false false R30.htm 9954708 - Disclosure - Hedging Activities (Tables) Sheet http://mckesson123.com/role/HedgingActivitiesTables Hedging Activities (Tables) Tables http://mckesson123.com/role/HedgingActivities 30 false false R31.htm 9954709 - Disclosure - Fair Value Measurements (Tables) Sheet http://mckesson123.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://mckesson123.com/role/FairValueMeasurements 31 false false R32.htm 9954710 - Disclosure - Commitments and Contingent Liabilities (Tables) Sheet http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables Commitments and Contingent Liabilities (Tables) Tables http://mckesson123.com/role/CommitmentsandContingentLiabilities 32 false false R33.htm 9954711 - Disclosure - Stockholders' Deficit (Tables) Sheet http://mckesson123.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://mckesson123.com/role/StockholdersDeficit 33 false false R34.htm 9954712 - Disclosure - Segments of Business (Tables) Sheet http://mckesson123.com/role/SegmentsofBusinessTables Segments of Business (Tables) Tables http://mckesson123.com/role/SegmentsofBusiness 34 false false R35.htm 9954713 - Disclosure - Significant Accounting Policies - Narrative (Details) Sheet http://mckesson123.com/role/SignificantAccountingPoliciesNarrativeDetails Significant Accounting Policies - Narrative (Details) Details 35 false false R36.htm 9954714 - Disclosure - Business Acquisitions and Divestitures - Acquisitions (Details) Sheet http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails Business Acquisitions and Divestitures - Acquisitions (Details) Details 36 false false R37.htm 9954715 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details) Sheet http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details) Details 37 false false R38.htm 9954716 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details) Sheet http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details) Details 38 false false R39.htm 9954717 - Disclosure - Business Acquisitions and Divestitures - Divestitures and Other (Details) Sheet http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails Business Acquisitions and Divestitures - Divestitures and Other (Details) Details 39 false false R40.htm 9954718 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Narrative (Details) Sheet http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails Restructuring, Impairment, and Related Charges, Net - Narrative (Details) Details http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables 40 false false R41.htm 9954719 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details) Sheet http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details) Details 41 false false R42.htm 9954720 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details) Sheet http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details) Details 42 false false R43.htm 9954721 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details) Sheet http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails Income Taxes - Schedule of Components of Income Tax Expense (Details) Details 43 false false R44.htm 9954722 - Disclosure - Income Taxes - Narrative (Details) Sheet http://mckesson123.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 44 false false R45.htm 9954723 - Disclosure - Earnings Per Common Share - Narrative (Details) Sheet http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails Earnings Per Common Share - Narrative (Details) Details 45 false false R46.htm 9954724 - Disclosure - Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details) Sheet http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details) Details 46 false false R47.htm 9954725 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details) Sheet http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details) Details 47 false false R48.htm 9954726 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) Sheet http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) Details 48 false false R49.htm 9954727 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details) Sheet http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails Goodwill and Intangible Assets, Net - Narrative (Details) Details 49 false false R50.htm 9954728 - Disclosure - Debt and Financing Activities - Schedule of Long-Term Debt (Details) Sheet http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails Debt and Financing Activities - Schedule of Long-Term Debt (Details) Details 50 false false R51.htm 9954729 - Disclosure - Debt and Financing Activities - Long-Term Debt Narrative (Details) Sheet http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails Debt and Financing Activities - Long-Term Debt Narrative (Details) Details 51 false false R52.htm 9954730 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities Narrative (Details) Sheet http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails Debt and Financing Activities - Revolving Credit Facilities Narrative (Details) Details 52 false false R53.htm 9954731 - Disclosure - Debt and Financing Activities - Commercial Paper Narrative (Details) Sheet http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails Debt and Financing Activities - Commercial Paper Narrative (Details) Details 53 false false R54.htm 9954732 - Disclosure - Hedging Activities - Narrative (Details) Sheet http://mckesson123.com/role/HedgingActivitiesNarrativeDetails Hedging Activities - Narrative (Details) Details 54 false false R55.htm 9954733 - Disclosure - Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details) Sheet http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details) Details 55 false false R56.htm 9954734 - Disclosure - Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details) Sheet http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details) Details 56 false false R57.htm 9954735 - Disclosure - Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details) Sheet http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details) Details 57 false false R58.htm 9954736 - Disclosure - Hedging Activities - Schedule of Fair Value of Derivatives (Details) Sheet http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails Hedging Activities - Schedule of Fair Value of Derivatives (Details) Details 58 false false R59.htm 9954737 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 59 false false R60.htm 9954738 - Disclosure - Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details) Sheet http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details) Details 60 false false R61.htm 9954739 - Disclosure - Commitments and Contingent Liabilities - Narrative (Details) Sheet http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails Commitments and Contingent Liabilities - Narrative (Details) Details 61 false false R62.htm 9954740 - Disclosure - Commitments and Contingent Liabilities - Estimated Accrual Liability (Details) Sheet http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails Commitments and Contingent Liabilities - Estimated Accrual Liability (Details) Details 62 false false R63.htm 9954741 - Disclosure - Stockholders' Deficit - Narrative (Details) Sheet http://mckesson123.com/role/StockholdersDeficitNarrativeDetails Stockholders' Deficit - Narrative (Details) Details 63 false false R64.htm 9954742 - Disclosure - Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) Sheet http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) Details 64 false false R65.htm 9954743 - Disclosure - Segments of Business - Narrative (Details) Sheet http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails Segments of Business - Narrative (Details) Details 65 false false R66.htm 9954744 - Disclosure - Segments of Business - Reportable operating segment (Details) Sheet http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails Segments of Business - Reportable operating segment (Details) Details 66 false false All Reports Book All Reports mck-20230630.htm mck-20230630.xsd mck-20230630_cal.xml mck-20230630_def.xml mck-20230630_lab.xml mck-20230630_pre.xml mck_ex101x2022stockplanstcs.htm mck_ex102xmipstcsmay2023.htm mck_exhibit311x630202310-q.htm mck_exhibit312x630202310-q.htm mck_exhibit32x630202310-q.htm mck-20230630_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 85 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mck-20230630.htm": { "axisCustom": 0, "axisStandard": 30, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 844, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 4 }, "contextCount": 278, "dts": { "calculationLink": { "local": [ "mck-20230630_cal.xml" ] }, "definitionLink": { "local": [ "mck-20230630_def.xml" ] }, "inline": { "local": [ "mck-20230630.htm" ] }, "labelLink": { "local": [ "mck-20230630_lab.xml" ] }, "presentationLink": { "local": [ "mck-20230630_pre.xml" ] }, "schema": { "local": [ "mck-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] } }, "elementCount": 635, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 5, "total": 5 }, "keyCustom": 32, "keyStandard": 277, "memberCustom": 55, "memberStandard": 46, "nsprefix": "mck", "nsuri": "http://mckesson123.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://mckesson123.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Business Acquisitions and Divestitures", "menuCat": "Notes", "order": "10", "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestitures", "shortName": "Business Acquisitions and Divestitures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Restructuring, Impairment, and Related Charges, Net", "menuCat": "Notes", "order": "11", "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet", "shortName": "Restructuring, Impairment, and Related Charges, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "12", "role": "http://mckesson123.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Earnings Per Common Share", "menuCat": "Notes", "order": "13", "role": "http://mckesson123.com/role/EarningsPerCommonShare", "shortName": "Earnings Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Goodwill and Intangible Assets, Net", "menuCat": "Notes", "order": "14", "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNet", "shortName": "Goodwill and Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Debt and Financing Activities", "menuCat": "Notes", "order": "15", "role": "http://mckesson123.com/role/DebtandFinancingActivities", "shortName": "Debt and Financing Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Hedging Activities", "menuCat": "Notes", "order": "16", "role": "http://mckesson123.com/role/HedgingActivities", "shortName": "Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "17", "role": "http://mckesson123.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Commitments and Contingent Liabilities", "menuCat": "Notes", "order": "18", "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilities", "shortName": "Commitments and Contingent Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Stockholders' Deficit", "menuCat": "Notes", "order": "19", "role": "http://mckesson123.com/role/StockholdersDeficit", "shortName": "Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "2", "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Segments of Business", "menuCat": "Notes", "order": "20", "role": "http://mckesson123.com/role/SegmentsofBusiness", "shortName": "Segments of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "menuCat": "Notes", "order": "21", "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "shortName": "Pay vs Performance Disclosure", "subGroupType": "", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995445 - Disclosure - Insider Trading Arrangements", "menuCat": "Notes", "order": "22", "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "shortName": "Insider Trading Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "ecd:Rule10b51ArrAdoptedFlag", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - Business Acquisitions and Divestitures (Tables)", "menuCat": "Tables", "order": "24", "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresTables", "shortName": "Business Acquisitions and Divestitures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - Restructuring, Impairment, and Related Charges, Net (Tables)", "menuCat": "Tables", "order": "25", "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables", "shortName": "Restructuring, Impairment, and Related Charges, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "26", "role": "http://mckesson123.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - Earnings Per Common Share (Tables)", "menuCat": "Tables", "order": "27", "role": "http://mckesson123.com/role/EarningsPerCommonShareTables", "shortName": "Earnings Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - Goodwill and Intangible Assets, Net (Tables)", "menuCat": "Tables", "order": "28", "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables", "shortName": "Goodwill and Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - Debt and Financing Activities (Tables)", "menuCat": "Tables", "order": "29", "role": "http://mckesson123.com/role/DebtandFinancingActivitiesTables", "shortName": "Debt and Financing Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "menuCat": "Statements", "order": "3", "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - Hedging Activities (Tables)", "menuCat": "Tables", "order": "30", "role": "http://mckesson123.com/role/HedgingActivitiesTables", "shortName": "Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "31", "role": "http://mckesson123.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - Commitments and Contingent Liabilities (Tables)", "menuCat": "Tables", "order": "32", "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables", "shortName": "Commitments and Contingent Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Stockholders' Deficit (Tables)", "menuCat": "Tables", "order": "33", "role": "http://mckesson123.com/role/StockholdersDeficitTables", "shortName": "Stockholders' Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Segments of Business (Tables)", "menuCat": "Tables", "order": "34", "role": "http://mckesson123.com/role/SegmentsofBusinessTables", "shortName": "Segments of Business (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - Significant Accounting Policies - Narrative (Details)", "menuCat": "Details", "order": "35", "role": "http://mckesson123.com/role/SignificantAccountingPoliciesNarrativeDetails", "shortName": "Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - Business Acquisitions and Divestitures - Acquisitions (Details)", "menuCat": "Details", "order": "36", "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "shortName": "Business Acquisitions and Divestitures - Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-47", "decimals": "2", "lang": "en-US", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details)", "menuCat": "Details", "order": "37", "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "shortName": "Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-48", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details)", "menuCat": "Details", "order": "38", "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails", "shortName": "Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-53", "decimals": "-6", "lang": "en-US", "name": "mck:BusinessCombinationConsiderationTransferredOwnershipInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - Business Acquisitions and Divestitures - Divestitures and Other (Details)", "menuCat": "Details", "order": "39", "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "shortName": "Business Acquisitions and Divestitures - Divestitures and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-56", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "4", "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "mck:RestructuringImpairmentAndOtherRelatedCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Narrative (Details)", "menuCat": "Details", "order": "40", "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails", "shortName": "Restructuring, Impairment, and Related Charges, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-61", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)", "menuCat": "Details", "order": "41", "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "shortName": "Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)", "menuCat": "Details", "order": "42", "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "shortName": "Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details)", "menuCat": "Details", "order": "43", "role": "http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails", "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "mck:EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - Income Taxes - Narrative (Details)", "menuCat": "Details", "order": "44", "role": "http://mckesson123.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "mck:EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954723 - Disclosure - Earnings Per Common Share - Narrative (Details)", "menuCat": "Details", "order": "45", "role": "http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails", "shortName": "Earnings Per Common Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954724 - Disclosure - Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)", "menuCat": "Details", "order": "46", "role": "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "shortName": "Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954725 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)", "menuCat": "Details", "order": "47", "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "shortName": "Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954726 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)", "menuCat": "Details", "order": "48", "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954727 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)", "menuCat": "Details", "order": "49", "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails", "shortName": "Goodwill and Intangible Assets, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954728 - Disclosure - Debt and Financing Activities - Schedule of Long-Term Debt (Details)", "menuCat": "Details", "order": "50", "role": "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails", "shortName": "Debt and Financing Activities - Schedule of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-118", "decimals": "4", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954729 - Disclosure - Debt and Financing Activities - Long-Term Debt Narrative (Details)", "menuCat": "Details", "order": "51", "role": "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "shortName": "Debt and Financing Activities - Long-Term Debt Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-156", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954730 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)", "menuCat": "Details", "order": "52", "role": "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails", "shortName": "Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-156", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-165", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954731 - Disclosure - Debt and Financing Activities - Commercial Paper Narrative (Details)", "menuCat": "Details", "order": "53", "role": "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails", "shortName": "Debt and Financing Activities - Commercial Paper Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-165", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954732 - Disclosure - Hedging Activities - Narrative (Details)", "menuCat": "Details", "order": "54", "role": "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "shortName": "Hedging Activities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-170", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-172", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954733 - Disclosure - Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details)", "menuCat": "Details", "order": "55", "role": "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "shortName": "Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-174", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "cad", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954734 - Disclosure - Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)", "menuCat": "Details", "order": "56", "role": "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "shortName": "Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-174", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "cad", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-189", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954735 - Disclosure - Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)", "menuCat": "Details", "order": "57", "role": "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "shortName": "Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-189", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-201", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954736 - Disclosure - Hedging Activities - Schedule of Fair Value of Derivatives (Details)", "menuCat": "Details", "order": "58", "role": "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "shortName": "Hedging Activities - Schedule of Fair Value of Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-201", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954737 - Disclosure - Fair Value Measurements - Narrative (Details)", "menuCat": "Details", "order": "59", "role": "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-27", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT", "menuCat": "Statements", "order": "6", "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-27", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954738 - Disclosure - Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)", "menuCat": "Details", "order": "60", "role": "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails", "shortName": "Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-205", "decimals": "-6", "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-221", "decimals": "0", "first": true, "lang": "en-US", "name": "mck:LossContingencyNumberOfFormerOfficers", "reportCount": 1, "unique": true, "unitRef": "officer", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954739 - Disclosure - Commitments and Contingent Liabilities - Narrative (Details)", "menuCat": "Details", "order": "61", "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "shortName": "Commitments and Contingent Liabilities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-221", "decimals": "0", "first": true, "lang": "en-US", "name": "mck:LossContingencyNumberOfFormerOfficers", "reportCount": 1, "unique": true, "unitRef": "officer", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-214", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954740 - Disclosure - Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)", "menuCat": "Details", "order": "62", "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "shortName": "Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-214", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "INF", "first": true, "lang": "en-US", "name": "mck:CommonStockVotingRightsNumberofVotesPerCommonShare", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954741 - Disclosure - Stockholders' Deficit - Narrative (Details)", "menuCat": "Details", "order": "63", "role": "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails", "shortName": "Stockholders' Deficit - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-6", "decimals": "INF", "first": true, "lang": "en-US", "name": "mck:CommonStockVotingRightsNumberofVotesPerCommonShare", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-8", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954742 - Disclosure - Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details)", "menuCat": "Details", "order": "64", "role": "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails", "shortName": "Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-253", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954743 - Disclosure - Segments of Business - Narrative (Details)", "menuCat": "Details", "order": "65", "role": "http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails", "shortName": "Segments of Business - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954744 - Disclosure - Segments of Business - Reportable operating segment (Details)", "menuCat": "Details", "order": "66", "role": "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails", "shortName": "Segments of Business - Reportable operating segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "mck:CorporateOperatingExpenseandOtherIncomeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "8", "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://mckesson123.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mck-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 106, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Canada" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada, Dollars", "terseLabel": "CAD" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "EUR" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "GBP" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "USD" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r774" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r807" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r772" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r772" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r772" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r846" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r772" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r772" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r772" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r772" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r771" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r773" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "ecd_Additional402vDisclosureTextBlock": { "auth_ref": [ "r808" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "localname": "Additional402vDisclosureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToCompAmt": { "auth_ref": [ "r814" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "localname": "AdjToCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AdjToCompAxis": { "auth_ref": [ "r814" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "localname": "AdjToCompAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "auth_ref": [ "r814" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "localname": "AdjToNonPeoNeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToPeoCompFnTextBlock": { "auth_ref": [ "r814" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "localname": "AdjToPeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AggtErrCompAmt": { "auth_ref": [ "r779", "r790", "r800", "r825" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "localname": "AggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "auth_ref": [ "r782", "r793", "r803", "r828" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "localname": "AggtErrCompNotYetDeterminedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AllAdjToCompMember": { "auth_ref": [ "r814" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "localname": "AllAdjToCompMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllExecutiveCategoriesMember": { "auth_ref": [ "r821" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "localname": "AllExecutiveCategoriesMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllIndividualsMember": { "auth_ref": [ "r786", "r794", "r804", "r821", "r829", "r833", "r841" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "localname": "AllIndividualsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllTradingArrangementsMember": { "auth_ref": [ "r839" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "localname": "AllTradingArrangementsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "ecd_AwardExrcPrice": { "auth_ref": [ "r836" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "localname": "AwardExrcPrice", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "perShareItemType" }, "ecd_AwardGrantDateFairValue": { "auth_ref": [ "r837" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "localname": "AwardGrantDateFairValue", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AwardTmgDiscLineItems": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "localname": "AwardTmgDiscLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMethodTextBlock": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "localname": "AwardTmgMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMnpiCnsdrdFlag": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "localname": "AwardTmgMnpiCnsdrdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardTmgMnpiDiscTextBlock": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "localname": "AwardTmgMnpiDiscTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgPredtrmndFlag": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "localname": "AwardTmgPredtrmndFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardUndrlygSecuritiesAmt": { "auth_ref": [ "r835" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "localname": "AwardUndrlygSecuritiesAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_AwardsCloseToMnpiDiscIndName": { "auth_ref": [ "r834" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "localname": "AwardsCloseToMnpiDiscIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTable": { "auth_ref": [ "r833" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "localname": "AwardsCloseToMnpiDiscTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "auth_ref": [ "r833" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "localname": "AwardsCloseToMnpiDiscTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ChangedPeerGroupFnTextBlock": { "auth_ref": [ "r812" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "localname": "ChangedPeerGroupFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CoSelectedMeasureAmt": { "auth_ref": [ "r813" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "localname": "CoSelectedMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_CoSelectedMeasureName": { "auth_ref": [ "r813" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "localname": "CoSelectedMeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "auth_ref": [ "r817" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "localname": "CompActuallyPaidVsNetIncomeTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "auth_ref": [ "r816" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "auth_ref": [ "r815" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompAnalysisTextBlock": { "auth_ref": [ "r779", "r790", "r800", "r825" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "localname": "ErrCompAnalysisTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompRecoveryTable": { "auth_ref": [ "r776", "r787", "r797", "r822" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "localname": "ErrCompRecoveryTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ExecutiveCategoryAxis": { "auth_ref": [ "r821" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "localname": "ExecutiveCategoryAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "auth_ref": [ "r783", "r794", "r804", "r829" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "auth_ref": [ "r783", "r794", "r804", "r829" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "auth_ref": [ "r783", "r794", "r804", "r829" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "auth_ref": [ "r783", "r794", "r804", "r829" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ForgoneRecoveryIndName": { "auth_ref": [ "r783", "r794", "r804", "r829" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "ForgoneRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_IndividualAxis": { "auth_ref": [ "r786", "r794", "r804", "r821", "r829", "r833", "r841" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "localname": "IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_InsiderTradingArrLineItems": { "auth_ref": [ "r839" ], "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "localname": "InsiderTradingArrLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTradingPoliciesProcLineItems": { "auth_ref": [ "r775", "r845" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "localname": "InsiderTradingPoliciesProcLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "auth_ref": [ "r775", "r845" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "localname": "InsiderTrdPoliciesProcAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "booleanItemType" }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "auth_ref": [ "r775", "r845" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "textBlockItemType" }, "ecd_MeasureAxis": { "auth_ref": [ "r813" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "localname": "MeasureAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_MeasureName": { "auth_ref": [ "r813" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "localname": "MeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_MnpiDiscTimedForCompValFlag": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "localname": "MnpiDiscTimedForCompValFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_MtrlTermsOfTrdArrTextBlock": { "auth_ref": [ "r840" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "localname": "MtrlTermsOfTrdArrTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "textBlockItemType" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "auth_ref": [ "r814" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "localname": "NamedExecutiveOfficersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonGaapMeasureDescriptionTextBlock": { "auth_ref": [ "r813" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "localname": "NonGaapMeasureDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonNeosMember": { "auth_ref": [ "r783", "r794", "r804", "r821", "r829" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "localname": "NonNeosMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "auth_ref": [ "r811" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoAvgTotalCompAmt": { "auth_ref": [ "r810" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "localname": "NonPeoNeoAvgTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoMember": { "auth_ref": [ "r821" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "localname": "NonPeoNeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonRule10b51ArrAdoptedFlag": { "auth_ref": [ "r840" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "localname": "NonRule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_NonRule10b51ArrTrmntdFlag": { "auth_ref": [ "r840" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "localname": "NonRule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_OtherPerfMeasureAmt": { "auth_ref": [ "r813" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "localname": "OtherPerfMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_OutstandingAggtErrCompAmt": { "auth_ref": [ "r781", "r792", "r802", "r827" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "localname": "OutstandingAggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryCompAmt": { "auth_ref": [ "r784", "r795", "r805", "r830" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "localname": "OutstandingRecoveryCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryIndName": { "auth_ref": [ "r784", "r795", "r805", "r830" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "OutstandingRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PayVsPerformanceDisclosureLineItems": { "auth_ref": [ "r809" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "localname": "PayVsPerformanceDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_PeerGroupIssuersFnTextBlock": { "auth_ref": [ "r812" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "localname": "PeerGroupIssuersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_PeerGroupTotalShareholderRtnAmt": { "auth_ref": [ "r812" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "localname": "PeerGroupTotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoActuallyPaidCompAmt": { "auth_ref": [ "r811" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "localname": "PeoActuallyPaidCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoMember": { "auth_ref": [ "r821" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "localname": "PeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_PeoName": { "auth_ref": [ "r814" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "localname": "PeoName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_PeoTotalCompAmt": { "auth_ref": [ "r810" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "localname": "PeoTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PvpTable": { "auth_ref": [ "r809" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PvpTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PvpTableTextBlock": { "auth_ref": [ "r809" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "localname": "PvpTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "auth_ref": [ "r776", "r787", "r797", "r822" ], "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "localname": "RecoveryOfErrCompDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_RestatementDateAxis": { "auth_ref": [ "r777", "r788", "r798", "r823" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "localname": "RestatementDateAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_RestatementDeterminationDate": { "auth_ref": [ "r778", "r789", "r799", "r824" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "localname": "RestatementDeterminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "dateItemType" }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "auth_ref": [ "r785", "r796", "r806", "r831" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "localname": "RestatementDoesNotRequireRecoveryTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_Rule10b51ArrAdoptedFlag": { "auth_ref": [ "r840" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "localname": "Rule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_Rule10b51ArrTrmntdFlag": { "auth_ref": [ "r840" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "localname": "Rule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "auth_ref": [ "r780", "r791", "r801", "r826" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "localname": "StkPrcOrTsrEstimationMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TabularListTableTextBlock": { "auth_ref": [ "r820" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "localname": "TabularListTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TotalShareholderRtnAmt": { "auth_ref": [ "r812" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "localname": "TotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TradingArrAxis": { "auth_ref": [ "r839" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "localname": "TradingArrAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TradingArrByIndTable": { "auth_ref": [ "r841" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "localname": "TradingArrByIndTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrAdoptionDate": { "auth_ref": [ "r842" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "localname": "TrdArrAdoptionDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrDuration": { "auth_ref": [ "r843" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "localname": "TrdArrDuration", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "durationItemType" }, "ecd_TrdArrIndName": { "auth_ref": [ "r841" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "localname": "TrdArrIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrIndTitle": { "auth_ref": [ "r841" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "localname": "TrdArrIndTitle", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrSecuritiesAggAvailAmt": { "auth_ref": [ "r844" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "localname": "TrdArrSecuritiesAggAvailAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "sharesItemType" }, "ecd_TrdArrTerminationDate": { "auth_ref": [ "r842" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "localname": "TrdArrTerminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_UndrlygSecurityMktPriceChngPct": { "auth_ref": [ "r838" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "localname": "UndrlygSecurityMktPriceChngPct", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "pureItemType" }, "mck_A090NotesDueDecember32025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.90% Notes Due December 3, 2025", "label": "0.90% Notes Due December 3, 2025 [Member]", "terseLabel": "0.90% Notes due December 3, 2025" } } }, "localname": "A090NotesDueDecember32025Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A130NotesDueAugust152026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.30% Notes Due August 15, 2026", "label": "1.30% Notes Due August 15, 2026 [Member]", "terseLabel": "1.30% Notes due August 15, 2026" } } }, "localname": "A130NotesDueAugust152026Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A1500NotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.500% Notes Due 2025", "label": "1.500% Notes Due 2025 [Member]", "terseLabel": "1.500% Notes Due 2025" } } }, "localname": "A1500NotesDue2025Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "domainItemType" }, "mck_A150EuroNotesDueNovember172025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.50% Euro Notes Due November 17, 2025", "label": "1.50% Euro Notes Due November 17, 2025 [Member]", "terseLabel": "1.50% Euro Notes due November 17, 2025" } } }, "localname": "A150EuroNotesDueNovember172025Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A1625NotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.625% Notes Due 2026", "label": "1.625% Notes Due 2026 [Member]", "terseLabel": "1.625% Notes Due 2026" } } }, "localname": "A1625NotesDue2026Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "domainItemType" }, "mck_A163EuroNotesDueOctober302026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.63% Euro Notes Due October 30, 2026", "label": "1.63% Euro Notes Due October 30, 2026 [Member]", "terseLabel": "1.63% Euro Notes due October 30, 2026" } } }, "localname": "A163EuroNotesDueOctober302026Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A3125NotesDue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.125% Notes Due 2029", "label": "3.125% Notes Due 2029 [Member]", "terseLabel": "3.125% Notes Due 2029" } } }, "localname": "A3125NotesDue2029Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "domainItemType" }, "mck_A313SterlingNotesDueFebruary172029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.13% Sterling Notes Due February 17, 2029", "label": "3.13% Sterling Notes Due February 17, 2029 [Member]", "terseLabel": "3.13% Sterling Notes due February 17, 2029" } } }, "localname": "A313SterlingNotesDueFebruary172029Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A380NotesDueMarch152024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.80% Notes Due March 15, 2024", "label": "3.80% Notes Due March 15, 2024 [Member]", "terseLabel": "3.80% Notes due March 15, 2024" } } }, "localname": "A380NotesDueMarch152024Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A395NotesDueFebruary162028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.95% Notes Due February 16, 2028", "label": "3.95% Notes Due February 16, 2028 [Member]", "terseLabel": "3.95% Notes due February 16, 2028" } } }, "localname": "A395NotesDueFebruary162028Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A475NotesDueMay302029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.75% Notes Due May 30, 2029", "label": "4.75% Notes Due May 30, 2029 [Member]", "terseLabel": "4.75% Notes due May 30, 2029" } } }, "localname": "A475NotesDueMay302029Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A488NotesDueMarch152044Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.88% Notes Due March 15, 2044", "label": "4.88% Notes Due March 15, 2044 [Member]", "terseLabel": "4.88% Notes due March 15, 2044" } } }, "localname": "A488NotesDueMarch152044Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A490NotesDueJuly152028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.90% Notes Due July 15, 2028", "label": "4.90% Notes Due July 15, 2028 [Member]", "terseLabel": "4.90% Notes due July 15, 2028" } } }, "localname": "A490NotesDueJuly152028Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A510NotesDueJuly152033Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.10% Notes Due July 15, 2033", "label": "5.10% Notes Due July 15, 2033 [Member]", "terseLabel": "5.10% Notes due July 15, 2033" } } }, "localname": "A510NotesDueJuly152033Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A525NotesDueFebruary152026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.25% Notes Due February 15, 2026", "label": "5.25% Notes Due February 15, 2026 [Member]", "terseLabel": "5.25% Notes due February 15, 2026" } } }, "localname": "A525NotesDueFebruary152026Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A600NotesDueMarch12041Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "6.00% Notes Due March 1, 2041", "label": "6.00% Notes Due March 1, 2041 [Member]", "terseLabel": "6.00% Notes due March 1, 2041" } } }, "localname": "A600NotesDueMarch12041Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_A765DebenturesDueMarch12027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "7.65% Debentures Due March 1, 2027", "label": "7.65% Debentures Due March 1, 2027 [Member]", "terseLabel": "7.65% Debentures due March 1, 2027" } } }, "localname": "A765DebenturesDueMarch12027Member", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest", "label": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized Losses on Net Investment Hedges, Net of Tax" } } }, "localname": "AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "mck_AcceleratedShareRepurchaseCompletionOfProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchase, Completion Of Program", "label": "Accelerated Share Repurchase, Completion Of Program [Member]", "terseLabel": "Accelerated Share Repurchase, Completion Of Program" } } }, "localname": "AcceleratedShareRepurchaseCompletionOfProgramMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_AcceleratedShareRepurchaseInitialShareSettlementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchase, Initial Share Settlement", "label": "Accelerated Share Repurchase, Initial Share Settlement [Member]", "terseLabel": "Accelerated Share Repurchase, Initial Share Settlement" } } }, "localname": "AcceleratedShareRepurchaseInitialShareSettlementMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_AcceleratedShareRepurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchase [Member]", "label": "Accelerated Share Repurchase [Member]", "terseLabel": "Accelerated Share Repurchase" } } }, "localname": "AcceleratedShareRepurchaseMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_AssetImpairmentChargesIncludingAcceleratedDepreciation": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Impairment Charges, Including Accelerated Depreciation", "label": "Asset Impairment Charges, Including Accelerated Depreciation", "terseLabel": "Asset impairments and accelerated depreciation" } } }, "localname": "AssetImpairmentChargesIncludingAcceleratedDepreciation", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "mck_AureliusElephantLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurelius Elephant Limited", "label": "Aurelius Elephant Limited [Member]", "terseLabel": "Aurelius Elephant Limited" } } }, "localname": "AureliusElephantLimitedMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" ], "xbrltype": "domainItemType" }, "mck_BritishPoundSterlingDenominatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "British Pound Sterling Denominated Notes [Member]", "label": "British Pound Sterling Denominated Notes [Member]", "terseLabel": "British Pound Sterling Denominated Notes" } } }, "localname": "BritishPoundSterlingDenominatedNotesMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_BusinessCombinationConsiderationTransferredOwnershipInterest": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Ownership Interest", "label": "Business Combination, Consideration Transferred, Ownership Interest", "terseLabel": "Contribution of USOR" } } }, "localname": "BusinessCombinationConsiderationTransferredOwnershipInterest", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Additional-Paid-In Capital", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Additional-Paid-In Capital", "negatedTerseLabel": "Additional paid-in capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Term Operating Lease Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Term Operating Lease Liabilities", "negatedTerseLabel": "Long-term operating lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)", "label": "Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)", "terseLabel": "Change in cash, cash equivalents, and restricted cash classified as Assets held for sale" } } }, "localname": "CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "mck_CherokeeNationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cherokee Nation", "label": "Cherokee Nation [Member]", "terseLabel": "Cherokee Nation" } } }, "localname": "CherokeeNationMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_CommonStockVotingRightsNumberofVotesPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Voting Rights, Number of Votes Per Common Share", "label": "Common Stock, Voting Rights, Number of Votes Per Common Share", "terseLabel": "Number of votes per share of common stock permitted on proposals presented to stockholders (vote)" } } }, "localname": "CommonStockVotingRightsNumberofVotesPerCommonShare", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "integerItemType" }, "mck_CorporateOperatingExpenseandOtherIncomeNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Corporate Operating Expense and Other Income, Net", "label": "Corporate Operating Expense and Other Income, Net", "negatedTerseLabel": "Corporate income (expenses), net" } } }, "localname": "CorporateOperatingExpenseandOtherIncomeNet", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "mck_CurrentAssetLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current Asset / Liability [Member]", "label": "Current Asset / Liability [Member]", "terseLabel": "Prepaid expenses and other/Other accrued liabilities" } } }, "localname": "CurrentAssetLiabilityMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "mck_DebtInstrumentRedemptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Redemption Period", "label": "Debt Instrument, Redemption Period", "terseLabel": "Debt instrument, redemption period (in days)" } } }, "localname": "DebtInstrumentRedemptionPeriod", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "mck_DerivativeNotionalAmountEnteredIntoDuringPeriod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative, Notional Amount, Entered Into During Period", "label": "Derivative, Notional Amount, Entered Into During Period", "terseLabel": "Derivative, notional amount, entered into during period" } } }, "localname": "DerivativeNotionalAmountEnteredIntoDuringPeriod", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mck_DerivativeTerminationProceedsAmortizationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative, Termination Proceeds, Amortization Period", "label": "Derivative, Termination Proceeds, Amortization Period", "terseLabel": "Derivative termination proceeds, amortization period (in years)" } } }, "localname": "DerivativeTerminationProceedsAmortizationPeriod", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Expected", "label": "Disposal Group, Including Discontinued Operation, Consideration, Expected", "terseLabel": "Gross purchase price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationExpected", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" ], "xbrltype": "monetaryItemType" }, "mck_EPSBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share, Basic and Diluted", "label": "EPS, Basic and Diluted [Abstract]", "terseLabel": "Earnings (loss) per common share attributable to McKesson:" } } }, "localname": "EPSBasicAndDilutedAbstract", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "stringItemType" }, "mck_EUBusinessesDisposalGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "E.U. Businesses (Disposal Group)", "label": "E.U. Businesses (Disposal Group) [Member]", "terseLabel": "E.U. Businesses (Disposal Group)" } } }, "localname": "EUBusinessesDisposalGroupMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount", "label": "Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount", "terseLabel": "Tax expense (benefit), intra-entity transfers of assets other than inventory, amount" } } }, "localname": "EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mck_EuroDenominatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Euro Denominated Notes [Member]", "label": "Euro Denominated Notes [Member]", "terseLabel": "Euro Denominated Notes" } } }, "localname": "EuroDenominatedNotesMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "mck_EvanstonPolicePensionFundVMcKessonCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Evanston Police Pension Fund v. McKesson Corporation", "label": "Evanston Police Pension Fund v. McKesson Corporation [Member]", "terseLabel": "Evanston Police Pension Fund v. McKesson Corporation" } } }, "localname": "EvanstonPolicePensionFundVMcKessonCorporationMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_ExciseTaxPayableCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excise Tax Payable, Current", "label": "Excise Tax Payable, Current", "terseLabel": "Excise taxes" } } }, "localname": "ExciseTaxPayableCurrent", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Estimated annual amortization expense, thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mck_FixedInterestRateSwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed Interest Rate Swap", "label": "Fixed Interest Rate Swap [Member]", "terseLabel": "Fixed interest rate swaps" } } }, "localname": "FixedInterestRateSwapMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" ], "xbrltype": "domainItemType" }, "mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income Tax Examination, Estimate Of Possible Liability Adjustment", "label": "Income Tax Examination, Estimate Of Possible Liability Adjustment", "terseLabel": "Tax liability increase due to proposed adjustment to taxable income" } } }, "localname": "IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mck_IncreaseDecreaseInLitigationReserve": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Litigation Reserve", "label": "Increase (Decrease) in Litigation Reserve", "terseLabel": "Litigation liabilities" } } }, "localname": "IncreaseDecreaseInLitigationReserve", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "mck_IndividualClaimantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Claimant", "label": "Individual Claimant [Member]", "terseLabel": "An individual" } } }, "localname": "IndividualClaimantMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_InternationalSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International Segment", "label": "International Segment [Member]", "terseLabel": "International", "verboseLabel": "International Segment" } } }, "localname": "InternationalSegmentMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "mck_LeaseAndOtherObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease and Other Obligations", "label": "Lease and Other Obligations [Member]", "terseLabel": "Lease and other obligations" } } }, "localname": "LeaseAndOtherObligationsMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages", "label": "Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages", "terseLabel": "Litigation settlement, amount awarded to other party, percentage of total settlement to be used to remediate damages" } } }, "localname": "LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "pureItemType" }, "mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Award Amount To Be Used by State and Local Government", "label": "Litigation Settlement, Award Amount To Be Used by State and Local Government", "terseLabel": "Portion of settlement award to be used by state and local government for remediation (percent)" } } }, "localname": "LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement", "label": "Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement", "terseLabel": "Loss contingency, claims settled, number of jurisdictions not participating in settlement" } } }, "localname": "LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mck_LossContingencyNumberOfCasesDismissed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Cases Dismissed", "label": "Loss Contingency, Number Of Cases Dismissed", "terseLabel": "Loss contingency, number of cases dismissed" } } }, "localname": "LossContingencyNumberOfCasesDismissed", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mck_LossContingencyNumberOfFormerOfficers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of Former Officers", "label": "Loss Contingency, Number of Former Officers", "terseLabel": "Number of former officers" } } }, "localname": "LossContingencyNumberOfFormerOfficers", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mck_LossContingencyNumberOfOtherDefendants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of Other Defendants", "label": "Loss Contingency, Number of Other Defendants", "terseLabel": "Number of other national distributors named in suit" } } }, "localname": "LossContingencyNumberOfOtherDefendants", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mck_LossContingencyNumberOfStatesFiledOnBehalfOf": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of States Filed On Behalf Of", "label": "Loss Contingency, Number of States Filed On Behalf Of", "terseLabel": "Number of states filed on behalf of" } } }, "localname": "LossContingencyNumberOfStatesFiledOnBehalfOf", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mck_LossContingencyNumberofStates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number of States", "label": "Loss Contingency, Number of States", "terseLabel": "Number of states in which court cases are pending" } } }, "localname": "LossContingencyNumberofStates", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mck_McKessonUSOncologyResearchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "McKesson U.S. Oncology Research", "label": "McKesson U.S. Oncology Research [Member]", "terseLabel": "USOR" } } }, "localname": "McKessonUSOncologyResearchMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mck_MedicalSurgicalSolutionsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical-Surgical Solutions Segment [Member]", "label": "Medical-Surgical Solutions Segment [Member]", "terseLabel": "Medical-Surgical Solutions" } } }, "localname": "MedicalSurgicalSolutionsSegmentMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "mck_NationalPrescriptionOpiateLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In re: National Prescription Opiate Litigation [Member]", "label": "National Prescription Opiate Litigation [Member]", "terseLabel": "National Prescription Opioid Litigation" } } }, "localname": "NationalPrescriptionOpiateLitigationMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "mck_NativeAmericanTribesOtherThanCherokeeNationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Native American Tribes Other Than Cherokee Nation", "label": "Native American Tribes Other Than Cherokee Nation [Member]", "terseLabel": "Native American Tribes Other Than Cherokee Nation" } } }, "localname": "NativeAmericanTribesOtherThanCherokeeNationMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest", "terseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "mck_NoncontrollingInterestDecreaseFromReclassificationToLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest, Decrease from Reclassification to Liability", "label": "Noncontrolling Interest, Decrease from Reclassification to Liability", "negatedTerseLabel": "Reclassification of recurring compensation to other accrued liabilities" } } }, "localname": "NoncontrollingInterestDecreaseFromReclassificationToLiability", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "mck_OpenMarketShareRepurchaseTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Open Market Share Repurchase Transactions [Member]", "label": "Open Market Share Repurchase Transactions [Member]", "terseLabel": "Open Market Share Repurchase Transactions" } } }, "localname": "OpenMarketShareRepurchaseTransactionsMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_OtherNonCurrentAssetsAndLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Non-Current Assets and Liabilities", "label": "Other Non-Current Assets and Liabilities [Member]", "terseLabel": "Other non-current assets/liabilities" } } }, "localname": "OtherNonCurrentAssetsAndLiabilitiesMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "xbrltype": "domainItemType" }, "mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt", "label": "Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt", "negatedTerseLabel": "Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt", "terseLabel": "Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt" } } }, "localname": "PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mck_PrescriptionTechnologySolutionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International Segment [Member]", "label": "Prescription Technology Solutions [Member]", "terseLabel": "Prescription Technology Solutions" } } }, "localname": "PrescriptionTechnologySolutionsMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "mck_RestructuringImpairmentAndOtherRelatedCharges": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructuring, Impairment and Other Related Charges", "label": "Restructuring, Impairment and Other Related Charges", "negatedTerseLabel": "Restructuring, impairment, and related charges, net", "terseLabel": "Restructuring, impairment, and related charges, net" } } }, "localname": "RestructuringImpairmentAndOtherRelatedCharges", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mck_RevenueDerivedFromServicesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Derived From Services, Percentage", "label": "Revenue Derived From Services, Percentage", "terseLabel": "Revenue derived from services, percentage (approximately or less than)" } } }, "localname": "RevenueDerivedFromServicesPercentage", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "percentItemType" }, "mck_RxSavingsSolutionsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rx Savings Solutions, LLC", "label": "Rx Savings Solutions, LLC [Member]", "terseLabel": "Rx Savings Solutions, LLC" } } }, "localname": "RxSavingsSolutionsLLCMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" ], "xbrltype": "domainItemType" }, "mck_RxTsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RxTs Segment", "label": "RxTs Segment [Member]", "terseLabel": "RxTs Segment" } } }, "localname": "RxTsSegmentMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" ], "xbrltype": "domainItemType" }, "mck_SCRIOncologyLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SCRI Oncology, LLC", "label": "SCRI Oncology, LLC [Member]", "terseLabel": "SCRI Oncology, LLC" } } }, "localname": "SCRIOncologyLLCMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "domainItemType" }, "mck_SarahCannonResearchInstituteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sarah Cannon Research Institute", "label": "Sarah Cannon Research Institute [Member]", "terseLabel": "SCRI" } } }, "localname": "SarahCannonResearchInstituteMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit", "label": "Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]", "terseLabel": "Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit" } } }, "localname": "SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Credit Facility (the 2022 Credit Facility)", "label": "Senior Unsecured Credit Facility (the 2022 Credit Facility) [Member]", "terseLabel": "Senior Unsecured Credit Facility (the 2022 Credit Facility)" } } }, "localname": "SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]", "label": "Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]", "terseLabel": "Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit" } } }, "localname": "SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Credit Facility (the 2020 Credit Facility) [Member]", "label": "Senior Unsecured Credit Facility (the 2020 Credit Facility) [Member]", "terseLabel": "Senior Unsecured Credit Facility (the 2020 Credit Facility)" } } }, "localname": "SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_StateOfAlabamaAndSubdivisionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State of Alabama and Subdivisions", "label": "State of Alabama and Subdivisions [Member]", "terseLabel": "State of Alabama and Subdivisions" } } }, "localname": "StateOfAlabamaAndSubdivisionsMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_StateOfWestVirginiaAndSubdivisionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State of West Virginia and Subdivisions", "label": "State of West Virginia and Subdivisions [Member]", "terseLabel": "State of West Virginia and Subdivisions" } } }, "localname": "StateOfWestVirginiaAndSubdivisionsMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures", "label": "Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures", "terseLabel": "Issuance of shares under employee plans, net of forfeitures (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures", "label": "Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures", "terseLabel": "Issuance of shares under employee plans, net of forfeitures" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization", "label": "Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization [Member]", "terseLabel": "Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization" } } }, "localname": "StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_ThreeLargestUSPharmaceuticalDistributorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Largest U.S. Pharmaceutical Distributors", "label": "Three Largest U.S. Pharmaceutical Distributors [Member]", "terseLabel": "Three Largest U.S. Pharmaceutical Distributors" } } }, "localname": "ThreeLargestUSPharmaceuticalDistributorsMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_ThreeNationalPharmaceuticalDistributorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three National Pharmaceutical Distributors", "label": "Three National Pharmaceutical Distributors [Member]", "terseLabel": "Three National Pharmaceutical Distributors" } } }, "localname": "ThreeNationalPharmaceuticalDistributorsMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_UKBusinessesDisposalGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.K. Businesses (Disposal Group)", "label": "U.K. Businesses (Disposal Group) [Member]", "terseLabel": "U.K. Disposal Group (Disposal Group)" } } }, "localname": "UKBusinessesDisposalGroupMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mck_USPharmaceuticalSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "U.S. Pharmaceutical Segment [Member]", "label": "U.S. Pharmaceutical Segment [Member]", "terseLabel": "U.S. Pharmaceutical" } } }, "localname": "USPharmaceuticalSegmentMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA", "label": "United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA [Member]", "terseLabel": "United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA" } } }, "localname": "UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember", "nsuri": "http://mckesson123.com/20230630", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r279", "r318", "r329", "r330", "r331", "r332", "r333", "r335", "r339", "r388", "r389", "r390", "r391", "r393", "r394", "r396", "r398", "r399", "r901", "r902" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r279", "r318", "r329", "r330", "r331", "r332", "r333", "r335", "r339", "r388", "r389", "r390", "r391", "r393", "r394", "r396", "r398", "r399", "r901", "r902" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r277", "r278", "r405", "r432", "r555", "r733", "r735" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [ "r914" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r382", "r383", "r384", "r385", "r454", "r561", "r605", "r637", "r638", "r689", "r691", "r693", "r694", "r705", "r726", "r727", "r739", "r746", "r753", "r757", "r903", "r918", "r919", "r920", "r921", "r922", "r923" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r382", "r383", "r384", "r385", "r454", "r561", "r605", "r637", "r638", "r689", "r691", "r693", "r694", "r705", "r726", "r727", "r739", "r746", "r753", "r757", "r903", "r918", "r919", "r920", "r921", "r922", "r923" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r382", "r383", "r384", "r385", "r447", "r454", "r479", "r480", "r481", "r560", "r561", "r605", "r637", "r638", "r689", "r691", "r693", "r694", "r705", "r726", "r727", "r739", "r746", "r753", "r757", "r760", "r891", "r903", "r919", "r920", "r921", "r922", "r923" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r382", "r383", "r384", "r385", "r447", "r454", "r479", "r480", "r481", "r560", "r561", "r605", "r637", "r638", "r689", "r691", "r693", "r694", "r705", "r726", "r727", "r739", "r746", "r753", "r757", "r760", "r891", "r903", "r919", "r920", "r921", "r922", "r923" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r277", "r278", "r405", "r432", "r555", "r734", "r735" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r343", "r344", "r633", "r634", "r635", "r690", "r692", "r695", "r706", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r729", "r747", "r760", "r904", "r927" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r343", "r344", "r633", "r634", "r635", "r690", "r692", "r695", "r706", "r714", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r729", "r747", "r760", "r904", "r927" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcceleratedShareRepurchasesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accelerated Share Repurchases [Line Items]", "terseLabel": "Accelerated Share Repurchases [Line Items]" } } }, "localname": "AcceleratedShareRepurchasesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcceleratedShareRepurchasesTable": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "A table reflecting activity in an accelerated share repurchase (ASR) program.", "label": "Accelerated Share Repurchases [Table]", "terseLabel": "Accelerated Share Repurchases [Table]" } } }, "localname": "AcceleratedShareRepurchasesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r39", "r756" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Drafts and accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r11", "r26", "r52", "r260", "r860", "r861" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Unrealized Losses and Other Components of Benefit Plans, Net of Tax" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r10", "r26", "r52", "r260", "r860", "r861" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Foreign Currency Translation Adjustments, Net of Tax" } } }, "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r252", "r260", "r514", "r860", "r861" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [ "r260", "r261", "r542", "r544", "r545", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r51", "r52", "r169", "r246", "r578", "r610", "r611" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r260", "r261", "r542", "r544", "r545", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r8", "r26", "r52", "r521", "r524", "r554", "r606", "r607", "r859", "r860", "r861", "r871", "r872", "r873" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted average life of intangibles" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r163", "r756", "r929" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r483", "r484", "r485", "r621", "r871", "r872", "r873", "r910", "r931" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r19", "r74" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r90", "r91", "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r19", "r71", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities excluded from diluted earnings per share (less than)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r8", "r26", "r52", "r859", "r860", "r861" ], "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "terseLabel": "Total Accumulated Other Comprehensive Loss" } } }, "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r211", "r241", "r275", "r316", "r331", "r337", "r346", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r399", "r400", "r510", "r515", "r540", "r573", "r657", "r756", "r770", "r901", "r902", "r916" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r235", "r248", "r275", "r346", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r399", "r400", "r510", "r515", "r540", "r756", "r901", "r902", "r916" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r7", "r143", "r154", "r191", "r233", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "verboseLabel": "Divested net assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r121", "r126" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r505", "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r93", "r95", "r505", "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business acquisition, percentage of controlling interest in combined business" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "auth_ref": [ "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "terseLabel": "Goodwill, expected tax deductible amount" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r98" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "negatedTerseLabel": "Noncontrolling interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r2", "r3", "r23" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total purchase consideration", "totalLabel": "Total purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r508", "r865" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedLabel": "Fair value adjustment gain" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r4", "r102", "r507" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "totalLabel": "Contingent consideration", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r5", "r102" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Other current liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r5", "r102" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "terseLabel": "Current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r97" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Receivables" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r97" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "negatedTerseLabel": "Current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r96", "r97" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Acquired identifiable intangible assets", "verboseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Identifiable assets acquired and liabilities assumed:" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r96", "r97" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r97" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "negatedTerseLabel": "Other non-current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other non-current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r96", "r97" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant, and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": { "auth_ref": [ "r97" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Purchase consideration:" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r19" ], "calculation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Exit and other-related costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r61", "r237", "r730" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents at end of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r61", "r180", "r272" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Cash, cash equivalents, and restricted cash at end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r6", "r180" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r229", "r243", "r244", "r245", "r275", "r296", "r300", "r302", "r304", "r310", "r311", "r346", "r388", "r391", "r392", "r393", "r399", "r400", "r430", "r431", "r434", "r437", "r443", "r540", "r613", "r614", "r615", "r616", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r645", "r666", "r684", "r707", "r708", "r709", "r710", "r711", "r847", "r868", "r874" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r195", "r762", "r763", "r764", "r767" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r193", "r379", "r380", "r715", "r894" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingent Liabilities" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r82", "r716" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per common share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical", "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r758", "r759", "r760", "r762", "r763", "r764", "r767", "r871", "r872", "r910", "r928", "r931" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r162", "r645" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r162", "r577", "r756" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at June 30, 2023 and March 31, 2023, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComparabilityOfPriorYearFinancialData": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reporting any exceptions to the comparability of prior year financial data with data shown for the most recent accounting period.", "label": "Comparability of Prior Year Financial Data, Policy [Policy Text Block]", "terseLabel": "Results of Operations" } } }, "localname": "ComparabilityOfPriorYearFinancialData", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r53", "r257", "r259", "r267", "r569", "r591" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to McKesson Corporation" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r16", "r108", "r112", "r257", "r259", "r266", "r568", "r590" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r112", "r207", "r257", "r259", "r265", "r567", "r589" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r109", "r736" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r32", "r330", "r331", "r332", "r333", "r339", "r877" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r176", "r562" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "negatedLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "netLabel": "Cross-currency swaps", "terseLabel": "Derivatives designated as net investment hedges", "verboseLabel": "Net Investment Hedges" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r216" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation.", "label": "Debt and Lease Obligation", "terseLabel": "Long-term debt" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r194", "r273", "r401", "r407", "r408", "r409", "r410", "r411", "r412", "r417", "r424", "r425", "r427" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt and Financing Activities" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r36", "r159", "r160", "r212", "r213", "r279", "r402", "r403", "r404", "r405", "r406", "r408", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r551", "r741", "r742", "r743", "r744", "r745", "r869" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r138", "r140", "r402", "r551", "r742", "r743" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r415", "r539", "r742", "r743" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair Value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r44", "r403" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate on debt instrument (percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r279", "r402", "r403", "r404", "r405", "r406", "r408", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r426", "r551", "r741", "r742", "r743", "r744", "r745", "r869" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r45", "r279", "r402", "r403", "r404", "r405", "r406", "r408", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r551", "r741", "r742", "r743", "r744", "r745", "r869" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price percentage of principal (percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Debt principal redeemed" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r45", "r86", "r87", "r137", "r138", "r140", "r141", "r197", "r198", "r279", "r402", "r403", "r404", "r405", "r406", "r408", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r426", "r551", "r741", "r742", "r743", "r744", "r745", "r869" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Credit facility term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r488", "r489", "r574" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Long-term deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r19", "r75" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotionalAmount": { "auth_ref": [ "r696", "r699", "r701", "r703", "r906", "r907", "r908" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative asset.", "label": "Derivative Asset, Notional Amount", "terseLabel": "U.S. Dollar notional amount, asset" } } }, "localname": "DerivativeAssetNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r636", "r638", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r658", "r659", "r660", "r661", "r672", "r673", "r674", "r675", "r678", "r679", "r680", "r681", "r696", "r698", "r702", "r704", "r758", "r760" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative, Name [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r33", "r124", "r168", "r249", "r735" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Fair value of derivative, asset" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r33", "r124", "r168", "r249", "r735" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Fair value of derivative, liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r122", "r125", "r127", "r130", "r636", "r638", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r658", "r659", "r660", "r661", "r672", "r673", "r674", "r675", "r678", "r679", "r680", "r681", "r696", "r698", "r702", "r704", "r735", "r758", "r760" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative, by Nature [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r210", "r519", "r526" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r28", "r122", "r127" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityNotionalAmount": { "auth_ref": [ "r697", "r699", "r700", "r703", "r906", "r907", "r908" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payments on the derivative liability.", "label": "Derivative Liability, Notional Amount", "terseLabel": "U.S. Dollar, notional amount, liability" } } }, "localname": "DerivativeLiabilityNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r907", "r908" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional", "verboseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r28", "r113", "r114", "r116", "r120", "r123", "r127", "r131", "r132", "r134", "r526" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives designated for hedge accounting" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r20", "r30" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposed of by sale" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r14", "r30", "r233" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "terseLabel": "Held-for-sale" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r19", "r20", "r190" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "netLabel": "European businesses, disposal group, losses (gains)", "terseLabel": "Loss (gain) to remeasure disposal group to fair value", "verboseLabel": "European businesses held for sale" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Cash dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per common share attributable to McKesson Corporation" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r268", "r285", "r286", "r287", "r288", "r289", "r294", "r296", "r302", "r303", "r304", "r308", "r529", "r530", "r570", "r592", "r737" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "totalLabel": "Total (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r268", "r285", "r286", "r287", "r288", "r289", "r296", "r302", "r303", "r304", "r308", "r529", "r530", "r570", "r592", "r737" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "totalLabel": "Total (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDilutedLineItems": { "auth_ref": [ "r296", "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareDilutedLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r293", "r305", "r306", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r541" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Reported income tax expense (benefit) rates (percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r849", "r905" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "terseLabel": "Tax expense (benefit), share-based payment arrangement" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r27", "r230", "r260", "r261", "r262", "r280", "r281", "r282", "r284", "r290", "r292", "r309", "r347", "r348", "r444", "r483", "r484", "r485", "r497", "r498", "r520", "r521", "r522", "r523", "r524", "r525", "r528", "r542", "r544", "r545", "r546", "r547", "r548", "r554", "r606", "r607", "r608", "r621", "r684" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r242", "r538", "r732" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Investments in equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimatedInsuranceRecoveries": { "auth_ref": [ "r857" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.", "label": "Estimated Insurance Recoveries", "terseLabel": "Probable loss recovery" } } }, "localname": "EstimatedInsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r532", "r533", "r536" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r532", "r533", "r536" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r135", "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of Fair Value of Derivatives" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r415", "r448", "r449", "r450", "r451", "r452", "r453", "r533", "r557", "r558", "r559", "r742", "r743", "r748", "r749", "r750" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r532", "r533", "r534", "r535", "r537" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedges" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r415", "r448", "r453", "r533", "r557", "r748", "r749", "r750" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair value, inputs, level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r415", "r448", "r453", "r533", "r558", "r742", "r743", "r748", "r749", "r750" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair value, inputs, level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r415", "r448", "r449", "r450", "r451", "r452", "r453", "r557", "r558", "r559", "r742", "r743", "r748", "r749", "r750" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r531", "r537" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r121", "r123", "r133" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r239", "r363" ], "calculation": { "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Estimated annual amortization expense, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Estimated annual amortization expense, remainder of 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Estimated annual amortization expense, 2028" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Estimated annual amortization expense, 2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Estimated annual amortization expense, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r361", "r362", "r363", "r364", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r188", "r564" ], "calculation": { "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r188", "r563" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted- Average Remaining Amortization Period (Years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiscalPeriod": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.", "label": "Fiscal Period, Policy [Policy Text Block]", "terseLabel": "Fiscal Period" } } }, "localname": "FiscalPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r866" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedTerseLabel": "Gain from sales of businesses and investments" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r895" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "verboseLabel": "Claims and litigation charges, net" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r19", "r84", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Gain on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r238", "r349", "r565", "r740", "r756", "r880", "r887" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": 1.0 }, "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets, Net" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r356" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation adjustments, net" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [ "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r740" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r1", "r886" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Other adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r174", "r275", "r316", "r330", "r336", "r339", "r346", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r399", "r400", "r540", "r738", "r901" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r28", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r107", "r175", "r182", "r285", "r286", "r287", "r288", "r301", "r304" ], "calculation": { "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Income from continuing operations attributable to McKesson Corporation" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r171", "r218", "r316", "r330", "r336", "r339", "r571", "r583", "r738" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income from continuing operations before income taxes", "totalLabel": "Income from continuing operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r207", "r275", "r283", "r316", "r330", "r336", "r339", "r346", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r399", "r400", "r530", "r540", "r583", "r738", "r901" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Income from continuing operations", "totalLabel": "Income from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r170", "r217", "r219", "r268", "r283", "r285", "r286", "r287", "r288", "r296", "r302", "r303", "r530", "r570", "r926" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Continuing operations (in usd per share)", "verboseLabel": "Continuing operations (in usd per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r170", "r268", "r283", "r285", "r286", "r287", "r288", "r296", "r302", "r303", "r304", "r530", "r570", "r926" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Continuing operations (in usd per share)", "verboseLabel": "Continuing operations (in usd per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r144", "r145", "r146", "r147", "r148", "r156", "r234", "r502", "r584" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Income from discontinued operations, net of tax", "verboseLabel": "Income from discontinued operations, net of tax" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r172", "r268", "r300", "r302", "r303", "r924", "r926" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Discontinued operations (in usd per share)", "verboseLabel": "Discontinued operations (in usd per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r209", "r300", "r302", "r303" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Discontinued operations (in usd per share)", "verboseLabel": "Discontinued operations (in usd per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r751", "r752" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r22", "r30", "r38", "r143", "r149", "r150", "r151", "r152", "r153", "r155", "r157", "r158", "r192" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r24", "r92", "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r276", "r486", "r492", "r495", "r496", "r499", "r501", "r503", "r504", "r618" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r222", "r228", "r291", "r292", "r324", "r490", "r500", "r593" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "terseLabel": "Income tax expense (benefit) related to continuing operations" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r18" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Drafts and accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "auth_ref": [ "r865" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.", "label": "Increase (Decrease) in Accrued Taxes Payable", "terseLabel": "Taxes" } } }, "localname": "IncreaseDecreaseInAccruedTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r18" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r18" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "Changes in assets and liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r852", "r865" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r18" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r18" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r297", "r298", "r299", "r304", "r456" ], "calculation": { "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Effect of dilutive securities (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r139", "r221", "r263", "r320", "r550", "r669", "r768", "r930" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r728", "r765", "r766" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Floating interest rate swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryLIFOReservePeriodCharge": { "auth_ref": [ "r185" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.", "label": "Inventory, LIFO Reserve, Period Charge", "negatedTerseLabel": "Pre-tax credits related to LIFO accounting", "terseLabel": "Credits associated with last-in, first-out inventory method" } } }, "localname": "InventoryLIFOReservePeriodCharge", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r247", "r731", "r756" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r167", "r215", "r581", "r756", "r870", "r878", "r911" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r43", "r236", "r275", "r346", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r399", "r400", "r511", "r515", "r516", "r540", "r756", "r901", "r916", "r917" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r36", "r213", "r925" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Amounts outstanding under facility" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [ "r869" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r40", "r869" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationReserveNoncurrent": { "auth_ref": [ "r47", "r895" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.", "label": "Estimated Litigation Liability, Noncurrent", "terseLabel": "Long-term litigation liabilities" } } }, "localname": "LitigationReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Award payable under proposed framework" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r895" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r895" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Term Loan", "verboseLabel": "Loans payable" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermCommercialPaperCurrent": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Long-Term Commercial Paper, Current", "terseLabel": "Commercial paper" } } }, "localname": "LongTermCommercialPaperCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r36", "r213", "r414", "r428", "r742", "r743", "r925" ], "calculation": { "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Debt outstanding", "totalLabel": "Total debt", "verboseLabel": "Carrying Value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r36", "r575" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-Term Debt and Lease Obligation", "terseLabel": "Total long-term debt", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-Term Debt and Lease Obligation, Current", "terseLabel": "Less: Current portion", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r45", "r83" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails", "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r381", "r382", "r383", "r387", "r896", "r898" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [ "r381", "r382", "r383", "r387", "r896", "r898" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r381", "r382", "r383", "r387", "r896", "r898" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r381", "r848" ], "calculation": { "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "totalLabel": "Total litigation liabilities" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "auth_ref": [ "r381" ], "calculation": { "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails": { "order": 2.0, "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Current", "verboseLabel": "Current litigation liabilities" } } }, "localname": "LossContingencyAccrualCarryingValueCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": { "auth_ref": [ "r381" ], "calculation": { "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails": { "order": 1.0, "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Noncurrent", "verboseLabel": "Long-term litigation liabilities" } } }, "localname": "LossContingencyAccrualCarryingValueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r382", "r383", "r386", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Loss contingency, estimate of possible loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r381", "r382", "r383", "r387", "r896", "r898" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r896", "r898" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Complaints filed against the entity" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r142", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Business Acquisitions and Divestitures" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestitures" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r50", "r214", "r275", "r346", "r388", "r391", "r392", "r393", "r399", "r400", "r540", "r580", "r647" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.", "label": "Equity, Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Payments to noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money market funds at carrying value" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r271" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r271" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r180", "r181", "r182" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r173", "r182", "r220", "r234", "r255", "r258", "r262", "r275", "r283", "r285", "r286", "r287", "r288", "r291", "r292", "r301", "r316", "r330", "r336", "r339", "r346", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r399", "r400", "r530", "r540", "r587", "r665", "r682", "r683", "r738", "r768", "r901" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to McKesson Corporation" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r111", "r208", "r255", "r258", "r291", "r292", "r586", "r861" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Net income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging", "verboseLabel": "Net Investment Hedges" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r105", "r444", "r871", "r872", "r873", "r931" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r876" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails", "http://mckesson123.com/role/SignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "negatedTotalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r316", "r330", "r336", "r339", "r738" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Total operating profit (loss)", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Income (Loss) [Abstract]", "terseLabel": "Segment operating profit (loss)" } } }, "localname": "OperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r915" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Non-cash operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r553" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r553" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r552" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r329", "r330", "r331", "r332", "r333", "r339" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetImpairmentCharges": { "auth_ref": [ "r866", "r890" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.", "label": "Other Asset Impairment Charges", "terseLabel": "Long-lived asset impairment charges" } } }, "localname": "OtherAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r240" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r35", "r52", "r261", "r542", "r545", "r548", "r859" ], "calculation": { "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r13", "r260", "r588" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss) before Reclassifications, Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r250", "r251" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Unrealized gains on cash flow and other hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r227", "r251", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "verboseLabel": "Derivatives designated as cash flow and other hedges:" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r9" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r517" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Derivatives designated as net investment hedges:", "verboseLabel": "Other comprehensive income (loss), net investment hedge, gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r35", "r256", "r259", "r264", "r542", "r543", "r548", "r566", "r588", "r859", "r860" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r16", "r25", "r207", "r256", "r259" ], "calculation": { "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Less: amounts attributable to noncontrolling interests" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r16", "r25", "r207", "r256", "r259" ], "calculation": { "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss) attributable to McKesson" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r12", "r169" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedTerseLabel": "Changes in retirement-related benefit plans" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "verboseLabel": "Other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r182" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "verboseLabel": "Other Non-Current Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r178" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Payments for Legal Settlements", "terseLabel": "Settlement payment" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r850", "r862" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r58" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Share repurchases" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r369", "r864" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r58" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r56", "r506" ], "calculation": { "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "netLabel": "Cash", "terseLabel": "Cash payments to acquire business", "verboseLabel": "Cash" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r56" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions, net of cash, cash equivalents, and restricted cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r179" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Payments for property, plant, and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireSoftware": { "auth_ref": [ "r179" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Acquire Software", "negatedLabel": "Capitalized software expenditures" } } }, "localname": "PaymentsToAcquireSoftware", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r161", "r430" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r161", "r645" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r161", "r430" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r161", "r645", "r663", "r931", "r932" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r161", "r576", "r756" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r858" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r855" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Collection of Notes Receivable", "terseLabel": "Proceeds from collection of notes receivable" } } }, "localname": "ProceedsFromCollectionOfNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Proceeds from debt issuance" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r55" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "terseLabel": "Proceeds from sales of businesses and investments, net" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommercialPaper": { "auth_ref": [ "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowing by issuing commercial paper.", "label": "Proceeds from Issuance of Commercial Paper", "terseLabel": "Proceeds from issuance of commercial paper" } } }, "localname": "ProceedsFromIssuanceOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r57", "r613" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuances of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r15", "r29" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuances" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised [Abstract]", "terseLabel": "Common stock transactions:" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromLegalSettlements": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for the settlement of litigation during the current period.", "label": "Proceeds from Legal Settlements", "verboseLabel": "Proceeds from legal settlements" } } }, "localname": "ProceedsFromLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r57", "r869" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Borrowings under facility" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r851", "r863" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r57" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-Term Debt", "terseLabel": "Proceeds from short-term borrowings" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r234", "r255", "r258", "r270", "r275", "r283", "r291", "r292", "r316", "r330", "r336", "r339", "r346", "r388", "r389", "r391", "r392", "r393", "r395", "r397", "r399", "r400", "r509", "r512", "r513", "r530", "r540", "r571", "r585", "r620", "r665", "r682", "r683", "r738", "r754", "r755", "r769", "r861", "r901" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r21", "r572", "r582", "r756" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant, and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r756" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Receivables, net" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r35", "r52", "r261", "r542", "r547", "r548", "r859" ], "calculation": { "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified to earnings and other" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "terseLabel": "Reclassification of gains from AOCI" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r13", "r254", "r260", "r588" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "verboseLabel": "Accumulated other comprehensive loss adjustment" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfCommercialPaper": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow due to repaying amounts borrowed by issuing commercial paper.", "label": "Repayments of Commercial Paper", "terseLabel": "Repayments of commercial paper" } } }, "localname": "RepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r59", "r616" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedTerseLabel": "Repayments of long-term debt", "terseLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r59" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-Term Debt", "negatedTerseLabel": "Repayments of short-term borrowings" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r856", "r867" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "negatedTerseLabel": "Less: Restricted cash at end of period included in Prepaid expenses and other" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r366", "r367", "r369", "r372", "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring, Impairment, and Related Charges, Net" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r368", "r371", "r375", "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected total pre-tax charges" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r368", "r371", "r375", "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Restructuring and related cost, incurred cost to date" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r19", "r373", "r375", "r892" ], "calculation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring costs, anticipated total charges", "totalLabel": "Total", "verboseLabel": "Restructuring, impairment, and related charges, net" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [ "r368", "r369", "r370", "r371", "r375", "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r369", "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r369", "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "negatedTerseLabel": "Non-cash charges" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAndOtherAdjustment": { "auth_ref": [ "r79", "r893" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the restructuring reserve related to foreign currency translation (gain) loss and other increases (decreases).", "label": "Restructuring Reserve, Translation and Other Adjustment", "terseLabel": "Other" } } }, "localname": "RestructuringReserveTranslationAndOtherAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r164", "r199", "r579", "r609", "r611", "r617", "r646", "r756" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r230", "r280", "r281", "r282", "r284", "r290", "r292", "r347", "r348", "r483", "r484", "r485", "r497", "r498", "r520", "r522", "r523", "r525", "r528", "r606", "r608", "r621", "r931" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r317", "r318", "r329", "r334", "r335", "r341", "r343", "r345", "r445", "r446", "r562" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Segment revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r52", "r912", "r913" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of information regarding changes in accumulated other comprehensive income (loss), net of tax, by component" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Long-Term Debt" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r875" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computations for basic and diluted earnings per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "auth_ref": [ "r62", "r63", "r296", "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of information regarding intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r740" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r740", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of changes in the carrying amount of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": { "auth_ref": [ "r895", "r897", "r899", "r900" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.", "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]", "terseLabel": "Schedule of Estimated Accrual Liability" } } }, "localname": "ScheduleOfLossContingenciesByContingencyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r909" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r129", "r853" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r368", "r369", "r370", "r371", "r375", "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r76", "r78", "r80" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring, Impairment, and Related Costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r77", "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Restructuring and Asset Impairment Charges" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r67", "r68", "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r67", "r68", "r69", "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r313", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r339", "r345", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r371", "r377", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r740", "r854", "r927" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r312", "r313", "r314", "r315", "r316", "r328", "r333", "r337", "r338", "r339", "r340", "r341", "r342", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segments of Business" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]", "terseLabel": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r177" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "negatedTerseLabel": "Selling, distribution, general, and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceAgreementsMember": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service.", "label": "Service Agreements [Member]", "terseLabel": "Service agreements" } } }, "localname": "ServiceAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [ "r895" ], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r19" ], "calculation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and employee-related costs, net" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r232", "r313", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r339", "r345", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r365", "r371", "r377", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r740", "r854", "r927" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Business Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails", "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r229", "r243", "r244", "r245", "r275", "r296", "r300", "r302", "r304", "r310", "r311", "r346", "r388", "r391", "r392", "r393", "r399", "r400", "r430", "r431", "r434", "r437", "r443", "r540", "r613", "r614", "r615", "r616", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r645", "r666", "r684", "r707", "r708", "r709", "r710", "r711", "r847", "r868", "r874" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r27", "r48", "r230", "r260", "r261", "r262", "r280", "r281", "r282", "r284", "r290", "r292", "r309", "r347", "r348", "r444", "r483", "r484", "r485", "r497", "r498", "r520", "r521", "r522", "r523", "r524", "r525", "r528", "r542", "r544", "r545", "r546", "r547", "r548", "r554", "r606", "r607", "r608", "r621", "r684" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r280", "r281", "r282", "r309", "r562", "r612", "r632", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r658", "r659", "r660", "r661", "r662", "r664", "r667", "r668", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r684", "r761" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r280", "r281", "r282", "r309", "r562", "r612", "r632", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r658", "r659", "r660", "r661", "r662", "r664", "r667", "r668", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r684", "r761" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized repurchase amount (up to)" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Authorized amount available for future repurchases" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r27", "r161", "r162", "r199", "r616", "r684", "r710" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Share repurchases (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r27", "r161", "r162", "r199", "r621", "r684", "r710", "r769" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock", "terseLabel": "Shares repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r162", "r165", "r166", "r184", "r647", "r663", "r685", "r686", "r756", "r770", "r870", "r878", "r911", "r931" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "totalLabel": "Total McKesson Corporation stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "McKesson Corporation stockholders\u2019 deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r105", "r106", "r110", "r230", "r231", "r261", "r280", "r281", "r282", "r284", "r290", "r347", "r348", "r444", "r483", "r484", "r485", "r497", "r498", "r520", "r521", "r522", "r523", "r524", "r525", "r528", "r542", "r544", "r548", "r554", "r607", "r608", "r619", "r647", "r663", "r685", "r686", "r712", "r769", "r870", "r878", "r911", "r931" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r196", "r274", "r429", "r431", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r444", "r527", "r687", "r688", "r713" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "verboseLabel": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r549", "r556" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r549", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r549", "r556" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trademarks and trade names" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Shares Acquired, Average Cost Per Share", "terseLabel": "Average price of shares repurchased (in usd per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "negatedPeriodEndLabel": "Ending balance (in shares)", "negatedPeriodStartLabel": "Beginning balance (in shares)", "terseLabel": "Treasury shares (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r49", "r88", "r89" ], "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedLabel": "Treasury shares, at cost, 143 and 141 shares at June 30, 2023 and March 31, 2023, respectively" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r27", "r162", "r199" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Common stock repurchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredParValueMethod": { "auth_ref": [ "r27", "r88", "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.", "label": "Treasury Stock, Value, Acquired, Par Value Method", "terseLabel": "Shares repurchased" } } }, "localname": "TreasuryStockValueAcquiredParValueMethod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r487", "r493" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r494" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r64", "r65", "r66", "r223", "r224", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r295", "r304" ], "calculation": { "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in usd per share)", "totalLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average common shares outstanding", "verboseLabel": "Weighted-average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r294", "r304" ], "calculation": { "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 14 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//205-20/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.L)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org//350/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org//815/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org//280/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org//420/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483478/205-10-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(17))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column G))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column H))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column I))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column J))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column K))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r771": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r772": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r773": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r774": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r775": { "Name": "Form 20-F", "Paragraph": "a", "Publisher": "SEC", "Section": "16", "Subsection": "J", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r776": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r777": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r778": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "A", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r779": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "B", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "C", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r781": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "D", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r782": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "E", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r783": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r784": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "iii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r785": { "Name": "Form 20-F", "Paragraph": "2", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r786": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r787": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r788": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r789": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r791": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r792": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r793": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r794": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r795": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r796": { "Name": "Form 40-F", "Paragraph": "b", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r797": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r798": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r799": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r801": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r802": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r803": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r804": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r805": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r806": { "Name": "Form N-CSR", "Paragraph": "b", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r807": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r808": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r809": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r811": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r812": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r813": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "vi", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r814": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "3", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r815": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "4", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r816": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r817": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r818": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r819": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r821": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r822": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r823": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r824": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r825": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "B", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r826": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r827": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r828": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r829": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r831": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r832": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r833": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r834": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r835": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r836": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r837": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r838": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "F", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r839": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r841": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "A", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r842": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "B", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r843": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "C", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r844": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "D", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r845": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r846": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r894": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 86 0000927653-23-000062-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000927653-23-000062-xbrl.zip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�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®@1[57;N@!/"I7FWK"X M M.B FT_F\21 PK.7>2P+BK0@?L.K2S8E LF[';V9/K)86,NC)TIF"B3Z;G4 M\J[K\-4CEKM=)?#$EB:>,=WP>5,5%H-O:53@5D/ZSP39XQWC#6!98:CQAKSI MM9L'KXHABR%@WTF,LE%Y2S%4?5]X#K6)G;-(S%$MQV_'P?4P4S..$ID>,GSM M487U?G-&H7NH%(CD!>BS)O&JL?WUL/HW=^([ZHJSF7W:^:=2M(H@X^B#@"&D M^PRSD:>(*9;7Z7.XD>5D#XKM#]@>P:4C6TRQB\DK5.! P()F_\TQRGKP MAYY6S@ON0^9-JCS/,D)[ ]+^BHP0AQQ%K\^ /! J(&Q$TJV?PY+I [>)A+]U MV&M'W+5/I$L$VW)7P-8UYSI/B/#%IE3S_89$8+[0S_.W;3+1*O/ MY[5?BMY+1G\G\__KMYK_N]^N0/%6V[%48(\-A\5+02EGL7K8.2MPDA*CXDT% M #G:+1Y4(,9TP>]8H!)# K*H0'P1%?BF1@7^D,R@U>K0)1+/6/\S;(5='-;# M#&I3CR<7[Q>%/BP4^+ O:*S,QG@7E1_:"(=1 48]X+VF MJWRQ"1UU A=7POOX156_*)O+&/F8S22@(;I<^ >C]PGFC7YN_M);"1T\KP-4 MZSJQ%Z$36E(?[7J=I6EQ.R?$>6PNW1"?F?_Y'QY^QQLOW"D,NW;+,_&Z9E]# MNASKQS0*QRLE359[TOIUA.Y9^+V7!/8*]87PT.<-/D]\2-#<-;&1A:^W)W4_ MA@>AEF%V1C)MEG$7I>V0$00-,%'8.2]%U#Y\@Y@- 155XEXU!4?X-GQ[>B:T M%@)NABI$(6<_4 $.TA791VLS$\X2&36J@;[WXY&SQNE4( 77C(.6*W2$W;[Q M#0[%):28_Y1W/:(C*\7@=-4+P0=SQ?M_E?4NY/SOYL&+B&A;E.+/0D^S]<6> ML<#LFV,?AGLAUI9V%FUH'/R'=]>A)V$%T#2B#/] Q$W)#M4\, M>JC<7_-98%C.DLI[IM=?"0^\ 2'>:;,*'NOZ;47SP#)EIT"?LT$S0DC/[3@T ML^A[ G.]N)?+?<_,JWVU).OP&9!/%).C@0'/T QNX^J8@FQR/[_435VL0"H)' MZ^%$#9+U<*Y:_RQ7B*%Z6J8Y>*@EJ5_9XI6M0HE[Y+,O+I[(-O+"M28^M68S M\DQ#@6H)-E )*B_W[L\3L4#7@FSH8Y+F?+%XI[:7E[90H7OA+RB'OZMV+Z1$ M\XR,+JJO$OL.ODQD &5!Z$'@X)]4W=K]^*61F:E+['$4\@>[,K@%&)\/5\*; M?YGWN6>6&71>>();S%!74;56"Y(,UW/0K?PM%KKNNJ:XS):G"GY2]%O%2BOZP8-^H+&'VF M"QWA)QXJ^'N7;Y^^Z00X3JAO1TKJ.NF7ESA=JN9L[6NY_=PG[T?KU^,%4=^9(J'Y'C>V>H2VW+= #!EK8L7\IAT34= 1_<3MF^/SGW]3MR!@HH: MF01L2>V+Y%' 1_$Q(KI547^].JM@9?O!A]6OL#';/QZI^H9WJ3 M'IA>LZMSL*2*=[JP:=#N=N4W&:A'9J>-14D03F581@)G_R911/80=H@M=&9N'3VP?TY<@ M<&U4ZW,TOC#XYV/U+\D4QD1*)V(GI3T5]J6T)XOW8UEIR!2S[:T75U:\YPF_ MSLQ^?6SJ&[?<@YY:P7-@5/@QRYCD5 .L(,^"90])+"U;DK_.TJ.F)23S?$:X/ M>WFW3,MC]$M8^:*Z\JYP3$=?\L6B!M2X!0T8*ZJCL1ZG-2Q H^3>RK&WZ\OV MTY^-@\X=.5U64'IAY'Q^2VGLV&Z^:^.0$+D]BVHGJ[;?5']S;OK:GJ*Y7/4] M!L[0)&:I-:4#V)6Q(I)1WOA:)K]*;\:BT@6UW.]N=U]<"['_!-M7;-IN[<_[ M40[=9'>F IW5E[83(?Q/^J/U69L(AABN]@.AL.#\K[$OMDYRTAL5PS>P_Q'T MZS&3A12SZO:9V\@]%\P/]KUO;ZMBU1+?.2?ME!=-\D=@Q)X$>9!;0#L"Q!RL MGM53[0B]<:NM8.W4Q.DM >6HATEQ)_E_\R#V[-X@VK [WA16*E!B!SFV41'< MM9G],OI2Z$?Y>FFEG&VT@LJ$H29)@(,VF#T5P!3ZD464=B*Q=G]I&;;C4]=/ M#K^#7.DFH7TS#M]"*6MDB]Z0-V1"Z DSALE2>]X\EW.;3E3U)T3,:Z-C0)_!3!PTVV/.6AIT':0Q6]ELHI$M\= M@C16H7@N;?Y^K*RG;$",C:C"+_9C*D!A-R- *"=4X[.A,2J+O25QWLLF[PG+ M/Z/Z7:.M21,-;PY,P3 JP+;

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end